The role of coagulation factors in the regulation of bronchial epithelial repair<i> in vitro</i> by Ewen, Darleen
Universityof 
Portsmouth 
The Role of Coagulation Factors in the 
Regulation of Bronchial Epithelial Repair 
In Vitro 
Darleen Ewen 
Institute of Biomedical and Biomolecular Science 
University of Portsmouth 
Doctor of Philosophy 
September 2007 
University of Portsmouth 
DIVISION OF PHARMACOLOGY 
INSTITUTE OF BIOMEDICAL AND BIOMOLECULAR SCIENCE 
Doctor of Philosophy 
The Role of Coagulation Factors in the Regulation of Bronchial Epithelial Repair 
In Vitro 
Darleen Ewen 
Abstract 
The bronchial epithelium serves as a protective cellular barrier and the first site of contact for 
damaging inflammatory and physical stimuli from the environment. Previous in vivo studies in 
guinea pigs have demonstrated that normal bronchial epithelial repair is both rapid, and 
dependent on the formation of a provisional fibrin matrix that is exclusively plasma-derived. 
This study tests the hypothesis that local release of coagulation factors from bronchial epithelial 
cells and subsequent fibrin formation supports bronchial epithelial repair independently of 
plasma proteins. 
Cells of the 16HBE 140- cell line and primary normal human bronchial epithelial (NHBE) cells 
were cultured in serum-free medium to confluence and mechanically wounded. The expression 
of coagulation factors in response to wounding was examined at the protein and mRNA level 
using immunohistochemistry, immunoblot, western blot and RT-PCR. The role of coagulation 
factors in epithelial repair was investigated using neutralising antibodies and specific inhibitors 
and monitored by both standard light and kinetic video microscopy. The role of PARs in fibrin 
formation and epithelial repair was investigated using specific PAR-l and PAR-2 peptide 
agonists. 
Active TF was constitutively expressed in 16HBE 140- cells and initiated the coagulation 
cascade that was essential for epithelial repair. Fibrinogen and FXIII were rapidly released, 
within 20 minutes in response to wounding and were essential for wound repair. Fibrin 
formation and turnover was demonstrated by the release of D-dimers from epithelial cell layers 
in proportion to the degree of wounding. Expression of tissue factor (TF) and factor VII (FVII) 
mRNA increased post-wounding over an extended time course up to 12 hours. 
The bronchial epithelium is therefore a source of preformed coagulation factors released rapidly 
in response to mechanical wounding and the autonomous formation of a cross-linked fibrin 
matrix is essential for wound repair. 
In asthma, the bronchial epithelium has increased susceptibility to injury and normal repair 
mechanisms are compromised, contributing to bronchial hyper-reactivity. The data presented in 
this thesis suggests novel therapeutic strategies to enhance repair of the damaged bronchial 
epithelium in asthma, such as the delivery of recombinant FXIII by inhalation or the use of 
specific agonists ofPAR-2, which is associated with cytoprotection in the lung. 
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Chapter 1. 
General Introduction 
1 
1. General Introduction 
1.1. The bronchial epithelium 
The bronchial epithelium is primarily a protective cellular barrier, which acts as a first 
site of contact for inflammatory and physical stimuli from the environment (Holgate et 
al., 2000). The bronchial epithelium is comprised of specialised epithelial cells and the 
integrity of the epithelial layer is dependent upon various mechanisms of adhesion 
(Montefort et al. 1992). Irrespective of whether the phenotype is normal or asthmatic, 
the bronchial epithelium is continually subjected to inhaled pollutants, proteolytic 
allergens and microbes and is frequently injured as a consequence. An intact bronchial 
epithelium is vital for normal airway function; therefore the repair response must be 
rapid to restore the damaged epithelium following injury. The normal bronchial 
epithelium has exceptional ability to repair itself following injury. 
1.1.1. Structural composition of the bronchial epithelium as a protective barrier 
The structure of the airway epithelium has been extensively studied and it has been 
shown that at least eight distinct types of epithelial cell are present in the human 
respiratory tract (Jeffery, 1983). These may be classified into three main categories of 
cell type described as basal, ciliated and secretory. 
The predominant cell type within the airways accounting for over half of all epithelial 
cells is the columnar ciliated epithelial cell, which arises from either the basal or 
secretory cell (Knight et al., 2003). The important feature of the columnar ciliated cell is 
that it bears up to 300 cilia per cell on the apical surface, allowing it to perform its 
unique role of mucus transportation from the lung to the throat in order to be expelled. 
Basal cells are extensively present throughout the bronchial epithelium. In addition to 
their ability to differentiate into mucous and ciliated epithelial cells, they play a 
significant intermediary role in the binding of the columnar epithelial cells to the 
underlying basement membrane (Evans et al., 1990). This is made possible by the 
characteristic of basal cells to express hemidesmosomes, which in tum, possess the 
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necessary integrins (a6~4) to attach to the basement membrane. Basal cells are also 
thought to be involved in the secretion of a number of bioactive molecules, including 
neutral endopeptidase, 15-lipoxygenase products and cytokines (Knight and Holgate, 
2003). 
*-::-------Cilia 
... ---=:.- --Columnar cells 
.Eii~ i.--,.....j.- -Basal cells 
~iI-- -Basement membrane 
Submucosa 
Figure 1.1. Histological section through the bronchial epithelium of a non-asthmatic 
subject. The intact, normal bronchial epithelium is pseudostratified, with columnar 
cells, situated on top of basal cells, attached to a basal membrane. 
Of the eight epithelial cell types within the bronchial epithelium, the goblet, serous and 
clara cells comprise the three secretory cells (Reid et aI., 1980). The mucus lining of the 
respiratory tract originates from products of secretory cells interspersed among mucosal 
cells or within submucosal glands and protects the underlying mucosa from 
dehydration. Current understanding is that the lining is a two-fluid model in which the 
upper layer is a viscoelastic gel (mucous, cross-linked glycoproteins) that overlies a sol 
layer (serous). Thus, mucous propelled by ciliary beating flows above the sol layer and 
contains sloughed cells and xenobiotic materials that come into contact with it (Foster, 
2002). Goblet cells are highly abundant in the normal human airways. They produce 
mucous and are also involved in mucociliary clearance. Goblet cells contain acidic-
mucin granules, which swell to form mucin granules when released, in order to capture 
foreign particulates in the airway lumen (Jeffery, 1983). In addition to mucous 
production by these cells, the acidity of the mucin granules is also vital to the 
transportation of mucous across membranes into the airway lumen. The acidity of these 
mucin granules is substantially increased in response to exposure of hamlful agents 
such as sulphw' dioxide or cigarette smoke (Knight and Holgate, 2003). Goblet cells are 
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adaptive since they are capable of self-renewal and of differentiation into ciliated 
epithelial cells (Evans et al., 1988). 
Serous cells are structurally similar to goblet cells and share a role in mucociliary 
clearance. Until fairly recently, serous cells were only identified in the rat airway 
(Rogers et al., 1993). Little is known about these cells in the human trachea however it , , 
is well established that, in the rat airway they contain neutral mucin granules and an 
unidentified non-mucoid substance. 
Clara cells are present in both the bronchial and bronchiolar airways. They contain 
electron-dense granules, which in tum are considered to contain bronchiolar surfactant. 
In addition, they are believed to be involved in the metabolism of xenobiotic 
compounds by the action of p450 mono-oxygenases and are also speculated to produce 
specific antiproteases (Knight and Holgate, 2003). Clara cells are believed to play an 
important role as a progenitor for the ciliated columnar or mucous-secreting cells (Hong 
et al., 2001). 
1.1.2. Maintenance of the bronchial epithelium 
The three major components involved in the maintenance of a protective barrier consist 
of: desmosomes, zonula adherens (intermediate junction) and tight junctions (Rennard 
et al., 1991). Of these junctional complexes, desmosomes are a major structural 
adhesion mechanism and appear to be the most prominent. 
Desmosomes are symmetrical structures, which are composed largely of plaques and 
anchoring tonofilaments and serve as junctional 'spot-welds' between cells (Montefort 
et al., 1992). They are located between the basal cells and the differentiated cells, hence 
the reason that they have been associated with the regulation of cellular injury and 
detachment. Hemidesmosomes are responsible for anchoring the basal cells to the 
underlying basement membrane in order to maintain the bronchial epithelium. The few 
columnar cells that penetrate down to the basement membrane fail to form 
hemidesmosomal links with the basement membrane and are therefore dependent on 
their attachment to basal cells by desmosomes for their anchorage (Evans et al.. 1989; 
Evans et al.. 1988). In a study involving the analysis of bronchoalveolar lavage (BAL) 
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fluid from asthmatic subjects, Montefort et al (1992) concluded that the plane of 
cleavage lies between the columnar and basal cell layers following epithelial damage, 
since the BAL samples consisted almost entirely of columnar cells with very few basal 
cells present (Montefort et aI., 1992). 
The intermediate junctions form a ring-like adhesive mechanism around the cell and 
resemble desmosomes with the exception of possessing a narrower intercellular space 
with cytoplasmic filaments in place of the dense plaque, which is present in 
desmosomes. Little information is known about the composition of these structures; 
however, early studies demonstrated the presence of the cadherin, uvomorulin at this 
junction (Boller et al., 1985). Cadherins are calcium-dependent cell adhesion molecules, 
categorised into neural and epithelial varieties. Positive immunostaining for epithelial 
cadherin was reported within the bronchial epithelium, furthermore, the molecule was 
localised to epithelial contacts suggesting that it may be present in the intermediate 
junctions (Montefort et al., 1992). The desmosome and the intermediate junction are the 
most effective adhesion mechanism between cells. 
Tight junctions define the physiological interface between functionally distinct apical 
and basolateral plasma membrane domains, and more specifically, describe the sealing 
of adjacent epithelial cells in a narrow band just beneath their apical surface. Tight 
junctions are formed from macromolecular complexes of proteins and have a 
continuous distribution around the apical perimeter of epithelial cells. Tight junction 
proteins such as zonula occludens (ZO)-l, ZO-2, ZO-3, cingulin, symplekin and AF-6 
are localized to the cytoplasmic face of the junction and do not participate directly in the 
formation of an intercellular seal at tight junctions (Anderson et aI., 1995; Schneeberger 
et aI., 1992). However, as some of these proteins are anchored to the cytoskeleton, they 
may be able to regulate tight junction function indirectly. In contrast to the proteins 
mentioned, occludins and claudins are membrane-spanning proteins that are considered 
to seal tight junctions by creating homotypic interactions with neighbouring cells 
(Furuse et aI., 1993; Wong et aI., 1997). Tight junctions provide two types of barrier 
role. Firstly, they act by blocking the intercellular space and preventing the movement 
of material from the lumen of the airway to the serosal area. And secondly. they form a 
continuous barrier in the external region of the cell membrane separating the molecules 
on the apical surface from those on the basal lateral surface (Rennard et al .. 1991). The 
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formation of tight junctions by the epithelial cells is of great consequence since it 
decreases permeability and allows ion transport mechanisms to function efficiently. The 
high degree of order in the structure of the tight junction, and its ability to undergo rapid 
structural and functional changes in response to environmental stimuli, has created a 
great deal of interest in the underlying structural and organisational components of this 
array. 
In addition to these junctional complexes, a number of integrins have been identified in 
the bronchial epithelium and appear to exert an important role, not only in adhesion but 
also in epithelial repair following injury. Integrins represent a large family of 
heterodimeric transmembrane glycoproteins consisting of a- and p-chains. At least 
seven different integrins are expressed on airway epithelial cells of healthy adults, 
namely: a2pl, a3pl, a6p4, a9pl, avpS, avp6, and avp8. Studies using mice that 
express null mutations of these integrins have identified roles for epithelial integrins 
(Sheppard, 2002). Table 1.1 displays a summary of the integrins expressed, their known 
ligands and their distribution within the bronchial epithelium. 
Of the integrins listed, a3 PI and a6p4 are receptors for laminins S, 10 & 11 and are 
therefore, the only ones to recognise matrix protein ligands, which are present in the 
normal epithelial basement membrane. However, the pattern of distribution of these 
integrins is distinct. Expression of a6p4 is completely restricted to the basal surface of 
basal cells where it forms a fundamental component of hemidesmosomes and IS 
therefore essential for the maintenance of epithelial integrity. Whereas, a3p 1 IS 
expressed at the basal surface but is also distributed in lower levels throughout the 
bronchial epithelium and is directly involved in the organisation of the basement 
membrane into an ordered structure. Even though a2p 1 is primarily associated with 
collagen I, it is possible that this receptor may interact with collagen IV within the 
basement membrane. a2pl and a3pl are assumed to play important roles in homotypic 
cell-cell adhesion in the bronchial epithelium, however, this fact is not fully certain 
(Sheppard, 2003). 
6 
Integrin I Known ligand(s) 
I 
Distribution 
~ Collagen I (IV), tenascin C, echovirus I Ubiquitous with greatest expression on basal cells 
-=-J 
Laminins 5, 10& 11 
I 
Ubiquitous with highest I 
degree of expression on I 
basal surface of basal cells I 
a6~4 I Laminins 5, 10& 11 
I 
Expression is restricted to 
I basal surface of basal cells 
a9~1 Tenascin C, osteopontin, *VCAM-l, Ll- Ubiquitous with increased 
CAM, *vWF, FXIII, tissue transglutaminase, expression on basal cells 
fibronectin EIIIA, angiostatin, ADAMS 
I 1,2,3,9 & 15 
~ Fibronectin I Ubiquitous but only after .. Injury 
~ Vitronectin, adenovirus, osteopontin Ubiquitous but mainly expressed on basal cells 
-=:J *LAP of *ITGF-~I, -3, fibronectin, tenascin Ubiquitous expression on C, osteopontin, vitronectin, foot and mouth all cells ( dramatically disease virus increased by injury) 
~ LAP ofTGF-~I, -3, vitronectin I Widespread expression on I basal cells -
Table 1.1. Expression of integrins on bronchial epithelial cells. 
Adapted from review (Sheppard, 2003). 
The remaining integrins expressed by the basal cells, including a5~1, a9~1, av~5 and 
a5 ~6 recognise a wide range of ligands which are not components of the healthy 
bronchial epithelium. Among these are fibronectin, tenascin C and osteopontin, all of 
which are highly abundant at the site of epithelial injury. In addition, vitronectin, the 
principal known ligand for av~5, is a plasma protein and is likely to be induced 
following injury. These integrin receptors play an important role in allowing epithelial 
cells to rapidly detect and respond to changes in the extracellular matrix that accompany 
airway inflammation and injury. 
Other types of epithelial adhesion molecules include CD44, which represent a family of 
adhesion molecules that are widely expressed within the bronchial epithelium. CD44 is 
the principal receptor for the glycosaminoglycan, hyaluronan but may also interact with 
* VCAM, vascular cell adhesion molecule; vWF, von Willebrand factoc LAP. latency-
associated peptide; TGF, transforming growth factor. 
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fibronectin, collagen and some cytokines. It addition to its adhesive role, CD44 is also 
suggested to playa vital part in epithelial repair as well as cell-cell communication 
(Knight and Holgate, 2003). 
1.1.3. The basement membrane 
When considering the integrity of the bronchial epithelium, the role of the basement 
membrane must not be underestimated. Among other functions, it serves a critical role 
in the anchorage of the epithelium; the facilitation of adhesion and migration of the 
epithelial cells; regulation of the phenotype of epithelial cells and it acts as a barrier 
between the surface epithelium and the underlying mesenchyme (Knight et at., 2003). 
Under normal conditions, there is little, or no direct contact between epithelial cells and 
other structural cells, however; there is passive movement of infiltrating inflammatory 
cells and immune cells between the epithelium and underlying compartments via pores 
in the basement membrane (Howat et ai., 2001). The major molecular constituents of 
basement membranes are collagen and laminin. Collagen IV provides a scaffold for the 
other structural macromolecules by forming a network via interactions between 
specialized N- and C-terminal domains. Collagen IV and laminin V are predominant 
constituents of the upper layer of the basement membrane, the lamina densa and the 
lower lamina reticularis consists of types III and V collagen and fibronectin (Knight and 
Holgate, 2003). Laminins are heterotrimeric molecules made up by one a-, one ~- and 
one y- chain. At present, it is recognised that there are five a-chains, three ~-chains and 
three y-chains. These chains combine into at least 14 different laminins (Amin et ai., 
2005). The roles of laminins include the mediation of cell attachment as well as the 
facilitation of cellular proliferation, differentiation and motility (Paulsson, 1992). In the 
basement membrane, fibronectin exists as an insoluble glycoprotein dimer that plays a 
role in cell morphogenesis and differentiation through its effects on adhesion, cell 
shape, and cytoskeletal organisation (Sinkin et ai., 1995). 
1.1.4. The role of the bronchial epithelium in inflammation 
In addition to its role as a protective barrier, the bronchial epithelium is a regulator of 
airway inflammation. The bronchial epithelium secretes a large array of molecules 
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including cytokines, chemokines, lipid mediators, growth factors, reactive oxygen 
species, nitric oxide, matrix proteins and peptide mediators, which demonstrate both 
pro-inflammatory and anti-inflammatory roles in the airways (Polito et al.. 1998). In 
response to environmental triggers such as endotoxin, cigarette smoke, pollutants, 
allergens, bacteria and viruses, the epithelium is activated and a large number of 
mediators are expressed and secreted to a greater extent than normal including: 15-
Hydroxyeicosatetraenoic acid (I5-HETE), prostaglandin E2 (PGE2), fibronectin, 
endothelin, adhesion molecules, extracellular matrix proteins, eotaxin, chemokines, 
including IL-8, cytokines and nitric oxide synthase (NOS) (Vignola et aI., 1998). 
1.1.5. The occurrence of epithelial injury 
The bronchial epithelium is considered a prime target for injury due to its exposure to 
the environment. Inflammation of the epithelium and consequent damage of this 
delicate lining may be brought about by a number of diverse factors. These include 
normal exposure to harmful gases, vapours, fumes, aerosols, organic and inorganic 
particulates, tobacco smoke and diesel exhaust fumes (Mauderley et al., 1987). In 
addition to pollutants, other damaging factors include proteolytic allergens and 
microbes, and certain drugs may be responsible for pulmonary toxicity. 
1.1.5.1. Damaging effects of the environment 
The prevalence of allergic respiratory diseases such as bronchial asthma has increased 
in recent years, particularly in industrialised countries. The rise in asthma may be 
explained by changes in environmental factors including indoor and outdoor air 
pollution. Road traffic with its gaseous and particulate emissions is currently the main 
contributor to air pollution in most urban areas (Cacciola et al., 2002; Edwards et al., 
1994; Wjst et al., 1993). The most abundant air pollutants in urban areas with high 
levels of vehicle traffic are inhalable particulate matter, nitrogen dioxide and ozone 
(D'Amato et al., 2005). 
Particulate matter remains the most serious air pollution constituent and is consistently 
associated with adverse respiratory complications. Particulate matter is a mixture of 
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solid and liquid particles of different size, origin and composition and often contains 
pollen grains and mould spores. Particle size is critical, since inhalable particles 
between 5 and 10 /-lm in aerodynamic diameter are eliminated by mucociliary clearance 
if the bronchial mucosa is intact; however, particles that are less than 2.5 /-lm in 
diameter are able to reach the lower airways and are retained (Churg et al., 1997). It was 
hypothesised that fine particulate matter found in urban areas, by penetrating deep into 
the airways is capable of inducing alveolar inflammation which is responsible for 
variation in blood coagulation and release of mediators involved in acute episodes of 
respiratory disease (Seaton, 1995). Suggestions were made that transition metals in the 
particles initiate damage to the airways by the generation of free radicals. In particular, 
iron appears to be responsible for adverse respiratory problems by the generation of 
hydroxyl radicals (Smith et al., 1997). Particulate matter derives mainly from diesel 
exhaust particulate. Although diesel engines emit considerably less carbon dioxide than 
petrol engines, they emit over 10 times more nitrogen dioxide, aldehydes and inhalable 
particulate matter (D'Amato et al., 2005). Diesel exhaust particles (DEP) are deposited 
on the mucosa of the airways and due to their hydrophobic nature, are able to diffuse 
through cell membranes, bind to a cytosolic receptor complex and modify the growth 
and differentiation of cells (Diaz-Sanchez, 1997). Studies involving healthy subjects 
demonstrated an increase in the number of alveolar macrophages, neutrophils and T 
lymphocytes in BAL following exposure to DEP (Rudell et al., 1996). Following an in 
vitro study investigating the effects of DEP on the interaction of 16HBE 140- cells with 
the cell and matrix microenvironment, Doomaert et al (2003) demonstrated that DEP 
exposure induced: (1) a net dose-dependent decrease in cytoskeleton stiffness through 
actin fibres, (2) an associated, specific reduction of both U3- and ~I-integrin subunits 
extensively expressed on the bronchial epithelial cell surface, (3) a decrease in the level 
of CD44, which is a major bronchial epithelial cell-cell and cell-matrix adhesion 
molecule; and (4) an isolated decrease in matrix metalloproteinase (MMP)-1 expression 
without any change in tissue inhibitor of matrix metalloproteinase (TIMP)-1 or TIMP-2 
tissue inhibitors. Given the results of this study, Doomaert et al propose that DEPs may 
facilitate bronchial epithelial cell detachment in vivo (Doomaert et al., 2003). 
Nitrogen dioxide is abundant in urban and industrialised areas; it is an oxidant pollutant 
and a precursor for photochemical smog. In conjunction with sunlight and 
hydrocarbons, nitrogen dioxide is responsible for the production of ozone (D'Amato et 
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aI., 2005). Vehicle exhaust emISSIOns are the most significant source of outdoor 
nitrogen dioxide amongst power plants and sources that burn fossil fuels. Indoors, the 
most significant exposure to nitrogen dioxide occurs with the use of gas cooking stoves 
and kerosene heaters. Results of an epidemiological study suggest that exposure to 
nitrogen dioxide is associated with increased prevalence of asthma and rhinitis and a 
decrease in lung function in existing asthmatic subjects (de Marco et aI., 2002). 
Ozone is the main component of photochemical oxidants and 'summer smog' and is 
predominant in countries of warmer climate, such as those of the meditteranean; 
however, it is becoming an increasing problem in Europe and indeed in the UK. 
Inhalation of a high concentration of ozone induces deterioration of pulmonary function 
and increased hypersensitivity to both specific and non-specific bronchoconstrictor 
agents and is associated with exacerbation of asthma (Balmes, 1993). Furthermore, it 
was demonstrated that ozone, in conjunction with nitrogen dioxide modulates airway 
inflammation by increasing the release of inflammatory mediators from bronchial 
epithelial cells (Bayram et aI., 2001). Ozone also produces an increase in intracellular 
reactive oxygen species and in epithelial cell permeability, which could in turn lead to 
penetration of inhaled allergens and toxins in the airways, thus inducing an increase in 
the release of inflammatory mediators such as IL-l, IL-6, IL-8 and TNF. In addition, 
ozone has been shown to be detrimental to mucociliary clearance function (Schlesinger 
et al., 1987). Studies have indicated a significant increase in the levels of inflammatory 
mediators such as IL-6, IL-8, granulocyte macrophage colony-stimulating factor (GM-
CSF) and fibronectin in BAL fluid in response to ozone (Balmes et aI., 1997). Further 
studies involving the analysis of BAL fluid have demonstrated an increased abundance 
of neutrophils, and cytokines and evidence of increased epithelial permeability 
following short-term exposure to ozone in subjects with mild asthma compared to 
healthy subjects (Basha et aI., 1994; Scannell et aI., 1996). Ozone inhalation also 
reduces exercise tolerance in non-asthmatic athletes (Adams et aI., 1983). Repeated 
daily, short-term exposure of healthy subjects to ozone has been implicated in the 
deterioration of pulmonary function and inflammatory response (Christian et aI., 1998). 
Pollen grains are the primary carriers of pollen allergens and are implicated in hayfever. 
whereby typical symptoms are designated to the eyes, nose and nasopharynx. However. 
the direct association of pollen with asthma is debatable, since intact pollen grains are 
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typically more than 10 J.!m in diameter and therefore do not enter the lower airways as 
they are eliminated by mucociliary clearance (D'Amato et aI., 2002). However, the 
release of pollen allergens from ruptured pollen grains into the atmosphere could 
provide a plausible explanation for this, as their small size would allow them to 
penetrate the peripheral airways following inhalation. Moreover, pollen allergens could 
combine with other small particles in the atmosphere, such as diesel exhaust particulate, 
which have the potential to penetrate into the airways and be retained (Knox et al.. 
1997). 
1.1.5.2. Damaging side effects of drugs 
Pulmonary drug toxicity is increasingly being diagnosed as a cause of acute and chronic 
lung disease. Numerous agents including noncytotoxic as well as cytotoxic drugs have 
the potential to cause pulmonary toxicity (Rossi et al., 2000). Drug-induced pulmonary 
disease is not a single disorder, but rather, a common clinical problem in which a patient 
without previous pulmonary disease develops respiratory problems, chest X-ray 
changes, deterioration of pulmonary function, and/or histological changes while 
receiving drug therapy. Over 150 drugs have been reported to cause pulmonary disease, 
many of which are thought to provoke a hypersensitivity response. The most common 
histopathological processes underlying pulmonary drug toxicity include pneumonitis 
and fibrosis. 
Patients undergoing chemotherapy are at particular risk of developing respiratory 
complications (Hagarty and Chisholm, 2002). An early inflammatory interstitial 
pneumonitis may be associated with the use of cytotoxic drugs such as methotrexate, 
bleomycin, busulphan, mitomycin, procarbazine and carmustine or non-cytotoxic drugs 
such as amidarone. Late onset pulmonary disease is more common and usually takes the 
form of pulmonary fibrosis. The lung is a common site of infection in cancer patients 
and the immunocompromised patient is vulnerable to a whole host of inhaled 
microorgamsms. 
Case studies have shown that safe medications such as the cyclooxygenase-2 (COX-2) 
inhibitors, which are widely prescribed for pain and arthritis, have been implicated in 
respiratory complications such as dyspnoea, severe pulmonary fibrosis and hypoxemia 
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(Chia et al., 2003). With respect to the prostaglandin pathway, inhibition of COX-2 by 
various drugs such as celecoxib or ibuprofen results in inhibition of PGE2 production. A 
decrease in PGE2 is associated with increased fibroblast proliferation, which contributes 
to the propensity for pUlmonary fibrosis (Bonner et al., 2002). 
1.1.5.3. Direct epithelial damage by house dust mite proteases 
High or persistent exposure to potential allergens, particularly the house dust mite 
antigen presents a major risk factor for the development of allergic airway diseases 
(Platts-Mills et aI., 1992). The Pyroglyphidae family of the common house dust mite is 
associated with human atopic disease. In Europe, the predominating species of 
pyroglyphidae are Dermatophagoides pteronissinus (Der p) (Roche et aI., 1997). 
Allergens from these mites are secreted in their faeces (Tonne I et al., 1983). House dust 
mites are ubiquitous and their growth is greatly influenced by relative humidity and 
temperature. Food sources of mites include skin scales or fungi that grow on them. 
Proteases produced by house dust mites are able to decrease the barrier function of the 
epithelial cell layer. One of the major house dust mite allergens, Der pI has been shown 
to have cysteine protease activity (Chua et aI., 1988; Simpson et aI., 1989) and has been 
associated with epithelial cell desquamation, facilitation of transport of allergens across 
cultured epithelial cell layers and release of cytokines (King et aI., 1998; Robinson et 
aI., 1997; Wan et aI., 2000; Winton et aI., 1998). The proteases may disrupt the tight 
junctions between epithelial cells and lead to the complete desquamation of the 
epithelial cell layer, hence facilitating the passage of allergens across the epithelial 
surface (Wan et aI., 1999). In particular, the occludin and claudin families of tight 
junction adhesion proteins were recognised as targets. Epithelial desquamation and a 
decline in epithelial integrity as a result of protease activity by house dust mite allergens 
leads to further exposure and susceptibility to allergens. Furthermore, it allows allergens 
without proteolytic activity to gain access to the submucosa. Studies demonstrated that 
Der PI activity was partially inhibited by cysteine protease and serine protease 
inhibitors that are naturally produced by the normal human lung, indicating that 
epithelial cells from asthmatic subjects have inherently lower levels of antiproteases to 
neutralise the proteolytic activity of house dust mite allergens (Mattoli, 2001). 
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In response to proteases present in house dust mite extracts, bronchial epithelial cells 
have been shown to increase the release of pro inflammatory cytokines such as IL-6 and 
GM-CSF, the chemokines IL-8 and eotaxin and the platelet derived growth factor 
(PDGF) (Asokananthan et al., 2002; Borger et al., 1999; Kauffman et al., 2000); the 
release of which, are mediated by protease activated receptors (P ARs) that are 
expressed on bronchial epithelial cells (Cocks et al., 1999; D'Andrea et al., 1998). 
There is some evidence that Der PI can trigger sensitisation to the allergen and then 
repeated exposure can lead to an allergic response in sensitised individuals (Sharma et 
al., 2003). One hypothesis is that asthma in house dust mite sensitive patients may be 
caused by recurrent inhalation of live dust mites which reside in the bronchioles for 
long periods of time and in order to provide themselves with a food source, they excrete 
proteolytic enzymes, including Der pI which promote epithelial shedding by releasing 
cells from the basement membrane, allowing the mites to feed on the shed epithelial 
cells. Consequent removal of the intact bronchial epithelium exposes the underlying 
mesenchyme to dust mite proteins and other allergens, triggering sensitisation to these 
proteins. Eventually, repeated infestation provokes an allergic response which manifests 
itself as asthma attacks (van Woerden, 2004). 
1.1.6. Mechanisms of normal bronchial epithelial repair 
Early techniques to denude the airways in vivo in order to study normal epithelial repair 
involved neck surgery. This proved to be difficult and traumatic and resulted in damage 
to the basement membrane as well as local bleeding (Dunnill, 1960; Wilhelm, 1953). 
Thereafter, many studies relied upon bronchial epithelial cell culture (Zahm et al., 
1991). However, a number of limitations were established with in vitro culture 
techniques, including the inability of the cells to differentiate (particularly in submerged 
cultures) and the variability that occurs with cell source and culture conditions. 
Moreover, it was evident that vital components from the airway microcirculation are 
lost in the in vitro model. Progress was therefore made with the development of a novel 
technique to create well-defined epithelial denudation in vivo, without causing bleeding 
or disruption to the basement membrane. This was carried out in the guinea pig, 
whereby an oral catheter was introduced into the tracheal lumen, thus, avoiding surgery 
or any disturbance to the tracheal mucosa, except for the required gentle denudation 
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effect (Erjefalt et aI., 1993; Erjefalt et aI., 1991). Mechanical deepithelialisation using 
an orotracheal steel probe created a wound of 800 /-tm wide. Immediately after epithelial 
removal, secretory, ciliated and presumably basal epithelial cells at the border of the 
denuded zone were shown to dedifferentiate, flatten and migrate rapidly to cover the 
denuded basement membrane (figure 1.2). The ciliated cells were shown to 
dedifferentiate into flat, poorly differentiated epithelial cells that migrate. These cells 
prove to be extremely adaptive since the cilia become internalised as a result of the 
differentiation into flattened cells. During the first few minutes after denudation, the 
speed of migration was determined to be several /-tm per minute, thus, acute repair is 
exceptionally quick compared to that observed in the in vitro model (Erjefalt et aI., 
1997). After 15 minutes, cells started to migrate over the denuded area, and after 8 
hours most of the denuded area was covered by a flat undifferentiated epithelium 
(Erjefalt et aI., 1995). This implies an important role for specific in vivo factors in the 
repair process. It was demonstrated that, almost immediately after removal of the 
epithelium, there was evidence of extravasation and bulk entry of plasma from the 
microcirculation beneath the denuded, but intact basement membrane (Erjefalt et aI., 
1994; Persson et al., 1998). 
It was recognised that plasma exudation created a fibronectin and fibrin rich gel to cover 
the denuded basement membrane and support the migration of the epithelial cells. There 
was also an abundance of leukocytes within the gel suggesting an important role for 
these cells in the rapid repair of the epithelium. It is thought that there are several 
sources for these cells including, the epithelium itself, the tissue underlying the 
basement membrane and the microcirculation. Another important observation was that 
eosinophils were found to be present in the denuded area. Eosinophils are capable of 
producing several factors including TGF-p, PDGF, hepatocyte growth factor (HGF) and 
heparin-binding growth factor (HB-EGF), all of which may promote wound healing. 
The repair process in the guinea pig proved to be extremely rapid with 
reepithelialisation occurring within 8-15 hours. Proliferation of cells in order to 
repopulate the wounded area occurred at approximately 15 hours when cell migration 
was complete. Remarkably, at 30 hours, the new epithelium consisted of 2-3 layers; and 
5 days following denudation, a normal, ciliated epithelium was established (Erjefalt et 
al., 1994). 
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Figure 1.2. Bronchial epithelial repair. Immediately after lllJury, columnar cells 
(lightly shaded) and basal cells (darkly shaded) are involved in a continuous resealing 
of the denuded basement membrane. The repair process is aided by plasma exudation 
(thick arrows) (Erjefalt et al. , 1997). 
In addition to mechanical wounding In VlVO, a second model was employed to 
investigate epithelial repair. This involved the induction of epithelial damage by 
allergen-challenge. Guinea pigs were subjected to non-traumatic, intratracheal mucosal 
super-fusion of ovalbumin, prior to removal of the trachea and examination of tissue 
(Erjefalt et aI. , 1997). A marked increase in neutrophils was demonstrated in tracheal 
lavage fluid and in tissue and was strongly associated with the challenge-induced areas 
of epithelial damage and restitution; eosinophils were elevated in the tracheal lumen 
whereas the surrounding tissues displayed a reversed pattern; gels rich in fibrinogen , 
neutrophils and eosinophils were present in areas of epithelial damage; clusters of free 
eosinophil granules, termed Cfegs, released through lysis of eosinophils; and 
neutrophils displaying long cytoplasmic protrusions were abundant in areas of epithelial 
damage. Taken together, these findings demonstrate the association of inflammation 
with epithelial damage-restitution processes in allergic airways. 
1.1. 7. The role of fibrin in bronchial epithelial repair 
In response to extravascular injury, the extrinsic coagulation cascade is activated (Davie 
et aI. , 1991). In brief, the cascade is initiated by the activity of tissue factor (TF). TF is 
found at extravascular sites only and acts as a receptor for factor VII (FVII), which is 
released from damaged vessels and is able to bind to TF to induce coagulation. TF bind 
and activates FVII, which in tum, activates factor X (FX). Activated factor X (FXa) 
acti vates prothrombin to generate thrombin, which cleaves soluble fibrinogen to 
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insoluble fibrin with subsequent removal of fibrinopeptide A (FPA) and fibrinopeptide 
B (FPB). Finally, the fibrin clot is stabilised by covalent cross-linking by the plasma 
transglutaminase factor XIII (FXIII). The resultant fibrin clot provides a provisional 
matrix for cell migration (figure 1.3). 
Bronchial epithelial injury 
TF + FVIIa 
FX • FXa 
FXIII 
Prothrombin __ ... ~ Thrombin (IIa) • 
, , 
Fibrinogen --... ~ FIBRIN 
•• ___ FXIIIa 
Figure 1.3. A simplified schematic representation of the extrinsic coagulation cascade. 
A fibrin provisional matrix is required for the successful repair of epithelial cells as it 
provides a surface onto which cells are able to migrate, proliferate and restore tissue 
integrity (Laplante et aI., 2001). The importance of fibrin is also demonstrated by the 
use of fibrin-containing sealants in severe wounds to provide a matrix to promote skin 
repair (Singer et al., 1999). A fibrin provisional matrix forms when damage to the blood 
vessel or to the tissue around it occurs. Evidence for a fibrin matrix in the airways came 
from a study of bronchial biopsies comparing asthmatic and normal subjects. Where the 
epithelium was denuded in the symptomatic group of patients a fibrin-like material 
associated with platelets was found where there was no epithelial coverage (Jeffery ef 
al., 1989). When the epithelium becomes damaged the neighbouring cells spread by 
reorganisation of the actin cytoskeleton and the extension of lamellaepodia. 
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When epithelial cells migrate in response to damage they move in sheets. The migration 
is controlled by activation of extracellular signal regulated kinase (ERK) mitogen-
activated protein kinase (MAPK) (Matsubayashi et a!., 2004). The change in structure 
of the cells allows the migration into the denuded area and once migration has occurred, 
the cells then proliferate (Zahm JM et aI, 1991). In vivo studies demonstrated that 
mechanical removal of the epithelial lining in the guinea pig resulted in rapid induction 
of plasma exudation from the underlying microcirculation followed by rapid production 
(within 30 minutes) of a fibrin-rich gel to cover the denuded basement membrane, 
displaying fibronectin-like immunoreactivity (Erjefalt et ai., 1993). In addition to 
providing a matrix to support migration of the epithelial cells, the fibrin clot also 
provides a matrix scaffold for the recruitment of a host of infiltrating leukocytes, 
adhesive plasma-derived proteins, fibronectin, eosinophils and growth factors, all of 
which are believed to promote wound healing. Thus, the role of fibrin in epithelial 
repair appears to be invaluable. However, net fibrin formation is dependent on 
fibrinolysis, the breakdown of the fibrin matrix in addition to fibrinogenesis, the 
formation of a fibrin matrix and it is imperative that the fibrin clot is broken down just 
as efficiently as it was deposited (Clark, 2001). Therefore, once fibrin has performed its 
duty, it must be degraded to soluble fragments as inadequate removal may lead to 
fibrosis. Fibrinolysis occurs in a sequence of distinct steps. Firstly, plasminogen is 
cleaved by plasminogen activators to generate plasmin. This event is primarily mediated 
by tissue-type plasminogen activator (t-PA). Plasmin has the capacity to reorganise and 
disintegrate the fibrin clot, until the final step of dissolution. The D-dimer molecule 
derives from cross-linked fibrin only and is therefore an indication of both fibrin 
formation and its dissolution. 
1.1.8. The role of integrins in wound repair 
Integrins have been shown to play an important role in the spreading, migration and 
proliferation of epithelial cells (Damjanovich et a!., 1992; Montefort et al.. 1993). 
Furthermore, integrins mediate adhesion of epithelial cells to the extracellular matrix 
(Bosman, 1993; Quaranta, 1990). Epithelial cells are known to express integrins for 
collagen, laminin-l and fibronectin found in basement membranes (Pilewski et a!.. 
1997). Moreover. one report demonstrates that one variant of laminin. laminin-2. is 
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expressed in the basement membrane of the airways in subjects with chronic asthma but 
not in non-asthmatic subjects (Altraja et al., 1996). It has been suggested that integrin 
receptors found on bronchial epithelial cells, such as a2~1 and a6~1 bind laminin-2 less 
well than laminin-1 (Brown et al., 1994). Thus, it is possible that expression of matrix 
proteins in asthmatic airways decreases epithelial cell migration and repair over the 
basement membrane. 
The majority of studies involving the participation of integrins in wound repair have 
been confined to squamous epithelia, such as the skin. Cutaneous wounds display a 
provisional matrix that is rich in integrin ligands including fibronectin, osteopontin and 
tenascin (Sheppard, 2003). In response to epithelial injury there is a major change in the 
distribution and expression of epithelial integrins (Figure 1.4). Expression of a2~1, 
a3~1, a5~1, a6~4, av~5, and av~6 is significantly upregulated at the wound edge 
suggesting an important role for these integrins in the regulation of normal wound 
repair. 
White et at (1999) investigated the role of integrins in an in vitro model of wound 
repair. Wounds were created in mono layers of 16HBE 140- cells cultured on either 
collagen IV, laminin-1 or laminin-2 matrix. Wound repair was inhibited by a 
monoclonal antibody to ~l-integrin, furthermore, treatment with a monoclonal antibody 
to a2-, a3- and a6-integrin blocked wound repair in mono layers of cells grown on 
collagen-IV but not laminin-1 or laminin-2. These data demonstrate that ~l-integrin 
subunit function is required to permit migration and spreading of epithelial cells, and 
that a-integrin subunits alone do not mediate migration of epithelial cells grown on 
either laminin-1 or laminin-2. These differences may become important if the matrix 
protein composition of airway basement membrane is altered in disease states such as 
asthma (White et al., 1999). 
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Figure 1.4. Changes in the level and distribution of expression of integrins in the 
airway epithelium in response to injury. Normal, unwounded epithelium is shown on 
the left, and the right hand side represents a theoretical site of denudation. Levels of 
expression are depicted by the size of the text characters corresponding to individual 
integrins (Sheppard, 2003). 
1.1.9. The role of trefoil factor family peptides in bronchial epithelial repair 
Three members of the trefoil factor family peptides (TFF-peptides), known as TFF1, 
TFF2 and TFF3 are found in humans (Hoffmann et al., 1993). These peptides are 
secreted from the lumen of a variety of mucous epithelia. In combination with mucins, 
these peptides are an important constituent of mucous gel. TFF3 is the predominant 
TFF -peptide within the bronchial epithelium. It is primarily released from the 
submucosal gland and to a lesser extent from the goblet cells. It is well established that 
all three TFF-peptides act as motogens during in vitro wound healing assays in various 
gastrointestinal cell lines (Dignass et al., 1994; Marchbank et al., 1998; Wilson et al., 
1997). Using an in vitro model of wound repair involving the culture of a cell line of 
human bronchial epithelial cells, Oertel et al (2001) discovered that all three TFF-
peptides act as motogens, stimulating rapid repair of the wounded epithelium, and in the 
presence of epidermal growth factor (EGF), this effect is synergistic (Oertel et al., 
2001). 
In order to identify a role for TFF3 in differentiation of the human airway surface 
epithelium, Lesimple et al. (2006) analysed the temporal expression pattern of TFF3. 
goblet cells and ciliated cell markers during human airway epithelial regeneration using 
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in vivo humanised xenograft and in vitro air-liquid interface (ALI) culture models. They 
observed that TFF3, goblet cells and ciliated cell markers were expressed in a \veU-
differentiated airway epithelium. The addition of exogenous recombinant human TFF3 
to epithelial cell cultures prior to the initiation of differentiation resulted in no change in 
goblet cells but induced an increase in the number of FOXJ1 positive cells, indicating 
ciliagenesis and an increase in the number of ciliated cells. Furthermore, the effect on 
ciliated cell differentiation was reversed by specific epidermal growth factor receptor 
(EGFR) inhibition indicating that TFF3 is able to induce ciliagenesis and to promote 
airway epithelial ciliated cell differentiation via an EGFR-dependent pathway (Lesimple 
et al., 2006). 
1.1.10. The role of nitric oxide in bronchial epithelial repair 
Nitric oxide (NO), is a gaseous molecule generated endogenously during the conversion 
of the amino acid L-arginine to L-citrulline by a family of NO synthases (NOSs) 
(Ignarro et aI., 1987; Palmer et aI., 1987). Constitutive and inducible forms of NOS, 
abbreviated to cNOS and iNOS respectively, have been described and are both present 
in the airways with divergent effects. iNOS expression is induced by pro inflammatory 
cytokines and releases large quantities of pro inflammatory NO in a sustained manner 
(Morris et aI., 1994). However, calcium-dependent cNOS activity, represented by 
neuronal (nNOS) and endothelial (eNOS) isoforms respectively, leads to the rapid 
release of small amounts ofbronchoprotective NO (Folkerts et aI., 1998). 
The bronchial epithelium continuously produces NO, largely due to constitutive 
expression of iNOS (Xu et aI., 2006). Although iNOS is typically induced under 
conditions of infection or inflammation, constitutive iNOS expression within the airway 
may serve functions in innate host defence (Xu et aI., 2006), or regulation of epithelial 
ion transport (Duszyk, 2001; Hardiman et aI., 2004). Gookin et al (2001) investigated 
the effects of iNOS on porcine ileum in an in vitro study of epithelial repair. They 
demonstrated that iNOS is constitutively expressed by the ileal epithelium and mediates 
a significant increase in endogenous NO synthesis following injury suggesting that NO 
is a key mediator of epithelial repair (Gookin et aI., 2002). Similarly, in an in \'i"o 
model of cutaneous wound repair in mice, Yamasaki et al (1998) demonstrated that 
iNOS is expressed in the healing wound and that inducible production of nitric oxide 
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accelerates the rate of excisional wound repair (Yamasaki et aI., 1998). The protective 
effect of NO in wound repair may be due to the ability of NO to promote cell migration 
in various cell types (Jade ski et aI., 2003; Kawasaki et aI., 2003), however, little is 
known about the importance of iNOS in bronchial epithelial repair. Bove et al (2007) 
investigated the involvement of epithelial iNOS in bronchial epithelial cell migration 
and repair in an in vitro wound model using an exogenous NO donor and stable 
transfection with iNOS in an attempt to mimic continuous NO production by bronchial 
epithelial cells in vivo. They demonstrated that low, physiologically relevant 
concentrations of NO promote bronchial epithelial cell migration and wound repair, 
involving cGMP-dependent expression and activation of MMP-9 (Bove et aI., 2007). 
1.1.11. The role of relaxin in bronchial epithelial repair 
Relaxin, a polypeptide of 6 kDa, belongs to the insulin-like growth factor family and 
was first described in 1926 by Frederick L. Hisaw (Hisaw, 1926). Relaxin was 
originally identified as a pregnancy related hormone and since then, the polypeptide has 
been attributed to a variety of tissues, including the lung (Bani, 1997; Cheah et al., 
1980). Bani et al (1997) demonstrated in an ovalbumin-sensitised guinea pig model of 
asthma, that relaxin has the potential to reduce the severity of respiratory abnormalities. 
This was signified by histological alterations, mast cell degranulation and leukocyte 
infiltration, suggesting an anti-asthmatic property of relaxin (Bani et al., 1997). Results 
of a clinical study revealed that decreased asthma severity correlates with elevated 
levels of relaxin in pregnant women (White et al., 1989). In addition to its involvement 
in the inflammatory process in asthma, relaxin has also been shown to stimulate 
epithelial proliferation in rat cervix (Burger et aI., 1998). Furthermore, relaxin was 
shown to inhibit the proliferation of human lung fibroblasts and to reduce fibrosis in the 
murine lung model (Unemori et aI., 1996). Thus with a combination of enhancing 
proliferation of epithelial cells and inhibiting fibroblast proliferation, relaxin may playa 
vital role in the repair of the injured lung. In addition to these beneficiary effects of 
inhibiting fibrotic events and stimulating epithelial cell growth, relaxin was reported to 
promote effective mucociliary clearance by increasing ciliary beating frequency (CBF). 
This effect was mediated via regulation of cAMP, and protein kinase A (PKA) 
(Sanderson et aI., 1989). Wyatt et al (2002) investigated the effects of relaxin on 
bronchial epithelial cell function using an in vitro model of wound repair and ciliary 
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beating. They demonstrated that relaxin accelerated the rate of wound repair compared 
to control and caused a significant stimulation of CBF in bronchial epithelial cells and 
speculated that relaxin promotes epithelial repair by increasing migration and CBF via 
PKA-dependent mechanisms (Wyatt et aI., 2002). 
1.1.12. The role of glycoproteins in bronchial epithelial repair 
Given that many adhesion molecules and cell surface receptors for growth factors and 
cytokines are glycoproteins, and the fact that epithelial damage results from a loss in 
epithelial integrity, recent interest has been taken in the role of glycoproteins in wound 
repair. Several studies support the theory that oligosaccharide moieties are crucial for 
the function of some of these glycoproteins and that variation in their glycosylation 
pattern often leads to changes in their function (Feige et aI., 1988; Leconte et aI., 1992; 
Rands et aI., 1990). Oligo saccharides on cell surface receptors have roles in cell 
adhesion, migration (Schnaar, 1991) and proliferation (Chammas et aI., 1994). Xiantang 
et al (2000) demonstrated in the guinea pig model that glycosylation profiles in the 
bronchial epithelium change over time following mechanical wounding (Xiantang et al., 
2000). Kauffmann et al (1996) reported an under-representation of carbohydrate 
structure with terminal fucose in asthmatic subjects, with a correlation between this 
deficiency and the severity of the disease. These data suggest that defects in epithelial 
repair in asthmatic subjects may be due, in part, to improper glycosylation of bronchial 
epithelial cells (Kauffmann et aI., 1996). Allahverdian et al. (2006) investigated the role 
of sialyl Lewisx in bronchial epithelial repair. Sialyl Lewisx is a fucose-containing 
tetrasaccharide present on membrane-bound and secreted proteins, is a ligand for E-
cadherin, which is found in tight junctions and thus mediates cell-cell interaction (Lowe 
et aI., 1990; Walz et aI., 1990). Using immunohistochemistry, an increased expression 
of sialyl Lewisx was demonstrated in areas of damaged bronchial epithelium compared 
with the intact regions. Reverse transcriptase polymerase chain reaction (RT-PCR) 
revealed an increase in expression of sialyl Lewisx with time post-wounding. Sialyl 
Lewisx accelerated wound repair and this effect was completely reversed by the use of 
an inhibitory antibody to the carbohydrate, suggesting an essential role for sialyl Lewisx 
in bronchial epithelial repair (Allahverdian et aI., 2006). Prior to this, similar in vitro 
studies revealed that the binding of specific lectins to their carbohydrate residues 
impaired the normal wound repair response in a bronchial epithelial cell model (Adam 
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et al., 2003). These results were in agreement with a study by White et al (2001), 
whereby, the addition of the lectin from triticum vulgaris to repairing cultures of a 
bronchial epithelial cell line resulted in inhibition of wound repair (White et al .. 2001). 
Lectins are naturally occurring glycoconjugate-binding molecules that can be isolated 
from a wide variety of plants and animals and provide selective tools to identify or 
inhibit specific glycoconjugate sites; for example, the lectin from the bacterium 
Pseudomonas aeruginosa has been shown to bind to fucose residues on the bronchial 
epithelium, resulting in the cessation of ciliary beating (Adam et aI., 1997). It is 
suggested that binding through this lectin could be a mechanism of attachment for the 
bacteria, which can then proliferate. The lectin from Triticum vulgaris has also been 
shown to bind to the apical surfaces of bronchial ciliated cells and inhibit ciliary beating 
(Adam et al., 1995). It must be noted that although this lectin would not normally be 
encountered in the airway, it demonstrates the importance of blocking carbohydrate 
residues on physiological processes such as epithelial repair. Li et al. (2000) have 
demonstrated that increased lectin binding is detected in guinea pig tracheal epithelial 
cells following damage, denoting an altered glycoconjugate profile as a result of 
damage, subsequent repair, or both (Li et al., 2000). Collectively, these studies provide 
strong evidence that carbohydrates are involved in epithelial repair of the damaged 
epithelium via surface interactions and that the use of lectins provide a good method of 
probing carbohydrate moieties on the surfaces of cells to establish their role in 
fundamental processes such as bronchial epithelial repair and in the repetitive cycles of 
injury and repair seen in asthma. 
1.2. Asthma 
Asthma is a respiratory disease characterised by recurrent respiratory symptoms, 
reversible variable airway obstruction, airway inflammation and increased airway 
responsiveness (Holloway et aI., 1999). T -helper 2 (Th2)-mediated inflammation is 
considered to provide the basis for altered structure and function that leads to airway 
hyperresponsiveness (AHR) and variable airflow obstruction (Davies et aI., 2002). 
Allergy or 'atopy' describes a disorder involving immunoglobulin E (lgE) antibody 
responses to ubiquitous allergens and is commonly associated with asthma. Although 
atopy is considered an important risk factor for asthma, a recent birth cohort study has 
shown that induction of specific IgE responses and development of childhood asthma 
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are determined by independent factors (Lau et al., 2000). Even though asthma has a 
strong genetic basis, the reason behind the inherent fragility of the asthmatic epithelium 
is not known. The increase in prevalence of this disease over that last 30 years has 
occurred in too short a time for new genetic changes to be responsible. Asthma may 
therefore be considered a complex disease in which the interaction between both genetic 
and environmental factors plays a fundamental role both in the pathogenesis and in the 
development of the disease. It has been hypothesised that atopy/airway inflammation 
and altered structure and function of the bronchial epithelium are parallel but interacting 
factors (Davies et al., 2002; Djukanovic, 2000). For asthma to develop as a chronic 
disease, genetic and environmental factors that drive each of these components are 
required. Fundamental to this is the concept of aberrant signalling between the bronchial 
epithelium and the underlying mesenchyme and persistent activation of the epithelial 
mesenchymal trophic unit (EMTU). 
1.2.1. Inflammation in asthma 
Inflammation is classified by four cardinal signs: calor and rubor (heat and redness, due 
to vasodilatation), tumour (swelling, due to plasma exudation and oedema) and dolor 
(pain, due to sensitisation and activation of sensory nerves). It is now recognised that 
inflammation is also characterised by infiltration with inflammatory cells and that these 
will differ, depending on the inflammatory process (Barnes, 2003). Inflammation is an 
important defence response that protects the body against invasion from 
microorganisms and the effects of harmful, external toxins. The inflammation in allergic 
asthma is characterised by the fact that it is driven by exposure to allergens through IgE-
dependent mechanisms, resulting in infiltration with eosinophils. The inflammatory 
process provides an acute defence against infection. However, in allergic asthma, the 
inflammatory response is activated inappropriately by exposure to allergens, such as 
house dust mite and pollen proteins that induce eosinophilic inflammation that is 
harmful rather than beneficial. Normally, such an inflammatory response would 
eliminate the invading parasite, but in allergic disease, the invading stimulus persists 
and the normally acute inflammatory response becomes converted into a chronic 
inflammation, which may have structural consequences in the bronchial wall (section 
1.2 . ./). The fact that there is a defect in the normal reparative mechanisms of the 
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bronchial epithelium signifies that it remams m an active state and additional 
proinflammatory mediators are released (Holgate et aI., 1999). 
In severe asthma cases, resulting in death from acute asthma attacks, the airway lumen 
is occluded by a mucous plug composed of plasma proteins exuded from airway vessels 
and mucous glycoproteins secreted from surface epithelial cells (Barnes, 2003). The 
airway wall is oedematous and infiltrated with inflammatory cells, including eosinophils 
and lymphocytes. Severe asthma differs to normal allergic asthma in that the 
inflammatory profile is commonly associated with greater involvement of neutrophils 
(Holgate et al., 2006). 
The airway epithelium is invariably shed in a patchy manner and clumps of epithelial 
cells may be found in the airway lumen. Occasionally, there have been opportunities to 
examine the airway of asthmatic patients who die accidentally and similar, although less 
marked changes have been identified (Dunnill, 1960). More recently, it has been 
possible to examine the airways of asthmatic patients by fibre-optic and rigid 
bronchoscopy, bronchial biopsy and BAL. Direct bronchoscopy reveals that the airways 
of asthmatics are often reddened and swollen, indicating acute inflammation. BAL 
analysis has revealed an increase in the numbers of lymphocytes, mast cells and 
eosinophils and evidence for activation of macrophages in comparison with non-
asthmatic controls. Similarly, biopsies have revealed evidence for increased numbers 
and activation of mast cells, macrophages, eosinophils and T-Iymphocytes (Bousquet et 
aI., 2000; Busse et al., 2001). These changes are found even in cases of mild asthma, 
suggesting that asthma is an inflammatory condition of the airways. And the presence of 
neutrophils in severe asthma and exacerbations of asthma is associated with viral and 
bacterial infection. 
1.2.2. Inflammatory mediators 
Many different mediators have been implicated in asthma and they may exert a variety 
of effects on the airways, which could account for all of the pathological features of 
asthma (table 1.2). Because each mediator has many effects, the role of individual 
mediators in the pathophysiology of asthma is not yet clear (Barnes et al.. 1998). 
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Source of 
inflammatory 
mediator 
Injlammatory cells 
Mast cells 
Eosinophils 
Th2 cells 
Basophils 
Platelets 
N eutrophils 
Structural cells 
Epithelial cells 
Endothelial cells 
Smooth muscle cells 
Fibroblasts 
Nerve cells 
Inflammatory 
mediator 
Lipid mediators 
LTC4 
LTD4 
LTE4 
PAF 
Prostaglandins 
J>roinjlammatory 
cytokines 
IL-lP 
IL-4 
IL-5 
IL-6 
IL-9 
IL-13 
TNF-a 
GM-CSF 
Lymphokines 
Regulatory cytokines 
IL-IO 
IL-12 
IL-18 
IFN-y 
Chemokines 
Eotaxin 
Eotaxin-2 
Eotaxin-3 
RANTES 
MCP-l 
MCP-3 
MCP-4 
MDC 
TARC 
Inflammatory effects 
Bronchoconstriction 
Increased AHR 
Recruitment of inflammatory 
cells (e.g. eosinophils) 
Recruitment, differentiation 
and survival of eosinophils 
Survival of mast cells 
Activation of p-Iymphocytes to 
produce IgE 
Amplification of the 
inflammatory response 
Increased AHR 
Activation of proinflammatory 
transcription factors (e.g. NF-
KB and AP-l) 
Inhibition of the inflammatory 
response 
Recruitment of eosinophils 
Recruitment of Th2 cells 
Increased AHR 
Table 1.2. A summary of the key cells and inflammatory mediators that are involved in 
asthma and their effects in the airway. LT, leukotriene; PAF, platelet activating factoc 
NF -KB. nuclear factor-KB; AP-l, activator protein-I; IFN, interferon; MCP. monocyte 
chemoattractant protein; MDC, monocyte derived chemokine: T ARC, thymus and 
activation regulated chemokine. 
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1.2.3. The consequence of epithelial damage in asthma 
In asthma, the bronchial epithelium has increased susceptibility to injury and normal 
repair processes are compromised (Adam et aI., 2003). Epithelial shedding is 
considered a major characteristic feature and pathogenic mechanism in asthma (Erjefalt 
et aI., 1997). The asthmatic epithelium has been shown to display a loss of columnar 
epithelial cells, which leads to a loss of epithelial integrity (Montefort et al., 1992). 
Defective desmosome structure and function has been proposed to lead to a suprabasal 
plane of cleavage. The occurrence of shedding is supported by findings of elevated 
numbers of epithelial cells in sputum and BAL fluid. Studies performed by Naylor in 
the 1960's demonstrated the presence of increased numbers of epithelial cell clusters 
known as 'creola bodies' in the BAL fluids from asthmatics representing significant 
shedding of columnar epithelial cells. Furthermore their numbers were further increased 
during exacerbations of the disease (Naylor, 1962). Evidence for epithelial shedding has 
also been supported by histological observations in bronchial biopsies and autopsies 
(Dunnill, 1960; Laitinen et aI., 1985; Ollerenshaw et aI., 1992). Epithelial shedding 
results in a poorly differentiated' activated' epithelium, consisting largely of cells with a 
basal phenotype (figure 1.5). The lamina reticularis is altered in patients with asthma. 
This region, which is composed of collagen I, collagen III, collagen V, fibronectin and 
tenascin and is situated just below the basement membrane, has an overall thickness of 
3-4 /-lm in non-asthmatic subjects, whereas in asthma this is increased two- to three-fold 
(Davies et aI., 2003). The damaged epithelium gives rise to further penetration of 
environmental agents, resulting in further damage and initiating a 'vicious circle' of 
inflammatory responses (Holgate et aI., 2000). 
The loss of the bronchial epithelium has a number of consequences that appear to be 
critical in the exacerbation of asthma. The loss of the epithelial barrier exposes mucosal 
afferent nerves to non-specific stimulation and allows molecules to penetrate deep into 
the tissues (Vignola AM et aI, 1998); noxious stimuli are harder to remove because the 
epithelium is unable to carry out sufficient mucociliary clearance (Montefort et aI., 
1992); loss of epithelial derived relaxant factors, NO and PGE2, makes smooth muscle 
more susceptible to stimulation (Folkerts et aI., 1998); the epithelium is also a source of 
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enzymes that are able to degrade proinflammatory neuropeptides, thus the absence of 
these enzymes would lead to a neural reflex that causes smooth muscle contraction 
(Vignola AM et aI , 1998); disruption in communication between the epithelium and the 
underlying mesenchymal cells leads to an increased amount of extracellular matrix 
deposition (collagens I, III & V, fibronectin and tenascin) and it stimulates the 
proliferation of (myo )fibroblasts, nerve cells, smooth muscle cells and blood vessels 
(Holgate ST et aI, 2000). 
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Figure 1.5. Histological section through the bronchial epithelium of an asthmatic 
airway. The columnar cells have been shed and the bronchial epithelium is denuded to 
the basement membrane. The section demonstrates airway remodelling, including 
thickening of the lamina reticularis. 
The reason behind the inherent fragility of the asthmatic airway is not fully known. 
Early studies involved endobronchial biopsies and BAL to obtain direct evidence for 
bronchial epithelial damage in asthma. Studies involving bronchial biopsies from 
normal and asthmatic patients demonstrated that the loss in bronchial epithelium was far 
greater in asthmatic subjects. However, the invasive technique of the bronchoscopy 
must not be dismissed. One study showed that there was no difference between the 
asthmatic and normal subjects as both had a large degree of epithelial shedding 
(Ordonez et aI. , 2000). On the contrary, studies have shown that the bronchoscopy 
procedure does result in a certain degree of epithelial shedding in both subj ects; 
however, the asthmatic epithelium is significantly more fragile and appears to be less 
securely attached to the underlying basement membrane, rendering it more susceptible 
to injury by the biopsy instruments (Jeffery et aI. , 1989). One of the first studies by 
Laitinen et al (Laitinen et aI. , 1985) involved the use of the rigid bronchoscope to obtain 
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bronchial biopsies from 8 asthmatics and one non-asthmatic subject. The bronchial 
mucosa showed widespread disruption of the epithelium, loss of cilia and disturbance of 
alignment of cilial basal bodies but analysis of the non-asthmatic biopsy revealed that 
the pseudo stratified epithelium was intact. In order for the results of this study to be 
conclusive, there should perhaps have been a larger sample of non-asthmatic controls. 
however, the results support the argument that epithelial damage in asthma is not due to 
an artefact. There is little doubt that the airway of asthmatics is abnormal or that it has 
increased susceptibility to injury compared with the normal epithelium. Tight junctions 
appear to be a likely target for epithelial injury and since they have a critical role in 
maintaining epithelial integrity, and are crucial to the regulation of cell permeability, 
cleavage of these junctions could be of major significance to the pathogenesis of 
asthma. 
1.2.4. Effects of inflammation in asthma: Ainvay remodelling 
While acute inflammation is a beneficial, non-specific response of tissues to injury that 
generally leads to repair and restoration of normal structure and function, asthma 
represents a chronic inflammatory process of the airways followed by healing, which 
characteristically leads to altered structure, referred to as airway remodelling (Beckett et 
aI., 2003). Airway remodelling encompasses both structural and functional 
consequences of altered airway morphology, however, the factors that initiate and 
perpetuate remodelling are not fully known. 
The presence of AHR implies a fundamental change in the function of airway smooth 
muscle (ASM) that is partially due to changes in ASM structure and its relationship 
with the surrounding airway wall structures. Airflow obstruction and AHR are a result 
of contraction of ASM and hence indicate alterations in smooth muscle function. 
Several studies have reported an increase in the apparent muscle mass within the airway 
wall in patients with severe asthma when compared to control subjects (Ebina et af., 
1993; Kuwano et aI., 1993). Furthermore, necropsy studies suggest that there may be 
two patterns: type 1, whereby there is increased muscle mass associated with 
hyperplasia that is restricted to the large central airways; and type 2 which describes the 
presence of mild hyperplasia in the large airways, but the detection of hypertrophy 
throughout the bronchial tree, especially in the small peripheral airways. Subjects with 
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fatal asthma have been reported to exhibit greater degrees of luminal narrowing and 
ASM mass when compared to patients with asthma whom experienced a non-asthma 
related death (Ebina et aI., 1993). The majority of the available evidence supports ASM 
hyperplasia as an important mechanism leading to increased ASM mass in the asthmatic 
airway. Growth factors that bind to receptor tyrosine kinases and ligands that bind to 
heterotrimeric G protein-coupled receptors have been shown to have the capacity to 
induce ASM hyperplasia. These agents might be produced by resident airway cells, 
secreted by infiltrating inflammatory cells, or secreted by ASM itself, which could then 
act in an autocrine manner (Howarth et aI., 2004). Total airways resistance and non-
specific AHR are increased in asthma. Potential mechanisms for the presumed ASM 
hypercontractility could include changes in the balance of contractile-relaxant receptors, 
changes in signalling, or changes in the actin-myosin force transduction apparatus. 
Histopathologic studies have demonstrated that the entirety of the airway wall, i.e. the 
mucosa, submucosa (including ASM) and adventitia is thickened; therefore it is likely 
that a greater force would need to be generated by the ASM contractile apparatus in the 
asthmatic airway (Jeffery, 2001). It has been reported that asthmatic ASM has an 
increased maximal velocity of muscle shortening attributable to an increase in the 
activity of myosin light chain kinase, which might explain the reduced bronchodilating 
effect of inspiration in asthmatics. This has been suggested as one of the main causes of 
AHR (Jiang et aI., 1992). Stimulated ASM cells have been shown to be capable of 
producing a wide range of inflammatory mediators that might contribute to airway 
remodelling (Howarth et aI., 2004; Panettieri, 2003). 
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Figure 1.6. A diagrammatic representation of the normal (top) and asthmatic (bottom) 
airways. The asthmatic airway demonstrates smooth muscle hyperplasia, subepithelial 
fibrosis, goblet cell hyperplasia and angiogenesis (Fahy et al., 2000). 
Thickening of the lamina reticularis below the true basement membrane is a 
characteristic, early feature of the asthmatic bronchus and is termed subepithelial 
fibrosis or sub-basement membrane thickening. An approximate two-fold increase in 
sub-membrane thickness has been reported in asthmatics of varying severity compared 
to non-asthmatic controls (Hoshino et aI., 1998). This thickening is associated with 
deposition of collagen I, collagen III and fibronectin (Roche et aI. , 1989). The 
predominant source of these matrix molecules is thought to be the subepithelial 
myofibroblast, which is a -smooth muscle actin positive and fom1s a specialised 
network beneath the lamina reticularis. Studies have demonstrated a correlation between 
the thickness of the lamina reticularis and the number of subepithelial myofibroblasts 
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(Brewster et al., 1990). Furthermore, several profibrotic cytokines, including TGF-p, 
and PDGF, and mediators such as endothelin-1 can be produced by epithelial cells and 
macrophages in the inflamed airway (Redington, 2000). MMPs are key regulators of the 
components of matrix and are involved in the degradation of collagen (Kelly et aI., 
2003). TIMPs are endogenously expressed and exist in equilibrium with the 
metalloproteinases in the airway wall. An imbalance between these agents, favouring 
TIMPs could result in increased matrix deposition and subsequent airway remodelling 
(Vignola et al., 2004). IL-13 is considered a major cytokine involved in inflammation 
and remodelling and many of the effects of IL-13 appear to be mediated by matrix 
metalloproteinases. In one study, the effects of IL-13 over-expression were found to be 
mediated by TGF -p, whose activation was MMP-9-dependent (Lee et aI., 2001). 
Notably, ADAM33 is a recently identified member of a family of genes encoding a sub-
group of the zinc-dependent metalloproteinase superfamily termed the A Disintegrin 
And Metalloproteinase (ADAM) family and recent epidemiological studies have 
identified a role for ADAM33 as a susceptibility gene for progressive and severe asthma 
(Holgate et aI., 2006). 
An increase in the number and size of blood vessels has been reported in biopsy 
samples from airways in asthmatic subjects compared with controls (Li et aI., 1997). In 
fatal asthma, there is an increase in the number and size of large blood vessels and a 
reduction in the number and size of small vessels (Carroll et al., 1997). 
The mucosal glands in the segmental bronchi of asthmatics are considerably enlarged, 
with a volume twice that of non-asthmatic subjects (Dunnill, 1960; Dunnill et al., 1969). 
Mucous production is an important feature of asthma and contributes substantially to 
morbidity and mortality, especially in severe asthma. Epithelial goblet cell hyperplasia. 
has been consistently demonstrated in asthma, irrespective of whether the disease is 
mild or severe. Similarly, enlargement and hyperplasia of mucous glands found in the 
subepithelium is also common in asthma (Pascual et al., 2005). In addition to mucous-
producing cells, the epithelium also consists of basal cells and pseudostratified cells that 
bear cilia. Basal cells are important for epithelial regeneration and hence its integrity. 
Ciliated cells move mucous in a general cephalad direction, providing an important 
mechanism for clearing secreted mucous, particulate matter, allergen particles and 
infectious agents. In a culture model of primary epithelial cells, IL-13 was shown to 
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increase the proportion of secretory cells, thereby altering epithelial cell morphology 
and reduce the number of ciliated epithelial cells (Laoukili et al., 2001). 
Asthmatic airway biopsies, autopsy studies and animal models all show that the 
epithelium is remodelled in asthma. Bronchial epithelial shedding is a characteristic 
feature of asthma and may be important in contributing to AHR. Epithelial cells appear 
to be an important source of mediators in allergic inflammation and release of these 
mediators may be stimulated by various inhaled stimuli, resulting in an increased 
inflammatory response. Epithelial cells may also release growth factors that stimulate 
structural changes. in the airways, including fibrosis, angiogenesis and proliferation of 
airway smooth muscle. These responses may be seen as an attempt to repair the damage 
caused by chronic inflammation (Holgate et al., 2000). Following injury, the epithelium 
responds by creating the necessary stimuli to recruit the underlying mesenchyme to 
participate in the repair process. This is mediated through the release of a range of 
growth factors, which together promote the remodelling and vasculogenesis that is 
typical in the asthmatic airways. However, in severe cases, the airways exhibit 
characteristics of a chronic wound with evidence of ongoing epithelial injury and repair. 
(Holgate et al., 2006). 
The historical perspective was that epithelial damage in asthma was induced by the 
release of cytotoxic factors such as highly basic proteins and reactive oxygen species 
from activated leukocytes (Erjefalt et al., 1997; Filley et al., 1982; Frigas et al., 1991; 
Mendis et al., 1990; Venaille et al., 1995; Yukawa et al., 1990). However, the currently 
favoured model describes a defective repair response or recurrent injury that leads to a 
self-perpetuating cycle of chronic inflammation, modulated by various cytokines and 
growth factors. Recent opinions are that exaggerated inflammation and remodelling in 
the airways are a consequence of abnormal injury and repair responses arising from the 
susceptibility of the bronchial epithelium to components of the inhaled environment 
(Davies et al., 2002). This represents a novel concept because up until now, 
inflammation has been considered the cause of injury and remodelling. 
34 
I Environmenta l trigger I 
\ 
1--'""'---. Intact 
epithelium 
/ .. . ~- ". ~. 
CHRONIC ~... .; ~:"" .~.> 
~FLAMM.A TION neutrophil eosinophfl 
• Tee" 
.---------------.. --~ GRO~H 
AIRWAY FACTORS AND 
HYPERRESPONSIVENESS CYTOKINES 
AIRWAY NARROWING I 
ASTHMA SYMPTOMS ... 
t 
MYOFIBROBLAST 
ACTIVATION 
AIRWAY REMODELLING 
epithelium 
Figure 1. 7. A diagrammatic model for the interaction between environmental agents 
and a susceptible epithelium as a trigger for persistent airway inflammation and 
remodelling in asthma. Susceptibility to environmental oxidants causes epithelial 
damage, which triggers an injury-repair response involving release of mediators that 
promote inflammation and tissue repair. However, the release of endogenous oxidants 
by inflammatory cells causes further injury to the susceptible epithelium, resulting in a 
chronic state of tissue damage and thus, persistent inflammation and tissue remodelling 
(Holgate et al. , 2000). 
In asthma, the bronchial epithelium is considered to be defective (Holtzman et aI. , 
2002) and there is accumulating evidence to support this. It has been demonstrated that 
the transcription factor STATI is constitutively activated in epithelial cells from 
asthmatic subjects compared with non-asthmatic controls. STATI is a key transcription 
factor in interferon (lFN)-mediated signalling, which is an important mechanism in viral 
airway infection, a known cause of asthma exacerbation. Epithelial STATl levels 
correlated with intercellular adhesion molecule 1 expression, which in tum correlated 
with T -lymphocyte accumulation in asthmatic tissue (Sampath et aI. , 1999). 
The bronchial epithelium in asthma has been shown to be unable to effectively defend 
the lung against human rhinovirus, which is normally considered an innocuous virus. 
The normal response of the epitheliLUl1 to vi ral infection is the induction of primary 
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IFNs, such as IFN-B, through activation of the Toll-like receptor 3, which recognises 
double-stranded viral RNA, leading to apoptosis and subsequent elimination of the 
infected cell and thus, limitation of viral infection and release. However, in asthmatic 
epithelial cells, a major defect in this pathway leads to enhanced viral replication and 
virus-induced cell toxicity. Furthermore, decreased expression of IFN-B and IFN-y have 
been reported in asthma (Holgate, 2006). An alternative explanation is that tight 
junctions are defective in asthma, resulting in increased susceptibility to infection. 
When epithelial surfaces are injured, the normal response is upregulation of receptor 
expression, specifically of members of the EGFR family that are responsible for 
proliferation and repair. Biopsies from patients with asthma demonstrate a marked 
increase in the expression of the EGFR, whose expression increases in proportion to 
disease severity and chronicity (Ami shima et al., 1998; Puddicombe et al., 2000). 
EGFR immunostaining in severe asthma is demonstrated throughout the repairing 
epithelium and also on the luminal surface, a feature not observed in the normal 
epithelium. However, contrary to expectations, the high level of EGFR expression in the 
asthmatic epithelium is not paralleled by an increase in markers of cell proliferation 
(Demoly et al., 1994). In mild asthma, there is also marked cytoplasmic staining of 
columnar cells for p21 waf, indicating an attempt to protect the surface epithelial cells 
from premature program cell death by inhibiting the cell cycle at the G 1 phase. 
However, in severe disease, p21 waf is found throughout the epithelium and specifically 
at a nuclear location, where it impairs proliferation by arresting cells at the G 1 phase of 
the cell cycle (Puddicombe et al., 2003). This negative regulator of G 1 cyclins can be 
induced by the antiproliferative TGF -B 1 and TGF -B2, the levels of which are increased 
in patients with asthma (Redington et al., 1997). In addition, the EGFR might contribute 
directly to inflammation because EGF and TGF-a are known to elicit IL-8 expression 
and release from bronchial epithelial cells. Since the EGFR is over-expressed in the 
morphologically intact epithelium in severe asthma and strongly correlates with IL-8 
expression, this may contribute to airway neutrophilia in patients with severe asthma 
(Hamilton et al., 2003). 
Taken together, these findings lead to the suggestion that in chronic asthma the airway 
epithelium is impaired in its ability to restitute itself after injury and, as a consequence. 
enters into a chronic wound response. In order to understand the mechanisms involved 
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in the repair of the asthmatic epithelium in response to injury, it IS imperative to 
determine the mechanisms of normal bronchial epithelial repair. 
1.3. Hypothesis of study 
The formation of fibrin to support bronchial epithelial repair in vitro is a result of the 
local release of coagulation factors from bronchial epithelial cells and is independent of 
plasma proteins. 
1.3.1. Aims of study 
The initial aim of the study was to establish whether the bronchial epithelium had the 
capacity to generate coagulation factors in the absence of plasma. Subsequent aims were 
to demonstrate the involvement of locally expressed coagulation factors in wound 
repair. Finally, it was imperative to identify the mechanisms involved in wound repair 
by incorporating pharmacological agents that manipulate the wound repair process. 
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2. Materials and general cell culture methods 
2.1. Materials 
2.1.1. Cell culture 
Cells of the human bronchial epithelial cell line, 16HBE 140-, were a gift from Dr 
Dieter Gruenert (University of Vermont, Burlington, VT). 
Foetal bovine serum (FBS) heat inactivated, sterile filtered; 100X Insulin-transferrin-
sodium selenite (ITS) media supplement, Tween-20, Triton-Xl 00, collagen IV and 
albumin from bovine serum (BSA) were from Sigma (Dorset, UK). 
Minimal essential medium (MEM) (IX) containing Earle's Salts and L-glutamine, lOX 
phosphate-buffered saline (PBS) without calcium and magnesium, lOX trypsin-EDTA 
(0.5% (w/y ) trypsin, 5.3mM EDTA), antibiotic/antimycotic (penicillin G 100 U/ml, 
streptomycin 100 /-lg/ml, amphotericin B 25 /-lg/ml), L-glutamine, HBSS and 0.4% 
trypan blue, were from Invitrogen Ltd (Paisley, UK). 
Normal human bronchial epithelial (NHBE) cells in bronchial epithelial growth medium 
(BEGM) with retinoic acid «1 /-lg/ml) and BEGM BulletKit® were from Cambrex 
BioScience W okingham Ltd (W okingham, UK). 
Nunc 6-well plates and Nunc Maxisorp® 96-well plates were from Fisher Scientific 
(Leicestershire, UK). 
24-well plates and 75 cm2 tissue culture flasks were from Triple Red Laboratory 
Technology (Buckinghamshire, UK). 
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2.1.2. General materials 
Acetic acid, ethanol, hydrochloric acid, methanol, sodium hydroxide, sulphuric acid, 
sodium chloride, sodium dodecylsulphate (SDS) and Tris were from Fisher Scientific 
(Leicestershire, UK). 
Biotinylated molecular weight ladder, HEPES, HGF, hydrogen peroxide, lactate 
dehydrogenase (LDH) kit: Tox-7, mouse IgG, rabbit IgG, sheep IgG, neutrophil 
elastase, tetramethylbenzidine (TMB), indomethacin, PGE2, DMSO, mitomycin C, 
sodium deoxycholate, ethidium bromide, sodium butyrate and trichostatin A were from 
Sigma (Dorset, UK). 
Factor Xa, DTSSP and protease cocktail inhibitor were from Calbiochem (supplied by 
Merck Chemicals Ltd; Nottingham, UK). 
Goat anti-mouse F(ab') fragments, biotinylated rabbit anti-mouse F(ab')2 fragments and 
streptavidin-biotin complex (StreptABComplex) were from Dako (Cambridgeshire, 
UK). 
Goat anti-mouse Alexa Fluor 488 F(ab')2 fragment and donkey anti-sheep Alexa Fluor 
594 were from Molecular Probes (supplied by Invitrogen Ltd; Paisley, UK). 
Human EGF, KGF, TGF-B1, HGF and PGE2 immunoassays were from R&D Systems 
(Oxfordshire, UK). 
IL-8 ELISA kit was from Sanquin Reagents (Amsterdam, The Netherlands). 
Loading dye, dNTP, random hexamer, 5X concentrated first strand buffer, RNaseOUT 
inhibitor, Superscript II reverse transcriptase, One-Step RT-PCR system, 100 base pair 
ladder and DTT were from Invitrogen Ltd (Paisley, UK). 
Mastermix was from Qiagen (West Sussex, UK). 
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Monoclonal mouse anti-human TF antibody, mouse anti-human D-dimer antibody and 
high molecular weight (HMW) D-dimer standard were from American Diagnostica 
(Stamford, CT, USA (supplied by Axis-shield, Dundee, UK)). 
Nitrocellulose membrane was from Bio-Rad Laboratories (Hertfordshire, UK). 
Normal reference plasma was from Alpha Laboratories Ltd (Hampshire, UK). 
P AR-l peptide agonist TFRIFD-amide, P AR-l control peptide agonist FTRIFD-amide, 
P AR-2 peptide agonist SLIGKVD-amide and P AR-2 control peptide agonist 
LSIGKVD-amide were from Peptide Protein Research Ltd (Hampshire, UK). 
Paraformaldehyde, agarose and EDT A were from BDH (Dorset, UK). 
Primer sets for 18SRNA, p-actin, TF, FVII, FGC, FX, FXIII, PAR-I, PAR-2, EP-l, EP-
2, EP-3 and EP-4 were from Sigma-Genosys Ltd (Cambridge, UK). 
Prothromplex TIM-4 was from Baxter Healthcare (Norfolk, UK). 
RNAgents® denaturing solution, sodium acetate, phenol:chloroform:isoamyl alcohol, 
isopropanol and nuclease-free water were from Promega (Hampshire, UK). 
S-2222 (Factor X substrate) was from Chromogenix (Milan, Italy (Supplied by 
Quadratech; Surrey, UK)). 
Sheep anti-human FXIIIA-HRP IgG, sheep anti-human fibrinopeptide A, affinity 
purified, IgG and sheep anti-human fibrinopeptide A-HRP IgG were from Affinity 
Biologicals (Ontario, Canada (supplied by Quadratech; Surrey, UK)). 
SuperSignal® West Pico Substrate and Seize® X protein A immunoprecipitation kit were 
from Pierce (Supplied by Perbio; Northumberland, UK). 
Thrombin inhibitor UK-156,406 and FXa inhibitors UK-220,047 and PD-031 were 
from Pfizer Global R&D (Kent, UK). 
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Vectashield mounting medium was from Vector Laboratories Ltd (Peterborough, UK). 
2.2. General cell culture methods 
2.2.1. Cell culture of 16HBE 140- cells 
All cell culture work was carried out in a class II laminar flow tissue culture hood. The 
16HBE 140- bronchial epithelial cell line was a kind gift from Dr Dieter Gruenert 
(University of Vermont, Burlington, VT). Stock cultures were originally seeded at a 
density of 3500 cells/cm2 in 75 cm2 tissue culture grade flasks and routinely maintained 
in full minimal essential media (MEM) with Earle's salts, supplemented with 10% (Iv) 
heat inactivated FBS, 2 mM L-glutamine and 100 Ulml antibioticlantimycotic at 37°C 
in a 5% CO2 incubator. 
At confluence, cells were washed in IX PBS pH 7.2, without calcium and magnesium. 
Cells were passaged by adding 3 ml of IX trypsin-EDTA (derived from lOX stock 
solution containing: 0.5% trypsin, 5.3 mM EDTA) to each flask for 10 minutes at 37°C. 
As a consequence, the cells became rounded and subsequently lifted from the flask into 
suspension. Once lifted, 2 ml of FBS was added to each flask of cells to neutralise 
trypsin activity. The cell suspension was centrifuged for 7 minutes at 670 x g (ALC 
PK120 Centrifuge, Winchester Virginia, USA) to create a cell pellet. The supernatant 
was discarded and the pellet resuspended in 1 ml full MEM. For determination of cell 
number, the cell suspension was diluted 1 in 10 with trypan blue and 10 /-ll was added to 
each grid of a haemocytometer. Cells were counted within the 5 x 5 grid and an average 
cell count was calculated for the two grids. The number of cells required for the 
appropriate cell seeding density was then calculated (figure 2.1). 
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No. cells/ml X 10 * X 104 ** Cell count 
* Dilution factor of cells in trypan blue 
** Dilution factor ofhaemocytometer 
Figure 2.1. The Equation used to calculate the number of cells required for cell 
seeding. 
Cells were seeded into 24-well plates at 100,000 cells per well and cultured for 48 h 
until fully confluent. At each passage, any remaining cells were transferred into new 
culture flasks at a seeding density of 3500 cells/cm2 to allow a continuous supply. At 
confluence, cells were washed by adding 500 J.ll of IX PBS (without calcium and 
magnesium) to each well and quiesced for 16 h in 250 J.lI per well of serum-free MEM-
ITS (basal MEM containing 2 mM L-glutamine and 100 U/ml antibiotic/antimycotic, 
supplemented with 1 % (/v) Insulin Transferrin Selenium solution). Immediately prior to 
each experiment, cells were washed by adding 500 J.lI of IX PBS to each well and the 
serum-free MEM-ITS was refreshed by adding 250 J.lI to each well. 
2.2.2. Collagen coating of flasks for NHBE cell culture 
5 ml of 0.1 mg/ml collagen IV in 3% (/v) acetic acid was added to each flask and 
incubated for one hour at room temperature. Excess collagen IV was removed and 
flasks were washed with 5 ml of IX Hanks' balanced salt solution (HBSS) (with phenol 
red and without calcium and magnesium). The wash step was repeated 3 times, until 
there was no further colour change of the phenol red, indicating complete removal of 
the acetic acid. 
2.2.3. Cell culture of NHBE cells 
NHBE cells in BEGM with retinoic acid «1 J.lg/ml) were purchased from Cambrex Bio 
Science Wokingham, LTD (Wokingham, UK). Stock cultures were originally seeded at 
a density of 3500 cells/cm2 on 10 J.lg/cm2 collagen IV -coated 75cm
2 
flasks and were 
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cultured in BEGM (BulletKit®: Cambrex, Wokingham, UK), supplemented with 1 % 
C/y) heat inactivated FBS at 37°C in a 5% CO2 incubator. At confluence, cells were 
washed in IX PBS pH 7.2 without calcium and magnesium. Cells were passaged by 
adding 3 ml of 0.5X trypsin-EDTA (derived from lOX stock solution containing: 0.5% 
trypsin, 5.3 mM EDTA) to each flask for 10 minutes at 37°C. As a consequence, the 
cells became rounded and subsequently lifted from the flask into suspension. Once 
lifted, 2 ml of FBS was added to each flask of cells to neutralise trypsin activity. The 
cell suspension was centrifuged for 7 minutes at 670 x g (ALC PK120 Centrifuge, 
Winchester Virginia, USA) to create a cell pellet. The supernatant was discarded and 
the pellet resuspended in 1 ml full BEGM. For determination of cell number, the cell 
suspension was diluted 1 in 10 with trypan blue and 10 !J.I was added to each grid of a 
haemocytometer. Cells were counted within the 5 x 5 grid and an average cell count was 
calculated between the two grids. The number of cells required for the appropriate cell 
seeding density was then calculated (figure 2.1). 
Cells were seeded into 10 !J.g/cm2 collagen IV -coated 24-well plates at 100,000 cells per 
well and cultured for 5 days until fully confluent. At each passage, any remaining cells 
were transferred into new collagen IV -coated culture flasks to allow a continuous 
supply. NHBE cells were used with a maximum of 3 passages. At confluence, cells 
were washed by adding 500 !J.I of IX PBS (without calcium and magnesium) to each 
well and quiesced for 16 hours in 250 !J.I of serum-free BEGM-ITS (basal BEGM 
containing 2 mM L-glutamine and 100 Ulml antibioticlantimycotic, supplemented with 
1 % C/y) ITS). Immediately prior to each experiment, cells were washed by adding 500 
!J.I of IX PBS to each well and BEGM-ITS was refreshed by adding 250 !J.I to each well. 
2.2.4. Harvesting of cells and cell culture supernatants 
Following mechanical wounding and subsequent incubation at 37°C, supernatants and 
cells were harvested and either analysed immediately or stored for future use. 
Supernatants were removed from cells into 1.5 ml centrifuge tubes and centrifuged at 
900 x g for 10 minutes at 4°C (ALC PM140R Centrifuge, Winchester Virginia, USA) to 
remove cell debris. The resultant, cleared supernatants were transferred into new 1.5 ml 
centrifuge tubes and stored at -80°C if not required immediately. The cells in the plate 
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were washed with 500 /-11 per well of ice-cold, IX PBS, and 250 /-11 of ice-cold lysis 
buffer (lOmM Tris-HCI pH 7.4, O.lmM CaCh, 0.1% (W/y) BSA and 1% ely) Triton-X-
100) was added to each well. Once the cells had lifted, the cell lysates were extracted 
from the plate into 1.5 ml centrifuge tubes and centrifuged at 900 x g for 10 minutes at 
4°C (ALC PM140R Centrifuge, Winchester Virginia, USA) to remove cell debris. The 
resultant, cleared celllysates were transferred into new 1.5 ml tubes and stored at -80°C 
if not required immediately. 
2.2.5. Mechanical wounding 
To induce mechanical damage, 16HBE 140- cells were grown to confluence in serum-
free MEM-ITS on 24-well plates and were mechanically wounded by scraping off a line 
of cells in a cross-hatch pattern using a P2 Gilson pipette tip as shown below: 
No wound W2 W4 W8 
r ............ 
L r-.. 
\ 
I 
/ 
" / 
Figure 2.2. Schematic representation of mechanical wounding. Black circle represents 
one cell of a 24-well plate; straight line denotes one mechanical wound, as described 
above. W2 = 2 mechanical wounds, W 4 = 4 mechanical wounds and W8 = 8 
mechanical wounds. Width of mechanical wound immediately after wounding measures 
approximately 0.5 mm. Diagram not to scale. 
2.2.6. Data analysis 
In all cases, statistical analysis was performed using a two-tailed unpaired Student's (-
test using GraphPad InStat software and are represented as the mean ± SEM. A two-
tailed p value of less than 0.05 was considered statistically significant. 
Figures representing n=3 are indicative of the mean of duplicate conditions within the 
experiment, performed on three separate occasions. 
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3. Coagulation and growth factor expression in response to wounding and role of 
inflammatory mediators 
3.1. Introduction 
3.1.1. Role of plasma derived coagulation factors in bronchial epithelial repair 
Many investigations have demonstrated that following the removal of the guinea pig 
bronchial epithelium in vivo, there is a rapid process of repair, whereby epithelial cells 
at the edge of the wound flatten and migrate to cover the denuded area, then proliferate 
and differentiate (Erjefalt et al., 1997; Persson et al., 1998). It has been suggested that a 
fibrin gel matrix is required to facilitate cell migration (Erjefalt et al., 1994). In the 
airways, there is a profuse network of microvessels directly beneath the pseudo stratified 
epithelium. Following epithelial damage and subsequent shedding, to the point of 
denudation, several tissue responses are initiated in order to minimise the harmful 
effects of an impaired epithelial barrier and ultimately restore the integrity of the 
bronchial epithelium. The mucosal microcirculation constitutes an important repair- and 
defence-promoting component during the initial repair phases. In guinea pig models of 
epithelial damage, interendothelial permeability pores are formed in subepithelial 
venules within minutes of epithelial shedding (Erjefalt et al., 1996); and a pronounced, 
local plasma exudation response is initiated (Erjefalt et al., 1994). Extravasated bulk 
plasma immediately enters the airway lumen and a gel-like network of fibrin and 
fibronectin fibres and other associated plasma proteins, is formed on the denuded 
basement membrane (Erjefalt et al., 1994). In vivo experiments involving wholemount 
three-dimensional morphology have demonstrated the presence of small round holes 
along short stretches of venules of the airway mucosa, correlating to increased vascular 
permeability (Erjefalt et al., 1996). Subsequently, it has been shown that non-sieved 
plasma flows through the gaps into extravascular sites by a hydrostatic pressure gradient 
(Grega et al., 1988). During the first 10-20 seconds after epithelial damage, the lamina 
propria is flooded with the plasma exudate, which then passes freely through the 
epithelial basement membrane and up between epithelial cells. Interestingly, the bulk 
plasma exudate has the capacity to flow through the tight junctions of the intact 
bronchial epithelium and into the airway lumen (Persson et al., 1986). One of the 
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predominant roles of the plasma exudate is to provide the coagulation factors that will 
form the fibrin gel matrix that is required for bronchial epithelial repair. The formation 
of fibrin, termed fibrinogenesis ultimately results from the initiation of the extrinsic 
coagulation cascade. 
3.1.2. The extrinsic coagUlation cascade 
The extrinsic coagulation cascade is initiated upon damage to the bronchial epithelium. 
This occurs by contact of plasma proteins with active TF at sites of extravascular injury. 
TF acts as a receptor for FVII, which is converted to active FVIIa by cleavage of a 
single peptide bond (figure 3.1) (Morrissey, 2001). This complex then activates FX 
which, together with FVa, is one of the main components of the prothrombinase 
complex, responsible for the conversion of prothrombin to active thrombin (Dabbagh et 
al., 1998). Thrombin in tum converts soluble fibrinogen to insoluble fibrin. Thrombin 
also activates FXIII to FXIIIa, which stabilises the fibrin clot in the presence of calcium 
via covalent cross-links between fibrin molecules and via cross-linking of plasmin 
inhibitor to fibrin (Sidelmann et al., 2000). The presence of fibrin at sites of injury is 
tightly regulated by the actions of initiators and inhibitors of the coagulation cascade, in 
addition to the fibrinolytic pathway, which is responsible for the degradation of the clot. 
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Figure 3.1. A schematic diagram of the processes of fibrin formation (fibrinogenesis) 
and fibrin degradation (fibrinolysis). Adapted from the review by Sidelmann et a1. 
(2000). 
3.1.3. Mediators of fibrinogenesis 
3.1.3.1. TF 
TF is an integral membrane glycoprotein of 295 amino acids, containing four N-linked 
glycosylation sites in an organised extracellular sequence of: 219 amino acids, a 23 
amino acid hydrophobic transmembrane region and a 21 amino acid cytoplasmic tail 
(Bazan, 1990). The extracellular domain is made up of two fibronectin type III domains, 
TF 1 and TF2 and has been shown to function as the receptor for FVII (Ruf et aI. , 1994). 
TF is a lipoprotein and requires both a protein and a phospholipid portion fo r fu ll 
procoagulant activity (Hvatum et aI. , 1969; Nemerson, 1968). Membrane anchoring of 
TF is essential to support full procoagulant activity by FVIIa (Paborsky et aI. , 1991 ). TF 
has been classified on the basis of distant sequence homology as a member of the 
cytokine receptor fami ly (Bazan, 1990). The mobility of TF on SDS gels suggests a 
molecular weight of 47,000 Da (Bjorklid et aI. , 1973 ; Broze et al. , 1985). TF is 
expressed at sites that are physically separated from the circulating blood . This 
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' envelope' pattern of TF expreSSIOn signifies that its activation may only occur in 
response to vascular injury. It is believed that TF is constitutively expressed by cells 
that playa vital role in repair following injury (Osterud, 1997). 
Tissue 
FVII 
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~ 
Tissue 
Factor---· 
FYIIa 
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Tissue 
Factor ~ 
FYIIa 
/ 
Figure 3.2. Formation of the TF:FVIIa:FXa complex to initiate the coagulation 
cascade. Transmembranous TF acts as a receptor for circulating FVII, which in turn, 
binds and activates FX. This complex can also activate PARs and induce signalling 
through the cytoplasmic domain of TF. Once activated, FXa is released and forms a 
prothrombinase complex to initiate fibrin formation. FXa may also activate PARs. 
The concept of TF encryption has been widely studied in cell culture and may represent 
a physiological mechanism for controlling expression of cellular coagulant activity in 
vivo. TF encryption describes the post-translational suppression of TF procoagulant 
activity on the cell surface. An intact endothelium is crucial in the prevention of TF-
initiated coagulation in vivo; however, there is evidence of TF in norn1al blood (G iesen 
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et al., 1999; Key et al., 1998). Thus, there is emerging evidence that TF in normal blood 
that is associated with monocytes and platelets is encrypted and that encryption may 
therefore be the primary mechanism controlling the expression of TF procoagulant 
activity by these cells (Bach, 2006). The first observations of TF encryption were 
demonstrated in cell culture studies. Unperturbed cells were shown to express very 
limited TF procoagulant activity despite the fact that TF, an integral membrane protein 
is localised to the cell surface where it can bind FVII. It was reported that a stimulus 
was required to express the latent proteolytic activity of the encrypted TF-FVIIa 
complex. However, a number of factors to induce cells to express encrypted TF 
procoagulant activity were established, including freezing and thawing, sonication, 
proteases, phospholipases, non-ionic detergents, apoptosis, complement and calcium 
ionophores (Bach et al., 1990; Le et al., 1992). The first step in the calcium ionophore-
induced decryption of TF procoagulant activity is the release of calcium from internal 
stores followed by a second and greater influx of extracellular calcium across the 
plasma membrane. In the plasma membrane of quiescent cells, phosphatidylserine, a 
major phospholipid, is localised on the inner leaflet of the bilayer (Zwaal et al., 1997); 
and an increase in cytosolic calcium of the same magnitude that decrypts TF 
procoagulant activity also disrupts phosphatidylserine asymmetry. The relevance of 
phosphatidylserine availability is that this phospholipid accelerates coagulation 
reactions on membrane surfaces (Hathcock et al., 2005; Kunzelmann-Marche et al., 
2000). Stimulating cells with a calcium ionophore subsequently alters 
phosphatidylserine asymmetry and increases the V max of the TF -FVIIa reaction. 
However, phosphatidylserine asymmetry may not be all that is required for TF 
encryption in vivo. Another possible contribution is suggested by the evidence of an 
association between TF and lipid rafts (Del Conde et al., 2005; Dietzen et al., 2004). It 
is not known where encrypted and decrypted TF reside in the plasma membrane, 
however, it is believed that encrypted TF is localised in lipid rafts and decrypted TF is 
released into the liquid disordered phase of the membrane following cell stimulation 
(Bach, 2006). TF procoagulant activity is expressed by decrypted TF-FVIIa, therefore 
proteolytic activation of FVII must occur at some point in the decryption process. Thus, 
in vivo, the suppressed proteolytic activity of encrypted intravascular TF-FVIIa may 
explain why infusions of FVIIIa do not trigger thrombosis. 
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Cell surface TF binds FVII to initiate coagulation, or alternatively, to trigger signalling 
via PAR -2. Recent evidence has emerged that TF -FVII -mediated coagulation and cell 
signalling involve distinct cellular pools of TF, of which the surface-accessible 
extracellular disulphide bond is critical for coagulation and protein disulphide isomerase 
(PDI) disables coagulation by targeting the disulphide bond (Ahamed et aI., 2006). 
Ahamed et al. demonstrated that under conditions that favoured TF-FVIIa signalling 
and disabled coagulant activity, PDI associates with TF on the cell surface, whilst 
inhibition of PDI expression or activity increased TF coagulant activity. TF-FVIIa 
signalling via P AR-2 contributes to inflammation in the airway; however, Ahamed et al. 
demonstrate that TF-FVIIa signalling can be specifically inhibited without 
compromising TF -dependent coagulation. 
3.1.3.2. FVII 
FVII is a glycosylated plasma protein consisting of a single polypeptide chain of 406 
amino acids and an overall molecular weight of 50,000 Da (Broze et aI., 1980; Kisiel et 
aI., 1975; Radcliffe et aI., 1975). FVII is synthesised by the liver and circulates in the 
plasma at about 500 ng/ml (10nM) (Fair, 1983), however, the free circulating enzyme 
has very low activity and only attains full activity when in complex with its cofactor TF 
(Kemball-Cook et aI., 1999). FVII is a multi-domain protein, consisting of a gamma-
carboxyglutamic acid-rich domain (Gla domain); a hydrophobic or aromatic stack, two 
EGF-like domains and a serine protease domain that is homologous to trypsin 
(Morrissey, 2001). The Gla domain confers the ability of FVII to bind to membranes 
containing negatively charged phospholipids. Membrane binding is calcium-dependent 
and the crystal structure of the TF -FVIIa complex shows that the Gla domain contains 
seven bound calcium ions (Banner et aI., 1996). FVII shares the same domain structure 
as factors IX, X and protein C and has a similar gene organisation (Hagen et aI., 1986; 
O'Hara et aI., 1987). FVII is converted to the enzymatically competent form, FVIIa via 
proteolysis of a single peptide bond between residues Arg152L (light chain) and 
Ile153H (heavy chain) (Kemball-Cook et aI., 1999). FVII is a single-chain protein, 
whilst FVIIa is composed of two polypeptide chains, held together by a disulphide 
bond. The light chain of FVIIa, consisting of the Gla domain, aromatic stack and both 
EGF domains comprises 152 amino acids and has a molecular weight of approximately 
20,000 Da; and the heavy chain, consisting of the serine protease domain, has 254 
52 
amino acids and a molecular weight of approximately 30,000 Da (Morrissey, 2001). 
FVIIa is a highly elongated protein, forming extended contacts with TF. The main sites 
of contact on FVIIa for TF are located in the first EGF domain and the protease domain, 
with additional points of contact involving the aromatic stackiGla region and the second 
EGF domain. Furthermore, the main sites of contact on TF for FVIIa are located on 
both fibronectin III domains and the interfacial region between them (Chang et al., 
1995; Edgington et al., 1997; Martin et al., 1995). In addition to the enhancement of 
FVII activity, it has been suggested that TF may play other roles. Firstly, TF may act to 
locate the active site of FVIIa at the appropriate distance from the membrane to allow it 
to cleave the macromolecular substrate FX (McCallum et al., 1996; McCallum et al .. 
1997). There is also evidence that binding of TF to FVIIa alters the FVIIa active site 
conformation, and the protease domain has been suggested to exist in equilibrium 
between 'zymogen-like' and fully active forms (Kemball-Cook et al., 1999). The TF-
FVIIa complex has extremely restricted substrate specificity and will only bind factors 
VII, IX and X. However, under most in vitro conditions, FX is the preferred substrate 
(Komiyama et al., 1990). 
3.1.3.3. FXa 
The serine protease FXa plays a central role in the coagulation cascade, linking the 
extrinsic and intrinsic pathways by catalysing the conversion of prothrombin to 
thrombin (Davie et al., 1991). FX associates with the TF-FVIIa complex by interacting 
with various domains on both proteins (Kirchhofer et al., 2000). In order for FXa 
activation, calcium is required to promote the binding of enzyme and substrate and 
subsequent catalysis requires a phospholipid membrane (Nesheim et al., 1979; Rodgers 
et al., 1983). The y-carboxyglutamic acid (Gla) domain of FX interacts with 
phospholipid membrane as well as the C-terminal region of TF and the Gla domain of 
FVIIa (Ruf et al., 1998).The conversion of FX to FXa results in a reduced affinity for 
the TF -FVIIa complex and it can be released to form the prothrombinase complex, 
consisting of phospholipid bound FXa and the cofactor FVa which converts 
prothrombin to thrombin (Riewald et al., 2002). 
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3.1.3.4. Thrombin 
Thrombin is a trypsin-like member of the chymotrypsin family of serine proteases and 
is the product of prothrombin cleavage by FXa. Prothrombin is synthesised in the liver 
as a pre-propeptide and undergoes a number of post-translational processes prior to 
secretion. Following damage to the epithelium and subsequent initiation of the 
coagulation cascade, circulating prothrombin is converted to active thrombin. This 
proteolytic activation is mediated by the prothrombinase complex consisting of 
prothrombin, FXa, FVa and negatively charged phospholipids, in the presence of 
calcium ions. During its activation by FXa, prothrombin is cleaved; firstly to generate 
meizothrombin and then to generate thrombin and fragments that contain the Gla and 
kringle domains, which function to localize prothrombin onto membrane surfaces to 
form part of the prothrombinase complex, that includes FVa and FXa (figure 3.3). Once 
prothrombin is activated, thrombin can escape the complex and is free to bind to its 
substrates. Prothrombin is unique among the activated coagulation proteases in that it 
completely loses the domains important for initial recognition interactions when it is 
activated to its serine protease derivative, thrombin. Loss of these domains allows 
thrombin to diffuse freely to encounter, recognize, cleave, and dissociate from its 
substrates (Lane et aI., 2005). Furthermore, loss of the domains permits exposure of 
cryptic functional regions (Wu et aI., 1994), the active site, and the charged anion 
binding regions, termed exosites (Bode et aI., 1992) which are crucial for extending the 
range and specificity of the actions of thrombin. 
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Figure 3.3. Prothrombin activation to thrombin. 
Prothrombin is first cleaved and activated as part of the prothrombinase complex to 
form meizothrombin. The Gla and kringle (Kl and K2) domains are then cleaved, 
allowing thrombin to diffuse away. AI-A2 = FYa domain fragments that are non-
covalently bonded to A3-C l-C2 FYa domain fragments. Thrombin has 3 regions that 
are functionally inaccessible in prothrombin and become exposed on activation: the 
active site, exosite I, and exosite II (Lane et al. , 2005). 
The resultant 39 KDa thrombin molecule comprises two chains, which are cross-linked 
by four disulphide bonds, that surround a narrow groove containing the catalytic triad 
consisting of His-57, Asp-l02 and Ser-205. This groove is hydrophobic and exhibits a 
preference for apolar amino acids preceding arginine at a thrombin susceptible bond 
such as Leu Asp Pro Arg/Ser, whereby / represents the cleavage site. The high 
specificity of thrombin towards its substrates and receptors is conferred by its unique 
anion binding exosite (Goldsack et al., 1998). 
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Figure 3.4. Structure and function of thrombin. 
A schematic representation of thrombin and its interaction with fibrinogen and PAR-I. 
Thrombin has several discrete sites; the anion binding exosite of thrombin lies within 
the deep groove and binds its substrates. The substrate binding sites within this deep 
groove orientates thrombin' s substrates (fibrinogen or PAR-I) enabling cleavage at the 
catalytic site at an Arg/Ser susceptible bond (Goldsack et aI. , 1998). 
Active thrombin mediates the conversion of fibrinogen to fibrin and hence, the 
formation of the fibrin clot. In addition, thrombin cleaves the FXIIIA subunit releasing 
an amino terminal activation peptide, resulting in exposure of its active site and 
initiation of fibrin stabilisation by covalent cross-linking (Wolberg, 2007). 
3.1.3.5. Fibrinogen 
Fibrinogen is a complex plasma glycoprotein with a molecular weight of 340 KDa 
(Herrick et aI. , 1999). Fibrinogen is primarily synthesised in the liver and the plasma 
concentration is 2-4 giL (Sidelmann et aI. , 2000). It consists of two symmetric half 
molecules consisting of three pairs of di sulphide-bonded polypeptide chains temled Au. 
B~- and y-chains (figure 3.5). Electron microscopy studies of fibrinogen demonstrate a 
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trinodular structure. The central nodule, termed the E domain represents the amino-
terminal disulphide knot of the six chains and the two end nodules termed the D-
domains represent the carboxyl terminal regions of the B~- and y-chains and are 
connected to the E domain by a rod-like a -helical, coiled coil region. The carboxyl 
terminal is more flexible than the remainder of the fibrinogen molecule and folds back 
onto the E-domain (Clark, 2003). The three constitutive chains and the two halves of the 
fibrinogen molecule are held together by a series of 29 disulphide bonds with all 58 
cysteine residues of fibrinogen participating in these interactions (Herrick et aI. , 1999). 
aC-domain 
-50kDa 
N-terminal 
fibrin opeptides 
C-terminal 
a.,p, y globular 
domains 
.. O-domain ... t .. E-domain~t .... ___ D_-d_o_m_a_in ____ • 
-------94-k-D-a-- ---.. -50 kDa I . -94 kDa 
plasm In p asm In 
Figure 3.5. Molecular representation of fibrinogen showing the major structural 
domains. There are three sets of non-identical chains, which are bound by disulphide 
bonds at the N-terminal end. Removal of FPA and FPB via the action of thrombin leads 
to cross-linking and formation of the fibrin clot. 
The last step in the coagulation cascade involves the conversion of fibrinogen to fibrin 
by the enzyme thrombin. This is a complex process involving a series of reactions 
(simplified infigure 3.6). 
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Figure 3.6. A simplified scheme of the thrombin-induced conversion of fibrinogen to 
fibrin. Thrombin cleaves FP A and FPB from the fibrinogen molecule, converting it to a 
fibrin monomer that polymerises into soluble fibrin. Simultaneously, thrombin activates 
FXIII to FXIIIa, which then stabilises the soluble fibrin by generation of irreversible 
disulphide D-D binding to form cross-linked, insoluble fibrin (Wolberg, 2007). 
Thrombin activates fibrinogen by cleaving two small peptides, namely FP A and FPB 
from the N-terminal regions of the Au- and B~-chains respectively resulting in the 
exposure of previously cryptic sites, which can then function cooperatively in fibrin 
polymerisation. Following the release of FPA, new Au-chain amino terminal ends are 
generated which interact with sites in the y-chain carboxyl termini of adjacent molecules 
to promote non-covalent, lateral assembly. Subsequent removal of FPB creates new B~­
chain amino-terminal ends that also interact with sites in the y-chain carboxyl termini of 
adjacent molecules, reinforcing lateral aggregation and leading to thicker fibrin 
formation. The activated fibrinogen molecule forms soluble complexes with fibrin and 
fibrinogen molecules designated fibrin monomers . Due to persistent thrombin activity, 
the concentration of soluble fibrin monomers increases and subsequently fo rms long, 
double-stranded protofibrils . These structures are then combined laterally to fom1 fib rin 
fibres of varying diameters, resulting in polymerisation of soluble fibrin into cova lentl y 
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bonded polymerised fibrin. This process is dependent on the presence of thrombin, 
calcium and activated FXIIIa (Clark, 2003; Mosesson, 1998; Sidelmann et aI., 2000). 
3.1.3.6. FXIII 
Plasma FXIII is a tetrameric molecule composed of two A-subunits of 83.2 KDa and 
two B-subunits of 79.7 KDa that are bonded non-covalently in a heterologous tetramer 
of325.8 KDa (Ashcroft et aI., 2000; Schwartz et al., 1973). The A-subunit contains the 
active site of the enzyme and is synthesised by hepatocytes and monocytes (Nagy et al., 
1988). Analysis of the protein phenotype following liver and bone marrow 
transplantation showed that the A-subunit circulating in the plasma is derived from both 
the liver and the bone marrow (Wolpl et aI., 1987). The B-subunit serves as a carrier for 
the catalytic A-subunit in plasma, is synthesised by the liver and is secreted as a 
monomer that binds free A-subunit in plasma (Nagy et al., 1988). The A-subunit is 
divided into four domains termed; the p-sandwich, the catalytic core, barrel 1 and barrel 
2 (Yee et aI., 1994). It contains an activation peptide of 37 amino acids that limits the 
access of the substrate to the active site cysteine. The activation peptide from one 
subunit of the molecule crosses the opening of the active site on the other. This structure 
is stabilised by several hydrogen bonds and disulphide bridges between the activation 
peptide, the p-sandwich and the catalytic core of one subunit and the catalytic core and 
p-barrel of the second subunit (Weiss et aI., 1998). The main function of the B-subunit 
is the stabilisation and transport of the hydrophobic A-subunit in the aqueous 
environment of plasma (Ariens et aI., 2002). 
Plasma FXIII is transformed into an active transglutaminase (FXIIIa) by the proteolytic 
action of thrombin in the presence of calcium in the final phase of the coagulation 
cascade. Thrombin removes an activation peptide of 37 amino acid residues from the N-
terminal end of subunit-A, then in the presence of calcium, the B-subunits dissociate 
and subunit-A assumes an enzymatically active configuration. The presence of fibrin 
greatly accelerates the activation process (Bereczky et aI., 2003). In contrast, the 
cellular form of FXIII is a dimer of the A subunit only (Muszbek et aI., 2007). 
FXIII plays a vital role in the conversion of the loose meshwork of hydrogen-bonded 
soluble fibrin into a covalently bonded polymer, which is believed to improve the 
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mechanical strength, rigidity and elasticity of the clot and increase its resistance to 
fibrinolysis (Gaffney et al., 1979; Schwartz et aI., 1971). FXIIIa also has the capacity to 
cross-link several plasma proteins to the fibrin clot including plasmin inhibitor, which 
protects fibrin against plasmin-induced breakdown (Muszbek et aI., 1996; Muszbek et 
al., 1999). The basic mechanism of fibrin cross-linking involves the a- and y-, but not 
the p-chains of fibrin. Antiparallel y-chains of adjacent fibrin monomers are cross-
linked quickly by FXIIIa to form y-dimers. a-Chain cross-linking proceeds more 
slowly, resulting in the formation of highly crossed a-chain polymers (Sidelmann et aI., 
2000). The thrombin-mediated cleavage of FP A from fibrinogen and the activation of 
FXIII occur simultaneously (Brummel et aI., 1999), allowing the fibrin clot to be 
strengthened as it forms. 
3.1.4. Vitamin K-dependent carboxylase 
Vitamin K-dependent proteins including the coagulation factors (FVII, FIX, FX and 
prothrombin) and coagulation regulatory proteins (protein C and protein S) require post-
translational modifications by vitamin K -dependent carboxylase. The enzyme 
recognises a pro-sequence that precedes the NH2-terminus of the proteins and carboxyl 
groups are introduced to glutamine residues during protein biosynthesis (Berkner, 2000; 
Furie et aI., 1999). The synthesis of the noted coagulation factors by bronchial epithelial 
cells would therefore require the presence of vitamin K-dependent carboxylase within 
the cells. Whole lung extracts have been demonstrated to express a large amount of 
vitamin-K dependent carboxylase (Houben et aI., 1997; Vermeer et al., 1982). 
Furthermore, alveolar epithelial cells display a significant amount of vitamin K-
dependent carboxylase activity (Wallin et aI., 1988). 
Protein C is a vitamin K -dependent protein that is important in regulating coagulation 
by forming a complex with thrombomodulin and protein S, which inactivates the 
coagulation cofactors FV and FVIII (Esmon, 2000). Protein C is produced, in vitro by 
alveolar epithelial cells and has been detected at the gene, protein and activity levels 
(Hataji et al., 2002). Given that protein C is produced by these cells and that it is 
capable of being activated indicates that this cell type contains vitamin k-dependent 
carboxylase and therefore would be capable of introducing the post-translation 
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modifications to vitamin K-dependent proteins. Vitamin K-dependent carboxylase is 
located within the endoplasmic reticulum; therefore, the processing and secretion of the 
vitamin K-dependent proteins is likely to occur through a regulated pathway (Furie et 
al., 1999). 
A vitamin K inhibitor, such as warfarin, would dysregulate the carboxylation of vitamin 
K -dependent proteins (Houben et al., 1997). Warfarin may therefore be a useful tool to 
investigate whether 16HBE 140- or NHBE cells demonstrate vitamin K -dependent 
carboxylase by determining the effects of the inhibitor on the release of vitamin K-
dependent coagulation factors. 
3.1.5. Inhibition of fibrinogenesis 
In addition to the fibrinolytic pathway, whereby the fibrin clot is degraded, the amount 
of fibrin, present at sites of tissue injury is tightly regulated by the actions of inhibitors 
of the coagulation cascade. 
3.1.5.1. Inhibitors of TF:FVIIa 
Free FVIIa is unreactive with any of the plasma protease inhibitors; however, when 
FVII is bound to TF, it becomes susceptible to inhibition~ In particular, two plasma 
inhibitors termed tissue factor pathway inhibitor (TFPI) and antithrombin III can react 
with the TF:FVIIa complex. TFPI is composed of three Kunitz-type protease inhibitor 
domains. The first Kunitz domain reacts with the active site of factor VIla in the 
TF:FVIIa complex (Broze, 1995). The second Kunitz domain reacts with the active site 
of FXa. Once the TFPI:Xa complex forms, it binds with higher affinity to TF:FVIIa 
than does the TFPI molecule alone (Broze, 1995). This results in the formation of a 
fully inhibited tetramolecular complex. A second molecule related to TFPI, termed 
TFPI-2 was later identified and shown to inhibit the TF:FVIIa complex (Sprecher et al.. 
1994). However, the presence of TFPI-2 has not yet been determined in plasma, 
therefore it is not known whether this molecule plays a physiological role in the 
regulation of TF -dependent coagulation. Antithrombin III is able to inhibit the activities 
of all of the serine proteases (FX, thrombin, FIX and FXI), although it is only \\'eakly 
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inhibitory for the TF:FVIIa complex (Mann et aI., 1998). As with TFPI, antithrombin 
can only react with FVIIa when it is bound to TF. Furthermore, the reaction rate is 
considerably slow in the absence of heparin (Kondo et al., 1987). Studies haye 
demonstrated that the binding of antithrombin to FVIIa of the TF:FVIIa complex results 
in the accelerated release of FVIIa, and the resulting FVIIaiantithrombin complex was 
unable to re-bind to cell surface TF (Rao et al., 1995). Platelet factor 4 (PF4). which 
can bind to the Gla-domain of vitamin K-dependent FX has also been reported to inhibit 
TF:FVIIa activation ofFX (Slungaard et aI., 1994). 
3.1.5.2. Inhibitors of thrombin 
The proteolytic activity of thrombin is under tight regulatory control. The activity half-
life of thrombin in plasma is only 14 seconds as it is rapidly bound by inhibitors, 
including antithrombin III, a2-macroglobulin, heparin cofactor II, protease nexin-l and 
al-anti-trypsin. The most important mode of inactivation occurs via complexing with 
antithrombin III. This complex is transported to the liver and undergoes degradation in 
Kupfer cells (Goldsack et aI., 1998). In addition to circulating anti-proteases, there are 
two additional highly efficient thrombin inhibitors, thrombomodulin and Protein S. 
Thrombin binds to thrombomodulin, leading to the activation of Protein S, inactivating 
FVa and FVlIIa, preventing further thrombin activation. The binding of thrombin to 
thrombomodulin also increases the rate at which thrombin is inhibited by plasma 
inhibitors (Esmon, 2000). 
3.1.6. Fibrinolysis 
Fibrin provides a matrix for the processes of wound repair, but is not a permanent 
structure. The fibrinolytic system counterbalances the coagulation system (Astrup, 
1952) and when fibrin has performed its duty, it is degraded to soluble fragments. The 
fibrinolytic process is surface-related and involves a number of circulating (intrinsic) 
and tissue-related ( extrinsic) factors (figure 3.1). The fibrin matrix is degraded into a 
number of fragments, including D-dimers, primarily through the action of plasmin. 
Plasmin is generated by proteolytic cleavage of the proenzyme plasminogen circulating 
in human blood. Plasminogen has a high affinity for fibrin and subsequently localises 
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the fibrinolytic process to the fibrin surface. There are three distinct pathways 
associated with the activation of plasminogen. Tissue-type plasminogen activator (t-
PA), a direct activator of plasminogen, is produced and released from vascular 
endothelial cells (Pennica et al., 1983). Circulating t-PA is a weak plasminogen 
activator, but t-PA also binds strongly to fibrin and in consequence, becomes a strong 
activator of plasminogen (Astrup, 1966). An alternative pathway is related to the 
intrinsic single-chain urokinase-type plasminogen activator (scu-PA), which can be 
converted into active urokinase-type plasminogen activator (u-PA) by various proteases 
(Gunzler et al., 1982). The activation of scu-P A is not known in detail but in vitro 
studies have revealed that plasmin and kallikrein, a serine protease, are responsible for 
the conversion ofscu-PA into u-PA (Binnema et al., 1991; Hauert et al., 1989; Ichinose 
et al., 1986). The third pathway initiated by activation of coagulation factor XII (FXII) 
and termed the FXII-dependent pathway. Plasminogen activation is induced by contact 
activation and FXIIa, kallikrein and FXIa all have the capacity to activate plasminogen 
directly (Bouma et al., 1978; MandIe et al., 1979; Saito, 1980). Recent studies indicate 
that assembly of high molecular weight kininogen on its multiprotein receptor allows 
for prekallikrein activation. On endothelial cells, FXII activation is secondary to 
prekallikrein activation and amplifies it. The immediate consequence of plasma 
prekallikrein activation is the cleavage of high molecular weight kininogen with 
liberation of bradykinin. Bradykinin stimulates t-P A liberation. In addition, formed 
plasma kallikrein promotes scu-P A activation and subsequent plasminogen activation 
(Schmaier, 2000). Plasmin degradation of cross-linked fibrin results in the formation of 
more complex fragments designated as X-oligomers (Gaffney et al., 1979; Graeff et al., 
1982). These oligomers consist of the D- and E-fragments of fibrin in various 
combinations. Large oligomers are released in the initial phase of fibrin breakdown and 
as the fibrinolytic process continues, the fragments decrease in size. The final fragments 
generated by degradation of cross-linked fibrin are fragment-E and D-dimer, which 
consist of two covalently bound D-domains (Doolittle, 1981). 
In addition to the plasmin-induced fibrinolytic pathway, other proteases, such as 
neutrophil elastase, mast cell tryptase, matrix metalloproteinases and cathepsins D and 
G also have the capacity to degrade fibrin (Herrick et al., 1999). Elastase can facilitate 
plasmin expression via an alternative pathway of plasminogen activation. Elastase 
modifies plasminogen to yield a zymogen that is a better substrate for activators than 
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native plasminogen. Furthennore, elastase inactivates plasminogen activator inhibitor-1 
(P AI -1) and a2-antiplasmin without affecting plasmin and plasminogen activators. 
While plasmin activity develops from a blood zymogen as a consequence of activators 
synthesized and secreted by endothelium and possibly other cells, elastase is secreted in 
an active fonn primarily by polymorphonuclear leukocytes. Plasmin and elastase may 
play mutual roles in fibrinolysis and inflammation (Machovich et al., 1990). 
The potential importance of elastase-mediated fibrin( ogen) degradation was 
demonstrated in a study involving patients with homozygous plasminogen deficiency. 
Such patients are not prone to thrombosis and have a nonnal concentration of fibrinogen 
in the blood. Fibrinogen and fibrin degradation occur in these patients despite the 
plasminogen deficiency (Dempfle et al., 1997). 
3.1.6.1. Inhibitors of fibrinolysis 
There are a number of factors that regulate fibrinolysis. The activity of plasmin and 
plasminogen activators is regulated by a2-antiplasmin and PAI-1 respectively (figure 3). 
Moreover, plasminogen activation may be reduced by the binding of other positively 
charged proteins, such as histidine-rich glycoprotein (Vestergaard et al., 1990) and B2-
glycoprotein I (Schousboe, 1985) to the activating surface. Further regulation of 
fibrinolysis is achieved via the action of thrombin activatable fibrinolysis inhibitor 
(T AFI). T AFI is activated to T AFla by thrombin and this reaction is accelerated in the 
presence of thrombomodulin (Bajzar et al., 1996), a protein in the membrane of 
endothelial cells. T AFla removes lysine residues from the fibrin surface and 
subsequently reduces the amount of plasminogen binding to fibrin. The concentration of 
thrombin required for the activation of T AFI is greater than that needed for fibrin 
fonnation, nevertheless, thrombin has the capacity to activate FXI that in tum, produces 
more thrombin via the intrinsic coagulation cascade (Gailani et al., 1991; Mosnier et al.. 
1998). Elastase-mediated fibrinolysis is primarily regulated by aI-protease inhibitor 
(Bernstein et al., 1994). 
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3.1.7. Fibrinogen expression in vitro 
It has previously been shown that the A549 cell line, derived from alveolar basal 
epithelial cells synthesise their own fibrinogen in response to inflammatory stimuli 
which is in tum incorporated into a matrix independently of thrombin cleavage (Guadiz 
et al., 1997; Haidaris, 1997). A549 cells in culture were treated with IL-6 and 
dexamethasone to induce inflammation and subsequent epithelial injury. In response to 
injury, northern blot analysis demonstrated that the levels of fibrinogen gamma chain 
mRNA increased from 2- to 10-fold in the A549 cells. Furthermore, RT-PCR 
amplification demonstrated increased accumulation of fibrinogen Au, BB and y chain 
mRNA in the same cell type. They showed that the newly synthesised fibrinogen was 
secreted and incorporated into a matrix to support epithelial wound repair. 
In view of the evidence that lung alveolar epithelial cells synthesise fibrinogen in 
response to injury in vitro, it was of great interest to investigate the synthesis of 
coagulation factors by epithelial cells, in the absence of plasma, to form a fibrin matrix 
to support epithelial repair. 
3.1.8. The role of growth fact()rs in bronchial epithelial repair 
3.1.8.1. Epidermal growth factor 
EGF is a potent mitogen originally isolated by Cohen (1983) from murine salivary 
glands (Cohen, 1983). Members of the epidermal growth factor family (i.e., EGF, TGF-
u, HB-EGF, amphiregulin, betacellulin, and epiregulin) are likely to be important 
regulators of epithelial restitution by virtue of their ability to stimulate cell migration, 
proliferation, differentiation, and survival (Kheradmand et al., 1994; Kim et aI., 1998; 
Puddicombe et al., 2000). Immunolocalisation studies have revealed that EGF is 
primarily expressed in bronchial glands (Aida et aI., 1994; Polo sa et aI., 1999), 
however, there is weak expression in the bronchial epithelium and smooth muscle 
(Ami shima et aI., 1998). The EGF family of growth factors exert their biological effects 
by binding to and activating EGFR, a 170 kDa tyrosine kinase receptor (Ullrich et al.. 
1990). EGFR, also known as ErbBl SInce it is a member of the ErbB family, is 
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expressed on the majority of cells types, including fibroblasts and epithelial cells of the 
bronchial epithelium. The receptors have a restricted expression pattern in polarised 
lung epithelial cells; with ErbB receptors expressed basolaterally and therefore, are only 
exposed after epithelial damage. Following epithelial injury, ErbB ligands can activate 
EGFR or ErbB2 at the edge of the wound, thus facilitating restoration of epithelial 
integrity (Puddicombe et aI., 2000; Vermeer et al., 2003). Expression of EGF and 
EGFR is upregulated in the epithelium of asthmatic subjects (Puddicombe et aI., 2000). 
More recently, evidence has emerged that while upregulation of EGFR expression is 
important in repair of the damaged epithelium associated with asthma, impairment of 
EGFR activity may promote abnormal healing and remodelling, most likely through the 
uncontrolled release of TGF-~ (Knight, 2001). A direct role for EGF in cutaneous 
wound healing is already well established (Lawrence et al., 1994; McCarthy et al., 
1996). In an in vivo study involving the gene transfer of a human EGF expression 
plasmid into wound keratinocytes of porcine skin, Andree et al (1994) demonstrated 
that wounds that were treated with EGF healed 2.1 days quicker compared to controls 
(Andree et aI., 1994). EGF also appears to playa physiologically relevant role in wound 
healing in the oral epithelium; Noguchi et al (1993) demonstrated that EGF promotes 
healing of superficial tongue wounds in mice. The removal of submandibular salivary 
glands (the major source of salivary EGF) reduced the rate of wound repair, and the 
inclusion of EGF in drinking water restored the rate of wound healing to normal levels 
(Noguchi et aI., .1993). Barrow et al (1993) showed that administration of aerosolised 
EGF for 2 weeks enhanced repair of sheep tracheal epithelium after cotton smoke injury 
in vivo. It was suggested that cell proliferation and differentiation were responsible for 
accelerated epithelial restitution, but the cellular mechanisms were not identified 
(Barrow et al., 1993). Similarly, in cultured guinea pig airway epithelial cells, EGF was 
shown to promote the repair of mechanically wounded mono layers by stimulating cell 
migration with no effect on cell proliferation in the wound margin (Kim et al., 1998). 
EGF has also been demonstrated to accelerate the repair of mechanical wounds in 
monolayers of the 16HBE 140- cell line (Puddicombe et al., 2000). Wadsworth et al 
(2006) demonstrated in an in vitro study that 1.0 ng/ml EGF accelerated the rate of 
wound repair in a monolayer of undifferentiated primary bronchial epithelial cells. This 
effect was shown to occur via an EGFR-dependent mechanism since wound repair was 
inhibited by a blocking antibody directed to an epitope located in or adjacent to the 
EGF-binding site of the EGFR. Interestingly, exogenous EGF did not enhance wound 
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repair of the differentiated, ALI cell model, however, wound repair was nonetheless 
inhibited by the presence of the same blocking antibody, suggesting that repair of 
differentiated cell cultures is dependent on autocrine EGF signalling. Repair of the 
damaged epithelium in undifferentiated cells was shown to occur in the initial stages, 
predominantly by cell migration and independent of proliferation (Wadsworth et al.. 
2006). Thus, there is increasing evidence that EGFR is an important factor in the 
regulation of epithelial repair following injury. 
3.1.8.2. Keratinocyte growth factor 
Keratinocyte growth factor (KGF) is a 28 kDa peptide classified as a heparin-binding 
member of the fibroblast growth factor family (FGF-7) (Galiacy et al., 2003). KGF was 
shown to be produced by various types of mesenchymal cells both in vitro and in vivo 
(Smola et al., 1993; Winkles et al., 1997) and to target epithelial cells (Rubin et al., 
1989). KGF is recognised as a key growth factor for the bronchial epithelium and has 
been shown to stimulate proliferation of alveolar epithelial cells in vitro (Panos et al., 
1993) and in vivo (Ulich et al., 1994). Furthermore, in vivo, KGF is able to prevent or 
overcome tissue injury caused by experimental insults (Deterding et al., 1997; Waters et 
al., 1997; Yi et al., 1996). Using an in vitro model of wound repair involving rat 
alveolar epithelial cells, Galiacy et al (2003), observed by video microscopy, that 
almost immediately after wounding, alveolar epithelial cells form lamellipodia at the 
wound edge. This was followed by the appearance of plasma membrane protrusions 
directed toward the wounded area, assembly of fibres and cell migration. The 
participation of the lamellipodia signified that migration speed was enhanced, since 
these structures are known to initiate cell mobility. KGF was demonstrated to enhance 
wound repair at 24 hours compared to the serum-free control; furthermore, wound 
repair was shown to occur by spreading and migration and not proliferation. Using this 
in vitro model of wound repair, the absence of proliferation is in accordance with other 
studies (Garat et al., 1996; Kheradmand et al., 1994). The other important observation 
was that KGF was shown to induce fibronectin expression. Furthermore, KGF enhanced 
bronchial epithelial cell adhesion to exogenous fibronectin, possibly via integrins. in 
particular, a5~1 or av-integrins. Fibronectin is well documented to playa key role in 
cell migration and tissue repair, therefore by increasing the expression of this molecule; 
KGF plays an important indirect role in epithelial repair. 
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3.1.8.3. Transforming growth factor-p 
Transforming growth factor (TGF)-P is a multifunctional cytokine with significant 
regulatory effects on extracellular matrix production from mesenchymal cells in the 
lung (Coker et aI., 1997). More than 30 members of the TGF-p superfamily have been 
identified and are divided into four main families: TGF-p family, bone morphogenic 
family, inhibinlactivin family and Mullerian-inhibiting substance family (Miyazono et 
aI., 2001). There are three TGF-p isoforms identified in mammals, namely TGF-P1, -P2 
and -P3 (Boxall et aI., 2006). TGF-pl and -P2 appear to be the prominent isoforms in 
the airway (Balzar et aI., 2005; Puddicombe et aI., 2000; Tschumperlin et aI., 2003). 
Although TGF -PI was first isolated and characterised in human platelets (Assoian et aI., 
1983), it is produced in the airways by most cell types, including fibroblasts, smooth 
muscle, inflammatory and epithelial cells. 
TGF-p is produced in an inactive form, tethered to a latency-associated peptide (LAP) 
by covalent bonding and its signalling through TGF-p receptors requires exposure of the 
active site of the ligand, either by conformational change or by cleavage of the LAP 
(Grande, 1997). Large latent TGF -P consists of a mature 25-kDa polypeptide dimer 
(TGF-P), latency associated protein (LAP), and latent TGF-p binding protein (LTBP). 
The complex is targeted to the extracellular matrix structures via L TBP. Disruption of 
the non-covalent association between TGF -P and LAP is needed for the release of the 
active TGF-p, which is then able to bind to the cell surface receptors. Thrombospondin-
1 binds to the LSKL sequence in LAP, which leads to conformational changes and 
TGF-p activation. Integrins, in turn, bind to the RGD recognition sequence in LAP, 
leading to release of TGF -P either by force directed against the TGF -P complex (avp6) 
or by membrane-type 1 matrix metalloproteinase (MTI-MMP)-dependent proteolytic 
activity (avp8). Reactive oxygen species (ROS) can activate TGF-p directly through 
oxidation induced conformational change in LAP or indirectly though the activation of 
proteolytic enzymes (Koli et aI., 2008). 
Many different cellular responses are elicited by TGF-p, and these are often cell-type 
specific (Massague, 2000). The complicated signalling patterns triggered by cellular 
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exposure to TGF-~ are incompletely understood. The classic response pathway involyes 
Smad-mediated changes in target gene transcription. The cell surface TGF -~ receptor 
complex is composed of type I and II serine/threonine kinases (Feng et al.. 2005). TGF-
~ binds first to the type II receptor (TGF-~RII), after which the type I receptor (TGF-
~RI, ALK-5) is recruited to the complex and activated by phosphorylation. The 
regulatory Smads 2 and 3 are phosphorylated by TGF-~RI and transported in a complex 
with Smad4 into the nucleus to alter gene transcription. Specific Smad-binding elements 
have been identified in the promoter regions of target genes and association with the 
AP-l transcription factor has been described in the regulation of gene transcription 
(Verrecchia et aI., 2001). 
The three isoforms of TGF -~ have been studied extensively with regards to cutaneous 
wound healing, whereby, TGF-~1 and TGF-~2 have been shown to enhance wound 
repair (Shah et aI., 1995). However, in an in vitro study of bronchial epithelial repair, a 
divergence in function between TGF -~ 1 and TGF -~2 was identified (Howat et aI., 
2002). They confirmed that activation mechanisms that facilitate the conversion of 
latent to active forms of TGF-~ are enhanced at an early stage in the repair process and 
concluded that although active forms of both TGF-~1 and TGF-~2 are produced during 
wound repair, only TGF -~ 1 increases the speed of epithelial repair. 
TGF -~ has also been implicated in the repair phase of airway remodelling (Davies et al.. 
2003). TGF-~ promotes differentiation of fibroblasts into myofibroblasts that secrete 
interstitial collagens, as well as growth factors, such as endothelin 1 and vascular 
endothelial growth factor, which are mitogens for smooth muscle and endothelial cells 
(Richter et aI., 2001). It has been demonstrated that human bronchial epithelial cells can 
produce TGF-~2 at levels that alter gene expression and migration of fibroblasts (Mio et 
aL 1998; Puddicombe et aI., 2000; Tschumperlin et al., 2003). Thus, through the 
release of TGF -~ and its effects on the underlying fibroblasts and myofibroblasts, 
remodelling signals initiated in the repairing epithelium are propagated and amplified 
into the deeper layer of the submucosa. Furthermore, TGF -~ is reported to prolong the 
longevity of myofibroblasts by blocking IL-l f3-induced apoptosis (Zhang et al.. 1999). 
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U sing an in vitro model of epithelial-mesenchymal trophic unit (EMTU). referring to 
the bronchial epithelium and underlying mesenchyme, Thompson et al (2006) 
demonstrated that TGF-p2 regulates tenascin C protein expression and collagen 
organisation in the matrix under basal conditions and that epithelial injury can increase 
the concentration of TGF-p2 approximately two-fold and induce changes in the matrix 
that are consistent with subepithelial fibrosis (Thompson et al., 2006). These findings 
suggest that regulation of epithelial derived TGF -P2 may be necessary for normal 
EMTU function. 
Dosanjh et al (2006) demonstrated in an in vitro study, that following inoculation of 
bronchial epithelial cells with human rhinovirus, expression of TGF -P 1 is increased 
compared to control, both at the level of transcription and translation (Dosanjh, 2006). 
These findings, along with other studies linking rhinovirus to asthma, suggest that TGF-
P has a pathophysiologic role in the development of asthma and remodelling. The 
pleiotropic cytokine, TGF-pl, has been reported to function as a negative regulator of 
AHR and airway inflammation in a murine model of asthma (Hansen et al., 2000). 
TGF -P 1 is inhibitory for inflammatory cells such as T cells, B cells, dendritic cells, mast 
cells and eosinophils, and also modifies the functions of structural cells such as 
bronchial epithelial cells, fibroblasts and bronchial smooth muscle cells (Hirst, 2000; 
Holgate, 2000; Wahl, 1992). Interestingly, these cells develop the capacity to produce 
TGF-pl following their activation (Wahl, 1992). Thus, it appears that TGF-pl acts in a 
negative-feedback loop to suppress activation of these cells. However, persistent 
activity of TGF-pl induced by chronic inflammation, which might be caused by 
repeated stimulation with allergens, could have a detrimental effect and lead to tissue 
fibrosis or airway remodelling, which results in chronic airflow obstruction. TGF is 
over-expressed in the asthmatic lung (Boxall et aI., 2006). A study of Smad3-knockout 
mice suggests that there are complexities in understanding the various roles of the TGF-
P signalling pathway (Ashcroft et aI., 1999), indicating that further investigation will be 
necessary before the precise role of this cytokine is known. Accumulating knowledge 
on TGF-p signal transduction will help reveal the detailed mechanisms by which TGF-
PI elicits its effects on target cells in the airways of the experimental models, eventually 
suppressing AHR and airway inflammation. It is hoped that when the roles of TGF -P 1 
in human asthma are clearer. the modification of TGF-pi activity inside or outside the 
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cells, possibly via molecular approaches such as using anti-sense Smad7 
oligonucleotide, will offer a potential therapeutic intervention for asthma. 
3.1.8.4. Hepatocyte growth factor 
Hepatocyte growth factor (HGF) is an 85 kDa growth factor and is synthesised and 
secreted by mesenchymal cells, such as macrophages, endothelial cells and fibroblasts. 
HGF is renowned for its ability to exert a number biological functions including 
mitogenesis, motogenesis, morphogenesis and differentiation in a variety of cell types 
within the bronchial epithelium (Zahm et aI., 2000). Studies by Yanagrita et al. (1993), 
showed evidence of a change in HGF mRNA, HGF activity and HGF c-met receptor 
expression in the rat lung following tracheal epithelial injury, induced by hydrochloride. 
Furthermore, higher concentrations of HGF were observed in the sera of patients with 
lung disease compared to that of normal subjects (Yanagita et al., 1993). Studies have 
demonstrated the presence of elevated levels of HGF in the BAL fluid of patients with 
pulmonary fibrosis, compared to healthy patients (Sakai et aI., 1997). The significance 
of this finding is that HGF is likely to playa role in the repair of inflammatory lung 
damage. Little is known about the specific role of HGF in wound repair; however, 
Zahm et al (2003) suggest that the motogenic activity of HGF may be of therapeutic 
potential in the treatment of bronchial epithelial injury (Zahm et aI., 2000). 
More recently, Okunishi et al (2005) demonstrated a role for HGF in immune regulation 
(Okunishi et al., 2005). Results of the study revealed that HGF suppressed antigen-
induced immune response through inhibition of dendritic cells and thus played a 
protective role in a murine model of allergic airway inflammation. Antigen presentation 
from antigen presenting cells (APCs) initiates T cell activation and differentiation. 
Among APCs, dendritic cells are the most potent and important, thus playa central role 
and are a logical target in many airway inflammatory diseases involving T cells 
(Banchereau et aI., 1998). Prior to this study, it was emphasized that dendritic cells are 
crucial in asthma pathogenesis beyond antigen sensitization, and that these cells could 
be a therapeutic target for asthma (Lambrecht et aI., 2003; Lambrecht et aI., 1998). 
Okunishi et al (2005) demonstrated that HGF potently suppressed the antigen-
presenting capacity of dendritic cells, thus reducing an antigen-induced Immune 
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response. It may therefore be concluded that HGF is of potential benefit in the treatment 
of asthma (Okunishi et aI., 2005). 
3.1.9. The role of prostaglandin E2 in bronchial epithelial repair 
Prostaglandin E2 (PGE2) is the predominant prostanoid produced by bronchial epithelial 
cells and is an end product of cyclooxygenase (COX) metabolism of arachidonic acid 
(Savla et al., 2001). 
Arachidonic acid 
Cox inhibitors: 
COX-l ~...... - Indomethacin ........ ,. 
......... - Ibuprofen 
COX-2 •...... 
- Celecoxib 
PGG2 
P "d 1 COX-l ~." .. . erOXl ase ....... :::.: ....... 
COX-2····· 
- Indomethacin 
- Ibuprofen 
- Celecoxib 
PGH2 
PGb 
Figure 3.7. The prostaglandin pathway. Bronchial epithelial cells metabolise 
arachidonic acid to biologically active prostanoids via the enzymes cyclooxygenase 
(COX)-l and COX-2. 
There are two cyclooxygenase enzymes, abbreviated COX-l and COX-2 that convert 
arachidonic acid to PGH2 (Smith et aI., 2000). Expression of COX enzymes by 
epithelial cells is controversial. Mostly, it is believed that COX-l is constitutively 
expressed and that COX-2 expression is more tightly regulated and is not expressed 
under most normal physiological conditions; however, under a variety of 
pathophysiological conditions, its expression can be rapidly induced, as in asthma 
(Regan, 2003). However, there are reports that COX-l is undetectable in A549, 16HBE 
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140- and primary human tracheal epithelial cells in culture; however, COX-2 expression 
was found to be constitutive in both stimulated and unstimulated cells (Asano et al., 
1996; Walenga et al., 1996). Arachidonic acid is oxidised to PGG2 via COX actiyity. 
which in tum is reduced to PGH2. PGH2 is then converted to the final prostanoid 
products through the actions of specific synthases; in particular, PGE2 synthase 
catalyses the conversion of PGH2 to PGE2 (figure 3.7) (Kamei et al., 2003). In addition 
to bronchial epithelial cells, PGE2 is produced by a variety of cell types in the airway. 
including smooth muscle, alveolar macrophages and pulmonary endothelial cells 
(Meyrick et al., 1989; Widdicombe et al., 1989). 
PGE2 has been shown to exert a variety of anti-inflammatory and bronchoprotective 
effects both In vitro and In vivo. PGE2 may prevent allergen-induced 
bronchoconstriction (Gauvreau et al., 1999), relax airway smooth muscle (Knight et al., 
1995), inhibit cholinergic neurotransmission (Ito et al., 1990) and modulate fibroblast 
proliferation (McAnulty et al., 1997). PGE2 mediates its effects via G protein-coupled 
receptors to alter cyclic nucleotide levels in cells or stimulate phosphatidylinositol, 
thereby causing effects such as airway smooth muscle relaxation or uterine muscle 
contraction (Sheller et al., 2000). The receptors for PGE2 have been classified into four 
subtypes, entitled E-prostanoid (EP)-I, EP-2, EP-3 and EP-4. These EP receptors 
modulate a variety of effects: EP-l receptors binding PGE2 signal via G proteins to 
activate phospholipase C, generate phosphatidylinositol, mobilise calcium and create a 
chloride current (Breyer et al., 1998); EP-2 and EP-4 receptors characteristically relax 
smooth muscle by signalling through a Gs to increase intracellular cyclic adenosine 
monophoshate (cAMP) levels and the EP3 receptor consists of a number of splice 
variants displaying various degrees of constitutive activity (Jin et aI., 1997). 
In vitro studies have demonstrated that PGE2 causes relaxation of airway smooth 
muscle and also has effects on airway cholinergic nerve activity (Madison et al., 1989; 
Sweatman et al., 1968). Furthermore, PGE2 released from epithelial cells has been 
shown to inhibit vagal cholinergic efferent transmission via a prejunctional mechanism 
(Matsumoto et al., 1996). Fortner et al. (2001) reported that relaxation of constricted 
mouse tracheal smooth muscle by substance P and ATP is mediated through PGE:: 
acting on EP-2 receptors (Fortner et al., 2001). A number of in vil'o studies involving 
inhalation of PGE2 by human subjects have revealed that the prostanoid may cause 
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aIrway constriction or bronchodilation, which may be dependent on the timing of 
measurements following PGE2 administration (Mathe et al., 1975; Walters et al.. 1982). 
Sheller et al (2000) demonstrated that bronchodilation and thus relaxation of airway 
smooth muscle results from the activation of EP2 receptors in a murine model (Sheller 
et al., 2000). Conversely, PGErmediated airway constriction is dependent on activation 
of the EP-1 and EP-3 receptors (Tilley et al., 2003). In the cat trachea, PGE2 acts as a 
bronchodilator but is a constrictor in the guinea pig ileum (Gardiner, 1986). Clinical 
studies have reported that, for the majority of asthmatic patients, PGE2 produces 
beneficial bronchodilatory and bronchoprotective effects, however, a subset of patients 
have developed profound bronchoconstriction in response to PGE2 (Cuthbert, 1969; 
Mathe et al., 1975), hence the reason that PGE2 has never been exploited as a therapy 
for asthma. Ideally, the development of a suitable EP2 receptor-specific agonist to 
generate a bronchodilatory response would be a potential treatment for asthma. 
In vitro studies by Savla et al (2001) showed that inhibition of COX with indomethacin 
resulted in a dose-dependent inhibition of wound repair in both human and cat species 
of bronchial epithelial cells. Specific inhibitors of both COX-1 and COX-2 isoforms, 
resulted in impairment of wound repair. This effect was overcome by the addition of 
exogenous PGE2, which was shown to enhance the rate of wound repair in a dose-
dependant manner. Importantly, inhibition of COX with indomethacin only resulted in 
sustained inhibition of wound repair at initial time-points, suggesting that this 
prostanoid is involved in the early repair process of spreading and migration. The fact 
that indomethacin inhibits wound repair signifies that PGE2 is secreted by bronchial 
epithelial cells to promote wound repair and it is likely that this effect is mediated via 
the EP-1 and EP-4 receptor subtypes (Savla et al., 2001). 
3.1.10. IL-8 
IL-8 is an inflammatory chemokine that is abundantly expressed in the bronchial 
epithelium. IL-8 is considered a potent chemoattractant for neutrophils (Kunkel et aI., 
1991) and eosinophils (Shute, 1994; Walker et aL 1994). There is increasing evidence 
to suggest that IL-8 is a marker of severe asthma. The presence of IL-8 was 
demonstrated in the sera and bronchial tissue of subjects with severe atopic asthma, that 
was undetectable in that of normal subjects and subjects \vith mild atopic asthma (Shute 
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et aI., 1997). More recently, Silvestri et al. (2006) confirmed that severe asthmatics 
demonstrate higher concentrations of IL-8 in serum compared to mild-moderate 
asthmatics or healthy controls (Silvestri et aI., 2006). Furthermore, it was recently 
shown that epithelial expression of the neutrophil chemoattractant, IL-8 is increased in 
severe asthma and its appearance correlates with increased EGFR expression as a 
marker of epithelial damage. Further in vitro studies have revealed the EGF treatment of 
primary bronchial epithelial cells enhances IL-8 release (Hamilton et al.. 2003). Since 
the EGFR is over-expressed in the epithelium of patients with severe asthma and 
strongly correlates with IL-8 expression, this may contribute to airway neutrophilia in 
patients with severe asthma. It has been suggested that TGF -a is the ligand for the 
EGFR mediated IL-8 release from bronchial epithelial cells in response to cigarette 
smoke (Richter et aI., 2002). 
3.1.11. Neutrophil elastase 
Neutrophil elastase, a member of the chymotrypsin superfamily of serine proteases, is a 
33 kDa enzyme with several isoforms that differ in their extent of glycosylation (Bruch 
et al., 1986; Ohlsson et al., 1974). In neutrophils, the concentration of neutrophil 
elastase exceeds 5 mM and its total cellular amount has been estimated to be up to 3 pg. 
Such a high concentration of elastase is tightly regulated by compartmentalisation in the 
azurophil granules (Bruch et aI., 1986). Upon activation, neutrophil elastase is rapidly 
released from the granules into the extracellular space with a portion remaining bound 
to the neutrophil plasma membrane (Owen et al., 1995) and its activity is regulated by 
multiple endogenous inhibitors. It has also been reported that neutrophils contain a 1-
protease inhibitor (du Bois et aI., 1991). 
Neutrophil elastase has been demonstrated to playa role in stimulating mucus secretion 
(Fahy et aI., 1992), decreasing ciliary function (Amitani et aI., 1991), increasing 
epithelial permeability (Peterson et aI., 1995) and tissue destruction (Janoff, 1985); and 
in doing so, may contribute to several inflammatory disorders, including emphysema 
(Snider et aI., 1991), chronic bronchitis (Weitz et aI., 1987), bronchiectasis (Stockley et 
aI., 1984), cystic fibrosis (Jackson et aI., 1984), adult respiratory distress syndrome 
(ARDS) (Lee et aI., 1981) and there is accumulating evidence to suggest that neutrophil 
elastase is associated with severe asthma (Fahy ef al.. 1995; Holgate et at.. 2006; 
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Vignola et aI., 1998; Wenzel et aI., 1999; Wenzel et al., 1997). However, human airway 
epithelial cells (HAEC) are reported to play important bronchoprotective and 
immunomodulatory roles in chronic neutrophilic inflammation. A study involving the 
stimulation of HAEC with neutrophil elastase demonstrated a significant increase in 
PGE2 release via activation of p44/42 MAP kinases and upregulation of COX-2 (Pemg 
et aI., 2003). Neutrophil elastase is considered one of the most destructive enzymes due 
to its ability to degrade almost all extracellular matrix proteins (Chua et aI., 2006) and 
soluble proteins including coagulation factors V, VII, X, VIII, XI and XIII (Havemann 
et aI., 1984; Okada et al., 1988), leading to their loss of function. See table 3.1 for a 
more specific list of the proteolytic substrates of neutrophil elastase. In addition to its 
proteolytic activity, neutrophil elastase is also known to induce the expression of IL-6, 
IL-8, GM-CSF (Bedard et al., 1993) (Nakamura et aI., 1992) and mucin from epithelial 
cells (Sommerhoff et aI., 1990), and the release of TGF-B which binds to extracellular 
matrix (Taipale et aI., 1995). Interestingly, neutrophil elastase degraded fragments such 
as those from fibrin (Cepinskas et aI., 1997) and laminin (Steadman et aI., 1993) are 
known to be chemotactic toward neutrophils. 
ECM components 
Elastin and elastic fibres 
Collagen (types II, III, IV, VI, VIII, IX and X) 
Fibrillin micro fibrils 
Fibrin (cross-linked) 
Fibronectin 
Laminin 
Proteoglycans 
Latent TGF -B 1 
Bubepidermal BP-180 
Soluble proteins 
Coagulation factors 
Complement factors 
Fibrinogen 
Immunoglobulins 
Pro enzyme s 
Tenascin 
1NF-a 
Proteinase inlnbitors 
MMPs 
TIMP 
-------
Surfactant protein D 
Table 3.1. The proteolytic substrates of neutrophil elastase. 
Until relatively recently, all asthma cases were regarded as being similar, differing only 
in severity and therefore treatment type; but research over the last two decades has 
identified subphenotypes of asthma that differ in their allergic pathways. Most mild-
moderate asthma is associated with atopy, but the most severe and chronic phenotype of 
asthma is now commonly associated with greater involvement of neutrophils and 
evidence of tissue destruction and airway remodelling. With regards to wound repair, 
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appropriate regulation of neutrophil elastase in the normal airway can be beneficial, 
particularly in the degradation and removal of the fibrin matrix, once it has performed 
its duty. However, the excessive abundance of this enzyme may contribute to the 
chronic inflammation and remodelling associated with severe asthma. 
3.2. Aims and objectives 
The predominant aim of this section was to determine the expression of coagulation 
factors by 16HBE 140- cells cultured in serum free medium at the protein level using 
immunoblot and immunohistochemistry. Further aims were to investigate the 
contribution of growth factors by analysis of their concentration in cell culture 
supernatants derived from 16HBE 140- cells by ELISA. Finally, it was of interest to 
investigate the contribution of inflammatory mediators including PGE2, IL-8 and 
neutrophil elastase by analysis of their concentration in cell culture supernatants from 
16HBE 140- cells using immunoblot and ELISA assays. 
3.3. Methods 
3.3.1. Immunostaining for TF 
16HBE 140- cells were cultured in Microtek 8-well chamber slides (Nunc) at 50,000 
cells per well for 48 hours. At confluence, cells were washed with 500 J.lI of IX PBS per 
well and quiesced for 16 hours in MEM-ITS. Prior to each experiment, MEM-ITS was 
refreshed. Cells were mechanically wounded with a P2 Gilson pipette tip in a cross-
hatch manner (+) and returned to the incubator at 37°C for a time-course of 30 minutes, 
1 hour and 2 hours. Supernatants were removed and cells were washed with 500 J.lI of 
IX PBS per well. Cells were fixed by adding 500 J.lI per well of 4% (Iv) 
paraformaldehyde in PBS for 30 minutes at room temperature then washed 3 times by 
adding 500 J.lI of 1 X PBS per well and permeabilised by adding 500 J.lI per well of ice-
cold methanol (100%), for 5 minutes at -20°C. Cells were washed 3 times by adding 
500 J.lI of 1 X PBS per well and incubated for 16 hours in PBS containing 1 % C'/\) 
bovine serum albumin (BSA) at 4°C to block non-specific binding sites. Cells \\ere 
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incubated with primary antibody (mouse anti-human TF, 1 mg/ml, American 
Diagnostica, Dundee, UK) diluted 1 in 200 in IX PBS-l % BSA for 1 hour at room 
temperature. Cells were washed 5 times for 5 minutes each with 500 /-11 of IX PBS-
0.02% C/y) Tween-20 per well and incubated with secondary antibody (goat anti-mouse 
Alexa Fluor® 488 F(ab')2 fragment, Molecular Probes, UK), diluted 1 in 400 in IX 
PBS-l % BSA for 1 hour at room temperature. Cells were washed 5 times for 5 minutes 
each with 500 /-11 of IX PBS-0.02% C/y) Tween-20 and the slide mounted using 
Vectashield mounting medium (Vector Labs, UK). Cells were viewed using a Zeiss 
LSM 510 confocal microscope. 
3.3.2. TF activity assay 
The TF activity assay was conducted on cells in a 96-well plate, using an adaptation of a 
method (Lwaleed et aI., 2001). 16HBE 140- cells were seeded at a density of 25,000 
cells per well in a 96-well plate and grown to confluence for 2 days. At confluence, the 
cells were washed in IX PBS and quiesced overnight in serum-free MEM-ITS. 
Immediately prior to experiment, the MEM-ITS was discarded, cells were washed in IX 
PBS and 90 /-11 fresh MEM-ITS was added to each well. Cells were mechanically 
wounded in a cross-hatch manner (+) and incubated at 37°C for 2 hours. Following 
incubation the supernatants were removed and the cells washed in IX PBS. The activity 
assay was conducted to determine the cell surface TF activity in response to wounding. 
To each well, 60 /-11 of 0.05 M Tris-NaCl pH 7.8, 20 /-11 of 0.025 M CaCh and 15 /-11 of 
0.75 IUlml Prothromplex TIM-4 were added to the 96-well plate which was then 
incubated for 15 minutes at 37°C. Prothromplex TIM -4 is a concentrate of the human 
coagulation factors II, VII, IX and X that can collectively form the prothrombinase 
complex. The cascade is initiated through the interaction of FVII with TF and the 
activity of FX was measured, as this was proportional to the TF activity of the cells. 
After the 15 minute incubation period the further generation of coagulation factors by 
the extrinsic coagulation pathway was prevented by adding 100 /-11 0.05 M Tris-NaCI 
pH 7.8 containing 7 mM EDTA. The activity ofFX was measured by the addition of 40 
/-11 1 mM S-2222. The plate was read at 405 nm (Dynex MRX microplate reader. West 
Sussex, UK) for 1 hour at 37°C. 
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3.3.3. Immunoblotting 
16HBE 140- cells were cultured for 48 hours in 24-well plates until fully confluent and 
quiesced for 16 hours in 1 ml per well of serum-free MEM-ITS, as described in section 
2.2.1. Prior to wounding, MEM-ITS was refreshed, a concentration range of drugs were 
added to the cells and the plates were incubated for 30 minutes at 37°C. Cells were 
mechanically wounded with a P2 Gilson pipette tip in a cross-hatch manner with 
different degrees of wounding, as described in section 2.2.5, and returned to the 
incubator at 37°C for 20 minutes and 2 hours. Supernatants were removed from cells 
and centrifuged for 7 minutes at 670 x g (ALC PK120 Centrifuge, Winchester Virginia, 
USA) to remove cell debris. 
Fibrinogen and FXIII 
For the purpose of immunoblotting, 3 JlI of supernatant from each well was applied to 
0.45 Jlm nitrocellulose membrane, using an 8 x 12 grid to locate the spots. A series of 
plasma standards in the range of 0.01-10% were prepared from normal plasma (Alpha 
Laboratories, Hampshire, UK), diluted in MEM-ITS and added to the membrane as a 
reference. The membrane was left to dry at room temperature for 60 minutes and 
incubated for 16 hours at 4°C in IX PBS-2% (/y) Tween-20 to block non-specific 
binding sites. Membrane blots were then washed three times for 10 minutes each in 
PBS-0.05% (/y) Tween-20, with shaking at room temperature. 
For the detection of fibrinogen (sheep anti-human FPA IgG-peroxidase conjugate, 2 
mglml, Affinity Biologicals) and FXIII (sheep anti-human FXIIIA IgG-peroxidase 
conjugate, 2 mglml, Affinity Biologicals), antibodies were diluted in PBS-2% (/y) 
Tween-20 (FXIII: 1 in 20,000 and fibrinogen: 1 in 10,000) and 5 ml of the antibody 
solution was applied to each membrane blot. Membrane blots were placed on parafilm 
in plastic trays and incubated with antibodies for 60 minutes at room temperature. 
Membrane blots were washed five times for 10 minutes each in PBS-0.05% (Iv) 
Tween-20 with shaking at room temperature. 
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D-dimers 
F or the purpose of immunoblotting, 20 JlI of supernatant and standard was applied to 
0.45 Jlm nitrocellulose membrane using a dot blot hybridisation manifold (Jencons PLS, 
UK) under vacuum. A concentration range of D-dimer standards were prepared using a 
high molecular weight D-dimer standard (American Diagnostica: 492 ng/ml). The 
nitrocellulose membranes were left to dry at room temperature for 1 hour and incubated 
for 16 hours at 4°C in IX PBS-2% ely) Tween-20 to block non-specific binding sites. 
Membrane blots were washed three times for 10 minutes each in PBS-0.05% ely) 
Tween-20, with shaking at room temperature. 
For the detection of D-dimers, the primary antibody (mouse anti-D-dimer, 0.5 mglml, 
American Diagnostica) was diluted 1 in 500 in IX PBS-2% ely) Tween-20. To each 
membrane blot, 5 ml of the antibody solution (l Jlg/ml) was applied. Membrane blots 
were placed on parafilm in plastic trays and incubated with antibody for 1 hour at room 
temperature. Blots were washed three times for 10 minutes each in PBS-0.05% ely) 
Tween-20, with shaking at room temperature. Secondary antibody (biotinylated goat 
anti-mouse, Dako) was diluted 1 in 10,000 in IX PBS-2% ely) Tween-20 and 5 ml of 
the antibody solution was applied to each membrane blot and incubated for 1 hour at 
room temperature. Blots were washed three times for 10 minutes each in PBS-0.05% 
ely) Tween-20, with shaking. Membranes were incubated in 40 ml SAB complex 
(StreptABComplex) for 45 minutes at room temperature. The SAB complex was 
prepared 90 minutes prior to use by adding 2 JlI A (streptavidin) and 2 JlI B (biotin-
HRP) to 496 JlI PBS and made up to 40 ml with PBS-2% ely) Tween-20 immediately 
before use. The blots were washed five times for 10 minutes each with PBS-0.05% ely) 
Tween-20, with shaking at room temperature. 
For chemiluminescent detection following immunoblotting for fibrinogen, FXIII and D-
dimers, Pierce West Pico SuperSignal substrate (Perbio, Northumberland, UK) was 
used. Activator and peroxidase solutions were added together in a 1: 1 ratio and 5 ml 
was added to the membrane blot for 5 minutes at room temperature. Blots were 
transferred into plastic, zip-lock bags and excess substrate removed by blotting. Blots 
were placed in a cassette and exposed to X-ray films overnight. Films were developed 
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using the Kodak X-ray developer and the intensity of the dots were measured using 
ChemiGenius GeneSnap densitometry software. 
3.3.4. Lactate dehydrogenase (LDH) assay 
The lactate dehydrogenase (LDH) assay (TOX-7, Sigma, Dorset, UK) was used to 
determine whether the effects of wounding on the release of coagulation factors were 
due to cytotoxicity. LDH is an intracellular cytoplasmic protein that is released into cell 
culture supernatants when cells become non-viable and sustain damage to their 
membrane (Legrand et al., 1992). The assay works on the principle that LDH released 
from cells, reduces NAD to NADH, and the NADH then converts a tetrazolium dye into 
a soluble, coloured formazan derivative. The assay was adapted for use in a 96-well 
plate. Cell culture supernatants and cell lysates were diluted I in 10 by adding 5 ~l of 
sample to 45 ~l of IX PBS. The LDH assay solution was prepared by mixing equal 
. volumes of LDH substrate, LDH enzyme and LDH tetrazolium dye. To each well, 25 
~l of the LDH assay mixture was added. The plate incubated for 5 minutes at room 
temperature, protected from light. In order to stop the reaction, 8.33 ~l of 1M HCI was 
added to each well and the absorbance at 490 nm was measured using a microplate 
reader (Dynex MRX microplate reader, West Sussex, UK). 
3.3.5. Immunoassays for growth factors 
16HBE 140- cells were seeded at a density of 400,000 cells per well in 6-well plates and 
cultured for 48 hours in 2 ml per well of full MEM until fully confluent. At confluence, 
cells were quiesced for 16 hours in 1 ml per well of serum-free MEM-ITS. Prior to 
experiment, MEM-ITS was refreshed. Cells were maximally wounded, i.e. 4 horizontal 
scrapes and 4 vertical scrapes, as described in section 2.2.5 and subsequently incubated 
for 2, 4, 6, 8 and 10 hours at 37°C. The supernatants were removed from cells and 
centrifuged for 7 minutes at 670 x g (2000 rpm: ALC PK120 Centrifuge, Winchester 
Virginia, USA) to remove cell debris. 
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HumanEGF 
Centrifuged supernatants were analysed for EGF using a Quantikine® human EGF 
immunoassay (R&D Systems). EGF standards were prepared in IX calibrator diluent 
RD5E (provided) in the concentration range of: 3.9, 7.8, 15.6,31.2,62.5, 125 and 250 
pg/ml. To each well, 200 J.lI of standards and supernatants were added and the plate was 
covered and incubated for 2 hours at room temperature. Wells were aspirated and 
washed by adding 400 J.lI of wash buffer (provided) to each well. This was repeated for 
a total of three washes, ensuring complete removal of wash buffer each time. After the 
final wash, wells were aspirated and any remaining wash buffer was removed by 
inverting the plate and blotting it against clean paper towels. To each well, 200 J.lI of 
EGF conjugate was added and the plate was covered and incubated for 1 hour at room 
temperature. Wells were aspirated and washed for a total of three washes, as previously 
described. Substrate solution was prepared 15 minutes before required by adding equal 
volumes of colour reagents A and B together and protecting from light. 200 J.lI of the 
resultant substrate solution was added to each well, the plate was covered and incubated 
for 20 minutes at room temperature, protected from light. In order to stop the reaction, 
50 J.lI of stop solution (2 N sulphuric acid) was added to each well. 
HumanKGF 
Centrifuged supernatants were analysed for KGF using a Quantikine® human KGF 
immunoassay (R&D Systems). To each well, 100 J.lI of assay diluent RDI-25 was 
added. KGF standards were prepared in calibrator diluent RD5R (provided) in the 
concentration range of 31.2, 62.5, 125, 250, 500, 1000 and 2000 pg/ml. To each well, 
100 J.lI of standards and cell culture supernatants was added and the plate was covered 
and incubated for 3 hours at room temperature. Wells were aspirated and washed by 
adding 400 J.lI of diluted wash buffer (provided) to each well for a total of three washes, 
ensuring complete removal of liquid each time. After the final wash, wells were 
aspirated and any remaining wash buffer was removed by inverting the plate and 
blotting it against clean paper towels. To each well, 200 J.lI of KGF conjugate was 
added and the plate was covered and incubated for 1.75 hours at room temperature. 
Wells were aspirated and washed as previously described. Substrate solution was 
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prepared 15 minutes before required by adding equal volumes of colour reagents A and 
B together and protecting from light. To each well, 200 ~l of the substrate solution was 
added and the plate was covered and incubated for 30 minutes at room temperature, 
protected from light. In order to stop the reaction, 50 ~l of stop solution (2 N sulphuric 
acid) was added to each well. 
Human TGF-J31 
Centrifuged supernatants were analysed for TGF-J31 using a Quantikine® human TGF-
J31 immunoassay (R&D Systems). TGF was assayed as active and total TGF-J3l, before 
and after acid activation of the samples respectively. To acid activate TGF-p1, the 
following procedure was carried out in a separate 96-well plate and samples were 
assayed after neutralisation (pH 7.2-7.6). To 100 ~l of cell culture supernatant in the 
well, 20 ~l of 1 N HCL was added and the plate was incubated for 10 minutes at room 
temperature. The acidified sample was neutralised by adding 20 ~l of 1.2 N NaOH/O.5 
M HEPES. TGF-pl standards were prepared in calibrator diluent RD5-26 (provided) in 
the concentration range of31.2, 62.5, 125,250,500, 1000 and 2000 pg/ml. To each well 
of the 96-well plate provided, 50 JlI of assay diluent RDl-21 (provided) was added. This 
was followed by the addition of 50 JlI of TGF -P 1 standard and samples containing 
active and total TGF -P 1 to each well. The plate was tapped gently to mix, covered and 
incubated for 2 hours at room temperature. Wells were aspirated and washed by adding 
400 JlI of wash buffer to each well for a total of three washes, ensuring complete 
removal of liquid each time. After the final wash, wells were aspirated and any 
remaining wash buffer was removed by inverting the plate and blotting it against clean 
paper towels. To each well, 100 JlI of TGF-pl conjugate was added and the plate was 
covered and incubated for 2 hours at room temperature. The wells were aspirated and 
washed as previously described. Substrate solution was prepared 15 minutes before 
required by adding equal volumes of colour reagents A and B together and protecting 
from light. To each well, 100 JlI of the substrate solution was added and the plate was 
covered and incubated for 30 minutes at room temperature, protected from light. In 
order to stop the reaction, 100 Jll of diluted HCL (provided) was added to each well. 
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HumanHGF 
Centrifuged supernatants were analysed for HGF using a Quantikine® human HGF 
immunoassay (R&D Systems). To each well of a 96-well plate pre-coated with a murine 
monoclonal antibody against HGF, 150 /-ll of assay diluent RD 1 W was added. HGF 
standards were prepared in IX calibrator diluent RD5P (provided) in the concentration 
range of 125, 250, 500, 1000, 2000, 4000 and 8000 pg/ml. To each well. 50 /-ll of 
standards and cell culture supernatants was added and the plate was covered and 
incubated for 2 hours at room temperature. Wells were aspirated and washed by adding 
400 /-ll of diluted wash buffer (provided) to each well for a total of three washes, 
ensuring complete removal of liquid each time. After the final wash, wells were 
aspirated and any remaining wash buffer was removed by inverting the plate and 
blotting it against clean paper towels. To each well, 200 /-ll of HGF conjugate was 
added and the plate was covered and incubated for 1.75 hours at room temperature. 
Wells were aspirated and washed as previously described. Substrate solution was 
prepared 15 minutes before required by adding equal volumes of colour reagents A and 
B together and protecting from light. To each well, 200 /-ll of the substrate solution was 
added and the plate was covered and incubated for 30 minutes at room temperature, 
protected from light. In order to stop the reaction, 50 /-ll of stop solution (2 N sulphuric 
acid) was added to each well. 
For each growth factor assay, the optical density of each well was determined using a 
microplate reader (Dynex MRX: West Sussex, UK) set to 450 nm. The optical density 
at 540 nm was also determined and subtracted from the optical density at 450 nm to 
correct for any optical imperfections in the plate. 
3.3.6. Immunostaining for HGF, c-Met receptor and FXIII 
16HBE 140- cells were cultured in Microtek 8-well chamber slides (Nunc) at 50,000 
cells per well for 48 hours. At confluence, cells were washed with 500 /-ll of IX PBS per 
well and quiesced for 16 hours in MEM-ITS. Prior to each experiment, MEM-ITS was 
refreshed. A final concentration of 100 ng/ml HGF (Sigma, Dorset. UK) was added to 
cells which were then incubated at 37°C for 30 minutes. Cells were mechanically , 
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wounded with a P2 Gilson pipette tip in a cross-hatch manner (+) and returned to the 
incubator at 37°C for a time-course of 2 hours. Supernatants were removed and cells 
were washed with 500 JlI of IX PBS per well. Cells were fixed by adding 500 JlI per 
well of 4% (w/y ) paraformaldehyde in PBS for 30 minutes at room temperature then 
washed 3 times by adding 500 JlI of 1 X PBS per well and perrneabilised by adding 500 
JlI per well of ice-cold methanol (l 00%), for 5 minutes at -20°C. Cells were washed 3 
times by adding 500 JlI of 1 X PBS per well and incubated for 16 hours in PBS 
containing 1 % (w/y ) BSA at 4°C to block non-specific binding sites. Cells were 
incubated with primary antibodies: mouse anti-human HGF (0.2 mg/ml stock diluted in 
sterile IX PBS; R&D Systems, Oxfordshire, UK), goat anti-human c-Met (0.1 mg/ml 
stock diluted in sterile IX PBS; R&D Systems, Oxfordshire, UK), and sheep anti-
human FXIII (2 mg/ml stock diluted in DMSO; Affinity Biologicals, distributed by 
Quadratech Diagnostic Ltd, Surrey, UK), diluted 1 in 400 in IX PBS-1% BSA for 1 
hour at room temperature. Cells were washed 5 times for 5 minutes each with 500 JlI of 
IX PBS-0.02% e/y) Tween-20 per well and incubated with secondary antibodies for c-
Met receptor and FXIII (Donkey anti-sheep Alexa Fluor® 594, 2 mg/ml; Molecular 
Probes, UK) and HGF (goat anti-mouse Alexa Fluor® 488 F(ab')2 fragment, 2 mg/ml; 
Molecular Probes, UK), diluted 1 in 400 in IX PBS-l % BSA for 1 hour at room 
temperature. Cells were washed 5 times for 5 minutes each with 500 JlI of IX PBS-
0.02% e/y) Tween-20 and the slide mounted using Vectashield mounting medium 
(Vector Labs, UK). Cells were viewed using a Zeiss LSM 510 confocal microscope. 
3.3.7. Immunoassay for PGE2 
16HBE 140- cells were cultured for 48 hours on 24-well plates until fully confluent and 
quiesced for 16 hours in serum-free MEM-ITS, as described in section 2.2.1. Following 
mechanical wounding and subsequent incubation for 20 minutes and 2 hours, the 
supernatants were removed from cells and centrifuged for 7 minutes at 670 x g (2000 
rpm: ALC PK120 Centrifuge, Winchester Virginia, USA) to remove cell debris then 
analysed for PGE2 using a Parameter™ PGE2 high sensitivity immunoassay (R&D 
Systems, Oxfordshire, UK). This assay is based on the competitive binding technique in 
which PGE2 present in a sample competes with a fixed amount of horseradish 
peroxidase (HRP)-labelled PGE2 for sites on a mouse monoclonal antibody. During the 
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incubation, the mouse monoclonal antibody becomes bound to the goat anti-mouse 
antibody coated onto the microplate. Following a wash step to remove the excess 
conjugate and unbound sample, a substrate solution is added to the wells to determine 
the bound enzyme activity. The colour development is stopped, and the absorbance is 
read at 450 nm. The intensity of the colour is inversely proportional to the concentration 
of PGE2 in the sample. 
PGE2 standards were prepared in calibrator diluent RD5-39 in the concentration range 
of: 7.8, 15.6,31.2,62.5, 125,250, 500 and 1000 pg/ml. Calibrator diluent RD5-39 was 
added to non-specific binding (NSB) wells (150 /-ll) and zero standard Bo wells (100 /-ll) 
and 100 /-ll of standards and supernatants were added to remaining wells. To each well, 
50 /-ll of primary mouse monoclonal antibody to PGE2 was added, excluding NSB wells, 
followed by the addition of 50 /-ll of PGE2 conjugate to each well. The plate was covered 
and incubated for 20 hours at 4°C. Wells were aspirated and washed by adding 400 /-ll 
of diluted wash buffer (provided) for a total of four washes, ensuring complete removal 
of liquid after each wash. After the final wash, wells were aspirated and any remaining 
wash buffer was removed by inverting the plate and blotting it against clean paper 
towels. Substrate solution was prepared 15 minutes before required by mixing together 
equal volumes of colour reagents A and B and protecting from light. To each well, 200 
/-ll of the substrate solution was added and the plate was incubated for 20 minutes at 
room temperature, protected from light. In order to stop the reaction, 50 /-ll of stop 
solution (2 N sulphuric acid) was added to each well and the optical density of each 
well was determined using a microplate reader (Dynex MRX: West Sussex, UK) set to 
450 nm. The optical density at 540 nm was also determined and subtracted from the 
optical density at 450 nm to correct for any optical imperfections in the plate. 
3.3.8. Immunoassay for IL-8 
16HBE 140- cells were cultured, wounded and incubated and supernatants were 
harvested as described in section 3.3.5. Centrifuged supernatants were analysed for IL-8 
using a Pelikine Compact™ human IL-8 ELISA kit (Sanquin Reagents, Amsterdam). 
Monoclonal anti-human IL-8 antibody was diluted 1 in 100 in coating buffer (coating 
buffer: 1 capsule of carbonatelbicarbonate (Sigma, UK) dissolved in 100 ml deionised 
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H20). 100 !J.I of coating antibody was added to each well and the plate was covered and 
incubated overnight at room temperature. Prior to use, all reagents (with the exception 
of streptavidin-HRP) were brought to room temperature. The plate was washed 5 times 
with 200 !J.I per well of IX PBS. To each well, 200 !J.I of blocking buffer (provided) was 
added and the plate was incubated for 60 minutes at room temperature. The plate was 
washed five times with 200 !J.I per well of IX PBS-0.005% e/v) Tween-20. Leaving the 
substrate blank wells empty, 100 !J.I of IL-8 standards, in the concentration range of: 1, 
2.5, 6.l, 15.4, 38.4, 96 and 240 pglml and 100 !J.I of cell culture supernatants diluted 1 in 
10 with MEM-ITS were added. The plate was covered and incubated for 60 minutes at 
room temperature. The plate was washed five times with 200 !J.I per well of IX PBS-
0.005% e/v) Tween-20. Leaving the substrate blank wells empty, 100 !J.I ofbiotinylated 
sheep antibody to human IL-8, diluted 1 in 100 with dilution buffer (provided) was 
added to each well and the plate was covered and incubated for 60 minutes at room 
temperature. The plate was washed five times with 200 !J.I per well of IX PBS-0.005% 
e/v) Tween-20. Leaving the substrate blank wells empty. Streptavidin-HRP conjugate 
was diluted 1 in 10,000 in dilution buffer (provided) and 100 !J.I was added to each well. 
The plate was covered and incubated at room temperature for 30 minutes. Immediately 
before use, substrate solution was prepared: 12 ml substrate buffer (0.11 M acetate 
buffer pH 5.5), 200 !J.I of tetramethylbenzidine (TMB, 6 mglml in DMSO: Sigma, UK) 
and 12 !J.I H20 2 (3% H20 2 in deionised water: Sigma, UK). The plate was washed five 
times by adding 200 !J.I per well of IX PBS-0.005% e/v) Tween-20. To all wells 
including substrate blank wells, 100 !J.I of the resultant substrate solution was added and 
the plate was covered and incubated for 30 minutes at room temperature, protected from 
light. In order to stop the reaction, 100 !J.I of stop solution (1.8 M H2S04) was added to 
each well and the optical density at 450 nm was determined for each well using a 
microplate reader (Dynex MRX: West Sussex, UK). IL-8 concentration in the samples 
was determined from the standard curve, taking into account the 1 in 10 dilution. 
3.3.9. Stimulation of 16HBE 140- cells with neutrophil elastase 
A concentration range of: 0, 0.1, 0.03, 0.1, 0.3 and 0.5 Ulml neutrophil elastase (3 Ulml 
stock dissolved in IX PBS: Sigma, Dorset, UK) was added to cells in a volume of 250 
!J.1 per well and the plate was incubated for 30 minutes at 37°C. Cells were then 
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mechanically wounded (W8) as described in section 2.2.5 and incubated for 20 minutes 
and 2 hours at 37°C. Cell culture supernatants were then harvested as described in 
section 2.2.4 and the concentration of fibrinogen and FXIII was determined by 
immunoblot as described in section 3.3.3. 
3.4. Results 
3.4.1. TF 
3.4.1.1. Immunohistochemistry for TF 
TF is an integral membrane glycoprotein and is important in the initiation of the 
coagulation cascade. It is believed that TF is constitutively expressed by cells that playa 
vital role in repair following injury (Osterud, 1997), therefore, its presence was 
investigated in the intact and wounded mono layers of 16HBE 140- cells. 
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Figure 3.8. Fluorescent immunolocalisation of TF on 16HBE 140- cells visualised by 
confocal laser scanning microscopy (CLSM) at x400 magnification. Scale bar 
represents 20 /-Lm. (A) represents an unwounded monolayer of 16HBE 140- cells. (B) 30 
minutes post-wound. (C) 1 hour post-wound. (D) 2 hour post-wound. 
The image represented by figure 3.8 A shows positive immunostaining for TF in the 
unwounded cell monolayer. Consistent with the literature, the strong staining at the 
periphery of the cell indicates that TF is a trans-membranous protein but more 
importantly, it shows that TF is constitutively expressed by 16HBE 140- cells. At 1 and 
2 hours post-wound (figures 3.8 C and 3.8 D respectively), there is evidence of TF 
upregulation at the wound edge suggesting involvement of the protein in wound repair. 
Moreover, figure 3.9 B demonstrates polarised cells with pseudopodia proj ecting in the 
direction of the wound. Immunostaining for TF is also evident in vesicles within th 
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cells at the edge of the wound, implying that TF may be pre-formed and subsequently 
inserted into the membrane following wounding. 
Figure 3.9. Fluorescent immunolocalisation of TF on 16HBE 140- cells visuali sed by 
CLSM at x400 magnification. Scale bar represents 20 ~m. (A) 2 hours post-wound . (B) 
16HBE 140- cells at the wound edge with pseudopodia projecting towards the centre of 
the wound, indicative of directed migration. 
In order to verify that the immunostaining for TF was specific, negative control s were 
included, whereby staining was investigated in the absence of primary antibody and in 
the absence of secondary antibody (figure 3.10). 
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Figure 3.10. Negative immunostaining for TF on 16HBE 140- cells. Scale bar 
represents 20 ~m. (A) No fluorescence for TF on 16HBE 140- cells in the absence of 
primary antibody. (B) Differential interference contrast (DIC) image of the unwounded 
monolayer of 16HBE 140- cells. (C) Combination of images A and B. (D) No 
fluorescence for TF on 16HBE 140- cells in the absence of secondary antibody. (E) DIC 
image of the unwounded monolayer of 16HBE 140- cells. (F) Combination of images D 
andE. 
Negative controls displayed by DIC images of the unwounded cell monolayer indicate 
that in the absence of primary antibody (i.e. secondary antibody alone, figures 3.10 A, B 
and C) and in the absence of secondary antibody (i.e. primary antibody alone, figures 
3.10. D, E and F), there is no immunostaining for TF. 
3.4.1.2. TF activity 
Since immunohistochemistry demonstrated constitutive expression of TF by 16HBE 
140 - cells, it was of interest to measure the activity of TF, at baseline and in response to 
wounding. 
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Figure 3.11. The effect of wounding on TF activity in 16HBE 140- cells. Data represent 
mean ± SEM of replicates of 5 and representative of two experiments. 
TF activity at baseline was 4.0 ± 0.89 mOD/minute compared to 4.8 ± 2.0 mOD/minute 
in the wounded cell cultures of 16HBE 140- cells. The effect of wounding on TF 
activity was not significant. 
3.4.2. Effect of wounding on the release of coagulation factors 
3.4.2.1. Fibrinogen 
Figure 3.12 represents a typical standard curve for the detection of fibrinogen in cell 
culture supernatants. A linear relationship between immunoblot density and fibrinogen 
concentration measured in arbitrary units (AU) was demonstrated up to 20 ~g/ml. At 
higher concentrations, the density values tended to plateau, therefore samples were 
analysed in the linear range of 0-20 ~g/ml. 
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Figure 3.12. Representative graph illustrating the standard curve of fibrinogen. A serial 
dilution of normal plasma was used as a reference for fibrinogen concentration. 
Figure 3.13. Illustrates the release of fibrinogen into cell culture supernatants at 2 homs 
post-wounding determined by immunoblot analysis. 
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Figure 3.13. Effect of wounding on the concentration of fibrinogen in cell cultme 
supernatants of 16HBE 140- cells at 2 hours. C=unwounded cells, W2=2 wounds, 
W4=4 wounds and W8=8 wounds. Data represent mean ± SEM (n=3). * Indicates 
P<0.05 and * * indicates P<O.OO 1 compared to the unwounded control. 
Cell culture supernatants were removed from 16HBE 140- cells 2 hours post-wounding 
and analysed for fibrinogen . Supernatants displayed a significant increase in the 
concentration of soluble fibrinogen with the degree of wounding (W4=4.08 ± 0.20 
Jlg/ml and W8=11.58 ± 0.78 ~Lg/ml) compared to the unwounded cell control (C=0.35 ± 
0.08 Jlg/ml), indicating that there is release of fibrinogen that is dependent on the extent 
of wounding. 
93 
3.4.2.2. FXIIIA 
The cellular form of coagulation FXIII represents a dimer of two potentially active A 
subunits (FXIIIA) (Katona et aI. , 2005). Therefore, an antibody that recognises the 
FXIIIA subunit was used, since this subunit represents the cell associated form . 
Figure 3.14 represents a typical standard curve for the detection of FXIIIA in cell 
culture supernatants. A linear relationship between immunoblot density and FXIIIA 
concentration measured in AU was demonstrated up to 4 ng/ml. At higher 
concentrations, the density values tended to plateau, therefore samples were analysed in 
the linear range of 0-4 ng/ml. 
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Figure 3.14. Representative graph illustrating the standard curve for ~XIIIA . A serial 
dilution of normal plasma was used as a reference of FXIIIA concentratIOn. 
Figure 3.15 Illustrates the release of FXIIIA into cell culture supernatants at 2 hours 
post-wounding determined by immunoblot analysis. 
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Figure 3.15. Effect of wounding on the concentration of FXIIIA in cell culture 
supernatants of 16HBE 140- cells at 2 hours. C=unwounded cells, W2=2 wounds, 
W4=4 wounds and W8=8 wounds. Data represent mean ± SEM (n=3). * Indicates 
P<0.05 compared to the unwounded control. 
Cell culture supernatants were removed from 16HBE 140- cells 2 hours post-wounding 
and analysed for FXIIIA. Supernatants displayed a significant increase in FXIII 
concentration with the degree of wounding (W2=17.00 ± 1.06 ng/ml, W4=22.30 ± 0.51 
ng/ml and W8=24.43 ± 0.59 ng/ml) compared to the unwounded cell control (C=4.49 ± 
1.50 ng/ml) at 2 hours, indicating that FXIII was released from cells with the extent of 
cell damage. 
3.4.2.3. D-dimers 
D-dimer concentration, a measure of both fibrin formation and breakdown was 
measured in cell culture supernatants from intact and wounded cell layers. Figure 3.16 
represents a typical standard curve for the detection of D-dimers in cell culture 
supernatants. A linear relationship between immunoblot density and D-dimer 
concentration measured in AU was demonstrated up to 70 ng/ml. At higher 
concentrations, the density values tended to plateau, therefore samples were analys\?d in 
the linear range of 0-70 ng/ml. 
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Figure 3.16. Representative graph illustrating the standard curve for D-dimers. A high 
molecular weight D-dimer standard was used as a reference of D-dimer concentration. 
Figure 3.17 illustrates the release of D-dimers into cell culture supernatants at 2 hours 
post-wounding determined by immunoblot analysis. 
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Figure 3.17. Effect of wounding on the concentration of D-dimers in ce ll culture 
supernatants of 16HBE 140- cells at 2 hours. C=unwounded cells, W2=2 wound . 
W4=4 wounds and W8=8 wounds. Data represent mean ± SEM (n=3). * Indicate 
P<0.05 and ** indicates P<O.OI compared to C. 
96 
Cell culture supernatants were removed from 16HBE 140' cells 2 hours post-wounding 
and analysed for D-dimers. Supernatants displayed a significant increase in the 
concentration of D-dimers with increasing cell damage (W2=7 .79 ± l.0 1 ng/ml, 
W4=12.40 ± 0.58 ng/ml and W8=19.28 ± 0.58 ng/ml) compared to the unwounded cell 
control (C=2.77 ± l.04 ng/ml) indicating that wounding stimulated an increase in the 
release of D-dimers from the cells into cell culture supernatants. 
3.4.3. Effect of wounding on LDH levels 
Supernatants and celllysates were assayed for LDH to determine whether the release of 
coagulation factors in response to wounding was due to cytotoxicity as a consequence 
of the rupturing of the dislodged cells by mechanical wounding. 
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Figure 3.18. LDH levels in cell culture supernatants and cell lysates of 16HBE 140' 
cells at 2 hours post-wounding. C=unwounded cells, W2=2 wounds, W4=4 wounds and 
W8=8 wounds. Data represent mean ± SEM (n=3) . 
Analysis of LDH levels in cell culture supernatants revealed a small but non-signi ficant 
increase, dependent on the extent of wounding (C=0.002 ± 0.001 , W2=0.004 ± 0.002. 
W4=0.006 ± 0.002 and W8=0.01 ± 0.002). This correlated to a small , non-significant 
decrease of LDH in the cell lysates dependent on the extent of wounding (C=0. 19 ± 
0.004, W2=0.17 ± 0.006, W4=0.16 ± 0.01 and W8=0.1 4 ± 0.02) . In the unwounded 
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cells, supernatants displayed 1 % LDH relative to the total cell number and this 
proportion was unaltered with the extent of wounding. 
3.4.4. Growth Factors 
Since growth factors have been implicated in wound repair, their expreSSIOn was 
investigated in this model of 16HBE 140- wound repair. 
3.4.4.1. EGF 
It is well established that EGF is an important regulator of bronchial epithelial 
restitution in vivo. Weak expression of EGF has been demonstrated in the bronchial 
epithelium and the epithelium has also been shown to express the EGFR. Therefore, the 
involvement of EGF was investigated in wound repair by analysis of EGF concentration 
in cell culture supernatants up to 12 hours post-wounding. The assay was highly 
sensitive, with a detection limit of 0.7 pg/ml. Figure 3.19 illustrates the standard curve 
for EGF. A linear relationship between the optical density and the concentration of EGF 
was seen up to 250 pg/ml; therefore the concentration of EGF in the cell culture 
supernatants was determined within the range of 0-250 pg/ml. 
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Figure 3.19. Representative graph illustrating the standard curve for EGF. 
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Time (b) post- Mean optical Mean concentration of SEM 
wound density (OD) at 450 EGF (pglml) 
nm 
UW J 0.004 I 0.123 --~)Q.007 
2 I 0.005 I 0.256 I 0.006 
4 I 0.003 I 0.025 I 0.005 
6 I 0.003 I 0.059 I 0.020 
8 I 0.003 I 0.085 I 0.009 
10 I 0.004 I 0.016 I 0.011 
12 I 0.003 I 0.063 I 0.003 
Table 3.2. Optical density values indicating the effect of time post-wounding on the 
concentration of EGF in cell culture supernatants from 16HBE 140- cells. 
UW=unwounded cells. Data represent mean ± SEM (n=5). 
The values illustrated in table 3.2 indicate that the concentration of EGF released into 
cell culture supernatants at baseline and in response to wounding was extremely low. 
Furthermore, there was no statistically significant difference between the wounded cell 
cultures at any of the time-points investigated compared to the unwounded cell control. 
3.4.4.2. KGF 
KGF is a member of the fibroblast growth factor family and has been shown to target 
the bronchial epithelium and promote repair. Thus, the involvement of KGF was 
investigated in wound repair by analysis of KGF concentration in cell culture 
supernatants up to 12 hours post-wounding. The assay was highly sensitive, with a 
minimal detectable concentration of 15 pg/ml KGF. Figure 3.20 illustrates the standard 
curve for KGF. A linear relationship between the optical density and the concentration 
of KGF was seen up to 2000 pg/ml; therefore the concentration of KGF in the cell 
culture supernatants was determined within the range of 0-2000 pg/ml. 
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Figure 3.20. Representative graph illustrating the standard curve for KGF. 
Time (h) post- Mean optical Mean concentration I wound density (OD) at 450 of KGF (pglml) nm 
I UW I 0.017 I 13.862 I 2.206 
I 2 I 0.012 I 10.111 I 4.661 
I 4 I 0.012 I 10.111 I 3.442 
I 6 I 0.013 I 10.945 I 4.955 
I 8 I 0.014 I 11.445 I 4.836 
I 10 I 0.015 I 12.611 I 2.971 
I 12 I 0.016 I 12.861 I 2.974 
Table 3.3. Optical density values indicating the effect of time post-wounding on the 
concentration of KGF in cell culture supernatants from 16HBE 140- cells. 
UW=unwounded cells. Data represent mean ± SEM (n=5). 
Similarly, the analysis of cell culture supernatants for KGF revealed that the 
concentration of this growth factor in supernatants of unwounded cells and those 
investigated at time intervals post-wounding was also very low with reference to the 
standard curve for KGF and there was no significant difference between any of the 
conditions measured. 
100 
3.4.4.3. TGF -131 
Since TGF-J31 has been shown to be synthesised by epithelial cells and has been 
implicated in repair of 16HBE 140- cell mono layers in culture (Howat et aI.. 2002), its 
role was investigated in this model of 16HBE 140- wound repair by analysis of total and 
active concentration of TGF-J31 in cell culture supernatants up to 12 hours post-
wounding. The assay was highly sensitive, with a mean minimal detectable 
concentration of 4.61 pg/ml total TGF-J31. Figure 3.21 illustrates the standard curve for 
TGF-J31. A linear relationship between the optical density and the concentration of 
TGF-J31 was seen up to 2000 pg/ml; therefore the concentration of TGF-J31 in the cell 
culture supernatants was determined within the range of 0-2000 pg/ml. Total TGF-J31 
refers to the concentration of TGF -131 as a consequence of acid-activation and includes 
both latent and active TGF -131; and active TGF -131 refers to the concentration of TGF-
131 in samples before acid-activation. The concentration of latent TGF -131 may be 
calculated from the active and total concentrations. 
Figure 3.21. Representative graph illustrating the standard curve for TGF-J3l. 
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Time (b) post- I Mean optical Mean concentration I wound i density (OD) at 450 of total TGF -(31 I nm (pglml) 
I UW 0.015 16.753 I 1.680 
I 2 0.018 19.698 I 1.780 
I 4 0.027 30.309 * I 5.389 
I ... 6 0.027 30.309 * 14.595--· 
1 
8 0.029 31.809 * I 6.356 
10 I 0.029 32.531 * I 3.285 
12 I 0.027 29.975 * I 2.773 
Table 3.4. Optical density values indicating the effect of time post-wounding on the 
concentration of latent TGF-J31 in cell culture supernatants from 16HBE 140· cells. 
UW=unwounded cells. Data represent mean ± SEM (n=5). * Indicates P<0.005 
compared to UW. 
Time (b) post- Mean optical Mean concentration I wound density (OD) at 450 of active TGF -(31 nm (pg/ml) 
I UW I 0.011 I 13.650 I 3.840 
I 2 I 0.011 I 13.300 I 3.302 
1 
4 I 0.007 I 8.80 I 1.880 
I 6 I 0.009 I 11.200 I 1.823 
I 8 I 0.011 I 14.025 I 4.474 
I 10 I 0.015 I 16.600 I 3.292 
I 12 1 0.014 I 16.975 I 2.268 
Table 3.5. Optical density values indicating the effect of time post-wounding on the 
concentation of active TGF -J31 in cell culture supernatants from 16HBE 140· cells. 
UW=unwounded cells. Data represent mean ± SEM (n=5). 
Wounded cell cultures displayed higher concentrations of TGF -J31 in its total form 
compared to active TGF -J31, although concentrations were found to be very low. 
However, there was a significant increase in the total concentration of TGF -J31 in cell 
culture supernatants 4 hours post-wound (30.31 ± 5.39 pg/ml) compared to 16.75 ± 1.68 
pg/ml in the unwounded cell cultures. This effect was maintained up to 12h pOSf-
wounding (6 hours = 30.31 ± 4.60 pg/ml; 8 hours = 31.81 ± 3.29 pg/ml; 10 hours = 
32.53 ± 3.29 pg/ml; 12 hours = 29.98 ± 2.77 pg/ml). This increase was associated with 
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I 
I 
I 
I 
I 
I 
I 
an increase in latent TGF -~ 1 since there was no effect of wounding on the concentration 
of active TGF-~ 1 in cell culture supernatants. 
Time (b) Mean concentration Mean concentration Mean concentration 
post- of total TGF-~1 of active TGF-~1 of latent TGF -~1 
wound (pg/ml) 
... 
(pg/ml) (pglml) 
UW I 16.753 I 13.650 I 3.10 
2 I 19.698 I 13.300 I 6.40 
4 I 30.309 * I 8.80 I 21.51 
6 I 30.309 * I 11.200 I 19.12 
8 I 31.809 * I 14.025 I 17.78 
10 I 32.531 * I 16.600 I 15.93 
12 I 29.975 * I 16.975 I 13.00 
Table 3.6. Mean concentration of latent TGF-~ 1 calculated from the active and total 
concentrations. 
3.4.4.4. HGF and c-Met receptor 
HGF is synthesised by mesenchymal cells and has been implicated in bronchial 
epithelial repair by enhancing cell migration in vitro. HGF and corresponding HGF (c-
Met) receptor expression was therefore investigated in this model of 16HBE 140- cells. 
HGF was not detected by immunohistochemistry of 16HBE 140- cells or by ELISA 
(data not shown). However, the c-Met receptor was expressed by these cells (figure 3.22 
A), and its expression was upregulated in response to 100 ng/ml HGF (figure 3.22.B) 
and in response to wounding (figure 3.22 C). 
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Figure 3.22. Fluorescent immunolocalisation of c-Met receptor on 16HBE 140· cells 
visualised by CLSM at x400 magnification. Scale bar represents 20 ~m. (A) represents 
an unstimulated monolayer of 16HBE 140· cells. (B) An intact monolayer of 16HBE 
140· cells stimulated with 100 ng/ml HGF (C) A wounded monolayer of unstimulated 
16HBE 140· cells. Images are representative of two separate experiments. 
3.4.4.5 Effect of HGF on FXIIIA expression 
Since HGF has been implicated in wound repair, it was of interest to investigate its 
effects on expression of FXIIIA, the trans glutaminase cross-linking enzyme that is 
important in fibrinogenesis. 
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Figure 3.23. Fluorescent immunolocalisation of FXIIIA on 16HBE 140- cell s 
visualised by CLSM at x400 magnification. Scale bar represents 20 Ilm. (A) represents 
an intact monolayer of 16HBE 140- cells. (B) An intact monolayer of 16HBE 140- cell s 
stimulated with 100 ng/ml HGF. Images are representative of two separate experiments. 
Immunostaining for FXIIIA demonstrated that this coagulation factor is expressed by 
16HBE 140- cells (figure 3.23 A) and that HGF stimulates the diffusion of FXIIIA from 
the cytoplasm to the plasma membrane (figure 3.23 B). 
3.4.5. PGE2 
Since PGE2 is the predominant prostanoid produced by the bronchial epithelium and has 
been implicated in wound repair, its release was investigated in this model of 16HBE 
140 - wound repair. 
3.4.5.1. PGE2 ELISA 
Figure 3.24 represents the standard curve for PGE2. Since the assay re lies on 
competitive binding, the optical density of the standard decreases with increasing 
concentration of PGE2. 
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Figure 3.24. Representative graph illustrating the standard curve for PGE2. 
The effect of wounding on the concentration of PGE2 in cell culture supernatants at 20 
minutes was investigated (table 3.7). 
~egreeOf Mean optical Mean 
wounding at density (OD) at concentration of SEM 
20m ins 405nm PGE2 (pglml) 
I C 0.421 [ 9.391 0.822 
I W8 0.424 I 8.841 1.577 
Table 3.7. Optical density values indicating the effect of wounding on the concentration 
of PGE2 in cell culture supernatants of 16HBE 140- cells at 20 minutes. C=unwounded 
cell control and W8=8 wounds. Data represent mean ± SEM (n=3). 
Similarly, the effect of wounding on the concentration of PGE2 III cell culture 
supernatants at 2 hours was investigated (table 3.8). 
Degree of Mean optical Mean 
wounding at density (OD) at concentration of SEM 
2h 405nm PGE2 (pglml) 
C 0.420 9.526 0.338 
W8 0.417 9.792 0.523 
Table 3.8. Optical density values indicating the effect of wounding on the concentration 
of PGE2 in cell culture supernatants of 16HBE 140- cells at 2 hours. C=unwounded cell 
control and W8=8 wounds. Data represent mean ± SEM (n=3). 
106 
The concentration levels of this prostanoid were found to be very low in cell culture 
supernatants at baseline and in response to wounding at 20 minutes and 2 hours. 
Furthermore, there was no significant difference between conditions at each of the time-
points investigated. 
3.4.5.2. Effect of PGE2 on fibrinogen expression 
Previous studies had indicated a positive effect of PGE2 at concentrations of up to 10 
/-lg/ml on repair of wounded 16HBE 140- monolayers (Savla et a!. , 2001 ). Therefore, the 
effect of exogenously added PGE2 (0-20 /-lg/ml) on the release of fibrinogen from intact 
and wounded cell monolayers at 20 minutes and 2 hours was investigated by 
immunoblot analysis. 
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Figure 3.25. Effect of PGE2 on the concentration of fibrinogen in cell culture 
supernatants of 16HBE 140- cells at 20 minutes. C denotes control (unwounded) cell s 
and W8 represents maximum scrape damage. Data represent mean ± SEM (n =3) . 
* Indicates P<0.05 compared to unwounded cell control. 
The concentration of fibrinogen in supernatants of the wounded cell culture control was 
significantly increased compared to the unwounded cell culture control at 20 minutes 
(W8=5.38 ± 0.55 compared to C=0.45 ± 0.20). This pattern remained the same with the 
addition of PGE2. With respect to the wounded cell cultures, the addition of 20 /-lg/ml 
PGE2 resulted in a slightly higher concentration of fibrinogen in cell culture 
supernatants compared to the no drug control, however, thi s effect was insignificant. 
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Thus, the prostanoid did not induce any significant effects on the levels of fibrinogen in 
cell culture supernatants in the intact or the wounded cell cultures at 20 minutes. 
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Figure 3.26. Effect of PGE2 on the concentration of fibrinogen in cell culture 
supernatants of 16HBE 140- cells at 2 hours. C denotes control (unwounded) cells and 
W8 represents maximum scrape damage. Data represent mean ± SEM (n =3) . 
* Indicates P<0.05 compared to unwounded cell control. 
At 2 hours, there was a significant increase in the concentration of fibrinogen released 
into supernatants of the wounded cell cultures compared to baseline in the absence of 
PGE2 (W8=4.78 ± 1.25 Jlg/ml compared to C=0.96 ± 0.06 Jlg/ml). With the addition of 
PGE2, the difference between fibrinogen concentration in supernatants of baseline and 
wounded cell cultures remained significant, however, PGE2 did not affect the release of 
fibrinogen into supernatants under either condition. 
3.4.5.3. Effect of PGE2 on FXIII concentration 
Similarly, the effect of PGE2 (0-20 Jlg/ml) on the release of FXIII from intact and 
wounded cell monolayers at 20 minutes and 2 hours was investigated by immunoblot 
analysis. 
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Figure 3.27. Effect of PGE2 on the concentration of FxnI in cell culture supernatants 
of 16HBE 140- cells at 20 minutes. C denotes control (unwounded) cells and W8 
represents maximum scrape damage. Data represent mean ± SEM (n=3). * Indicates 
P<O.OI compared to unwounded cell control. 
With respect to the control cell cultures, a significantly higher level of FXIn was 
present in supernatants derived from wounded cells (17.01 ± 0.91 ng/ml) compared to 
those from unwounded cell mono layers (3 .67 ± 0.98 ng/ml) at 20 minutes. The addition 
of PGE2 (1-20 Jlg/ml) had no effect on the concentration of FXIn in supernatants at 
baseline or in the wounded cell cultures . 
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Figure 3.28. Effect of PGE2 on the concentration of FXIn in cell culture supernatants 
of 16HBE 140- cells at 2 hours. C denotes control (LillwoLillded) cells and W8 represents 
maximum scrape damage. Data represent mean ± SEM (n =3) . * Indicates P<O.O 1 
compared to unwounded cell control. 
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The concentration of FXIII in supernatants derived from wounded cell culture controls 
was significantly higher (16.05 ± l.55 ng/ml) than that demonstrated in supernatants 
from the unwounded cell culture controls (2.04 ± 0.68 ng/ml) at 2 hours . This pattern 
remained the same following the addition of PGE2 and the prostanoid had no effect on 
the concentration of FXIII in supernatants at baseline or the wounded cell cultures. 
3.4.5.4. Effect of PGE2 on D-dimer concentration 
Finally, the effect of PGE2 (0-20 /-lg/ml) was investigated on the release of D-dimers, 
the marker of fibrin formation and breakdown, from intact and wounded cell 
mono layers at 20 minutes and 2 hours by immunoblot analysis. 
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Figure 3.29: Effect of PGE2 on the concentration of D-dimers in cell culture 
supernatants of 16HBE 140- cells at 20 minutes. C denotes control (unwounded) cell s 
and W8 represents maximum scrape damage. Data represent mean ± SEM (n =3). 
* Indicates P<O.OI and * indicates P<O.OOI compared to unwounded cell control. 
Analysis of D-dimer concentration in supernatants at 20 minutes revealed that 
wounding alone stimulated a significantly higher level of D-dimers compared to 
baseline (W8=11.73 ± 1.53 ng/ml and C=2.27 ± 0.31 ng/ml). This effect remained the 
same with the addition of PGE2 and the prostanoid had no effect on the levels of D-
dimers in supernatants at baseline or those of cells subj ected to wounding. 
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Figure 3.30. Effect of PGE2 on the concentration of D-dimers in cell culture 
supernatants of 16HBE cells at 2 hours. C denotes control (unwounded) cells and W8 
represents maximum scrape damage. Data represent mean ± SEM (n =3). * Indicates 
P<O.Ol compared to unwounded cell control. 
Similarly, at 2 hours, supernatants of wounded cell cultures displayed a significantly 
higher level of D-dimers compared to that seen at baseline (W8= 1 0.46 ± 1.45 ng/ml and 
C=2.00 ± 0.18 ng/ml). This effect was unaltered by PGE2 and the prostanoid did not 
induce any effect on the D-dimer concentration in supernatants at baseline or of the 
wounded cell cultures. 
3.4.6.IL-8 
IL-8, an inflammatory cytokine abundantly expressed in human bronchial epithelial 
cells, was measured in intact and wounded 16HBE 140- cell culture supernatants, as 
described in section 3.3.8. Figure 3.31 illustrates a typical standard curve for the 
detection of IL-8 in cell culture supernatants. The assay was highly sensitive, with a 
detection limit of 1 pg/ml, therefore samples were diluted 1 in 10 prior to assay. 
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Figure 3.31. Representative graph illustrating the standard curve for IL-8. 
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Figure 3.32 represents the release of IL-8 into cell culture supernatants up to 12 hours 
post-wounding, determined by IL-8 ELISA. 
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Figure 3.32. Effect of time post-wounding on the concentration of IL-8 in cell culture 
supernatants of 16HBE 140- cells. UW= unwounded cells. 12 hours cell culture 
supernatant. Data represent mean ± SEM (n=5). * Indicates P<O.05 and ** indicates 
P<O.005 compared to unwounded cell control. 
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Analysis of cell culture supernatants for IL-8 revealed that there was a significant 
increase with time 4 hours post-wounding (1093.3 ± 188.9) and this was maintained up 
to 12 hours (1450.8 ± 120.5) compared to the unwounded cell control (449.2 ± 186.3). 
3.4.7. Neutrophil elastase 
Neutrophil elastase has previously been reported to enhance IL-8 expression (Devaney 
et al., 2003) and increase PGE2 production (Perng et ai., 2003) in bronchial epithelial 
cells and might therefore enhance coagulation factor expression in the current model. 
Activation of P AR-2 was shown to enhance the release of coagulation factors from 
16HBE 140- cells in Chapter 5, however, neutrophil elastase has been reported to 
inactivate PAR-2 (Dulon et ai., 2003); therefore neutrophil elastase might inhibit the 
release of coagulation factors in the current model. Neutrophil elastase is also known to 
cleave coagulation factors (Anders sen et al., 1993; Turkington, 1991). Therefore, the 
effect of neutrophil elastase on coagulation factor expression was investigated. 
3.4.7.1. Effect of neutrophil elastase on fibrinogen concentration 
The effect of neutrophil elastase was investigated on the release of fibrinogen into cell 
culture supernatants 20 minutes and 2 hours post-wounding by immunoblot analysis. A 
concentration range of 0-0.5 Vlml was used since 50 nM neutrophil elastase 
(corresponding to approximately 0.5 Vlml) was previously shown to upregulate IL-8 
(Devaney et ai., 2003). 
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Figure 3.33. Effect of neutrophil elastase on the concentration of fibrinogen in cell 
culture supernatants of 16HBE 140- cells at 20 minutes. Control bars denote 
unwounded cells and wounded bars represent maximum scrape damage, W8 . Data 
represent mean ± SEM (n =3). * Indicates P<O.Ol and ** indicates P<O.OOl compared 
to control (unwounded) cells at each concentration of elastase. t Indicates P<O.OS 
compared to the no elastase control in the wounded cells. 
With respect to the control cell cultures, wounding alone stimulated a significant 
increase in the concentration of fibrinogen in supernatants (S .66 ± 0.31 J.lg/ml) 
compared to baseline (0.41 ± 0.01 J.lg/ml) at 20 minutes. This pattern was maintained up 
to O.S U/ml elastase. However, the addition of O.S U/ml elastase induced a significant 
decrease in the concentration of fibrinogen in supernatants of the wounded cell cultures 
(3 .0S ± 0.21 J.lg/ml) compared with the no drug control (S.66 ± 0.31 J.lg/ml). Elastase 
had no effect on the concentration of fibrinogen in supernatants of the unwounded cell 
cultures. 
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Figure 3.34. Effect of elastase on the concentration of fibrinogen in cell culture 
supernatants of 16HBE 140- cells at 2 hours. Control bars denote unwounded cells and 
wounded bars represent maximum scrape damage, W8. Data represent mean ± SEM 
(n =3). * Indicates P<O.OI and ** indicates P<0.001 compared to control (unwounded) 
cells at each concentration of elastase. t Indicates P<0.05 and t indicates P<O.OO 1 
compared to the no elastase control in the wounded cells. 
With respect to the control cell cultures, the concentration of fibrinogen in supernatants 
derived from wounded cell mono layers (6.77 ± 0.04 /-lg/ml) was significantly higher at 2 
hours compared to that seen at baseline (0.85 ± 0.33 /-lg /ml). This pattern was 
maintained following addition of up to 0.1 U/ml elastase. Supernatants of wounded cell 
cultures subjected to 0.3 U/ml elastase displayed a significantly lower concentration of 
fibrinogen (1.96 ± 0.64 /-lg/ml) compared to the no drug control (6.77 ± 0.04 /-l g/ml ). 
Supernatant concentration of fibrinogen was further diminished to 0.49 ± 0.09 /-lglml 
with the addition of 0.5 U/ml elastase in the wounded cell cultures. The concentration of 
fibrinogen in the unwounded cell culture supernatants was unaffected by elastase. 
3.4.7.2. Effect of neutrophil elastase on FXlII concentration 
The effect of neutrophil elastase (0-0.5 U/ml) on the release of FXIII into ce ll cul ture 
supernatants at 20 minutes and 2 hours was investigated by immunoblot analysis. 
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Figure 3.35. Effect of elastase on the concentration of FXIIIA in cell culture 
supernatants of 16HBE 140- cells at 20 minutes. Control bars denote unwounded cells 
and wounded bars represent maximum scrape damage, W8. Data represent mean ± 
SEM (n =3). * Indicates P<0.01 and ** indicates P<0.001 compared to control 
(unwounded) cells at each concentration of elastase. t Indicates P<0.05 compared to no 
drug control in the wounded cells. 
Analysis of cell culture supernatants at 20 minutes revealed that in the absence of 
elastase, the wounded cell cultures demonstrated a significantly higher concentration of 
FXIIIA (7.26 ± 0.05 ng/ml) compared to baseline (2.25 ± 0.04 ng/ml). This effect was 
evident with addition of each concentration of elastase up to 0.5 U/ml, however, in the 
wounded cultures subjected to 0.5 U/ml elastase, the concentration of FXIIIA (3 .38 ± 
0.09 ng/ml) was significantly lower than that seen in the wounded cultures of the no 
drug control (7.26 ± 0.05 ng/ml). There was no significant effect of elastase on the 
concentration of FXIIIA in supernatants of the unwounded cells. 
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Figure 3.36. Effect of elastase on the concentration of FXIIIA in cell culture 
supernatants of 16HBE 140- cells at 2 hours. Control bars denote unwounded cells and 
wounded bars represent maximum scrape damage, WS. Data represent mean ± SEM 
(n =3). * Indicates P<O.OS compared to control cells at each concentration of elastase. 
t Indicates P<O.OS compared to the no elastase control in the wounded cells. 
With reference to the no drug control, the concentration of FXIIIA in supernatants of 
the wounded cell cultures (6.77 ± 0.11 ng/ml) was significantly increased with respect 
to that seen at baseline (3.03 ± O.OS ng/ml). This pattern was maintained with the 
addition of elastase up to 0.1 U/ml. There was a significant decrease in the 
concentration of FXIIIA following the addition of 0.3 U/ml elastase (3.10 ± 0.2S ng/ml) 
compared to the wounded cell cultures of the no elastase control (6.77 ± 0.11 ng/ml) . 
Furthermore, the concentration of FXIIIA in cell culture supernatants of the wounded 
cells was further decreased to 1.76 ± 0.13 ng/ml following the addition of O.S U/ml 
elastase compared to the wounded cell cultures of the no drug control. Finally, there 
was no effect of elastase on the concentration of FXIIIA in the unwounded cell cultures. 
3.5. Summary of results 
16HBE 140- cells demonstrated constitutive expression and activity of TF. A significant 
increase in the release of fibrinogen, FXIIIA and D-dimers from 16HBE 140- cells in 
response to wounding was demonstrated in the absence of plasma. Moreover, 16HBE 
140- cells demonstrated expression of FXIIIA by immunohistochemistry. Analysis of 
supernatant concentration levels of EGF, KGF, TGF- ~1 by ELISA indicated that 
expression of these growth factors was negligible and expression of HGF was not 
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determined by either ELISA or immunohistochemistry. With respect to the analysis of 
inflammatory mediators, supernatant concentrations of PGE2 were determined to be low 
and levels were unaffected by wounding. Subsequently, the prostanoid had no effect on 
the concentrations of fibrinogen, FXIIIA or D-dimers in neither the unwounded or 
wounded 16HBE 140- cell cultures. A significant increase in the release of IL-8 was 
demonstrated in 16HBE 140- cell culture supernatants at 4 hours post-wounding. 
Finally, elastase was demonstrated to induce a significant decrease in the release of 
fibrinogen and FXIIIA in cell culture supernatants of wounded 16HBE 140 - cell 
monolayers. 
3.6. Discussion 
The 16HBE 140- cell line was chosen for its human ongm, physiological barrier 
properties and convenience of culture. The 16HBE 140- cell line describes an SV40 
large T -antigen transformed epithelial cell line derived from human bronchial 
epithelium (Cozens et ai., 1994). The well established cell line retains many features of 
bronchial epithelial cells in vivo, including the 'cobblestone' appearance and possession 
of tight junctions. The cell line is known to mimic the barrier properties that are 
displayed in the airways in vivo. Monolayers of 16HBE 140- cells have been shown to 
generate transepithelial resistance, as measured by U ssing chambers that is comparable 
to that reported for airway epithelia (Bhat et al., 1993; Rojanasakul et ai., 1992). 
This in vitro model is highly reductive in nature, since it solely consists of a monolayer 
of undifferentiated 16HBE 140- cells and rules out the contribution of the underlying 
mesenchyme, a source of growth factors including EGF, KGF, TGF-p and HGF, all of 
which are reported to play a role in wound repair; plasma, a source of coagulation 
factors and sensory neuropeptides such as vasoactive intestinal peptide (V~P), which is 
mainly produced by non-adrenergic and non-cholinergic nerve fibres and has recently 
been shown to enhance wound repair and proliferation of bronchial epithelial cells "ia 
VIP receptors (Guan et ai., 2006). The 16HBE 140- cells were grown in submerged 
cultures and remained undifferentiated as a consequence. Cells were cultured on bare 
plastic to rule out the effect of the extracellular matrix and individual components such 
as laminin and collagen type IV, which are known to play a role in cell migration 
(Rickard et ai., 1993). One of the features of the inflammatory process in asthma is the 
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presence of increased plasma leakage due to plasma extravasation from the blood-
airway lumen barrier; however, plasma exudation following allergen challenge does not 
occur in normal subjects (Nocker et al., 1999). To rule out the effect of plasma-derived 
proteins, 16HBE 140- cells were quiesced overnight in serum-free medium and prior to 
each experiment, the serum-free medium was refreshed and the experiments were 
performed in the same medium. Although this model may be considered far removed 
from the conditions demonstrated in vivo, it allows the contribution of the bronchial 
epithelium alone to be investigated, in the absence of plasma proteins. 
Preliminary results from western blotting indicated both high molecular weight forms of 
coagulation factors as well as proteolysed fragments. For example, FVII was 
demonstrated as part of the TF:FVII complex as described in Chapter 7 and two low 
molecular weight fragments of 32 and 20 kDa, indicative of tryptic digestion (Kazama 
et ai., 1993). Trypsin is a product of injured epithelial cells (Reed et al., 2004) and may 
account for the proteolysis. Proteolysis clearly occurred during cell culture, as adding a 
cocktail of protease inhibitors (including: 500 JlM AEBSF, hydrochloride; 150 nM 
aprotinin; 1 JlM E-64; 0.5 mM EDTA, disodium and IJlM leupeptin, hemisulphate: 
protease inhibitor cocktail set 1; supplied by Calbiochem®) to harvested cells did not 
prevent its occurrence. With the exception of FXIII, the coagulation factors are 
themselves proteases; therefore protease inhibitors could not be added to cell cultures. 
Thus, immunoblotting was considered the most appropriate technique for protein 
analysis since it detects the sum of both high molecular weight complexes and tryptic 
fragments. 
It is well established that TF is an integral membrane glycoprotein that is constitutively 
expressed in cells, at sites where it may playa protective role in wound repair (Osterud, 
1997). TF is the principal initiator of coagulation in vivo as a consequence of its binding 
to FVII and the formation of a complex that activates FX (Nemerson, 1966). In the 
airways, TF is expressed at epithelial barriers which are physically separated from the 
circulating blood. The specific localisation ofTF provides a 'hemostatic envelope', such 
that only vascular injury may initiate the activation of coagulation (Martin et al., 1998). 
16HBE 140- cells demonstrated positive, specific immunostaining for TF by confocal 
laser scanning microscopy. TF immunostaining was constitutive and was localised to 
the periphery of cells within the 16HBE 140- monolayer. The expression of TF by 
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16HBE 140- cells in the current model supports the results of a previous in\"estigation 
which showed that TF was expressed and active on primary normal human bronchial 
epithelial (NHBE) cells in culture (Keller et al., 2001). Analysis of TF activity of 
16HBE 140- cells demonstrated that TF is constitutively active. Wounding induced a 
small but non-significant increase in TF activity compared to baseline. It is likely that 
the small increase relates to the upregulation of TF in the small proportion of cells at the 
wound edge as indicated by immunohistochemistry images in section 3.4.1.1. 
The data presented in this chapter provide evidence that the bronchial epithelium is a 
source of coagulation factors that are released in response to injury. Following 
wounding, cell culture supernatants demonstrated a significant increase in the 
concentrations of fibrinogen and FXIIIA at 2 hours, indicating release of these factors 
from 16HBE 140 - cells dependent on the extent of wounding. The functional 
significance of these observations is described in Chapter 4. 
The liver is the primary source of plasma fibrinogen in vivo, and hepatic fibrinogen is 
upregulated as part of the innate immune response to inflammation (Baumann et al., 
1994; Otto et al., 1987). Previous studies have demonstrated expression and synthesis of 
fibrinogen in extraheptic, alveolar epithelial (A549) cells in vitro, the production of 
which was found to be regulated by interleukin (IL )-6 and dexamethasone and was 
independent of cleavage by thrombin. The fibrinogen was demonstrated to be released 
from alveolar cells and incorporated into a fibrinogen matrix, independently of 
conversion to fibrin (Guadiz et al., 1997; Haidaris, 1997). The data presented here 
confirm that a bronchial epithelial cell line also expresses fibrinogen and that its 
abundance is increased in response to injury. The expression and release of fibrinogen 
from 16HBE 140 - cells, whereby mechanical wounding is the stimulus for its 
upregulation is a novel finding. Cell culture supernatants at baseline contained 0.35 
/-lg/ml fibrinogen, which is comparable to 0.64 /-lg/ml fibrinogen reported in 
supernatants derived from a human hepatoma cell line at baseline (Fair et al., 1983) and 
0.15 /-lg/ml fibrinogen reported in BAL fluid from patients with mild, stable asthma 
(Pizzichini et al., 1998). 
Plasma FXIII is a zymogen of tetrameric structure (A2B2) consisting of two potentially 
active A subunits (FXIIIA) and two inhibitory/carrier B subunits (FXIIIB) (Muszbek et 
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aI., 1999). The A-subunit contains the active site of the enzyme and is expressed by 
platelets, monocytes, macrophages (Henriksson et al., 1985; Kradin et al.. 1987: 
Muszbek et aI., 1999) and hepatocytes (Adany et al., 1996). The B-subunit is 
synthesised in the liver, and is secreted as a monomer that binds free FXIIIA in plasma 
(Nagy et al., 1988). The main function of the B-subunit is the stabilisation and transport 
of the hydrophobic A-subunit in the aqueous environment of human plasma (Ariens et 
al., 2002). An antibody to FXIIIA was used in this model, since this is the cell-
associated form. The data in this chapter demonstrate that FXIIIA is expressed in the 
16HBE 140- cell line and its expression is increased in response to injury. This 
represents a highly novel observation since bronchial epithelial cells have not 
previously been shown to express FXIIIA. A study involving the analysis of BAL fluid 
from healthy children compared to those with bronchoalveolar inflammation 
demonstrated a low amount of FXIIIA present in BAL fluid from non-diseased subjects 
that derived from alveolar macrophages and not from plasma; and FXIIIB was not 
present. Subjects with bronchoalveolar inflammation displayed elevated concentrations 
of FXIIIA in the BAL fluid with the additional presence of FXIIIA2B2, indicating a sign 
of increased capillary permeability and plasma exudation as a marker of inflammation 
(Katona et aI., 2005). Interestingly, cellular FXIII, which lacks the inhibitory B subunit, 
does not require the release of the activation peptide for its activation, since Ca2+ 
present in the bronchoalveolar lining fluid is sufficient to convert this zymogen into an 
active enzyme (Polgar et aI., 1990). In order to determine the activity of the FXIIIA 
released into cell culture supernatants in this model, a FXIII activity assay would need 
to be performed. The assay was not employed since it was deemed to be both too 
complicated and time-consuming to optimise. 
Bronchial epithelial repair is reported to rely on the formation of a provisional fibrin 
matrix (Erj efalt et al. , 1994). TF, fibrinogen and FXIII are all mediators of 
fibrinogenesis, therefore, detection of these factors in this model and an increase in their 
expression in response to wounding suggests that these factors are available for fibrin 
formation. 
D-dimers represent the breakdown products of either a fibrin or fibrinogen clot that has 
been stabilised by FXIIIA cross-linking. Fibrin provides a matrix for wound repair but 
is not a permanent structure. In order to prevent fibrosis, it must be degraded into 
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soluble D-dimer fragments once it has performed its duty (Sidelmann et aI., 2000). The 
fibrinolytic pathway is described in section 3.1.6. In brief, the fibrin clot is degraded by 
plasmin, the fibrinolytic enzyme, which is generated by the proteolytic cleavage of 
plasminogen, which circulates in the blood. Activation of plasminogen may either occur 
directly by t-P A, which is produced and released from vascular endothelial cells; by 
scu-PA, a part of the intrinsic system, which can be converted into active u-PA by 
various proteases; or by the FXII-dependent pathway. D-dimers are a marker of both 
fibrinolysis and fibrinogenesis; therefore the increased expression of these fragments in 
cell culture supernatants provides evidence that cross-linked fibrin was generated in 
response to wounding and then degraded, and that its formation was dependent on the 
extent of cell damage. 
In addition to the expression of TF, FVII and fibrinogen that was demonstrated by 
16HBE 140- cells in the current study, the generation of both FXIII and D-dimers 
suggests that there is thrombin expression and activity in the current 16HBE 140- cell 
model. Subsequently, this implies that coagulation factors Xa and Va and prothrombin 
are present in the current model and thus synthesised by 16HBE 140- cells in order for 
the generation of thrombin. Furthermore, the expression of D-dimers in this model 
suggests that plasmin must be present. This is conceivable since alveolar epithelial cells 
have been shown to express u-PA and have the capacity to promote fibrinolysis 
following fibrin deposition (Marshall et aI., 1992). 
LDH measurements of cell culture supernatants demonstrated a small, insignificant 
increase in release of LDH in response to wounding. The increase in LDH in the 
supernatants correlated with the slight decline of LDH in the lysates of the 16HBE 140-
cells with the extent of wounding. The levels of LDH in supernatants of unwounded cell 
culture controls represent 1 % of the total and indicate that there is a limited amount of 
cell death under the current culture conditions. However, wounding did not induce a 
significant increase in the proportion of LDH in the supernatants. This signifies that the 
release of coagulation factors into cell culture supernatants was predominantly from 
intact cells within the wounded cell monolayer and not from cells that were damaged 
and lysed by mechanical wounding. Furthermore, it is reported that bronchial epithelial 
cells that are shed from asthmatic subjects remain viable (Montefort et al.. 1992). 
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Mechanical wounding destroys the tight junctions that maintain the integrity of the 
bronchial epithelium. Tight junctions comprise at least four types of transmembrane 
proteins, including occludin, claudins, junctional adhesion molecules and cadherins, and 
a number of cytoplasmic peripheral proteins, such as the PDZ proteins, which include 
the ZO family. Whereas the transmembrane proteins mediate cell-cell adhesion (Tsukita 
et at., 1999), the cytosolic tight junction plaque contains various types of proteins that 
link tight junction transmembrane proteins to the underlying cytoskeleton (Balda et al.. 
2000; Itoh et at., 1999; Wittchen et al., 1999). These adapter proteins also recruit 
regulatory proteins, such as protein kinases, phosphatases, small GTPases and 
transcription factors, to the tight junction. As a result, structural proteins such as actin 
and spectrin; and regulatory proteins such as actin-binding proteins, GTPases and 
kinases are juxtaposed with transmembrane proteins. This protein scaffolding facilitates 
the assembly of highly ordered structures, such as junctional complexes or signalling 
patches, that regulate epithelial cell polarity, proliferation and differentiation. Epithelial 
permeability is tightly regulated by intracellular messengers (Lawrence et al., 2002). A 
number of signalling pathways have been implicated in tight junction biogenesis; 
however, the precise molecular mechanisms are not fully understood. Since 16HBE 
140· cells are known to form confluent monolayers and express various tight junction 
proteins such as occludin and ZO-1, it would therefore be of interest to further 
investigate a role for these proteins in wound repair by use of neutral ising antibodies to 
these proteins in order to disrupt the tight junctions. For example, a mouse monoclonal 
E-cadherin blocking antibody was used to demonstrate that E-cadherin promotes 
EGFR-mediated cell differentiation and MUC5AC mucin expression in cultured human 
airway epithelial cells (Kim et at., 2005). 
TF was demonstrated to be constitutively expressed and constitutively active in this 
model; and its expression was increased at the wound edge. The presence of D-dimers 
in the cell culture supernatants suggests that the binding of FVII with TF is likely, since 
these fragments are indicative of fibrin formation and subsequent degradation. This was 
confirmed by preliminary experiments in Chapter 7, which demonstrated the formation 
of a TF:FVII complex. The rapid formation of D-dimers indicates the release of pre-
formed coagulation factors. This is supported by data in Chapter 6 which demonstrates 
that wounding initiates a significant increase in TF and FVII mRNA over a longer time 
course. The formation of fibrin represents the final step within the coagulation cascade. 
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In order to initiate coagulation, TF expressed by the epithelium combines with FVIL 
which when activated, activates FX. The main source of FVII and FX is considered to 
be the liver (Greenberg et aI., 1995; Hung et aI., 1996). In addition, FVII is synthesised 
by macrophages, smooth muscle cells, fibroblasts and keratinocytes (Wilcox et al.. 
2003) and FX is expressed by alveolar macrophages (Osterud et aI., 1980). However, 
both FVII and FX have previously been shown to be expressed by 16HBE 140- cells 
(PhD thesis; Perrio, 2006) and these coagulation factors have been demonstrated in 
16HBE 140- cells at the mRNA level in Chapters 6 and 7. 
A number of growth factors have been previously reported to playa role in epithelial 
repair, therefore their expression in this model was investigated. The concentration of 
EGF in cell culture supernatants, as determined by ELISA, was 0.26 pg/ml 2 hours post-
wounding. Its expression did not change with time post-wounding and was not 
significantly different to the levels detected at baseline. The levels of EGF detected in 
this model may be considered too low to stimulate migration compared to a study which 
demonstrated that 1 ngiml EGF significantly enhanced wound repair in a model of 
undifferentiated NHBE cells (Wadsworth et aI., 2006). EGF at 10 ng/ml was 
demonstrated to stimulate the migration of 16HBE 140- cells (Puddicombe et aI., 2000). 
EGF is a potent mitogen that is considered to be an important regulator of epithelial 
restitution due to its ability to stimulate cell migration, proliferation, differentiation and 
survival (Puddicombe et aI., 2000). Weak expression ofEGF has been demonstrated in 
the bronchial epithelium (Amishima et aI., 1998). Interestingly, EGFR is reported to be 
widely expressed by the epithelium. However, its pattern of expression is restricted 
given that it is expressed basolaterally and is therefore only exposed to EGFR ligands in 
response to injury. Puddicombe et al. demonstrated that following injury of 16HBE 140-
cells, the EGFR was rapidly activated and that this was likely to occur by the binding of 
either TGF-a or amphiregulin, which are both expressed by 16HBE 140- cells. Thus, the 
fact that EGF was not found to be abundant in cell culture supernatants and that its 
expression was unaffected by wounding does not rule out a role for EGFR in wound 
repair. It is conceivable that EGFR expressed by epithelial cells respond to either TGF-
a or amphiregulin released from epithelial cells themselves or EGF released from 
underlying mesenchymal cells, such as fibroblasts to mediate repair. EGF. TGF-a, HB-
EGF, amphiregulin, betacellulin, and epiregulin each have the capacity to bind to the 
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EGFR and are all regulators of bronchial epithelial restitution (Puddicombe et aI., 
2000). 
KGF is recognised as a key growth factor for the bronchial epithelium. It was first 
isolated in a lung fibroblast line (Rubin et aI., 1989). Within the mesenchyme, KGF is 
predominantly produced by fibroblasts and smooth muscle; however. unlike other 
growth factors, KGF displays epithelial specificity since its receptor (KGFR) is 
expressed only in epithelial cells and therefore only acts in a paracrine manner (Finch et 
aI., 1989). Specifically, KGF targets alveolar epithelial cells in vitro (Panos et aL 1993) 
and in vivo (Ulich et aI., 1994), acting as a potent mitogen. In addition to its role in lung 
development and inflammation, KGF plays an important role in wound repair (Ware et 
aI., 2002). Galiacy et al. (2003) demonstrated an increase in the rate of epithelial repair 
compared to unstimulated controls by the presence of 100 ng/ml KGF in a model of 
primary alveolar epithelial cells. However, the concentration of KGF in the cell culture 
supernatants of 16HBE 140- cells in the current model was 13.9 pg/ml at baseline and is 
therefore considerably lower than the levels of KGF required to facilitate epithelial 
repair. Furthermore, its expression was unaffected by mechanical wounding. However, 
the fact that only low levels were detected does not rule out a role for KGF.ln vivo, it is 
likely that KGF plays an important role in epithelial-mesenchymal interactions to 
support epithelial repair, therefore it would be of interest to investigate the expression of 
the KGFR in this model of 16HBE 140- cells. 
The TGF-~ 1 ELISA was used to measure active and total TGF-~ 1 in cell culture 
supernatants. The concentration of latent TGF-~1 was calculated from the active and 
total concentrations. Mechanical wounding did not elicit any changes in the 
concentration of active TGF -~ 1 in cell culture supernatants. However, following acid-
activation of samples, the concentration of total TGF -~ 1 was significantly increased at 4 
hours post-wounding, whereby 30.3 pg/ml TGF-~ 1 was detected in cell culture 
supernatants. Since the active form of TGF-~ 1 remained constant, the increase in total 
TG F -~ 1 refers to the latent form of this growth factor. In a time-lapse model of wound 
repair of a 16HBE 140- monolayer, stimulation with 0.25 ng/ml TGF-~1 resulted in a 
significantly enhanced migratory rate over 4 hours, whereas TGF-~2 was not found to 
playa role in cell migration during repair of 16HBE 140- cells (Howat et aI., 2002). 
Thus, the concentration of TGF-~ 1 detected in the current study is considerably lower 
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than that required to promote wound repair. In the same study, Howat et at. 
demonstrated an increase in active TGF -~ 1 2 hours post-wounding, however, this 
accumulation was only seen in cultures in which serum containing medium was used, 
indicating that latent TGF -~ 1 in the serum was the substrate for activation. TGF _~ is 
produced by bronchial epithelial cells, mesenchymal cells, eosinophils and macrophages 
and has regulatory effects on extracellular matrix production in the lung and hence 
epithelial repair (Coker et aI., 1997). The use of serum-containing media in cell culture 
models of wound repair reflects the in vivo situation where immunocytochemistry has 
shown that the majority of TGF-~1 is found in the subepithelial compartment 
(Redington et aI., 1998). Therefore, it is likely that the presence of serum in Howat's 
model enhanced the ability of the 16HBE 140- cells to convert latent TGF-~1 into its 
active form in response to wounding. In the absence of serum, 16HBE 140- cells have 
the capacity to produce latent TGF -~ 1 in response to wounding. Hence, TGF -~ 1 IS 
unlikely to contribute to wound repair in this model. 
In hindsight, the design of the cell experiments to generate supernatants for both the 
growth factor and IL-8 assays was flawed as they displayed a lack of time-matched 
controls. If these experiments were to be repeated, they would include both unwounded 
and wounded cell cultures for each time-point investigated. 
HGF is demonstrated to be a potent biological mediator of mitogenesis, motogenesis 
morphogenesis and differentiation in a variety of cell types, including bronchial 
epithelial cells (Jiang et aI., 1997). The addition of 20 ng/ml HGF has been reported to 
enhance repair of nasal epithelial cells (Zahm et aI., 2000). HGF was not detected in cell 
culture supernatants by ELISA (data not shown) at baseline or in response to wounding. 
Furthermore, immunohistochemistry demonstrated that HGF is not expressed by 
16HBE 140- cells of intact or wounded monolayers. However, the same cell type 
demonstrated strong expression of the HGF (c-Met) receptor, confirming reports in the 
literature that the c-Met receptor is predominantly expressed on the surface of various 
epithelial cell types including those of the lung (Shen et al., 1997). HGF expression is 
predominantly confined to the mesenchyme. In human bronchial epithelial cells, HGF 
appears to act mainly as a paracrine factor produced by mesenchymal cells such 
fibroblasts, which interact with epithelial cells (Singh-Kaw et aL 1995: Sonnenberg e! 
aI., 1993). However, there is a conflicting report that demonstrates that normal human 
126 
bronchial epithelial cells can produce HGF in culture as an autocrine motogenic factor 
(Tsao et aI., 1993). The role of HGF in immune-mediated disorders such as asthma is 
unclear, however, there is a report to suggest that HGF might be effective in preventing 
asthma exacerbation preceded by viral infection as well as suppressing antigen-induced 
Th2-type immune response in an in vivo mouse model (Okunishi et al., 2005). In vivo, it 
is likely that HGF mediates its effects by epithelial-mesenchymal interactions. A recent 
study using a primary HBE-fibroblast co-culture model has demonstrated that HGF 
secreted by subepithelial fibroblasts modulates HBE cell differentiation (Myerburg et 
al., 2007). Thus, it would be of interest to develop a co-culture with HBE cells and 
fibroblasts to investigate the effect of endogenous HGF on wound repair. 
Interestingly, 16HBE 140- cells demonstrated positive, specific immunostaining for 
FXIII, a highly novel observation. Stimulation with 100 ng/ml HGF resulted in the 
diffusion of FXIII from perinuclear sites to the plasma membrane of the cells. Since 
FXIII plays an important role in the final step of fibrin formation by cross linking the 
fibrin clot, it appears that HGF may be involved in the modulation of this process, by 
stimulating the diffusion of this factor to the periphery of the cell and thereby making it 
more available to perform its duty. 
Savla et al. demonstrated that exogenously added PGE2 (l0 J.lgiml) stimulated wound 
repair in an in vitro model of 16HBE 140- cells and that the COX inhibitor 
indomethacin retarded repair (Savla et aI., 2001). Since PGE2 was reported to enhance 
wound repair, its release from 16HBE 140- cells and effects on fibrin formation were 
investigated. Analysis of cell culture supernatants by ELISA indicated that endogenous 
PGE2 was present at a low concentration of9.4 pg/ml and that its release was unaffected 
by wounding at 20 minutes or 2 hours. Immunoblot analysis indicated that exogenous 
PGE2 in the concentration range of 0-20 J.lg/ml did not elicit any changes in the 
concentrations of fibrinogen, FXIII or D-dimers in cell culture supernatants of the intact 
or wounded mono layers at 20 minutes or 2 'hours in this model, suggesting that PGE2 is 
not involved in the formation of fibrin to support bronchial epithelial repair. According 
to Savla et al., the effects of PGE2 are mediated via EP-l and EP-4 receptors; however. 
mRNA for these receptors was not detected in 16HBE 140- cells (Chapter 6) under the 
current culture conditions. 
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IL-8 is is a neutrophil chemotactic factor that is produced in abundance by mononuclear 
phagocytic cells, as well as a number of non-inflammatory cells including fibroblasts. 
bronchial and alveolar epithelial cells. Synthesis of IL-8 by fibroblasts and alveolar 
epithelial cells involves stimulus specificity, as the production of this mediator by non-
inflammatory cells is dependent upon an initial host response. Alveolar macrophages 
appear to playa central role in inflammatory airway diseases by generating factors, such 
as IL-I and TNF, which are potent stimuli for the induction ofIL-8 by lung fibroblasts 
and alveolar epithelial cells. This cascade-like interaction may lead to the rapid 
production of significant quantities of IL-8 by the lung and subsequent recruitment of 
neutrophils to the airway lumen; and may be particularly important in asthma which is 
associated with abundant expression of this inflammatory chemokine (Kunkel et al.. 
1991). 
In addition to their role in fibrin formation, there is broad evidence to suggest that 
coagulation factors VII, Xa and thrombin may evoke inflammatory responses by 
stimulating expression of inflammatory mediators, such as IL-8 (figure 3.36) (Daubie et 
al., 2006; Schulman, 2003). When coagulation is initiated, cell signalling occurs 
simultaneously. TF-induced signalling can occur via the cytoplasmic tail of TF or the 
proteolytic activity of FVII in association with TF (Pendurthi et aI., 2002). TF-FVII 
proteolytic activity mediates signalling via PAR-2 receptor, to induce the expression of 
a number of inflammatory mediators, including IL-8. There is general agreement that 
thrombin activates P AR-l and P AR-4 to stimulate the release of IL-8, however, it is 
unclear whether FXa stimulates the release of IL-8 by effector cell protease receptor 1 
(EPR-l) (Cirino et aI., 1997), PAR-l (Schulman, 2003) or PAR-2 (Camerer et aI., 
2000). Since this study demonstrates activation of the coagulation cascade, it was of 
interest to measure the levels of IL-8 in cell culture supernatants of 16HBE 140- in 
response to wounding in order to investigate a link between coagulation and 
inflammation. The concentration of IL-8, as measured by ELISA, demonstrated a 
significant increase in IL-8 at 4 hours post-wounding compared to the unwounded 
control. This is indicative of an effect on IL-8 expression rather than release of the pre-
formed mediator. Interestingly, FVII mRNA expression was increased 4 hours post-
wounding as demonstrated in Chapter 6, which might indicate that IL-8 expression was 
dependent on TF:FVII signalling via PAR-2. 
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Figure 3.36. The coagulation cascade as a vertical flow chart and horizontal reactions 
outside the coagulation system indicating a role for these factors in inflammation. 
VEGF, vascular endothelial growth factor; IL, interleukin; GF, growth factor ; uP AR, 
urokinase type plasminogen activator receptor; MCP, monocyte chemotactic protein; 
CD54, ligand for a cell adhesion receptor; MMP, matrix metalloproteinase (Schulman, 
2003). 
IL-8 stimulates the recruitment of neutrophils in the airways. Severe asthma is typically 
associated with an abundance of IL-8 and neutrophils and subsequent tissue destruction 
and airway remodelling (Heinzmann et a!. , 2004). In severe asthma and exacerbations 
of asthma, neutrophil elastase is considered to playa role in the chronic inflammation 
associated with the uncontrolled remodelling response (Holgate et a!. , 2006). Elastase 
has a number of effects in the airway, as discussed in section 3.1.11. In the normal 
airway, elastase may remove fibrin (Kolev et a!. , 1996) and prevent fibrosis ; and cleave 
a number of coagulation factors , including FVII (Anders sen et a!. , 1993), FX 
(Turkington, 1991) and FXIII (Klingemann et a!. , 1982) following wound repair. Since 
these coagulation factors have been detected in this model, it was of interest to 
investigate the effects of elastase on the levels of these factors in cell culture 
supernatants. Elastase (0.5 U/ml) significantly reduced the levels of fibrinogen and 
FXIII in the wounded mono layers at 20 minutes. Elastase is known to inactivate PAR-2 
(Dulon et a!. , 2003); however, PAR-2 is demonstrated to strongly enhance the re lease of 
coagulation factors in the subsequent repair response. Therefore, this effect may signify 
either elastase-mediated inhibition of PAR-stimulated release of these factors or damage 
to the factors induced by proteolytic cleavage. However, 500 nM elastase was u ed to 
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disarm PAR-2, therefore low concentrations of neutrophil elastase such as those 
employed in the current study are more likely to degrade coagulation factors. Elastase 
was subsequently shown to inhibit wound repair in Chapter 4, providing evidence that 
the stimulated release of coagulation factors are important in bronchial epithelial repair. 
Studies by Erjefalt et al., demonstrated that immediately after removal of the guinea pig 
epithelium in vivo, there was evidence of extravasation and bulk entry of plasma from 
the microcirculation beneath the denuded, but intact basement membrane, resulting in 
the formation of a fibrin gel matrix to facilitate epithelial restitution. Erjefalt et al. 
concluded that the coagulation factors involved in the formation of fibrin were 
exclusively derived from the bronchial microcirculation. In the current serum-free 
model, extrinsic coagulation factors that mediate fibrinogenesis were detected at 
baseline and released from 16HBE 140- cells in response to wounding. Moreover, the 
significant release of D-dimers at 2 hours post-wounding signifies that cross-linked 
fibrinogen or fibrin was formed in response to epithelial damage. The early formation of 
a fibrin( ogen) matrix supports Erjefalt's findings in vivo. However, in this reductive 
model that investigates the role of bronchial epithelial cells alone, there is novel 
evidence that these cells are themselves a source of coagulation factors that are released 
in response to wounding, independently of plasma-derived proteins or any other 
influences that may be present in vivo. Erjefalt et a!., also demonstrated the early 
accumulation of neutrophils in areas of epithelial damage induced mechanically or by 
allergen challenge. This correlates with the significant increase in IL-8 release 4 hours 
post-wounding in this model since IL-8 is a major chemoattractant for neutrophils. 
Furthermore, D-dimers can be proinflammatory and stimulate the recruitment of 
neutrophils (Wojtecka-Lukasik et aI., 1992). Dysregulation of D-dimer production by 
the bronchial epitheium could lead to amplification of the inflammatory process, 
therefore, it would be of interest to investigate the levels of D-dimers at later time-
points, or indeed to measure the activity of plasmin, the fibrinolytic enzyme. over a 
range of time-points. 
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Chapter 4. 
Role of Coagulation Factors 
in Wound Repair 
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4. The role of coagulation factors in wound repair 
4.1. Introduction 
In vivo studies in the guinea pig lung have demonstrated that bronchial epithelial repair 
following injury is both rapid and efficient and is dependent on the formation of a 
provisional fibrin matrix which is believed to be exclusively plasma-derived (Erjefalt et 
aI., 1994). However, data presented in Chapter 3 has demonstrated the ability of 
bronchial cells to release coagulation cascade factors in response to injury, 
independently of plasma proteins. Furthermore, the increase in the release of D-dimers 
from 16HBE 140- cells post-wounding indicates that wounding initiates fibrin 
formation, since D-dimers are a marker of both fibrinolysis and fibrinogenesis. 
Fibrinogen has long been established as serving an important haemostatic role in vivo 
because it is converted from a soluble plasma protein to an insoluble fibrin gel by the 
action of thrombin and FXIIIa (Doolittle, 1981). The fibrin clot provides a scaffold for 
cell migration. Fibrinogen is predominantly synthesised by hepatocytes and its 
expression is upregulated in response to inflammation as part of the systemic acute 
phase response (Lawrence et aI., 2004). However, cultured lung epithelial (A549) cells 
have been demonstrated to synthesise and secrete fibrinogen following stimulation with 
IL-6 and dexamethasone (Haidaris, 1997). It was reported that alveolar epithelial cell-
derived fibrinogen assembled into an ECM at sites of epithelial damage and the 
resultant matrix fibrinogen was demonstrated to significantly enhance wound repair, 
independently of exogenously added growth factors. 
Fibrinogen and fibrin can bind collagen IV (Jones et aI., 1988), the major component of 
the basement membrane (Legrand et aI., 1999) and it is likely that this provides a 
mechanism of attachment of the provisional matrix to the basement membrane. 
Integrins are required for the anchorage of cells and during epithelial wound repair there 
is an up-regulation of the integrins that bind to fibrin( ogen), fibronectin and vitronectin 
(Pilewski et aI., 1997). Fibronectin is an important constituent of the provisional matrix 
and it promotes the chemotaxis of epithelial cells and fibroblasts for repair (Polito et at.. 
1998; Yamada, 2000). 
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The lack of a fibrin provisional matrix compromises wound repair and an unstable 
provisional matrix due to FXIII deficiency has been demonstrated in a number of 
diseases, such as venous leg ulcers (Herouy et ai., 2000), Crohn's disease (Chamouard 
et al., 1998) and ulcerative colitis (D'Argenio et ai., 2000), resulting in defecti\'e 
epithelial repair. In addition to fibrin and integrins, a number of factors including TFF 
peptides, NO, relaxin and glycoproteins are established to facilitate cell migration and 
wound repair. Moreover, following epithelial injury, several members of the MMP 
family are induced and activated. In particular, MMP-9 is typically produced by the 
bronchial epithelium and activated during injury (Bove et al., 2007). Migrating 
bronchial epithelial cells in vivo express increased levels of MMP-9 (Buisson et al., 
1996) located at the edge of lamellaepodia where it acts to modify collagen IV (Legrand 
et al., 1999). NO has been demonstrated to promote epithelial cell migration and wound 
repair via increased expression and activation of MMP-9 (Bove et al., 2007). Similarly, 
expression of MMP-7, also known as matrilysin is upregulated in migrating epithelial 
cells and its activity has been associated with epithelial wound repair (Parks et ai., 
2001). Moreover, TGF -~ 1 has been shown to enhance epithelial wound repair via 
upregulation of MMP-2 (Lechapt-Zalcman et al., 2006). However, little is known about 
the contribution of locally produced coagulation factors. 
A number of the proteases within the coagulation cascade have been shown to 
specifically act upon PARs. The coagulation response is therefore not just for 
haemostatic control and wound repair, but it also influences epithelial cell signalling. 
There are at least four coagulation cascade proteases involved in the coagulation 
pathway that have the capacity to activate PAR receptors, namely FVIIa, FXa, thrombin 
and activated protein C (Pendurthi et al., 2002), in addition to the ternary TF:FVIIa:FXa 
complex (Chambers et al., 2002). To date, four PARs (PAR-I, PAR-2, PAR-3 & PAR-
4) have been isolated and the table below shows a comparison of the serine proteases 
that activate the receptors (Chambers et al., 2002; Macfarlane et aL 2001). Refer to 
Chapter 5 for a full description of these receptors. 
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Proteinase 
Thrombin 
Trypsin 
Mast cell tryptase 
TF -FVIla-FXa 
FVIIa 
FXa 
Neutrophil proteinase-3 
HAT 
Der PI, Der P3, Der P9 
CathepsinG 
Matriptase 
MMP-I 
Blood 
Epithelium 
Source 
Mast cells, basophils 
Blood 
Blood 
Blood 
N eutrophils 
Epithelium 
Dust mite allergen 
Monocytes, neutrophils 
Epithelium 
Epithelium 
PAR 
PAR-I, PAR-3 and PAR-4 
PAR-I, PAR-2 and PAR-4 
PAR-2 
PAR-I and PAR-2 
PAR-2 
PAR-I and PAR-2 
PAR-2 
PAR-2 
PAR-2 
PAR-4 
PAR-2 
PAR-I 
Table 4.1. A Summary of PAR activating proteinases in the lung. 
Endogenous activators of PAR-I include thrombin, FXa, TF-FVIla-FXa and activated 
protein C. PAR-2 may be activated by trypsin, coagulation factors VIla and Xa and TF-
FVIla-FXa. In vivo models have shown that trypsin released from the epithelium can 
initiate powerful bronchoprotection in the airways via activation of PAR-2 and release 
of the cyclooxygenase product PGE2. PGE2 is presumed to have a bronchoprotective 
effect by stimulating smooth muscle relaxation, and inhibiting stimulated 
bronchoconstriction. The transient ternary TF -FVIIa-FXa complex also activates PAR-1 
and PAR-2 supporting the notion that the TF-FVIIa-initiated coagulation cascade is 
inseparably linked to PAR activation and cell signalling as reviewed by Chambers and 
Laurent (2002). 
Pseudomonas aeruginosa, a major lung pathogen in cystic fibrosis (CF), is known to 
secrete elastolytic metalloproteinase (EPa), also known as elastase. EPa was 
demonstrated to disarm PAR-2, thereby preventing its subsequent activation by trypsin. 
Inactivation of PAR-2 occurred through proteolysis of the extracellular N-terminal 
domain downstream from the trypsin cleavage/activation site (Dulon et aI., 2005). Since 
one of the roles of P AR-2 in the lung is to contribute to the control of the innate 
response of this organ to invading pathogens like Pseudomonas aeruginosa, and to the 
preservation of respiratory functions through production of mediators such as IL-8 and 
PGE2, its inactivation by EPa in an infectious/inflammatory environment as 
demonstrated in CF, could provide an explanation of some of the pathogenic acti\"ities 
associated with this microorganism. 
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The majority of the literature to date describes the role of FXa on the endothelium. 
However, FXa activity has been demonstrated on the surface of alveolar A549 cells that 
could be inhibited with the use of the synthetic FXa inhibitor DX9065a (Nakata ef a!., 
1998). An immunohistochemical study demonstrated that FXa expression is also 
localised to the bronchial epithelium (Yamada et aI., 1996). EPR-1 is a cell surface 
receptor for FXa (Nicholson et aI., 1996) that is involved in localising FXa to the 
endothelial cell surface leading to the formation of the prothrombinase complex 
(Bouchard et aI., 1997; Chambers et aI., 2002). However, its expression on bronchial 
epithelial cells has not yet been reported. Binding of FXa to EPR-l has been 
demonstrated to stimulate the release of PDGF and enhance the mitogenic effect of FXa 
on lung fibroblasts (Blanc-Brude et aI., 2005) and smooth muscle cells (Herbert ef aL 
1998). Moreover, EPR-1 has previously been reported to be necessary to localise FXa in 
close proximity to the endothelial cellular membrane in order to selectively cleave and 
activate PAR-2 (Bono et aI., 2000). 
FXa is an activator of both P AR-l and P AR-2, which are expressed in the normal 
bronchial epithelium (Lan et aI., 2002; Riewald et aI., 2001). Several studies have 
demonstrated that FXa stimulates fibroblast proliferation and induces collagen 
production through activation of PAR-1 (Blanc-Brude ef aI., 2005; Chambers ef a!., 
2002). A role for P AR-1 in tissue fibrosis has been identified (Chambers ef a!., 2002) 
and activation of this receptor by FXa might potentially contribute to airway 
remodelling by regulation of fibroblast proliferation and collagen deposition. Thus, FXa 
can regulate asthmatic events. A recent study using a murine model has demonstrated 
that FXa is involved in airway remodelling (Shinagawa et aI., 2007). The presence of 
FXa led to increased mucin production through upregulation of amphiregulin in lung 
epithelial cells. It was reported that FXa might also contribute to remodelling by 
activation of PARs and a resultant increase in fibroblast proliferation and collagen 
production. 
Whether the activation of PARs results in inflammation and/or wound repair IS 
presently unclear. Moreover, the relationship between PAR activation, coagulation 
factor release and fibrin formation is not known. It was therefore of interest to 
investigate a functional role for the coagulation factors and fibrin formation in wound 
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repair of bronchial epithelial cells using a model of 16HBE 140- and NHBE cells, which 
examines the role of bronchial epithelial cell-derived coagulation factors in the repair 
response. 
4.2. Aims and objectives 
Having established that TF, fibrinogen and FXnI were expressed by 16HBE 140- cells 
at the protein level, it was of interest to investigate the roles of these coagulation 
cascade proteins in wound repair of both 16HBE 140- and NHBE cells. This was to be 
achieved by the use of corresponding neutralising antibodies to these proteins. Further 
aims were to investigate the roles of FXa and thrombin in wound repair of 16HBE 140-
cells by the use of selective inhibitors. Results in chapter 3 demonstrated that the 
concentration of PGE2 in supernatants derived from 16HBE 140- cells was negligible, 
however, PGE2 has previously been reported to enhance repair of 16HBE 140- cells, 
therefore, it was of interest to confirm whether or not PGE2 was involved in wound 
repair of 16HBE 140- cells in the current model. This was to be established by the use 
of the COX inhibitor indomethacin. Finally, since neutrophil elastase reduced the 
supernatant levels of coagulation factors in 16HBE 140- cells, it was imperative to 
determine the effects of this inflammatory mediator on wound repair. 
4.3. Methods 
4.3.1. Culture of 16HBE 140- cells 
16HBE 140- cells were cultured for 48 hours in 24-well plates as described in section 
2.2.1 until fully confluent. At confluence, cells were washed by adding 500 J.lI of 1 X 
PBS (without calcium and magnesium) to each well. To quiesce the cells, 500 J.lI of 
serum-free MEM-ITS (basal MEM containing 2 mM L-glutamine and 100 V/ml 
antibiotic/antimycotic, supplemented with 1 % ITS) was added to each vvell and the 
plates were incubated for 16 hours at 37°C. Prior to each experiment, cells were washed 
by adding 500 J.lI per well of IX PBS, and 250 J.lI of fresh, serum-free MEM-ITS was 
added to each well. 
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4.3.2. Culture of NHBE cells 
NHBE cells were cultured for 5 days in 10 J.lg/cm2 collagen IV -coated 24-well plates, as 
described in section 2.2.3 until fully confluent. At confluence, cells were washed by 
adding 500 J.lI of IX PBS (without calcium and magnesium) to each well. To quiesce 
the cells, 500 J.lI of serum-free BEGM-ITS (basal MEM containing 2 mM L-glutamine 
and 100 U/ml antibiotic/antimycotic, supplemented with 1 % ITS) was added to each 
well and the plates were incubated for 16 hours at 37°C. Prior to each experiment, cells 
were washed by adding 500 J.lI per well of IX PBS, and 250 J.lI of fresh, serum-free 
BEGM-ITS was added to each well. 
4.3.3. Effect of neutralising coagulation factor antibodies on repair of epithelial 
monolayers 
A concentration range of: 0, 1,5 and 10 J.lg/ml (for 16HBE 140- cells) and 0,0.1,0.5 
and 1 J.lg/ml (for NHBE cells) of: a mouse monoclonal antibody to human TF (1 mg/ml 
stock dissolved in sterile deionised water; American Diagnostica Inc; supplied by Axis-
Shield, Dundee, UK); rabbit polyclonal antibody to human fibrinogen (IgG-peroxidase 
conjugate, 1 mg/ml stock dissolved in IX PBS: Affinity Biologicals Inc; supplied by 
Quadratech, Surrey, UK) or sheep antibody to human FXIII (subunit A, IgG-peroxidase 
conjugate, 2 mg/ml stock dissolved in DMSO: Affinity Biologicals Inc; supplied by 
Quadratech, Surrey, UK) and corresponding mouse IgG (purified mouse IgG, 1 mg/ml 
stock dissolved in IX PBS: Sigma, Dorset, UK), rabbit IgG (purified rabbit IgG, 1 
mg/ml stock dissolved in IX PBS: Sigma, Dorset, UK) or sheep IgG (purified sheep 
IgG, 1 mg/ml stock dissolved in IX PBS: Sigma, Dorset, UK) was added to cells in a 
volume of 250 J.lI per well and the plate was incubated for 30 minutes at 37°C. Wound 
repair was then carried out as described in section 4.3.10. 
4.3.4. Stimulation of 16HBE 140- cells with exogenous FXa 
A concentration range of: 0, 50, 100 and 200 nM FXa (20 mM stock dissolved in IX 
PBS: Calbiochem®, supplied by Merk Chemicals LTD. Nottingham. UK) was added to 
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cells in a volume of 250 /-11 per well and the plate was incubated for 30 minutes at 3 7°e. 
Wound repair was then carried out as described in section 4.3.10. 
4.3.5. Effect of thrombin and FXa inhibitors on repair of 16HBE 140- monolayers 
A concentration range of: 0, 0.05, 0.1, 0.2, 0.5 and 1 /-1M of a selective thrombin 
inhibitor (UK-156,406; 10 mM stock dissolved in DMSO: Pfizer Global R&D 
compound), selective FXa inhibitor (UK-220,047-01, the Daiichi compound DX9065a: 
10 mM stock dissolved in DMSO; supplied by Pfizer Global R&D) or alternative more 
selective FXa inhibitor (PD-031, 10 mM stock dissolved in DMSO: Pfizer Global R&D 
compound) was added to cells in a volume of 250 /-11 per well and the plate was 
incubated for 30 minutes at 37°C. DMSO controls at a final concentration of 0.0005. 
0.001, 0.002, 0.005 and 0.01 % corresponding to 0.05, 0.1, 0.2, 0.5 and 1 /-1M inhibitor 
respectively were also included. Wound repair was then carried out as described in 
section 4.3.10. 
4.3.6. Effect of indomethacin on repair of 16HBE 140- monolayers 
A concentration range of 0, 0.01, 0.1, 1, 3 and 10 /-1M indomethacin (1 mM stock 
dissolved in 1 % DMSO: Sigma, Dorset, UK) was added to cells in a volume of 250 /-11 
per well and the plate was incubated for 30 minutes at 37°C. A concentration range of 
up to 0.01 % DMSO, corresponding to 10 /-1M indomethacin was also included. Wound 
repair was then carried out as described in section 4.3.10. 
4.3.7. Effect ofPGE2 on repair of 16HBE 140- monolayers 
A concentration range of: 0, 0.1, 1, 5, 10 and 20 /-1g/ml PGE2 (2 mg/ml stock dissolved 
in 50% ethanol/50'Yo MEM-ITS: Sigma, Dorset, UK) was added to cells in a volume of 
250 /-11 per well and the plate was incubated for 30 minutes at 37°C. Ethanol controls at 
a final concentration of 0.0025, 0.025, 0.125, 0.25 and 0.5 % corresponding to 0.1. 1. 5. 
10 and 20 /-1g/ml PGE2 respectively were also included. Wound repair was then carried 
out as described in section 4.3.10. 
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4.3.8. Effect of neutrophil elastase on repair of 16HBE 140- monolayers 
A concentration range of: 0, 0.1, 0.03, 0.1, 0.3 and 0.5 Ulml neutrophil elastase (3 D/ml 
stock dissolved in IX PBS: Sigma, Dorset, UK) was added to cells in a volume of 250 
/J-I per well and the plate was incubated for 30 minutes at 37°C. Wound repair was then 
carried out as described in section 4.3.10. 
4.3.9. Effect of mitomycin C on repair of 16HBE 140- monolayers 
A final concentration of: 1 /J-g/ml mitomycin C (Imglml stock dissolved in deionised 
H20 : Sigma, Dorset, UK) was added to cells in a volume of 250 /J-I per well and the 
plate was incubated for 30 minutes at 37°C. Wound repair was then carried out as 
described in section 4.3.10. 
4.3.10. Wound repair of 16HBE 140- and NHBE cells 
Cells were mechanically wounded with a P2 Gilson pipette tip, one horizontal scrape 
per well. Immediately after wounding, one photograph per well was taken of a 
representative section of wound using the inverted microscope (Leica Microsystems, 
Wetzlar, Germany) and Ricoh XR-3000 35 mm camera. Cells were returned to the 
incubator, at 37°C for 13 hours. A second set of photographs was then taken of the same 
section of wound. Photographs were developed and wound repair was analysed by 
taking 10 measurements across the wound and the % original wound width was 
calculated at 13 hours. Supernatants and cells were harvested and stored at -80°C. as 
described in section 2.2.4. 
4.3.11. Immunoblotting for fibrinogen and FXIIIA 
Following wound repair in 16HBE 140- and NHBE cell layers, supernatants \vere 
removed at 13 hours and 20 hours respectively and centrifuged for 7 minutes at 670 x g 
(ALC PK120 Centrifuge, Winchester Virginia, USA) to remove cell debris. Cell culture 
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supernatants were then analysed by immunoblot for fibrinogen and FXIIIA as described 
in section 3.3.3. 
4.4. Results 
4.4.1. Effect of mitomycin C 
In order to determine whether wound repair III this model was occurnng by cell 
spreading and migration or proliferation to repopulate the denuded area, the effect of 
mitomycin C (MMC), a proliferation inhibitor was investigated. MMC is a 
chemotherapeutic agent that prevents DNA double-strand separation during cell 
replication by forming covalent cross-links between DNA opposite strands, allowing 
RNA and protein synthesis to continue and arresting cells in G 1, Sand G2 phases of the 
cell cycle (Barlogie et aI. , 1980; Tomasz et aI., 1987). A final concentration of 1 ~g/ml 
was chosen as a previous in vitro study demonstrated that treatment of retinal pigment 
epithelial cells with 1 ~g/ml MMC was sufficient to arrest cell proliferation without 
inducing apoptosis, which occurred at the higher concentration of 1 0 ~g/ml MMC 
(Kang et aI. , 2001). 
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Figure 4.1. Effect ofMMC on wound repair of 16HBE 140- cells at 9 hours. 
Data represent mean ± SEM (n =6). 
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The % original wound width in the untreated 16HBE 140- cell cultures at 9 hour was 
20.1 9 ± 4.680/0. Treatment of cells with 1 ).lg/ml MMC reduced the wound width to 15.4 
± 2.18%. There was no significant effect of MMC on wound repair. 
4.4.2. Role of TF in 16HBE 140- cells 
TF initiates the coagulation cascade and was shown to be constitutively expressed and 
active in 16HBE 140- cells (section 3.4.1.1), therefore the effect of a functi on blocking 
antibody to human TF in this model of 16HBE 140- wound repair was investigated. 
4.4.2.1. Wound repair 
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Figure 4.2. Effect of anti-TF on repair of 16HBE 140- cell layers at 13 hours. Data 
represent mean ± SEM (n =3). * Indicates P<O.OOO 1, compared to no-antibody contro l 
and t indicates P<O.OOO 1 compared to non-immune mouse immunoglobulin. 
In the absence of anti-TF, the % original wound width, i.e. the % of the wo und still 
open after 13 hours was 1.15 ± 0.57 %. Thus, the wound had almost completely 
repaired in 13 hours . With the addition of 1 ).lg/ml anti-TF, wo und repair was 
significantly inhibited (84.60 ± 2.40 %) compared to both no antibody contro l and non-
immune mouse immunoglobulin (3 .29 ± 0.89 %), with no fuliher signifi cant effect at 
higher antibody concentrations. There was no effect of the non-immune mOll e 
immunoglobul in on wound repair. 
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4.4.2.2. Concentration of fibrinogen in cell culture supernatants 
Because TF initiates the coagulation cascade, it was of interest to investigate the levels 
of other coagulation factors of the extrinsic cascade, including fibrinogen and FXIIIA in 
cell culture supernatants at 13 hours, following inhibition of wound repair by anti-TF. 
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Figure 4.3. Effect of anti-TF on the concentration of fibrinogen in cell culture 
supernatants of 16HBE 140- cells 13 hours post-wounding. Data represent mean ± SEM 
(n=3). * Indicates P<0.05 compared to no antibody control. 
Inhibition of wound repair by anti-TF led to the accumulation in culture supernatants of 
fibrinogen released from wounded cell monolayers. The concentration of fibrinogen in 
culture supernatants was significantly increased in the presence of 1 Ilg/ml anti-TF 
(11.22 ± 1.96 Ilg/ml) compared to the no antibody control (3.68 ± 0.19 Ilg/ml). 
However, there was no further significant increase in the presence of 5 Ilg/ml anti -TF 
(15.60 ± 0.63 /-lg/ml) or 10 /-lg/ml anti-TF (14.66 ± 0.68 Ilg/ml) . 
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4.4.2.3. Concentration of FXlIIA in cell culture supernatants 
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Figure 4.4. Effect of anti-TF on the concentration of FXIIIA in cell culture 
supernatants of 16HBE 140- cells 13 hours post-wounding. Data represent mean ± SEM 
(n=3). 
Analysis of cell culture supernatants following inhibition of wound repair by anti-TF 
indicated a trend of increasing concentration of FXIIIA with increasing concentration of 
anti-TF. In the presence of 10 ~g/ml anti-TF, the concentration of FXIIIA (7.02 ± 0.27 
ng/ml) was almost double that of the no-antibody control (3.83 ± 0.48 ng/ml), however, 
the effect was not significant (p=O.l 07). 
4.4.3. Role of fibrinogen in 16HBE 140- cells 
TF not only activates the extrinsic coagulation cascade, but also generates proteases that 
activate PARs that are present on bronchial epithelial cells. A direct role for cross-
linked fibrin formation in the wound repair process was therefore investigated using 
antibodies to fibrinogen (section 4.4.3.1) and FXIIIA (section 4.4.4. 1). 
4.4.3.1 Wound repair 
Fibrinogen is the precursor for fibrin , which has a role in bronchial epithelial repair. The 
concentration of fibrinogen in cell culture supernatants was shown to 1l1crea e, 
dependent on the extent of wounding (section 3. -I. 2. J) and accumulated wh n wound 
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repair was inhibited (section 4.4.2.2). Therefore, the effect of an antibody to fibrinogen 
was investigated in this model of 16HBE 140- wound repair. 
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Figure 4.5. Effect of anti-fibrinogen on repair of 16HBE 140- cell layers at 13 hours. 
Data represent mean ± SEM (n =3). * Indicates P<O.OOO 1, compared to no-antibody 
control and t indicates P<O.OOOI compared to non-immune rabbit immunoglobulin. 
The % original wound width in no antibody control wells was 1.55 ± 0.78 %, indicating 
almost complete repair at 13 hours. Bronchial epithelial repair was significantly 
inhibited with the addition of 1 Jlg/ml anti-fibrinogen (72.72 ± 0.76 %) compared to 
both no antibody control and non-immune rabbit immunoglobulin (3.37 ± 2.75%). 
Wound repair was further reduced in the presence of 5 /-lg/ml anti-fibrinogen (81.07 ± 
l.91 %) and 10 Jlg/ml anti-fibrinogen (94.03 ± 4.44%); however, there was no further 
significant effect at these concentrations. Non-immune rabbit immunoglobulin had no 
effect on bronchial epithelial repair. 
4.4.3.2. Concentration of fibrinogen in cell culture supernatants 
Since fibrinogen and FXIIIA are involved in the final step of fibrin formation, it was of 
interest to investigate the levels of these factors in cell culture supernatants 13 hours 
following inhibition of wound repair by anti-fibrinogen. 
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Figure 4.6. Effect of anti-fibrinogen on the concentration of fibrinogen in cell culture 
supernatants of 16HBE 140- cells 13 hours post-wounding. Data represent mean ± SEM 
(n=3). * Indicates P<0.05 compared to no antibody control. 
At 13 hours, the addition of 5 ~g/ml anti-fibrinogen generated a significant increase in 
the concentration of fibrinogen (11.49 ± 1.69 /J-g/ml) in the cell culture supernatants 
compared to the no antibody control (1.96 ± 0.88 /J-g/ml). The concentration of 
fibrinogen in culture supernatants was further increased to 13.33 ± 0.95 /J-g/ml with the 
addition of 10 /J-g/ml anti-fibrinogen. 
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4.4.3.3. Concentration of FXIIIA in cell culture supernatants 
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Figure 4.7. Effect of anti-fi brinogen on the concentration of FXIIIA in cell culture 
supernatants of 16HBE 140- cells at 13 hours. Data represent mean ± SEM (n =3). 
The concentration of FXIIIA in wounded cell monolayers was 5.83 ± 0.83 ng/ml and 
although anti-fibrinogen inhibited wound repair, there was no significant effect on the 
levels of this coagulation factor. 
4.4.4. Role of FXIII in 16HBE 140- cells 
4.4.4.1. Wound repair 
Since FXIII is known to play an important role in the cross-linking of fibrinogen to 
form a stable fibrin clot to support wound repair and its concentration in cell culture 
supernatants was shown to increase depending on the extent of wounding (section 
3.4.2.2), the effect of an antibody to FXIIIA was investigated in this model of 16HBE 
140- wound repair. 
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Figure 4.8. Effect of anti-FXIIIA on repair of 16HBE 140-cell layers at 13 hours. Data 
represent mean ± SEM (n =3). * Indicates P<0.001 , compared to no-antibody control 
and t indicates P<O.OOI compared to non-immune sheep immunoglobulin. 
Repair in the untreated cell layers was almost complete with 0.42 ± 0.21 % original 
wound width remaining at 13 hours of culture. This effect was significantl y inhibited 
with the addition of 1 Jlg/ml anti-FXIIIA and the % original wound width was 78 .49 ± 
6.06 %. This effect was also induced by the addition of 5 Jlg/ml anti-FXIIIA (88.22 ± 
4.54 %) and 10 Jlg/ml anti-FXIIIA (89.53 ± 5.01 %). There was no effect of the non-
immune sheep immunoglobulin on bronchial epithelial repair. 
4.4.4.2. Concentration of fibrinogen in cell culture supernatants 
Because FXIIIA is involved in the final step of fibrin formation, it was of interest to 
investigate the levels of fibrinogen and FXIIIA in cell culture supernatants 13 hours 
following inhibition of wound repair by anti-FXIIIA. 
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Figure 4.9. Effect of anti-FXIIIA on the concentration of fibrinogen in cell culture 
supernatants from 16HBE 140- cells at 13 hours. Data represent mean ± SEM (n =3). 
* Indicates P<0.05 , ** indicates P<O.OI and *** indicates P<0.005 compared to no 
antibody control. 
Inhibition of the function of FXIIIA with a neutralising antibody increased the amount 
of soluble fibrinogen detected in cell culture supernatants of 16HBE 140- cells. The 
addition of 1 Ilg/ml anti-FXIIIA induced a four-fold increase in the concentration of 
fibrinogen in cell culture supernatants from 0.84 ± 0.l2 Jlg/ml in the absence of 
antibody to 4.10 ± 1.43 Ilg/ml. Supernatant concentration of fibrinogen was further 
significantly increased to 15.40 ± 0.53 Ilg/ml with the addition of 5 Jlg/ml and 16.46 ± 
0.62 Ilg/ml with the addition of 10 Ilg/ml anti-FXIIIA. 
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4.4.4.3. Concentration of FXIIIA in cell culture supernatants 
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Figure 4.10. Effect of anti-FXIIIA on the concentration of FXIIIA in cell culture 
supernatants from 16HBE 140- cells at 13 hours. Data represent mean ± SEM (n=3) . 
FXIIIA concentration in wounded cell mono layers was 4.19 ± 0.53 ng/ml. The addition 
of anti-FXIIIA had no significant effect on the concentration of FXIIIA in cell culture 
supernatants from 16HBE 140- cells; however, at 10 I-lg/ml anti-FXIIIA, the 
concentration of FXIIIA (7.52 ± 0.20 J.lg/ml) was considerably higher than that of the no 
antibody control (4.19 ± 0.53 I-lg/ml), but this effect was not significant (p=0.083). 
4.4.5. Role of TF in NHBE cells 
Since anti-TF inhibited wound repair in the 16HBE 140- cell line, it was of interest to 
investigate its effect in wound repair of primary NHBE cells. It must be noted that 
NHBE cells did not adopt the 'cobblestone' appearance in culture and did not form the 
tight junctions, which are evident in the 16HBE 140- cell line. 
Wound repair of NHBE cells was monitored over 20 hours. This time-point was chosen, 
as repair of NHBE cells is considerably slower than that of 16HBE 140- cells. mo t 
likely due to the fact that NHBE cells do not possess tight junctions in submerged 
culture and may therefore lack the required cell signalling to initiate repair. 
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4.4.5.1. Wound repair 
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Figure 4.11. Effect of anti-TF and non-immune mouse IgG on bronchial epithelial 
repair of NHBE cells at 20 hours. Data represent mean ± SEM (n =3) . * Indicates 
P<0.05, ** indicates P<O.OOl compared to no-antibody control and t indicates P<0.05 
compared to non-immune mouse IgG. 
The time-course for NHBE wound repair was different to that seen in 16HBE 140- cells. 
After 20 hours, the wound had not completely closed but remained open at 33.16 ± 5.12 
% of the original wound width. Wound repair ofNHBE cells was significantly impaired 
with the addition of 0.1 Jlg/ml anti-TF, i.e. 79.88 ± 4.25 % original wound width 
compared to 33.16 ± 5.12 % in the absence of antibody. Inhibition of wound repair was 
maintained with the addition of 0.5 Jlg/ml anti-TF (80.30 ± 2.10 %) and 1 Jlg/ml anti-TF 
(88.86 ± 5.14 %). There was no effect of the non-immune mouse immunoglobulin on 
bronchial epithelial repair. 
4.4.5.2. Concentration of fibrinogen in cell culture supernatants 
Since TF is important in the initiation of the coagulation cascade, leading to fi brin 
formation and anti-TF significantly decreased wound repair in NHBE cell s. it was of 
interest to investigate the levels of fibrinogen and FXIIIA in cell culture supernatants at 
20 hours following stimulation with anti-TF. 
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Figure 4.12. Effect of anti-TF on the concentration of fibrinogen in cell culture 
supernatants ofNHBE cells at 20 hours. Data represent mean ± SEM (n =3) . 
Although anti-TF significantly decreased wound repair, there was no significant effect 
on the concentration of fibrinogen in cell culture supernatants ofNHBE cells. 
4.4.5.3. Concentration of FXIIIA in cell culture supernatants 
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Figure 4.13. Effect of anti-TF on the concentration of FXIIIA 111 cell cul ture 
supernatants ofNHBE cells at 20 hours. Data represent mean ± SEM (n=3). 
FXIIIA concentration in cell culture supernatants of wounded mono layers 20 hour 
post-wounding were 9.53 ± 0.14 ng/ml. Analysis of cell culture supernatants from 
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NHBE cells exposed to anti-TF revealed that there was no significant effect of the 
antibody on the concentration of FXIIIA, as seen in 16HBE 140- cells. 
4.4.6. Role of fibrinogen in NHBE cells 
4.4.6.1. Wound repair 
Fibrinogen is the precursor for fibrin, which has a role in bronchial epithelial repair. 
Anti-fibrinogen was shown to inhibit wound repair in the 16HBE 140- cell line' , 
therefore, its effects were investigated in primary NHBE cells. 
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Figure 4.14. Effect of anti-fibrinogen and non-immune rabbit IgG on bronchial 
epithelial repair of NHBE cells at 20 hours. Data represents mean ± SEM (n =3). 
* Indicates P<O.Ol , ** indicates P<O.OOl compared to no antibody control and t 
indicates P<0.05 compared to non-immune rabbit IgG. 
The addition of 0.1 ~g/ml anti-fibrinogen significantly reduced wound repair to 82.64 ± 
2.2 1 % original wound width at 20 hours compared to 28.98 ± 3.67 % in the absence of 
antibody. This effect was maintained with the addition of 0.5 /-lg/ml anti-fibrinogen 
(83.90 ± 2.2 1 %) and 1 Ilg/ml anti-fibrinogen, whereby wound repair (99.02 ± 1.11 % 
original wound width) was almost completely inhibited. There was no effect of the non-
immune rabbit immunoglobulin on bronchial epithelial repair. 
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4.4.6.2. Concentration of fibrinogen in cell culture supernatants 
Since fibrinogen is involved in the final step of fibrin formation and anti-fibrinogen 
significantly decreased wound repair in NHBE cells, it was of interest to investigate the 
levels of fibrinogen and FXIIIA in cell culture supernatants at 20 hours followino 
b 
stimulation with anti-fibrinogen. 
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Figure 4.15. Effect of anti-fibrinogen on the concentration of fibrinogen in cell culture 
supernatants from NHBE cells at 20 hours. Data represent mean ± SEM (n =3) 
* Indicates P<0.005 compared to no antibody control. 
Anti-fibrinogen did however stimulate a significant increase in the concentration of 
fibrinogen in cell culture supernatants with the addition of 0.5 J.lg/ml (5.82 ± 0.52 J.lg/ml 
fibrinogen) and 1 J.lg/ml (8.35 ± 0.86 J.lg/ml fibrinogen) compared to the no antibody 
control (1.21 ± 0.15 J.lg/ml fibrinogen). 
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4.4.6.3. Concentration of FXIIIA in cell culture supernatants 
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Figure 4.16. Effect of anti-fibrinogen on the concentration of FXIIIA in cell culture 
supernatants from NHBE cells at 20 hours. Data represent mean ± SEM (n =3). 
Analysis of cell culture supernatants at 20 hours revealed that there was no effect of 
anti-fibrinogen on the concentration of FXIIIA compared to the untreated cells despite 
inhibition of wound repair by anti-fibrinogen. 
4.4.7. Role of FXIII in NHBE cells 
4.4.7.1. Wound repair 
Since anti-FXIIIA was shown to significantly inhibit wound repair in 16HBE 140- cells, 
it was of interest to investigate its effects in a model of primary NHBE wound repair. 
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Figure 4.17. Effect of anti-FXIIIA and non-immune sheep IgG on bronchial epithelial 
repair of NHBE cells at 20 hours. Data represent mean ± SEM (n=3). ** Indicates 
P<O.Ol *** indicates P<O.OOI compared to no antibody control and t indicates P<0.05 
compared to non-immune sheep IgG. 
Anti-FXIIIA significantly reduced bronchial epithelial repair to 82.39 ± 2.39 % original 
wound width with the addition of 0.1 J.lg/ml anti-FXIIIA compared to the no antibody 
control (30.01 ± 1.34 %). This effect was maintained with the addition of 0.5 flg/ml 
anti-FXIIIA (83.82 ± 2.49 %) and 1 flg/ml anti-FXIIIA (91.79 ± 1.07 %). There was no 
effect of the non-immune sheep immunoglobulin. 
4.4.7.2. Concentration of fibrinogen in cell culture supernatants 
FXIII is important in the cross-linking of fibrinogen to form a stable fibrin clot. Since 
anti-FXIIIA was shown to significantly decrease wound repair ofNHBE cells, it was of 
interest to determine the levels of fibrinogen and FXIIIA in cell culture supernatants at 
20 hours following stimulation with anti-FXIIIA. 
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Figure 4.18. Effect of anti-FXIIIA on the concentration of fibrinogen in cell culture 
supernatants from NHBE cells at 20 hours. Data represent mean ± SEM (n =3). 
* Indicates P<0.05 compared to no antibody control. 
Analysis of cell culture supernatants at 20 hours revealed that the addition of 1 I-lg/mJ 
anti-FXIIIA resulted in a significant 5-fold increase in the concentration of fibrinogen 
(5.68 ± 1.45 J.lg/ml) compared to 1.32 ± 0.11 I-lg/ml fibrinogen in the no antibody 
control. 
4.4.7.3. Concentration of FXIIIA in cell culture supernatants 
c.-
o ---
14 
12 
10 
= a 8 0-.- ell 
~ = 6 -.'-' -= CI# 
(oJ 
= o 
U 
4 
2 
o 
o 0.1 0.5 
Concentration of anti-FXIIIA (J.lg/ml) 
Figure 4.19. Effect of anti-FXIIIA on the concentration of FXIIIA in ce ll culture 
supernatants from NHBE cells at 20 hours. Data represent mean ± SEM (n =3). 
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Despite inhibition of wound repair by anti-FXIIIA, there was no effect on the 
concentration of FXIIIA in cell culture supernatants at 20 hours compared to the no 
antibody control. 
4.4.8. Role of FXa 
4.4.8.1. Exogenous FXa 
The serine protease FXa plays a central role in the coagulation cascade, linking the 
extrinsic and intrinsic pathways by catalysing the conversion of prothrombin to 
thrombin, which subsequently leads to the formation of fibrin. It is also an acti vator of 
PAR-l and PAR-2. Thus, it was of interest to investigate the role of FXa. Since FXa is 
involved in fibrin formation, it was expected that an increase in coagulation by the 
addition of FXa would result in an increase in wound repair. 
The concentration range of FXa (0-200 nM) was employed as it corresponded to that 
which was previously reported and is physiologically relevant as plasma contains 130 
nMFXa. 
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Fivure 4.20. Effect of exogenous FXa on wOlmd repair of 16HBE 140- ce ll layers at 13 
b * I d' P<O 0005 and ** indicate hours. Data represent mean ± SEM (n =3). n lcates . 
P<O.OOO 1 compared to no drug control. 
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The addition of exogenous FXa to 16HBE 140- cells significantly enhanced wound 
repair in a dose-dependent manner. In the presence of 50 nM FXa, the % original 
wound width was reduced from 50.04 ± 1.83 % in the untreated cell cultures to 32.51 ± 
0.12 0/0. Wound repair was further enhanced in the presence of 100 nM FXa (2 1.39 ± 
4.09 %) and 200 nM, whereby the % original wound width was reduced to 4.42 ± 1.63 
%. 
4.4.8.2. Endogenous FXa 
Since the addition of FXa enhanced bronchial epithelial repair, the role of endogenous 
FXa in wound repair was investigated with the use of a selective FXa inhibitor encoded 
UK-220,047-01, also termed DX9065A, a Daiichi compound provided by Pfizer Global 
R&D. 
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Figure 4. 21. Effect of the FXa inhibitor, UK-220,047-01 on wound repair of 16HBE 
140- cell layers at 13 hours. Data represent mean ± SEM (n =3) . * Indicates P<0.05 , 
** indicates P<O.Ol and *** indicates P<O.OOOI compared to no drug control. 
Wound repair was significantly reduced, but only with the addition of the lowest 
concentration of 0.05 J..lM UK-220,047-01 , whereby the % original wound width was 
52.23 ± 1.09 % compared to 47.42 ± 1.15 % in the untreated cell cultures. 
However, contrary to expectations, the addition of the FXa inhibitor UK-220.047-0 1 \0 
the concentration range of 0.l-1 J..lM enhanced wound repair in a dose-re pon iv 
158 
manner suggesting an alternative role for endogenous FXa. Wound widths fo llowing the 
addition of: 0.1 /-lM UK-220,047-01 = 33.63 ± 5.62 %; 0.2 /-lM UK-220,047-0 1 = 22.73 
± 2.32 %; 0.5 /-lM UK-220,047-01 = 10.20 ± l.75 % and 1 /-lM UK-220,047-01 = 0.51 ± 
0.080/0. 
Because of this unexpected finding, a second more potent and selective FXa inhibitor 
encoded PD-031 (Pfizer Global R&D) was used to confirm the role of endogenous FXa. 
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Figure 4.22. Effect of the FXa inhibitor, PD-031 on wound repair of 16HBE 140- cell 
layers at 13 hours. Data represent mean ± SEM (n=3). * Indicates P<0.05 and 
** indicates P<0.0001 compared to no drug control. 
Similarly, the lowest concentration of PD-031 significantly reduced wound repaIr 
(54.43 ± 3.50 % original wound width) compared to 45.95 ± 1.62 % in the untreated cell 
cultures. However, higher concentrations of PD-03l stimulated wound repair in a dose-
responsive manner. Wound widths fo llowing the addition of: 0.1 ).lM PD-031 = 38 .62 ± 
4.31 %; 0.2 /-lM PD-031 = 26.85 ± 4.96 %; 0.5 ).lM PD-031 = 15.89 ± 2.70 % and 1 ).lM 
PD-031 = 3.55 ± 4.21 %. 
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4.4.9. Role of endogenous thrombin 
Since the FXa inhibitor unexpectedly enhanced wound repair, it was of interest to 
investigate the role of endogenous thrombin in wound repair with the use of a thrombin 
inhibitor encoded UK-156,406, which was provided by Pfizer Global R&D . 
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Figure 4.23. Effect of the thrombin inhibitor, UK156,406 on wound repair of 16HBE 
140- cell layers at 13 hours. Data represent mean ± SEM (n =3). * Indicates P<0.005 , 
** indicates P<O.OOI and *** indicates P<OOOI compared to no drug control. 
The % original wound width was significantly reduced and therefore wound repair 
enhanced in a dose-responsive manner with the addition of: 0.05 JlM UK-1 56,406 = 
38.42 ± 1.83 %; 0.1 JlM UK-156,406 = 27.01 ± 3.27 %; 0.2 JlM UK-156,406 = 14.59 ± 
2.l1 %; 0.5 JlM UK-156,406 = 7.01 ± 1.07 % and 1 JlM UK-156,406 = 1.24 ± 0.28 % 
compared to the no drug control (49.52 ± 2.41 %) at 13 hours. 
4.4.10. Involvement of the COX pathway in wound repair 
Since both FXa inhibitors : UK-220,047-01 and PD-031 enhanced wound repair ( eclion 
4.4.8.2: figures 4.21 and 4.22 respectively), the role of endogenous FXa in the 
coagulation cascade was questioned. Reports have demonstrated that cellular igna lling 
by FXa in tissue culture has been shown to have effects that are independent from 
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thrombin generation and that are considered to be pro-inflammatory (Feistritzer et af.. 
2005). Furthermore, it has been suggested that the effects of FXa may be mediated via 
the prostaglandin receptor EP-l to release VEGF, IL-6, IL-8, MCP-l and CD54 
(Schulman, 2003). It was hypothesised that FXa may have an alternative role in wOLmd 
repair, other than its involvement in the coagulation cascade. Thus, the effects of 
endogenous FXa mediated via inflammatory cascades were investigated. 
4.4.10.1. Indomethacin 
A study by Savla et af (2001) demonstrated that PGE2 regulates wound repair of the 
bronchial epithelium and that this effect is mediated via EP-l and EPA (Savla et af. , 
2001). PGE2 is the end product of COX metabolism of arachidonic acid and is actively 
secreted by bronchial epithelial cells. Indomethacin is a COX inhibitor and therefore 
inhibits the production of PGE2. Since wound repair was stimulated by the addition of 
two separate FXa inhibitors when added in the concentration range of 0.1-1 IlM, it was 
of interest to investigate the effects of the selective FXa inhibitor PD-031 in the 
presence of indomethacin in order to investigate a role for PGE2 in this response. 
The effects of the COX inhibitor indomethacin were firstly investigated alone and then 
in the presence of 1 /-lM PD-031 . 
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Fi.gure 4.24. Effect of indomethacin on wound repair of 16HBE 140· cell laye r at 13 
hours. Data represent mean ± SEM (n=3). 
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Addition of the COX inhibitor indomethacin in the concentration range of: 0.01 -10 !JM 
had no effect on wound repair compared to the untreated cell cultures. 
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Figure 4.25. Effect of indomethacin in the presence of 1 J.l.M PD-031 on bronchial 
epithelial repair of 16HBE 140- cells at 13 hours . Data represent mean ± SEM (n=3). * 
Indicates P<0.005 and * * indicates P<O.OOO 1 compared to 1 J.l.M PD-031 alone. 
In order to investigate a role for PGE2 in wound repair, the COX inhibitor indomethacin 
was added to cells in the presence of 1 J.l.M PD-031 , the FXa inhibitor. The addition of 
PD-031 alone stimulated wound repair, reducing the % original wound width to 0.81 ± 
0.26 0/0. This effect was significantly reversed with the addition of 0.01 J.l.M 
indomethacin (23.68 ± 4.89 %) and 0.1 J.l.M indomethacin (40.13 ± 0.95 %) and a 
plateau was reached with the addition of 1 J.l.M indomethacin (42.39 ± 4.10 %). 
4.4.10.2. PGE2 
The significant effects of the COX inhibitor indomethacin in the presence of the FXa 
inhibitor PD-031 suggested that PGE2 was involved in the repair response. Therefore, it 
was pertinent to investigate a role for the COX metabolite PGE2 on wound repair. The 
addition of PGE2 (0-10 J.l.g/ml) was previously shown to enhance wo und repair of 
16HBE 140- cells in the presence of 10% FBS, in a dose-responsive manner 0 er 12 
hours (Savla et a/. , 2001 ). In order to confirm a role for PGE2• its effects were 
investigated in the CWTent serum-free model of 16HBE 140- wo und repair. 
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Figure 4.26. Effect of PGE2 on wound repair of 16HBE 140- cell layers at 13 hours. 
Data represent mean ± SEM (n=3). 
However, addition of PGE2 in the concentration range of 0-20 Ilg/ml had no effect on 
wound repair compared to the untreated cell cultures in this serum-free model. 
4.4.11. Effect of neutrophil elastase on wound repair 
Elastase not only degrades coagulation factors (Chapter 3) but also inactivates PARs. 
Therefore, the effect of neutrophil elastase on wound repair was investigated. 
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Figure 4.2 7. Effect of elastase on bronchial epithelial repair of 16HBE 140- cells at 13 
hours. Data represent mean ± SEM (n =3). * Indicates P<0.05 and ** indicates 
P<O.OOOl compared to no elastase control. 
The addition of elastase significantly inhibited wound repaIr In a dose-responsive 
manner: 0.01 U/ml elastase = 13.74 ± 3.13 %; 0.03 U/ml elastase = 69.70 ± 3.66 %; 0.1 
U/mi elastase = 81.85 ± 5.35 0/0; 0.3 U/ml elastase = 93.36 ± 6.54 % and 0.5 U/ml 
elastase = 98.55 ± 0.89 %; compared to the untreated cell cultures, 6.75 ± 1.93 % at 13 
hours, indicating almost complete wound repair. 
4.4.11.1. E ffect of elastase on LDH levels 
In order to determine whether the effects of elastase on wound repair were due to 
cytotoxicity, an LDH assay was conducted on supernatants and celllysates at 13 hours. 
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Figure 4.28. The effect of elastase on the levels of LDH in cell culture supernatants at 
13 hours. Data represent mean ± SEM (n=3). 
Elastase in the concentration range of 0-0.5 U/ml had no effect on the distribution of 
LDH between the supernatants and cell lysates indicating that the inhibition of wound 
repair was not due to cytotoxicity induced by this enzyme. 
4.5. Summary of results 
Neutralising antibodies to TF, fibrinogen and FXIII inhibited wound repair of both 
16HBE 140- and NHBE cells and corresponding non-immune control antibodies had no 
effect. Inhibition of wound repair of both 16HBE 140- and NHBE cells corresponded to 
a significant increase in the levels of fibrinogen in cell culture supernatants and no 
effect on FXIII concentration. Inhibition of both FXa and thrombin significantly 
enhanced wound repair of 16HBE 140- cells. Both exogenous and endogenous PGE2 
had no effect on wound repair of 16HBE 140- cells. Finally, neutrophil elasta e 
significantly inhibited wound repair of 16HBE 140- cells. 
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4.6. Discussion 
A recent report indicated that both migration and proliferation were involved in the 
repair of 16HBE 140- cell mono layers (Zhu et al., 2007). However, wound repair in the 
model described in this thesis was dependent on cell migration and not proliferation as 
there was no significant effect of MMC on wound repair, as previously reported for 
16HBE 140- cells (Howat et al., 2002). The difference may relate to the different 
inhibitors of proliferation used. Zhu et al. used nocodazole compared to MMC in the 
current study. However, the stimulus for cell migration is not fully understood. It must 
be noted that as well as the use of MMC as a proliferation inhibitor, cell cycle kinetic 
markers including proliferating cell nuclear antigen (PCNA), Ki-67 (MIB-7) or 
bromodeoxyuridine (BRDU) may have been used as alternative and possibly more 
effective compounds. 
The normal bronchial epithelium forms a highly regulated, virtually impermeable 
barrier through the formation of tight junctions at the apical perimeter of the cell 
composed of occludins and claudins, which prevent the passage of molecules and ions 
through the space between cells in order that materials must traverse cells by diffusion 
or active transport (Sparrow et al., 1995). Structural integrity is maintained between 
cells by adherens junction proteins such as epithelial-cadherin (E-cadherin). Similarly, 
desmosomes are involved in the adhesion of adjacent cells and hemidesmosomes are 
responsible for the adhesion of epithelial cells to the basement membrane (Hackett et 
al., 2007). Thus, it is likely that removal of epithelial cells as a result of mechanical 
wounding results in physical cleavage of adherens junctions and that the disruption of 
epithelial integrity may be the signal for cell migration. This concept is supported by the 
immunohistochemical images (Chapter 3) demonstrating the formation of lamellipodia 
at the leading edge of the cells indicating directional epithelial cell migration. 
E-cadherin is recognised as one of the most important molecules in the maintenance of 
epithelial integrity and wound repair (Gumbiner, 1996; Takeichi, 1991). E-cadherin is a 
type I transmembrane glycoprotein of which the extracellular domain interacts 
homotypically with E-cadherin molecules on the surface of neighbouring cells to form 
calcium-dependent adherens junctions. The stabilisation of intercellular adhesion 
requires the cytoplasmic domain of E-cadherin, which associates with p-catenin, a dual 
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function protein which is linked to the cytoskeleton and plays a role in cell adhesion and 
gene expression (Maretzky et al., 2005). 
~-catenin activates the canonical Wnt pathway (Behrens et al., 1996; Miller el al.. 
1999). Following accumulation of ~-catenin, it translocates into the nuclear 
compartment where it binds to T cell factor (Tcf) and lymphoid enhancer factor (Lef)-l 
proteins and activates gene transcription (Miller et al., 1999). Recent evidence indicates 
a role for ~-catenin in wound repair of bronchial epithelial cells (Zhu et al.. 2007). It 
was demonstrated that glycogen synthase kinase 3~ (GSK3~)/~-catenin signalling was 
involved in wound repair that was due to both proliferation and migration of 16HBE 
140- cells. GSK3~ is a multifunctional serine/threonine kinase that is known to 
phosphorylate and down-regulate ~-catenin and is thereby a negative regulator of the 
Wnt signalling pathway (Doble et aI., 2003; Grimes et aI., 2001). Following inhibition 
of GSK3~ activity, J)-catenin accumulated and the rate of wound repair was enhanced. 
Moreover, mechanical wounding alone was demonstrated to cause inhibitory 
phosphorylation of GSK3J), which lead to accumulation of ~-catenin and subsequent 
wound repair (Zhu et al., 2007). Primary NHBE cells have been shown to express 
mRNA encoding Tcf and Lef-1 that are required for canonical Wnt cell signalling (Steel 
et al., 2005). In the same study cell density was shown to influence ~-catenin 
transcriptional activity, whereby a redistribution of activated ~-catenin into the nuclear 
compartment was demonstrated in sub-confluent NHBE cells. The relevance of the 
effect of cell density is that when monolayers of epithelial cells are mechanically 
wounded, they may be considered sub-confluent. 
Following neutralisation of E-cadherin, adherens junctions are weakened and cells 
become rounded and less adhesive in order to facilitate cell migration. It has been 
demonstrated that inhibition of E-cadherin function can be mediated through the 
shedding of its ectodomain as a result of cleavage by matrilysin (MMP-7) and 
stromelysin-1 (MMP-3) (Noe et al., 2001). In alveolar epithelial cells, transfection with 
MMP-7 resulted in shedding of E-cadherin and accelerated cell migration suggesting 
that shedding of the E-cadherin ectodomain is required for epithelial wound repair. 
MMP-7 was reported to facilitate migration of surviving cells by promoting the re-
organisation of cell-cell junctions (McGuire et al., 2003). In bronchial epithelial cells. 
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expression of MMP-7 is upregulated following injury (Dunsmore et aI., 1998: Lopez-
Boado et aI., 2001). Interestingly, TGF-p1 can upregulate the expression of MMPs 
(Lechapt-Zalcman et aI., 2006) and the total concentration of this growth factor was 
increased in response to wounding (section 3.4.4.3), possibly leading to shedding of E-
cadherin. Moreover, trypsin is a product of injured epithelial cells and has been 
demonstrated to mediate the removal of the E-cadherin ectodomain and induce tyrosine 
phosphorylation of p-catenin (Takahashi et aI., 1997) and may therefore be involved in 
the initial stimulus for cell migration. Activation of c-Met by HGF has recently been 
associated with decreased E-cadherin-dependent cell-cell contacts (Reshetnikova et aI., 
2007). Expression of c-Met was demonstrated in 16HBE 140- cells (section 3. -I, -I, -I) and 
was upregulated in response to wounding. Conversely, the same cell line was not shown 
to express HGF, however, HGF released from fibroblasts in vivo may bind to c-A1et on 
epithelial cells to stimulate cell migration. 
In asthma, the bronchial epithelium is highly fragile. Moreover. bronchial epithelial 
cells from asthmatic individuals appear to be more activated compared to non-
asthmatics and the release of inflammatory mediators such as TNF -a is increased 
(Holgate et aI., 1999; Montefort et aI., 1993). TNF-a released from NHBE cells 
mediates cell-cell dissociation associated with disordered expression of E-cadherin and 
p-catenin (Tabibzadeh et aI., 1995). It has been suggested that modifications in E-
cadherin binding to p-catenin may be involved in the weakening of the bronchial 
epithelium in asthma (Carayol et aI., 2002). Thus, in normal bronchial epithelial repair, 
removal of E-cadherin fragments and subsequent accumulation of p-catenin is 
beneficial in mediating wound repair, however, in asthma the continued release of pro-
inflammatory mediators such as TNF -a and subsequent E-cadherin shedding may be 
detrimental. 
It has been suggested that epithelial injury activates a repair response of basal cells 
targeted at the re-epithelialisation of the wound (Vignola et al., 2000). Such a repair 
process requires the release of ECM components including fibronectin and collagens 
and of factors that establish a chemotactic gradient influencing the migration of 
bronchial epithelial cells. Another fundamental step in the repair process is the ability of 
cells to adhere to the ECM and then migrate towards the wound. This e'v'ent relies 
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heavily upon integrins, which have the capacity to modulate the interactions between 
cell and ECM components (Sheppard, 2003). 
Following injury in vivo and denudation of the basement membrane, a provisional 
matrix is formed which is composed of remnants of the original basement membrane 
such as laminin and collagen IV. Plasma exudate contains fibrin and fibronectin as well 
as other ECM proteins such as vitronectin. However, bronchial epithelial cells are 
capable of producing fibronectin and collagen IV and fibroblasts underlying the wound 
are important sources of proteoglycans, collagens, fibronectin and cytokines 
(McGowan, 1992; Shoji et al., 1990). Besides being a major component of the 
provisional matrix and representing an important adhesive substrate for epithelial cells, 
fibronectin and its soluble fragments are active in promoting directional epithelial cell 
migration in the lung (Shoji et al., 1989). Vitronectin, collagen and laminin are also 
described as potent stimuli for bronchial epithelial cell migration and have been 
demonstrated to promote directional migration of bovine tracheal epithelial cells in vitro 
(Rickard et al., 1993). Epithelial cell migration over the provisional matrix is a complex 
process involving the adhesion and de-adhesion of the cells to matrix components. In 
order to migrate, epithelial cells must balance adhesive interactions with motility, which 
requires continual establishment and spreading of adhesive contacts. 
Bronchial epithelial cells express a variety of integrin receptors including the collagen-
laminin receptor (a2, a3 and a6 chains), fibronectin receptor (av chain) vitronectin 
receptor (av chain) and a6p4 receptor (Montefort et al., 1991; Rossi et al., 1990). An 
increased expression of specific integrins including avp 1 and avp6 occurs on the basal 
surface of regenerating epithelial cells after the deposition of fibronectin suggesting that 
fibronectin may induce integrin expression (Horiba et al., 1994). Bronchial epithelial 
cells also express a3 PI integrin, the counter-receptor of several ECM components 
including fibronectin, laminin and collagen. Since the cells in the vicinity of a wounded 
area produce ECM components and the deposition of ECM components on the 
basement membrane is followed by adhesion and spreading of bronchial epithelial cells 
eventually leading to wound repair, it has been suggested that the expression of a3p 1 
integrin by these cells may play an important role in the regulation of their interaction 
with ECM components (Vignola et al., 2000). Despite tight regulation of epithelial 
migration by integrins (Sheppard, 1996); these molecules themselves do not possess any 
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catalytic activity and are therefore unable to initiate signalling cascades independently. 
Instead, signal transduction from integrins to regulate migration occurs via several 
intermediate pathways (Parsons, 1996). 
A variety of proteoglycans have been described on the surface of bronchial epithelial 
cells such as syndecan that can bind collagen and fibronectin and might therefore 
participate in adhesion and cell migration (Dufour et al., 1986; Mette et al., 1993). 
Moreover, the adhesion molecule CD44 can bind fibronectin and collagen and there is 
evidence to suggest that it might playa role in bronchial epithelial repair (Cichy et al., 
2002; Holgate, 2000). 
Expression of the chemokine receptor CXCR3 has recently been demonstrated in 
NHBE and 16HBE 140- cells and was shown to induce directional cell migration when 
activated by its ligand, 1-T AC (Aksoy et a!., 2006). Thus, there are a number of possible 
mechanisms, which may provide the initial stimulus for epithelial cell migration and 
subsequent wound repair. 
Restitution to an intact undifferentiated epithelial barrier following wounding can take 
as little as one hour in the guinea pig lung in vivo (Erjefalt et a!., 1997), whereas the 
time taken for wound repair in the human lung has not been determined. Under serum-
free conditions, the rate of cell migration of controls as determined by the method 
described in section 4.3.10 was 0.83 umlmin and considerably greater than that reported 
in other studies whereby cell migration of A549 alveolar epithelial cells was 0.06 
umlmin (Galiacy et a!., 2003) and migration of primary bronchial epithelial cells 
cultured on collagen I-coated plastic ware was 0.34 um/min (Zahm et a!., 2000). 
Interestingly, Zahm et al. (2000) reported that the addition of HGF increased the rate of 
cell migration to 0.84 um/min, which is similar to that demonstrated in the current study 
in which cells were not exposed to exogenous motogenic factors and were not cultured 
on a collagen matrix. 
Inhibition of wound repair in both 16HBE 140- and NHBE cells by a blocking antibody 
to TF indicated that wound repair was dependent on TF expressed by these cells. 
However, the blocking of TF may not only inhibit initiation of the coagulation cascade 
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but also activation of PARs since TF-FVIIa-FXa can activate both PAR-l and PAR-2 
(Chambers et a!., 2002; Macfarlane et a!., 2001). 
TF exists in microdomains on the cell surface with a mixed population of active and 
encrypted protein. Most cell surface TF is latent and simple exposure of the cell surface 
to circulating FVII is not sufficient to trigger coagulation. Latent TF describes the 
encrypted form of this coagulation factor, whereby the procoagulant activity of TF on 
the cell surface is suppressed (Bach, 2006). Hence the reason that under nonnal 
conditions, TF associated with the surface of blood cells does not trigger coagulation. 
Thus TF encryption represents a physiological mechanism for controlling the 
expression of cellular coagulant activity in vivo. 
De-encryption of TF is associated with a release of calcium from internal stores, 
followed by a disruption in phosphatidylserine asymmetry. Phosphatidylserine has long 
been established to accelerate coagulation reactions on cell surfaces. It is believed that 
encrypted TF is sequestered in lipid rafts and the de-encrypted fonn is released into the 
liquid disordered phase of the membrane following cell stimulation (Bach, 2006). 
Cell surface TF binds FVIIa to initiate coagulation or, alternatively, to trigger signalling 
through PARs. It has been suggested that TF:FVIIa mediated coagulation and cell 
signalling involve distinct cellular pools ofTF, that signalling TF refers to the encrypted 
form and that de-encryption of TF is necessary to promote coagulation. Disulphide 
isomerisation has been demonstrated to facilitate a dynamic and reversible switch 
between these two distinct TF species (Ahamed et a!., 2006). The cell surface 
extracellular disulphide bond of TF is critical for coagulation and when targeted with 
protein disulphide isomerase (PDI), the bond is cleaved and coagulation is disabled. 
However, the disulphide bond was not found to be required for PAR-2 cleavage by 
TF:FVIIa. Ahamed et al. (2006) demonstrated that cleavage of the disulphide bond to 
inhibit coagulant function is also regulated by NO pathways and conclude that 
inhibition of TF:FVIIa signalling is feasible without impairing coagulation. 
Neutralising antibodies to fibrinogen and FXIIIA significantly inhibited wound repair of 
both 16HBE 140- and NHBE cells compared to untreated wounded cell culture controls 
and corresponding non-immune immunoglobulin controls. This signifies that these 
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coagulation factors are important in wound repair. Since the extrinsic coagulation 
cascade ultimately leads to fibrin formation and a fibrin matrix is required for wound 
repair (Erjefalt et aI., 1994), the fact that fibrinogen and FXIIIA playa functional role in 
16HBE 140- and NHBE wound repair suggests that wound repair is occurring via fibrin 
formation in this model and that a cross-linked fibrin matrix is essential for wound 
repair. In hindsight, it would have been useful to perform immunocytofluorescence for 
fibrin deposition in wounded mono layers of 16HBE 140- cells in order to confirm the 
formation of fibrin in response to wounding. 
Previous studies have reported that fibrinogen is synthesised and secreted by A549 
alveolar epithelial cells and is demonstrated to significantly enhance wound repair 
(Haidaris, 1997). However, synthesis and secretion of this coagulation factor followed 
stimulation of these cells with the inflammatory mediators IL-6 and dexamethasone 
whereas wounding was the stimulus in the current model. There is a possibility that the 
fibrinogen released from bronchial epithelial cells in the current study may constitute 
part of the ECM and facilitate cell migration independently of conversion to fibrin 
(Guadiz et aI., 1997). 
FXIII is a trans glutaminase and exists in the blood as a heterotetramer (A2B2) of which 
FXIIIA contains the active site. FXIIIa catalyses the formation of isopeptide cross-links 
between glutamine and lysine side chains of adjacent polypeptides and its main function 
is to cross-link fibrin chains (Muszbek et aI., 1999). However, the enzyme also plays a 
role in the cross-linking of fibrin with other proteins including fibronectin, u2-plasmin 
inhibitor and collagen leading to an increase in mechanical strength, elasticity and 
resistance to degradation of fibrin clots by plasmin and to the promotion of wound 
repair (Ichinose, 2001). There is accumulating evidence to support the concept that the 
interaction of cells with the ECM is essential for migration and subsequent wound 
repair. FXIII has been identified as a ligand for the integrins a9p 1 and a4p 1 which are 
transmembrane receptors that mediate cell-ECM interactions that are important in cell 
migration (Takahashi et aI., 2000) and of which u9p 1 is abundantly expressed by basal 
bronchial epithelial cells (Sheppard, 2003). The release of FXIII from bronchial 
epithelial cells and the anchoring of the fibrin clot to the ECM suggests that FXIII is 
directly involved in wound repair and this notion is confirmed by the fact that wound 
repair is inhibited in the absence of this enzyme. 
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In the current study, wound repair is dependent on cell migration, which is subsequently 
dependent on the formation of a cross-linked fibrin gel matrix. Blocking the formation 
of this matrix by antibodies to TF, fibrinogen and FXIII resulted in the accumulation of 
fibrinogen in cell culture supernatants, indicating not only that wounding was a strong 
stimulus for fibrinogen release but that when wound repair was inhibited, fibrinogen 
continued to be released but not consumed in the wound repair process. Despite 
inhibition of NHBE wound repair by anti-TF, there was no significant accumulation of 
fibrinogen released into cell culture supernatants. The fact that NHBE cells do not 
achieve full confluence in submerged cultures or posses the tight junctions of 16HBE 
140· cells may provide an explanation for the differences in responses. Alternatively, it 
is possible that the fibrinogen released from NHBE cells was incorporated into the ECM 
independently of conversion to fibrin as for A549 alveolar epithelial cells (Haidaris, 
1997). Analysis of the levels of D-dimers in cell culture supernatant levels would clarify 
whether or not fibrin was formed. 
Conversely, inhibition of wound repair with the noted blocking antibodies did not 
induce any significant changes in the levels of FXIII in either 16HBE 140· or NHBE 
cell culture supernatants compared to the untreated wounded cell culture controls. Thus, 
FXIII is released in response to wounding but does not accumulate following the 
blocking of the coagulation pathway. The lower levels of FXIII may signify the binding 
of this protein to ECM components or that FXIII is less stable than fibrinogen and is 
released and subsequently degraded. An investigation of the interaction of FXIII with 
cultured fibroblasts demonstrated that cell associated activated FXIIIA is involved in 
the cross-linking of fibronectin and is subsequently internalised and degraded by 
fibroblasts (Barry et al., 1990). 
In hindsight, it must be noted that the experiments involving the effect of neutral ising 
coagulation factor antibodies on the levels of fibrinogen and FXIII in supernatants 
derived from 16HBE 140· cells were flawed, as they did not include the corresponding 
isotype control antibodies. 
Incubation of 16HBE 140· cells with FXa resulted in a concentration-dependent 
promotion of wound repair. Since FXa plays a central role in the coagulation cascade. 
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catalysing the conversion of prothrombin to thrombin which ultimately leads to the 
formation of fibrin (Davie et al., 1991), it is conceivable that the addition of FXa 
enhanced the coagulation process on the cell surface. 
FXa is a serine protease and is known to activate both PAR-l and PAR-2 (Chambers et 
al., 2002; Macfarlane et al., 2001). Since activation of both PAR-l and PAR-2 was 
shown to stimulate repair, it is possible that exogenous FXa enhanced repair by a PAR-
mediated mechanism. Alternatively, incubation of HUVECS with FXa in a similar 
concentration range was previously shown to stimulate the release of NO as determined 
by the accumulation of cGMP in these cells which was inhibited by L-NAME, the NOS 
antagonist (Papapetropoulos et al., 1998). The bronchial epithelium continuously 
produces NO, largely due to constitutive expression of iNOS (Xu et al., 2006), and NO 
has been associated with cell migration and epithelial repair following injury. A recent 
study demonstrated that addition of an NO donor and stable transfection ofNHBE cells 
with iNOS in order to mimic constitutive epithelial iNOS expression in vivo lead to a 
promotion of wound repair via activation of MMP-9 (Bove et al., 2007). Thus, there is a 
possibility that wound repair occurred by FXa-mediated NO production. 
Interestingly, incubation of 16HBE 140- cells with two separate selective FXa inhibitors 
resulted in inhibition of wound repair only at low concentrations (0.05 JlM) but 
enhanced wound repair at higher concentrations (0.1-1 JlM). Given that FXa plays a 
crucial role in the coagulation cascade, it was therefore not expected that endogenous 
FXa would be found to inhibit repair. Since FXa binds to negatively charged 
phospholipids, two pools of FXa substrate exist, one of which is released from cells and 
is free in solution and the other which is membrane-bound (Papahadjopoulos et al.. 
1964). It has been demonstrated that free FX determines the rate of FX activation and 
that free FX is the true substrate for TF -FVIIa in the extrinsic pathway of coagulation 
(Forman et al., 1986). Thus, it is possible that the inhibition of wound repair at low 
concentrations was due to effects on FXa that was released into the cell culture 
supernatant and behaved in the same way as exogenously added FXa and that 
stimulation of wound repair was related to FXa that was phospholipid-bound. 
In addition to its role in coagulation, FXa is also considered to mediate inflammatory 
events via PAR-l and PAR-2. Activation of both PAR-l and PAR-2 stimulates PGE2 
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production by epithelial cells to initiate PGE2-dependent bronchoprotection (Cocks et 
al., 2000). However, in the current model, there is accumulating evidence to suggest 
that inhibition of wound repair by endogenous FXa is not mediated via PARs. Firstly, 
activation of PAR-1 and PAR-2 enhanced the rate of bronchial epithelial repair, as 
demonstrated in section 5.4.1; and data generated from immunoblotting in Chapter 5 
demonstrated that both P AR-1 and P AR-2 increased the release of fibrinogen, FXIII and 
D-dimers, at baseline and in response to wounding, indicating that PAR-stimulated 
wound repair involves the formation of fibrin. Secondly, PAR activation generates 
PGE2 that has been demonstrated to enhance bronchial epithelial repair in vitro (Savla et 
al., 2001). Thus, the observation that the FXa inhibitor enhances wound repair in the 
current model suggests that this effect is not via FXa-mediated PAR activation. In order 
to confirm this, it would have been useful to include an antagonist of PAR-1 and PAR-2 
or alternatively, a neutralising PAR antibody. 
The stimulatory effect on wound repair by the selective FXa inhibitor PD-031 was 
reversed by indomethacin in a concentration-dependent manner. Indomethacin inhibits 
COX activity and hence the conversion of arachidonic acid to PGE2, the predominant 
prostanoid produced by bronchial epithelial cells (Savla et al., 1997). Thus, when FXa 
was inhibited, PGE2 (or other prostanoids) was apparently involved in the wound repair 
process as determined by inhibition of wound repair by indomethacin. Therefore, it is 
possible that endogenous FXa suppresses PGE2 synthesis or that inhibition of FXa 
increases PGE2 synthesis suggesting that PGE2 may play a role in wound repair under 
these conditions. 
In order for FXa activation, calcium is required to promote the binding of enzyme and 
substrate and subsequent catalysis requires a phospholipid membrane (Nesheim et al., 
1979; Rodgers et al., 1983). Equally, PGE2 production is dependent upon the presence 
of polyunsaturated fatty acids. Previous studies have demonstrated that tracheal 
epithelial cells are dependent on serum-containing medium for essential fatty acids to 
support PGE2 synthesis. Cultured tracheal epithelial cells in serum-free medium were 
deficient in PGE2 production at baseline and in response to stimuli. unlike cells cultured 
in medium supplemented with serum, which displayed greater content of arachidonic 
acid. Cells that were maintained in serum-free media contained a higher proportion of 
palmitoleic acid and oleic acid and decreased proportion of linoleic acid and arachidonic 
175 
acid indicating essential fatty acid deficiency. Both human and rabbit species of tracheal 
epithelial cells cultured in serum-free conditions demonstrated a loss of 85-90% of the 
arachidonic acid found in freshly isolated cells and cellular linoleic acid content was 
decreased by 80%. Culture medium supplemented with 5% FBS was shown to increase 
the linoleic acid and arachidonic acid content of cultured rabbit and human tracheal 
epithelial cells, but was not sufficient to restore the fatty acid composition of freshly 
isolated cells. Instead, full restoration was achieved by the addition of a commercial, 
non-serum source of lipids, excyte III, in combination with exogenous arachidonic acid 
which in tum lead to restoration ofPGE2 syn~hesis (Alpert et al., 1991). 
In this reductive model of 16HBE 140- and NHBE cells, all experiments were carried 
out in a serum-free environment in order to study the regulation of cellular functions in 
the absence of coagulation factors. The absence of serum has proven invaluable in 
uncovering a role for the contribution of bronchial epithelial cells alone to wound repair. 
However, in the case of experiments investigating a role for PGE2, it appears that 
removal of serum from the medium is restricting the availability of membrane 
phospholipids containing arachidonic acid required for PGE2 production. Moreover. the 
requirement of phospholipids for FXa activity suggests that FXa may be reducing the 
availability for arachidonic acid and thus inhibiting PGE2 production even further. 
Inhibition of prostanoid production by FXa has also been demonstrated in other cell 
types. FXa has been demonstrated to inhibit the synthesis of thromboxane A2 (TXA2), 
the predominant prostanoid of platelets (Sinha et al., 1983) and is described as a potent 
inhibitor of prostacyclin (PGh) production in endothelial cells. In this cell type, PGh is 
the predominant prostanoid produced (Sinha et al., 1985). In both platelet and 
endothelial cells, the reaction catalysing the conversion of prothrombin to thrombin by 
FXa occurs on the cell surface and is dependent on the presence of calcium (Rodgers et 
al., 1983; Sinha et al., 1983). 
The stimulatory effect of FXa on wound repair may be via coagulation and/or PAR 
activation but the inhibitory effect of endogenous membrane-bound FXa may be via 
competition for phospholipids, or alternatively via EPR -1, which has not yet been 
described on bronchial epithelial cells. EPR-I was identified by Altieri et al. in 1995 
and so far has only been localised to leukocytes and endothelial cells. where it emerged 
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as a regulator of FXa-mediated mitogenic signalling. Through the interaction with EPR-
1, FXa has been demonstrated as a mediator of acute inflammation and subsequent 
tissue injury in a rat model in vivo (Cirino et aI., 1997). In order to determine whether 
FXa is mediated via EPR-l in this model, it would first be necessary to perform 
immunohistochemical staining for this receptor in 16HBE 140' and NHBE cells. In 
addition, EPR-l peptide agonists and corresponding scrambled control peptides could 
be employed to investigate the effects of EPR-l in 16HBE 140' and NHBE wound 
repair. However, the existence of EPR-l has been questioned since the initial 
identification of the gene. The current perception is that EPR-l is either a unique 
property of specific cell lines or that the published EPR-l cDNA contains sequence 
errors or includes sequences from clones that actually derived from survivin mRNA 
(Zaman et aI., 2000). 
In order to further investigate the suppressant effect of FXa on PGE2 production, it 
would be interesting to determine the levels of PGE2 in cell culture supernatants 
following stimulation of 16HBE 140' cells with the FXa inhibitor, PD-031 in the 
presence of indomethacin. Furthermore, the same experiment could be performed in the 
presence of serum or excyte III in combination with arachidonic acid. Indomethacin 
alone had no effect on wound repair confirming that PGE2 is not produced under the 
current culture conditions. Thus, this experiment could be repeated using medium 
containing serum or excyte III to investigate the effects of endogenous PGE2 on wound 
repair. 
Savla et al. (2001) demonstrated that the addition of PGE2 in the concentration range of 
0-10 /-lg/ml stimulated wound repair of 16HBE 140' cells, in a dose-dependent manner. 
However, the same concentration range of PGE2 employed in this model had no effect 
on wound repair. Moreover, Savla et al. also reported that indomethacin inhibited 
wound repair in a dose-dependent manner indicating inhibition of endogenous PGE2• 
whereas indomethacin had no effect on wound repair in the current model. It must be 
noted however, that wound repair in Savla's model was carried out in cell culture 
medium containing 10% FBS, increasing the availability of phospholipid for 
arachidonic acid release and subsequent PGE2 production. Promotion of wound repair 
by PGE2 was mediated via E-prostanoid (EP)-1 and EP-4 (Savla et at., 2001), howeyer. 
under serum-free conditions. mRNA for neither EP-l nor EP-4 was detected by RT-
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PCR (as discussed in chapter 6). It is therefore conceivable that these receptors are 
down regulated in the current model due to the lack of serum in the cell culture medium 
and provides an explanation for the fact that addition of exogenous PGE2 had no effect 
on wound repair. 
Interestingly, a thrombin inhibitor encoded UK-156,406 was also demonstrated to 
significantly enhance wound repair of 16HBE 140- cells. Given that thrombin is a vital 
component of the coagulation cascade by mediating the conversion of fibrinogen to 
fibrin and cleaving the FXIIIA subunit to initiate fibrin stabilisation by covalent cross-
linking, it was not expected that endogenous thrombin would inhibit wound repair. 
Thrombin also has the capacity to activate PAR-1 -3 and -4, however there is 
accumulating evidence that the majority of its cellular effects occurs via PAR-I. 
Detrimental effects of PAR-1 activation by thrombin in vascular and extravascular 
compartments includes the excessive deposition of extracellular matrix proteins and 
ongoing coagulation activity leading to fibrosis (Chambers et al., 2002). In view of this, 
the observation involving the thrombin inhibitor is therefore not likely to be mediated 
via PAR-1 activation by thrombin. Furthermore, PAR-1 activation in the current model 
lead to an increase in wound repair and an increase in release of coagulation factors and 
D-dimers (as described in Chapter 5), which implies that PAR-stimulated wound repair 
involved fibrin formation, supporting the concept that the effect of the thrombin 
inhibitor is not PAR-mediated. Since thrombin activation also requires a phospholipid 
cell surface, it is likely that endogenous thrombin may also be having a suppressant 
effect on' PGE2 production for the same reasons as explained for FXa. Thus. by 
inhibiting thrombin, this may increase the availability of phospholipids in the membrane 
for production of PGE2 and subsequent wound repair. It would therefore be interesting 
to measure the levels of PGE2 in cell culture supernatants of cells that were stimulated 
with UK-156,406 to confirm this effect. 
Elastase significantly inhibited repair of bronchial epithelial cell layers at the same 
concentrations that were shown in Section 3.4.7 to deplete the supernatant of fibrinogen 
and FXIII. Proteolytic degradation of these essential coagulation factors may therefore 
limit the repair response. Alternatively, elastase has been shown to disarm PAR-I 
(Renesto et al., 1997) and PAR-2 (Chignard et al., 2006). Studies have investigated the 
effects of neutrophil elastase (NE), cathepsin G (CG) and elastase from Pseudomonas 
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aeruginosa (Epa) in 16HBE 140- cells, A549 alveolar epithelial cells and a constitutive 
human P AR-2 expressing cell line (KNRKIP AR-2). None of the noted proteases 
activated any of these cell lines as determined by cytosolic calcium measurements, 
however following exposure of cells to these proteases, cells were subsequently 
unresponsive to trypsin. It must be noted that the concentration of elastase that has 
previously been demonstrated to cleave PAR-2 (500 nM) (Dulon et ai., 2003) is 10-fold 
higher than that employed in the current study (50 nM) whereas similar concentrations 
of elastase have previously been shown to cleave FX (23 nM) (Turkington, 1991) and 
FVII (18 nM) (Anders sen et aI., 1993). A cytotoxic effect of elastase was ruled out as 
determined by LDH release assays. This observation is consistent with previous reports 
that epithelial cells are resistant to cytolytic injury by elastase (Chung et ai., 1991; 
Peterson et aI., 1995). Therefore, proteolysis of essential coagulation factors seems the 
most likely explanation for the observed inhibition of repair in the presence of elastase. 
In order to confirm this and to rule out an effect on PARs, it would be necessary to pre-
incubate bronchial epithelial cells with neutrophil elastase prior to challenge with PAR 
peptides and to monitor the wound repair response. 
The significant reduction by elastase of the levels of coagulation factors in cell culture 
supernatants and subsequent concentration-dependent inhibition of wound repair 
supports the notion that coagulation factors are essential to wound repair, which is in 
accordance with the observations investigating the effect of blocking antibodies to the 
coagulation factors. 
The major source of elastase in the infected, inflamed human lung is the neutrophil 
(Cohen et ai., 1983). Neutrophils migrate from the blood vessel into the airway lumen 
during infection and inflammation and in doing so, they traverse both the endothelium 
and the epithelium (Hiemstra et aI., 1998). Neutrophils have previously been shown to 
damage the bronchial epithelium in vitro and in vivo. Activated neutrophils can directly 
contribute to increased epithelial permeability as determined by transepithelial electrical 
resistance measurements (Milks et ai., 1986; Peterson et aI., 1995). It has been 
demonstrated that neutrophils alter epithelial barrier integrity (Nash et al., 1987: 
Sugahara et aI., 1986) and gap formation in epithelial mono layers induced by neutrophil 
elastase has been reported (Kercsmar et aI., 1993). Neutrophil elastase is reported to 
cause epithelial detachment from the ECM (Amitani et al., 1991; Harlan et at.. 1981: 
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Van Wetering et al., 1997), however, there are several studies that did not demonstrate 
any significant cell detachment despite elastase-induced epithelial permeability 
(Peterson et al., 1995; Rickard et al., 1992). 
Neutrophil elastase also has the potential to further alter epithelial integrity indirectly by 
inducing the expression of the neutrophil chemoattractant IL-8 in bronchial epithelial 
cells (Nakamura et al., 1992) and it is now recognised that IL-8 regulation by neutrophil 
elastase occurs in part through the cell surface membrane bound toll-like receptor 4 
(Devaney et al., 2003). Since IL-8 is a potent chemoattractant for neutrophils (Kunkel et 
al., 1991), elastase contributes to sustained epithelial damage. Thus elastase both 
damages the epithelium and inhibits its repair. This may be relevant in severe asthma 
associated with viral infection where neutrophils dominate the inflammatory response 
(Fahy et al., 1995; Holgate et al., 2006; Vignola et al., 1998; Wenzel et al., 1999: 
Wenzel et al., 1997). 
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Chapter 5. 
Effect of PARs on Wound 
Repair & Coagulation 
Factor Expression 
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5. Effect of protease activated receptors (PARs) on wound repair and coagulation 
factor expression 
5.1. Introduction 
5.1.1. PARs 
PARs are a group of G-protein-coupled, seven transmembrane domain, cell surface 
receptors that enable cells to monitor extracellular proteolytic activity. To date, four 
PARs, namely PAR-I, PAR-2, PAR-3 and PAR-4, have been identified and cloned and 
are widely expressed on cells in blood vessels, connective tissue, leukocytes, epithelium 
and many cell types within the airway (Berger et al., 2001). PAR-I and PAR-2 are 
abundant in the bronchial epithelium and have been implicated in asthma (Cocks et al .. 
200 I; Knight et aI., 200 I). 
Unlike conventional agonist-receptor systems, PAR activation is dependent on the 
specific cleavage of the amino-terminus of the receptor. The newly formed amino 
terminus then functions as a 'tethered ligand', docking and interacting with the second 
extracellular loop of the PAR to trigger the sequence of events involving G-protein 
dissociation that confers receptor activation (figure 5.1) (Macfarlane et aI., 200 I; 
O'Brien et aI., 200 I). 
The predominant endogenous activators of PARs are thrombin (activating PAR-I, PAR-
3 and PAR -4), trypsin and tryptase (activating PAR -2 and PAR -4) (Bohm e tal., 1996: 
Dery et aI., 1998; Ishihara et aI., 1997; Nystedt et aI., 1994). PAR-2 is also activated by 
coagulation factors VIla and Xa, but not thrombin (Camerer et al .. 2000). The transient 
TF:FVIla:FXa complex also activates PAR-I and PAR-2; signifying that the TF:FVIIa 
initiated coagulation cascade is inseparably linked to PAR activation and cell signalling 
(Chambers et aI., 2002). It is now well established that short. synthetic peptide 
analogues that mimic the amino acid sequence of the PAR-tethered ligand can also 
activate PAR-I (encoded SFLLRN), PAR-2 (encoded SLIGKV) and PAR-4 (encoded 
GYPGQV). but interestingly, not PAR-3 (figure 5.1) (Macfarlane et al.. 2001). These 
synthetic agonists display a greater selectivity for their receptor than do endogenous 
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ligands such as trypsin and thrombin and they have proven to be an invaluable tool in 
establishing a role for the PARs in vivo. 
PAR-l peptide agonist: SFLLRN 
PAR-2 peptide agonist: SLIGKV 
Proteolytic cleavage 
Figure 5.1. PAR activation by synthetic peptide agonists. 
Peptide agonists, consisting of a short sequence of amino acids encoding the PAR-
tethered ligand bind directly to the second extracellular loop of the PAR receptor, 
resulting in its activation. 
Adapted from the review by Reed et aZ. (2004). 
Conversely, some proteases have the potential to inactivate PARs by cleaving the 
carboxyl terminus and removing the tethered ligand from the receptor. In doing so, 
activation of the receptor by PAR activators is prevented. Neutrophil elastase can 
inactivate PAR-I , PAR-2 and PAR-3 (Chignard et aI. , 2006; Parry et aI. , 1996). 
Inactivation of PARs involves desensitisation of the receptor and is reported to be 
independent of receptor phosphorylation and receptor intemalisation (Lan et aI. , 2002). 
Elastase-mediated PAR inactivation may be biologically relevant in airway 
inflammatory diseases such as severe asthma, cystic fibrosis , acute lung injury (ALI) 
and ARDS where the levels of this pro-inflammatory enzyme are reported to be 
elevated in the extracellular spaces (Cochrane et aI. , 1983 ; Dulon et aI. , 2005 ; Holgate 
et aI. , 2006; Lee et aI., 2001). Moreover, neutrophil elastase has been demonstrated to 
induce apoptosis of three different lung epithelial cell types BEAS-2B, human small 
airway epithelial (HSAE) cells and primary human alveolar type II (HAEC) cell 
through PAR-I dependent modulation of intrinsic apoptotic pathway via alterat ions in 
mitochondrial permeability and by modulation of c-Jun kinase (JNK) and kt, a 
serine/threonine kinase important in cell survival (Ginzberg et af., 2004~ Suzuki ef 0/ .. 
2005). 
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The disarming cleavage sites on P AR-2 by vanous proteases including neutrophil 
elastase, cathepsin G and proteinase 3 have been detennined by mass spectrometry and 
are indicated infigure 5.2 (Chignard et aI. , 2006). 
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Figure 5.2. Representation of the N-tenninal exodomain of PAR-2 expressed by 
epithelial cells showing the potential cleavage site of serine proteases. Activation and 
disarmament by proteases are indicated in blue and pink respectively. The amino acid 
sequence shown in red corresponds to the tethered activating sequence, which is 
revealed following activation cleavage of PAR-2 at Arg36 _Ser37 . Epa, elastase fro m 
Pseudomonas aeruginosa; CG, cathepsin G; NE, neutrophil elastase; PR3 , proteinase 3 
(Chignard et ai., 2006). 
5.1.1.1. Activation of PARs by exogenous proteases 
Airborne allergens, including house dust mite faecal pellets, fungi , pollen and 
occupational dust have been shown to stimulate the release of proinflammatory 
cytokines in vitro (Hassim et aI. , 1998; King et aI. , 1998; Wan et aI. , 1999) and can 
induce hyper-reactivity of the airways (figure 5.3) (Gavett et aI. , 2001 ; Riccioni el aI., 
2001). There is now evidence to suggest that these inhaled proteases may stimulate such 
responses such as the release of inflammatory mediators through the activation of th 
PARs. For example, house dust mite serine protease allergens from Der P3 and Der P9 
have been shown to interact with PAR-2 (Asokananthan el aI. , 2002; Sun el 01. . 200 1). 
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A wide range of proteases is known to be present in the lungs of t . . d' 'd a OplC III IVI uals 
suggesting that PARs are likely to be important in respiratory diseases such as asthma . 
.------~ Cytoklne production 
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Figure 5.3. PAR-mediated inflammation of the airways: cellular responses. 
Allergen proteases such as the house dust mite activate the PAR receptors, di srupt 
epithelial tight junctions, recruit inflammatory cells such as eosinophils into the airways 
and induce expression of proinflammatory cytokines. This is typical of the events that 
occur in the asthmatic airways. The normal bronchial epithelium is also exposed to 
allergen proteases, however, inflammation is overcome by mechanisms of normal 
bronchial epithelial repair (Reed et af., 2004). 
5.1.1.2. Pro-inflammatory response of PAR activation 
PARs are present on almost all of the cells involved in asthma, including mast cells, 
eosinophils, neutrophils, monocytes, macrophages, lymphocytes, smooth muscle, 
endothelium, fibroblasts , epithelial cells and neurons (Reed e/ af. , 2004). Asthmatic 
subjects have been reported to express an increase in PAR-2 on bronchial epithelial 
cells compared to non-asthmatics (Knight et af. , 2001) but not on smooth muscle or 
alveolar macrophages (Roche et af. , 2003). Activated PARs couple to G-signalling 
cascades that increase phospholipase C levels, wlLich in tum leads to an increa e in 
intracellular calciwll levels (Berger et al., 2001; Camerer et af.. 2002; chechter ef al .. 
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1998). The effects of increased intracellular calcium levels lead to events such as the 
secretion of inflammatory mediators from epithelial cells, degranulation of mast cells 
and airway smooth muscle contraction. Gene transcription produces integrins, 
chemokines and cytokines, as well as COX-2. Activation of PARs in vivo mediates the 
pro-inflammatory effects associated with chronic inflammation in asthma, including 
oedema, angiogenesis, fibrosis, enhanced IgE production, leukocyte infiltration, 
cytokine production and hyperresponsiveness. 
The bronchial epithelium expresses PAR-I, PAR-2 and PAR-4. Activation ofPAR-2 on 
epithelial cells is associated with the release of IL-6, IL-8, MMP-9 and PDGF, all of 
which have the potential to induce or prolong inflammation (Shimizu et aI., 2000; 
Vliagoftis et aI., 2000). Expression of PAR-l and PAR-2 has been demonstrated in 
16HBE 140- cells and activation ofPAR-2 but not PAR-l was demonstrated to increase 
IL-8 production in this cell line (Page et aI., 2003). Moreover, all four members of the 
PAR family have been demonstrated in the A549 and BEAS-2B epithelial cell lines, as 
well as in primary human bronchial epithelial cells (Asokananthan et aI., 2002). 
Activation of PAR-I, PAR-2 and PAR-4 by synthetic peptide agonists stimulated the 
secretion of IL-6, IL-8 and PGE2 from A549, BEAS-2B and primary NHBE cells. 
These processes were accompanied by changes in intracellular calcium ions 
concentration. In addition PAR-2 activation resulted in the secretion of GM-CSF. In 
support of this, it has been demonstrated that mice deficient in PAR-2 display delayed 
inflammatory responses to tissue trauma (Lindner et aI., 2000). Furthermore, 
polymorphisms in P AR-2 alter sensitivity to agonist activation and can modulate 
inflammatory responses (Compton et aI., 2000). The fact that asthma is associated with 
increased expression of PAR-2 suggests that PAR-2 might be involved III airway 
inflammation. However, it is not known whether increased expression reflects a 
contribution to asthma pathology or an attempt by the epithelium to modify the 
inflammatory response. 
5.1.1.3. A protective role for PARs 
It is well established that PAR-2 is involved in cytoprotection in the pancreas and upper 
small intestine. PAR-2 is abundantly expressed on epithelia in the pancreatic duct 
(Nguyen et aI., 1999) and intestine (Kong et aI., 1997) and its activation leads to a 
186 
variety of cytoprotective effects, largely mediated by the release of PGE
2 
from the 
epithelia (Cocks et aI., 2000). However, Cocks et al. have revealed that a similar P AR-2 
dependent cytoprotective system also operates in the epithelia of the airways, whereby 
PAR-2 is involved in the growth of the normal epithelium and the restitution of the 
damaged epithelium following injury (Cocks et aI., 1999; Cocks et aI., 2000). Firstl\", 
using an antibody directed against the carboxy terminus of mouse PAR-2 it was 
demonstrated by confocal fluorescence microscopy that specific PAR-2 
immunostaining was localised to epithelial cells, often within the cytoplasm and to 
smooth muscle and fibroblasts in the submucosa of the mouse bronchus. Administration 
of a PAR-2 peptide agonist, mimicking the tethered ligand, resulted in concentration-
dependent, rapid-onset and near-maximal relaxation of mouse bronchial rings, which 
had been pre-contracted by carbachol, the muscarinic agonist. These relaxations were 
abolished by removal of the epithelium or by inhibition of COX. The effects of 
relaxation due to nitric oxide were ruled out since relaxation was unaffected by the 
nitric oxide synthase inhibitor, L-NAME. Furthermore, addition of PGE2, the most 
predominant prostanoid released from the bronchial epithelium, was found to exert 
powerful relaxation in mouse bronchi. Similarly, Pavord et al. (1995) demonstrated that 
endogenous PGE2 conferred bronchoprotection against spasmogenic agents (Pavord et 
aI., 1995); and that inhaled PGE2 inhibited both the early and late response to allergen-
induced bronchial reactivity (Pavord et aI., 1993). A cytoprotective role for PAR-l 
mediated by PGE2 has been demonstrated in gastric epithelial cells (Toyoda et aI., 
2003), however, there is little evidence as yet of PAR-l mediated cytoprotection in the 
bronchial epithelium. 
Since enzymic activation of PARs is irreversible, rapid resensitisation is essential for 
maintaining tissue-responsiveness to PAR-activating proteases. Turnover of cloned 
PAR-2 expressed in selective cell lines is rapid and depends on the synthesis of new 
protein in addition to trafficking of pre-formed receptors from intracellular pools (Bohm 
et aI., 1996; Dery et aI., 1998). Cocks et al. (1999) showed that P AR-2 mediated 
relaxations in mouse bronchi returned rapidly, 45 minutes after desensitisation to 
trypsin. These findings, in addition to the fact that PAR-2 is often localised to the 
cytoplasmic regions of epithelial cells suggest that there is rapid turnover of PAR-2 
from intracellular stores in the airway epithelium. Moreover, the capacity of epithelial 
cells to rapidly recover their sensitivity to PAR-2 agonists follo\\"ing receptor 
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desensitisation indicates that epithelial P AR-2 participates in bronchoprotection. PAR-2 
mediated relaxation was also observed in the airways of other species, including the rat 
and guinea pig (Cocks et a!., 1999). 
Since PAR-2 is also expressed in the subepithelium, particularly on smooth muscle cells 
(D'Andrea et a!., 1998), the dual compartment model may explain the complex role of 
PAR-2 in the airways. It has been argued that epithelial and subepithelial PAR-2 could 
be differentially regulated by specific tryptic enzymes released in each compartment, 
i.e., epithelial trypsin and subepithelial mast-cell tryptase. Cocks et al (1999) 
demonstrated colocalised immunohistochemical staining of trypsin with PAR-2 in 
human bronchial epithelium, providing evidence that trypsin is the endogenous activator 
of epithelial PAR-2. They predict that the protective effects of epithelial PAR-2 
normally overrides any pro inflammatory effects of subepithelial PAR-2 activation, and 
that disruption of the epithelial barrier compromises the normal balance between the 
two compartments (Cocks et al., 1999). 
In this chapter, the effects of PAR-1 and PAR-2 agonists on wound repair, coagulation 
factor release and fibrin formation were investigated. 
5.2. Aims and objectives 
The initial aim was to investigate the effect of PAR -1 and PAR -2 on wound repair of 
16HBE 140- cells by use of kinetic video microscope analysis following stimulation of 
cells with synthetic PAR peptide agonists. Subsequent aims were to determine the effect 
of PAR -1 and PAR -2 activation on the release of coagulation factors into supernatants 
derived from 16HBE 140- cells of unwounded and wounded cell monolayers. Moreover, 
it was imperative to identify a role for PAR-l and PAR-2 in fibrin formation by analysis 
of D-dimers in 16HBE 140- cell culture supernatants from unwounded and wounded 
monolayers. Finally, it was of interest to investigate the effect of PAR activation in the 
presence of the COX inhibitor indomethacin on coagulation factor release and fibrin 
formation in order to determine whether these effects were mediated l'ia PGE 2· 
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5.3. Methods 
5.3.1. Stimulation of 16HBE 140- cells with PAR peptide agonists and 
immunoblotting 
16HBE 140- cells were cultured for 48 hours on 24-well plates until fully confluent and 
quiesced for 16 hours in serum-free MEM-ITS. Prior to experiments. MEM-ITS was 
refreshed. Synthetic PAR-1 peptide agonist (TFRIFD-amide, 10 mM stock dissolved in 
DMSO), PAR-2 peptide agonist (SLIGKVD-amide, 10 mM stock dissolved in DMSO) 
and corresponding scrambled PAR -1 control peptide (FTRIFD-amide, 10 mM stock 
dissolved in DMSO) and scrambled PAR-2 control peptide (LSIGKVD-amide, 10 mM 
stock dissolved in DMSO) and indomethacin were added to cells in a final 
concentration of 400 uM (PAR peptides) and 10 J.lM (indomethacin), in a volume of 250 
J.lI per well and the plate was incubated for 30 minutes at 37°C. For cells that were 
exposed to a PAR peptide agonist in the presence of indomethacin, cells were pre-
treated with indomethacin for 30 minutes at 37°C prior to the addition of PAR peptide 
agonist. Peptides were synthesised by Peptide Protein Research Ltd (Hampshire, UK). 
A final concentration of 0.04% DMSO was also included as a control. Cells were 
mechanically wounded with a P2 Gilson pipette tip in a cross-hatch manner with 
different degrees of wounding as described in section 2.2.5 and returned to the incubator 
at 37°C for 2 hours. Supernatants were removed from cells and centrifuged for 7 
minutes at 670 x g (ALC PK120 Centrifuge, Winchester Virginia, USA) to remove cell 
debris. Cell culture supernatants were then analysed by immunoblot for fibrinogen, 
FXIIIA and D-dimers as described in section 3.3.3. 
5.3.2. Kinetic analysis of wound repair of 16HBE 140- cells 
Following stimulation of 16HBE 140- cells with PAR peptide agonists as described in 
section 5.3.1, cells were mechanically wounded with a P2 Gilson pipette tip, one 
horizontal scrape per well. Immediately after wounding, the plate was placed on the 
heated stage at 37°C of the inverted wide field kinetic video microscope (Zeiss Axiovert 
200 m; Carl Zeiss Ltd, Hertfordshire, UK) and Volocity® software was used to take 
images of the same section of wound for 13 hours, with time intervals of 15 minutes. 
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Volocity® software was also used to analyse wound repair by taking 10 measurements 
across the wound at each time point up to 13 hours. (For movie clip of wound repair. 
refer to CD attached to back cover of thesis). 
5.4. Results 
5.4.1. Effect of PARs on wound repair 
The role of PARs in bronchial epithelial repair is incompletely understood, therefore it 
was of interest to investigate the direct effect of PARs in wound repair. In order to 
activate the PARs, short synthetic peptide agonists that mimic the 'tethered' region of 
the receptor were used. Wound repair was monitored in 'real-time' by kinetic video 
microscopy. The advantage of this technique is that it allows the migratory rate of 
epithelial cells to be calculated. 
5.4.1.1. P AR-1 
In order to activate PAR -1, the synthetic PAR -1 peptide agonist, TFRIFD-amide was 
added. A corresponding PAR-l control peptide agonist, FTRIFD-amide with the first 
two amino acids in reverse order was included to confinn the selectivity of the PAR-I 
peptide agonist for its receptor. A final concentration of 400 11M was used, as the 
potency of the peptides is very low and 400 11M was previously used to induce the 
release of cytokines in primary and human bronchial epithelial cell lines (Asokananthan 
et aI., 2002). 
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Figure 5.4. Effect of a PAR-l peptide agonist on the rate of wow1d repair of 
16HBE 140- cell layers. PAR -1 CP denotes PAR -1 control peptide agoni st. Data 
represent mean ± SEM (n=3). t Indicates P<0.05 and * indicates P<0.005 compared to 
no drug control. 
With respect to the untreated cell cultures, the mean wound width at 13 hours was 
263.58 ± 14.82 /-lm compared to 768.28 ± 19.89 /-lm at 0 hours , indicating 34.31 % of the 
original wound width remained open. The PAR-l control peptide (400 /-lM) had no 
effect on wound repair compared to the no drug control , which confirmed that it did not 
activate the PAR-1 receptor. The addition of PAR-l peptide agonist (400 /-lM) 
significantly enhanced wound repair and at 12 hours, wound repair was complete. 
5.4.1.2. PAR-2 
In order to activate PAR-2, the synthetic PAR-2 peptide agonist, SLIGKVD-amide was 
added. A corresponding PAR-2 control peptide agonist, LSIGKVD-amide wi th the first 
two amino acids in reverse order was included to check the selectivity of the PAR-2 
peptide agonist for its receptor. A concentration of 400 /-lM was added, as the potenc y of 
the peptides is very low and 400 /-lM was previously used to induce the release of 
cytokines in primary and human bronchial epithelial cell lines (Asokananthan et al . . 
2002). 
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Fig~re 5.5. Effect of a PAR-2 peptide agonist on the rate of wound repair of 16HBE 
140 cell layers. PAR-2 CP denotes PAR-2 control peptide. Data represent mean ± SEM 
(n =3). t Indicates P<0.05 , tt indicates P<0.005 and * indicates P<0.0005 compared to 
no drug control. 
With respect to the untreated cell cultures, the mean wound width at 13 hours was 
263.58 ± 14.82 ~m compared to 768.28 ± 19.89 ~m at 0 hours, indicating 34.3 1% 
original wound width remained open. The PAR-2 control peptide (400 ~M) had no 
effect on wound repair compared to the no drug control , which confirmed that it did not 
activate the PAR-2 receptor. The addition of PAR-2 peptide agonist (400 ~M) 
significantly enhanced wound repair and at 11 hours, wound repair was complete. 
In terms of wound repair, the effect of PAR-2 was significantly greater than that of 
PAR- l (P<0.05) between the time points of3 hours and 10 hours. 
The average migratory rate of 16HBE 140- wound repair was 0. 83 11m/min in contro l 
wells using the culture methods as described in section 4.3. 10. However, when wound 
repair was monitored on the heated stage of the kinetic video microscope as described in 
section 5.3.2, the migratory rate of wound repair was 0.65 Ilnv'min signifying 
differences in culture conditions. Epithelial cell migration in vivo is reported to be rapid 
(2-3 ~m/min) following mechanical deepithelialisation (Erj efalt e/ 01.. 1995). 
Understandably the migration rate is slower in vitro , however, the value ar somewhat 
impressive considering the reductive natw'e of the cutTent model. 
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5.4.2. Concentration of fibrinogen in cell culture supernatants 
5.4.2.1. Effect of PAR-l 
Since the activation of P AR-l by a P AR-l peptide agonist enhanced wound repair 
(section 5.4.1.1), it was of particular interest to investigate the effects of PAR-l 
activation on the release of coagulation factors into cell culture supernatants. If wound 
repair was occurring by fibrin formation as a result of P AR-l activation, it was expected 
that the concentration of coagulation factors and D-dimer fragments in cell culture 
supernatants would be increased in response to a PAR -1 peptide agonist. Cells were 
pre-treated with the COX inhibitor indomethacin, in order to determine whether the 
effect of PAR-l on coagulation factor release was mediated via prostanoid production. 
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Figure 5.6. Effect of mechanical wounding, PAR-l peptide agonists and indomethacin on the concentration of fibrino gen in cell culture 
supernatants of 16HBE 140· cell s 2 hours post-wounding. C=unwounded, W2=2 wounds, W4=4 wounds & W8= 8 wounds . t Indica tes 
P<0 .05; tt indicates P <0.005 compared to C and * indicates P<0.005 ; no drug versus 400 IJ.M PAR-I control peptide: + indica tes 
P<0 .005 ; 400 ~M PAR-l peptide versus 400 ~M PAR-l control peptide : $ indicates P<0.0005. Data represent mean ± SEM (n =3). 
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Figure 5.6 indicates the effect of a PAR-l peptide agonist in the absence and presence 
of indomethacin on the concentration of fibrinogen in cell culture supernatants of 
16HBE 140- cells 2 hours post-wounding. 
In the absence of the P AR-1 peptide agonist, there was a significant increase in the 
concentration of fibrinogen in cell culture supernatants with the degree of wounding: 
W2 = 3.18 ± 1.47 J.lg/ml; W4 = 8.41 ± 3.45 J.lg/ml and W8 = 21.23 ± 1.42 J.lg/ml 
compared to the unwounded control, C = 0.67 ± 0.17 J.lg/ml, confirming the results 
presented in section 3.4.2.1. 
Indomethacin is a non-specific COX inhibitor and was used to investigate whether the 
effects of wounding on fibrinogen release was mediated via the release of prostanoids. 
Pre-incubation of cells with indomethacin had no significant effect on the concentration 
of fibrinogen in cell culture supernatants compared to the wounded controls. 
The synthetic P AR-I peptide agonist, TFRIFD-amide enhanced the concentration of 
fibrinogen in cell culture supernatants compared to the no P AR-l peptide agonist 
control. Levels of fibrinogen in unwounded cell culture supernatants were significantly 
higher in cell cultures stimulated with PAR-1 (C = 12.02 ± 0.40 J.lg/ml) compared to the 
no PAR-1 peptide agonist control (C = 0.67 ± 0.17 J.lg/ml). The presence of the PAR-l 
peptide agonist increased the concentration of fibrinogen in cell culture supernatants 
with the degree of wounding (W2 = 20.28 ± 0.69 J.lg/ml and W4 = 30.65 ± 0.99 /-lg/ml) 
and with maximal wounding, PAR-l significantly enhanced the concentration of 
fibrinogen in cell culture supernatants (W8 = 58.24 ± 0.45 J.lg/ml) compared to the no 
PAR-l peptide agonist control (W8 = 21.23 ± 1.42 J.lg/ml). 
The synthetic scrambled P AR-l control peptide agonist, FTRIFD-amide had no 
significant effect on the levels of fibrinogen in supernatants of unwounded 16HBE 140-
cells and those denoted by W2 and W4. However, the control peptide significantly 
reduced the levels of fibrinogen in supernatants (W8 = 5.32 ± 0.48 /-lg/ml) compared to 
the no drug control (W8 = 21.23 ± 1.33 J.lg/ml). 
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Interestingly, the P AR-l control peptide agonist significantly reduced the levels of 
fibrinogen in cell culture supernatants (C = 0.22 ± 0.01 /-lg/ml; W2 = 0.91 ± 0.03 /-lg/ml: 
W4 = 3.54 ± 0.21 /-lg/ml and W8 = 5.32 ± 0.48 /-lg/ml) compared to the PAR-l peptide 
agonist (C = 12.02 ± 1.18 /-lg/ml; W2 = 20.28 ± 1.75 /-lg/ml; W4 = 30.65 ± 2.09 /-lg/ml 
and W8 = 58.24 ± 4.31 /-lg/ml). 
The presence of 10 /-lM indomethacin had no effect on the response to the PAR-l 
peptide agonist, suggesting that the effects of P AR-l on the release of fibrinogen from 
16HBE 140- cells is not mediated via prostanoids. 
Similarly, the presence of 10 /-lM indomethacin had no effect on the response to the 
scrambled PAR-l control peptide agonist. 
5.4.2.2. Effect of P AR-2 
Since the activation of PAR-2 by a PAR-2 peptide agonist enhanced repair (section 
5.4.1. 2), it was of interest to investigate the effects of PAR -2 activation on the release of 
coagulation factors into culture supernatants of 16HBE 140- cells. If wound repair was 
occurring via fibrin formation as a result of PAR-2 activation, it was expected that the 
concentration of coagulation factors and D-dimers would be increased in response to a 
PAR-2 peptide agonist. Because P AR-2 activation is known to elicit a 
bronchoprotective response, which is mediated via PGE2, the PAR-2 peptide agonist 
was added in the absence and presence of the COX inhibitor indomethacin, in order to 
determine whether the effect of PAR-2 on coagulation factor release was mediated via 
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Figure 5.7. Effect of mechanical wounding, PAR-2 peptide agonists and indomethacin on the concentration of fibrinogen in cell cu lture 
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Figure 5.7 indicates the effect of a PAR-2 peptide agonist in the absence and presence 
of indomethacin on the concentration of fibrinogen in cell culture supernatants of 
16HBE 140- cells 2 hours post-wounding. 
In the absence of the PAR-2 peptide agonist, there was a significant increase in the 
concentration of fibrinogen in cell culture supernatants with the degree of wounding: 
W2 = 3.18 ± 1.47 J.lg/ml, W4 = 8.41 ± 3.45 J.lg/ml and W8 = 21.23 ± 1.42 J.lg/ml 
compared to the unwounded control, C = 0.67 ± 0.17 /-lg/ml confirming the results 
presented in section 3.4.2.1. 
Addition of the COX inhibitor indomethacin to the medium had no significant effect on 
the release of fibrinogen into culture supernatants of 16HBE 140- cells compared to the 
wounded controls. 
The synthetic PAR-2 peptide agonist, SLIGKVD-amide significantly enhanced the 
concentration of fibrinogen in cell culture supernatants compared to the no PAR-2 
peptide agonist control. This was particularly evident at baseline, whereby the 
concentration of fibrinogen in unwounded cell culture supernatants of cell cultures 
stimulated with PAR -2 were 42.63 ± 1.91 J.lg/ml compared to 0.67 ± 0.17 J.lg/ml in the 
no PAR-2 peptide agonist control. In the wounded cell cultures, the PAR-2 peptide 
agonist significantly enhanced the concentration of fibrinogen in cell culture 
supernatants (W2 = 31.58 ± 0.35 J.lg/ml; W4 = 44.59 ± 0.67 J.lg/ml and W8 = 36.52 ± 
1.04 J.lg/ml) compared to the no PAR-2 peptide agonist control (W2 = 3.18 ± 1.47 
J.lg/ml; W4 = 8.41 ± 3.45 J.lg/ml and W8 = 21.23 ± 1.42 J.lg/ml). With respect to the 
effect of the PAR-2 peptide agonist alone, there was no further increase in the 
concentration of fibrinogen in cell culture supernatants with the degree of wounding. 
With respect to the unwounded cell cultures, the effect of the PAR-2 peptide agonist on 
supernatant concentration of fibrinogen was significantly greater (P<0.005) than that of 
PAR-I. 
The synthetic scrambled PAR-2 control peptide agonist, LSIGKVD-amide had no 
significant effect on the levels of fibrinogen in supernatants of unwounded 16HBE 1'+0-
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cells and those denoted by W2 and W4. However, the control peptide significantly 
reduced the levels of fibrinogen in supernatants denoted by W8 = 6.15 ± 0.31 J.lg/ml 
compared to the no drug control (W8 = 21.23 ± 1.33 J.lg/ml). 
Interestingly, the PAR-2 control peptide agonist significantly reduced the levels of 
fibrinogen in cell culture supernatants (C = 0.76 ± 0.64 J.lg/ml; W2 = 2.22 ± 0.24 J.lg/ml: 
W4 = 4.33 ± 0.32 J.lg/ml and W8 = 6.15 ± 0.31 J.lg/ml) compared to the PAR-2 peptide 
agonist (C = 42.63 ± 3.14 J.lg/ml; W2 = 31.58 ± 1.96 J.lg/ml; W4 = 44.59 ± 1.86 J.lg/ml 
and W8 = 36.52 ± 2.90 J.lg/ml). 
The presence of 10 J.lM indomethacin had no effect on the response to the P AR-2 
peptide agonist, suggesting that the effects of PAR-2 on the release of fibrinogen into 
cell culture supernatants are not mediated via PGE2. 
Similarly, the presence of 10 J.lM indomethacin had no effect on the response to the 
scrambled PAR-2 control peptide agonist. 
5.4.3. Concentration of FXIIIA in cell culture supernatants 
5.4.3.1. Effect of P AR-l 
Figure 5.8 demonstrates the effect of the PAR -1 peptide agonist on the concentration of 
FXIIIA in cell culture supernatants 2 hours post-wounding. In order to determine 
whether the effects of PAR -1 activation were mediated via prostanoids, the PAR-1 
peptide agonist was added in the absence and presence of the COX inhibitor 
indomethacin. 
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Figure 5.8. Effect of mechanical wounding, PAR-l peptide agonists and indomethacin on the concentration of FXIIIA in ce ll culture 
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In the absence of the P AR-1 peptide agonist, there was a significant increase in the 
concentration of FXIIIA in cell culture supernatants with the degree of wounding: \\'2 = 
17.00 ± 1.06 ng/m1; W4 = 22.30 ± 0.50 ng/ml and W8 = 24.43 ± 5.87 ng/ml compared 
to the unwounded control, C = 4.49 ± 1.50 ng/ml, as observed in previous experiments 
(section 3.4.2.2). 
Addition of the COX inhibitor indomethacin to the medium had no significant effect on 
the concentration of FXIIIA in cell culture supernatants compared to the wounded 
controls. 
The synthetic P AR-1 peptide agonist, TFRIFD-amide significantly enhanced the 
concentration of FXIIIA in unwounded and wounded cell culture supernatants (C = 
19.97 ± 1.07 ng/ml; W2 = 28.72 ± 1.93 ng/ml; W4 = 37.14 ± 1.85 ng/ml and W8 = 
41.57 ± 2.52 ng/ml) compared to the no PAR-1 peptide agonist controls (C = 4.49 ± 
1.50 ng/ml, W2 = 17.00 ± 1.06 ng/ml; W4 = 22.30 ± 0.50 ng/ml and W8 = 24.43 ± 5.87 
ng/ml). With respect to the effects of the PAR-1 peptide agonist alone, there was an 
increase in the concentration of FXIIIA in cell culture supernatants with the extent of 
wounding. 
The synthetic scrambled P AR-1 control peptide agonist, FTRIFD-amide significantly 
reduced the levels of FXIIIA in supernatants (W2 = 7.30 ± 0.22 J.lg/ml and W4 = 10.03 
± 0.75 J.lg/ml) compared to the no drug control (W2 = 17.00 ± 1.52 J.lg/ml and W4 = 
22.30 ± 2.40 J.lg/ml). 
Interestingly, the PAR-1 control peptide agonist significantly reduced the levels of 
FXIIIA in cell culture supernatants (C = 2.18 ± 0.08 J.lg/ml; W2 = 7.30 ± 0.22 J.lg/ml: 
W4 = 10.03 ± 0.75 J.lg/ml and W8 = 12.93 ± 0.42 J.lg/ml) compared to the PAR-1 
peptide agonist (C = 19.97 ± 1.35 J.lg/ml; W2 = 28.72 ± 1.65 J.lg/ml; W4 = 37.14 ± 1.48 
J-lg/ml and W8 = 41.57 ± 1.88 J.lg/ml). 
The presence of 10 J.lM indomethacin had no effect on the response to PAR-I. 
suggesting that the effects of PAR -Ion the concentration of FXIIIA in cell culture 
supernatants are not mediated via prostanoids. 
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Similarly, the presence of 10 J.lM indomethacin had no effect on the response to the 
scrambled PAR -1 control peptide agonist. 
5.4.3.2. P AR-2 
Figure 5.9 demonstrates the effect of the PAR-2 peptide agonist on the concentration of 
FXIIIA in cell culture supernatants 2 hours post-wounding. In order to determine 
whether the effects of PAR-2 activation were mediated via PGE2, the PAR-2 peptide 
agonist was added in the absence and presence of the COX inhibitor indomethacin. 
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Figure 5.9. Effect of mechanical wounding, PAR-2 peptide agonists and indomethacin on the concentration of FXIIIA in cell cultu re 
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In the absence of the PAR -2 peptide agonist, there was a significant increase in the 
concentration of FXIIIA in cell culture supernatants with the degree of wounding: \\'2 = 
17.00 ± 1.06 ng/ml; W4 = 22.30 ± 0.50 ng/ml and W8 = 24.43 ± 5.87 ng/ml compared 
to the unwounded control, C = 4.49 ± 1.50 ng/ml, as observed in previous experiments 
(section 3.4.2.2). 
Addition of the COX inhibitor indomethacin to the medium had no significant effect on 
the concentration of FXIIIA in cell culture supernatants compared to the wounded 
controls. 
The synthetic PAR-2 peptide agonist, SLIGKVD-amide enhanced the concentration of 
FXIIIA in cell culture supernatants (C = 27.05 ± 1.20 ng/ml; W2 = 29.26 ± 0.63 ng/ml; 
W4 = 39.72 ± 1.00 ng/ml and W8 = 39.25 ± 0.25 ng/ml) compared to the no PAR-2 
peptide agonist control (C = 4.49 ± 1.50 ng/ml, W2 = 17.00 ± 1.06 ng/ml, W4 = 22.30 ± 
0.50 ng/ml and W8 = 24.43 ± 5.87 ng/ml) and its effects were significant in the 
unwounded cell cultures and in those depicted by W4. With respect to the effects of the 
PAR-2 peptide agonist alone, there was an increase in the concentration of FXIIIA in 
cell culture supernatants with the degree of wounding, however, this effect was not 
quite significant (P=0.072). 
The synthetic scrambled PAR-2 control peptide agonist, LSIGKVD-amide significantly 
reduced the levels of FXIIIA in supernatants (W2 = 7.92 ± 1.26 ~g/ml and W4 = 15.23 
± 0.65 ~g/ml) compared to the no drug control (W2 = 17.00 ± 1.52 ~g/ml and W4 = 
22.30 ± 2.40 ~g/ml). 
Interestingly, the PAR-2 control peptide agonist significantly reduced the levels of 
FXIIIA in cell culture supernatants (C = 2.92 ± 0.25 ~g/ml; W2 = 7.92 ± 1.26 ~g/ml; 
W4 = 15.23 ± 0.65 ~g/ml and W8 = 18.39 ± 0.59 ~g/ml) compared to the PAR-2 
peptide agonist (C = 19.97 ± 1.35 ~g/ml; W2 = 29.26 ± 0.87 ~g/ml: W4 = 39.72 ± 0.95 
~g/ml and W8 = 39.25 ± 2.02 ~g/ml). 
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The presence of 10 /-lM indomethacin had no effect on the response to PAR-2 
suggesting that the effects of PAR-2 on the concentration of FXIIIA in cell culture 
supernatants are not mediated via PGE2. 
Similarly, the presence of 10 /-lM indomethacin had no effect on the response to the 
scrambled PAR-2 control peptide agonist. 
5.4.4. Expression of D-dimers 
5.4.4.1. PAR-l 
Figure 5.10 demonstrates the effect of the PAR -1 peptide agonist on the concentration 
of D-dimers, the marker of fibrin formation and fibrin breakdown in cell culture 
supernatants 2 hours post-wounding. In order to determine whether the effects of PAR-I 
activation were mediated via prostanoids, the P AR-1 peptide agonist was added in the 
absence and presence of the COX inhibitor indomethacin. 
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In the absence of PAR-1 peptide agonist, there was a significant increase in the 
concentration of D-dimers in cell culture supernatants with the degree of wounding: \\'2 
= 6.54 ± 0.85 ng/ml; W4 = 10.42 ± 2.39 nglml and W8 = 16.21 ± 0.49 nglml, compared 
to the unwounded control, C = 2.33 ± 0.88 ng/ml; indicative of fibrin turnover, 
confirming the results presented in section 3.4.2.3. 
Addition of the COX inhibitor indomethacin to the medium had no effect on the 
concentration of D-dimers in cell culture supernatants compared to the wounded 
controls. 
The synthetic P AR-1 peptide agonist, TFRIFD-amide significantly enhanced the 
concentration of D-dimers in cell culture supernatants (C = 13.87 ± 1.35 ng/ml; W2 = 
18.34 ± 0.36 ng/ml; W4 = 21.05 ± 1.32 ng/ml and W8 = 22.64 ± 1.03 ng/ml) compared 
to the no PAR-1 peptide agonist control (C = 2.33 ± 0.88 ng/ml; W2 = 6.54 ± 0.85 
nglml; W4 = 10.42 ± 2.39 ng/ml and W8 = 16.21 ± 0.49 ng/ml). With respect to the 
effects of the PAR -1 peptide agonist alone, there was an increase in the concentration of 
D-dimers in cell culture supernatants with the degree of wounding. 
The synthetic scrambled P AR-l control peptide agonist, FTRIFD-amide had no 
significant effect on the levels of D-dimers in supernatants of unwounded 16HBE 140-
cells and those denoted by W2 and W4. However, the control peptide significantly 
reduced the levels ofD-dimers in supernatants (W8 = 10.89 ± 0.75 Ilglml) compared to 
the no drug control (W8 = 16.21 ± 1.10 Ilg/ml ). 
Interestingly, the PAR -1 control peptide agonist significantly reduced the levels of D-
dimers in cell culture supernatants (C = 4.19 ± 1.32 Ilg/ml; W2 = 6.46 ± 1.17 Ilg/ml : 
W4 = 8.34 ± 0.95 Ilg/ml and W8 = 10.89 ± 0.75 Ilglml) compared to the PAR-1 peptide 
agonist (C = 13.87 ± 2.16 Ilg/ml; W2 = 18.34 ± 1.28 Ilglml ; W4 = 21.05 ± 2.26 Ilglml 
and W8 = 22.64 ± 0.62 Ilg/ml). 
The presence of 10 IlM indomethacin had no effect on the response to PAR-I. 
. h t th f~ t f PAR 1 on the concentration of D-dimers in cell culture suggestmg t a e e lee s 0 -
supernatants are not mediated ria prostanoids. 
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Similarly, the presence of 1 0 ~M indomethacin had no effect on the response to the 
scrambled PAR -1 control peptide agonist. 
5.4.4.2. P AR-2 
Figure 5.11 demonstrates the effect of the P AR-2 peptide agonist on the concentration 
of D-dimers, the marker of fibrin formation and breakdown, in cell culture supernatants 
2 hours post-wounding. In order to determine whether the effects of PAR-2 activation 
were mediated via PGE2, the PAR -2 peptide agonist was added in the absence and 
presence of the COX inhibitor indomethacin. 
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In the absence of PAR-2 peptide agonist, there was a significant increase in the 
concentration of D-dimers in cell culture supernatants with the degree of wounding: \\'2 
= 6.54 ± 0.85 ng/ml; W4 = 10.42 ± 2.39 ng/ml and W8 = 16.21 ± 0.49 ng/ml compared 
to the unwounded control, C = 2.33 ± 0.88 ng/ml, confirming the results presented in 
section 3.4.2.3. 
Addition of the COX inhibitor indomethacin to the medium had no significant effect on 
the concentration of D-dimers in cell culture supernatants compared to the wounded 
controls. 
The synthetic PAR-2 peptide agonist, SLIGKVD-amide significantly enhanced the 
concentration of D-dimers in cell culture supernatants compared to the no PAR-2 
peptide agonist control at baseline, whereby the concentration of D-dimers in cell 
culture supernatants of cell cultures stimulated with P AR-2 was 18.81 ± 0.67 ng/ml 
compared to 2.33 ± 0.88 ng/ml in the no PAR-2 peptide agonist control. In the wounded 
cell cultures, the PAR-2 peptide agonist enhanced the concentration of D-dimers in cell 
culture supernatants (W2 = 13.46 ± 3.74 ng/ml and W4 = 21.09 ± 0.31 ng/ml) compared 
to the no PAR-2 peptide agonist control (W2 = 6.54 ± 0.85 ng/ml and W4 = 10.42 ± 
2.39 ng/ml); however, these effects were only significant with regards to W4. With 
respect to the effect of the PAR-2 peptide agonist alone, there was no change in the 
concentration of D-dimers in cell culture supernatants with the degree of wounding. 
The synthetic scrambled P AR-2 control peptide agonist, LSIGKVD-amide had no 
significant effect on the levels of D-dimers in supernatants of unwounded 16HBE 140-
cells and those denoted by W2 and W4. However, the control peptide significantly 
reduced the levels of D-dimers in supernatants (W8 = 9.20 ± 1.34 f.lg/ml) compared to 
the no drug control (W8 = 16.21 ± 1.10 f.lg/ml). 
Interestingly, the PAR-2 control peptide agonist significantly reduced the levels of D-
dimers in supernatants of unwounded cell cultures (C = 2.94 ± 0.60 f.lg/ml) and those 
denoted by W4 = 7.36 ± 0.84 f.lg/ml compared to the PAR-2 peptide agonist (C = 18.81 
± 0.99 /-lg/ml and W4 = 21.09 ± 1.23 f.lg/ml). 
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The presence of 10 f.lM indomethacin had no ef~ect on th 
14 e response to PAR -:2. 
suggesting that the effects of PAR-2 on the concentratl'on of D d' . 11 - lmers In ce culture 
supernatants are not mediated via PGE2. 
Similarly, the presence of 10 f.lM indomethacin had no effect on the response to the 
scrambled PAR-2 control peptide agonist. 
5.5. Summary of results 
Activation of both PAR-1 and PAR-2 significantly enhanced the rate of wound repair of 
16HBE 140- cells and the effect ofPAR-2 was demonstrated to be significantly greater 
than that of P AR-1. With respect to the data generated from immunoblotting, activation 
of PAR-1 and P AR-2 induced a significant increase in the release of fibrinogen, FXIIIA 
and D-dimers from 16HBE 140- cells at baseline and from wounded mono layers. 
Indomethacin had no significant effect on the release of fibrinogen, FXIII or D-dimers 
in response to either PAR-1 or PAR-2 activation. 
5.6. Discussion 
With respect to data generated from immunoblotting, wounding alone stimulated an 
increase in the release of fibrinogen, FXIIIA and D-dimers from 16HBE 140- cells 
indicative of sequential fibrinogenesis and fibrinolysis as previously demonstrated in 
independent experiments described in Chapter 3. The COX inhibitor indomethacin had 
no effect on the observed response indicating that PGE2 was not involved. The lack of 
involvement of PGE2 is in accordance with evidence for the limited production of this 
prostanoid under the current culture conditions and the lack of EP-1 and EP--t 
expression by 16HBE 140- cells (Chapter 6). 
PAR-1 and PAR-2 are expressed by the bronchial epithelium (Cocks et aI., 1999; Cocks 
et aI., 2000; Lan et aI., 2002). Expression of both receptors has pre\'iously been 
demonstrated in 16HBE 140- cells (Page et aI., 2003) and their expression in this cell 
line has been confirmed (Chapter 6). Unlike conventional receptors that bind diffuse. 
soluble ligands, PARs are activated via a highly unique and specific mechanism. PARs 
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require specific site-directed amino-terminal proteolysis by select serine proteases to be 
self activated by newly formed amino-terminals, termed 'tethered ligands' (Cocks et al .. 
2000). 
Synthetic peptide analogues that mimic a portion of the amino acid sequence of the 
PAR-tethered ligand are routinely used to activate PARs -1, -2 and -4, but interestingly. 
not PAR-3. These agonists are reported to have greater selectivity for PARs than do the 
endogenous ligands such as trypsin and thrombin. However, they display a low potency. 
hence the requirement for high concentrations to activate the receptor (Lan et al.. 2002). 
A previous study determined the specificity of PAR peptide agonists using xenopus 
oocytes. P AR-l did not respond to trypsin or the human PAR-2 peptide agonist 
SLIGKVD, whereas PAR-2 was demonstrated to respond to the human PAR-l peptide 
SFLLRN -amide but not to TFRIFD-amide, the xenopus PAR -1 peptide agonist. 
TFRIFD-amide activated P AR-l with an ECso of 1 /-lM but was unable to activate PAR-
2 at concentrations up to 50 /-lM (Blackhart et aI., 1996). The genes for PAR-l and 
PAR-2 are both located on chromosome 5, therefore it is unsurprising that these 
receptors share a similar amino acid sequence and in terms of the second extracellular 
loop, which binds the tethered ligand, the identity is approximately 72% homologous 
(Blackhart et al., 1996), giving rise to the possibility of ligand cross-reactivity. 
In view of the report by Blackhart et al. that demonstrated ligand cross-reactivity. the 
synthetic xenopus peptide agonist TFRIFD-amide and human SLIGKVD-amide were 
employed in the current study to activate PAR-l and P AR-2 respectively. And 
corresponding partially scrambled peptides (FTRIFD-amide and LSIGKVD-amide) 
were included to verify PAR activation. The same PAR peptide agonists were 
previously used to activate PAR-l and PAR-2 on 16HBE 140· cells and to demonstrate 
PAR-2 specific effects on IL-8 expression (Page et al., 2003). The peptide concentration 
of 400 /-lM was the same as that employed previously to activate PAR-l and PAR-2 on 
human bronchial epithelial cells (Asokananthan et al., 2002). The specificity of 
scrambled PAR peptide agonists has been reported to be questionable in some assay 
systems. In a bioassay to determine the role of PAR-4, scrambled peptide agonist 
controls were demonstrated to exert biological effects (Moffatt, 2004). 
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Activation of both PAR-l and PAR-2 by synthetic peptide agonists significantly 
enhanced the release of fibrinogen and FXIIIA from 16HBE 140- cells at baseline and 
from wounded monolayers. This response was not inhibited by indomethacin, indicating 
that PGE2 was not involved in the observed response. Activation of P AR-l was 
previously demonstrated to stimulate the release of FXIII from chondrocytes (Rosenthal 
et al., 2004). The fact that PAR activation leads to the release of these coagulation 
factors signifies that following wounding of unstimulated 16HBE 140- mono layers, the 
repair response may involve initiation of the coagulation cascade and/or activation of 
PARs. 
The level of D-dimer release from 16HBE 140- cells at baseline and from wounded 
monolayers was significantly enhanced as a result of PAR-l and PAR-2 activation. 
Since D-dimers are indicative of fibrin formation and subsequent degradation, this 
implies that the increased release of fibrinogen and FXIIIA following PAR activation 
lead to an enhancement of coagulation that did not involve PGE2. The presence of D-
dimers provides evidence that fibrinolysis is occurring in the current model. This 
suggests that t-PA and plasminogen are present in the cell culture for the generation of 
plasmin that mediates fibrinolysis. 
With respect to the wounded cultures, in particular that denoted by 'W8' indicating 
maximal wounding, the effect of PAR-Ion the release of D-dimers was greater than 
that of PAR-2, although the difference was not significant (P=O.l4). However, it is 
possible that PAR -1 is more important in fibrinolysis. 
The partially scrambled PAR-l and PAR-2 control peptide agonists appeared to have a 
biological effect in the current model as they each demonstrated a significant reduction 
in the levels of fibrinogen, FXIIIA and D-dimers compared to both the no drug control 
and the corresponding PAR peptide. This may be indicative of a potential antagonistic 
effect. However, they did not demonstrate any effect in the wound repair assay. 
Activation of PAR receptors by peptide agonists of PAR-l and PAR-2 was also 
demonstrated to significantly enhance the rate of wound repair. Conceivably. wound 
repair may have occurred via the release of PGE2 (Asokananthan et al.. 2002) or 
I and subsequent fibrin formation. PAR-2 acti\ation was coagulation factor re ease 
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previously shown to facilitate wound healing by release of the secondary mediator 
PGE2 from the epithelium (Cocks et al., 2000). Given that the current culture conditions 
limit the production of this prostanoid, it is most likely that PAR-mediated wound repair 
involved the release of coagulation factors and subsequent fibrin formation. 
independently of PGE2 production. Interestingly, the effect of PAR-2 activation on 
wound repair was determined to be significantly greater than that of PAR -1 and PAR -.2 
was also shown to have a significantly greater effect on the release of fibrinogen 
compared to that of PAR-l suggesting that PAR-2 is more important in fibrin formation 
and wound repair. 
PAR-l activation is known to elicit an array of acute signalling responses including 
phosphoinositide hydrolysis, calcium mobilisation, PKC activation, ERK activation and 
c-fos expression, which are required for protein synthesis and protein tyrosine 
phosphorylation, which is required for thrombin-dependent mitogenesis (Berk et at., 
1991; Seuwen et al., 1990). 
PAR-l activation by thrombin has been demonstrated to transactivate EGFR and 
increase EGFR phosphorylation (figure 5.12) (Sabri et al., 2002). More recently. PAR-l 
has been shown to mediate the tyrosine phosphorylation of EGFR in human renal 
carcinoma cells (Bergmann et al., 2006). 
Previous in vitro studies have demonstrated that EGF stimulates IL-8 release from 
primary NHBE cells via activation ofEGFR (Hamilton et al., 2003). The release of IL-8 
from 16HBE 140- cells in response to wounding was demonstrated in the current study 
(section 3.4.6). Thus, the fact that PAR activation is reported to stimulate the release of 
IL-8 suggests the involvement of EGFR in the observed response. 
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activation are predicted to occur in parallel. Thrombin also activates Src famil y kinases . 
Both Src and Fyn are activated, which in tum associate with EGFR and increase 
phosphorylation (Sabri et af. , 2002). 
Activation of PAR-2 on epithelial cells has been demonstrated to induce the release of 
inflammatory mediators such as: IL-6, IL-8, MMP-9 and PDGF (Asokananthan et af. , 
2002; Shimizu et af. , 2000; Vliagoftis et af. , 2000). A separate study revealed that 
synthetic peptide agonists of both PAR-l and PAR-2 stimulated the release of IL-6 and 
IL-8 from bronchial epithelial cell lines and primary NHBE cells, however, the PAR-2 
peptide agonist was determined to be more effective than that of PAR-l at 400 /-lM 
(Asokananthan et af. , 2002). The same order of efficacy was observed in the current 
study whereby the effect of PAR-2 activation on the levels of fibrinogen re lease from 
16HBE 140- cells was significantly greater than that of P AR-l at baseline. The effect of 
PAR-l activation on the release of fibrinogen, FXIII and D-dimers was proportional to 
the extent of wounding whereas activation of PAR-2 stimulated maximal responses at 
baseline. PAR-mediated cytokine release is controversial as Page e/ a/. (2003) 
demonstrated that PAR-2 activation with 0.05 /-lM peptide agonist timulated IL-8 
release from 16HBE 140- cells, whereas activation of PAR-l did not. Other have 
shown that activation of both PAR- l and PAR-2 stimulated the relea e of I L-8 when 
peptide agonists were used at 400 /-lM (Asokananthan e/ al. - 2002). Due to the hi gh 
concentration of PAR peptide agonists that was employed in both th current tudy and 
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that of Asokananthan et al., the possibility of ligand cross-reactivity may not be ruled 
out as Blackhart et al. demonstrated that specificity of the xenopus PAR-I peptide 
agonist TFRIFD-amide was observed at concentrations up to 50 JlM. Therefore. 
specificity of PAR activation may be reduced at higher concentrations. 
PAR-2 activation is known to elicit a range of cytoprotective effects including wound 
healing, which is driven largely by release of the secondary mediator PGE2 from the 
epithelium (Cocks et aI., 2000). Moreover, activation of PAR-I in addition to PAR-2 
has been shown to stimulate the release of PGE2 from A549 cells and primary NHBE 
cells (Asokananthan et aI., 2002). However, PGE2 was not involved in the current study 
as indomethacin was without effect. Nevertheless, a cytoprotective effect of PAR-I and 
PAR-2 mediated via fibrin formation and enhanced epithelial repair is indicated. 
PARs are believed to play an important role in coagulation and inflammation. However, 
a recurring observation is the ability of PAR-activators to mediate both pro- and anti-
inflammatory effects. This chapter has demonstrated that activation of both PAR -1 and 
PAR-2 stimulates the release of coagulation factors, which are important in wound 
repair. However, over-stimulation of PARs could have detrimental effects such as 
excessive fibrin formation or over-production of inflammatory mediators. It must be 
noted that the current understanding of the relative contribution of PARs to pro-
inflammatory and cytoprotective processes during airway disease is incomplete. Further 
investigations are required, ideally with the use of novel PAR agonists and antagonists 
in order to provide a clearer overview for the role of PARs in the airways during 
homeostasis and disease states, and a better understanding of airway PARs when 
assessing their potential as therapeutic targets. 
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6. The effect of wounding on: coagulation factor, prostaglandin receptor and PAR 
expression at the mRNA level 
6.1. Introduction 
TF, the initiator of the coagulation cascade is nonnally expressed on cells extrinsic to 
the vascular compartment, however, endothelial cells, macrophages and monOC)1es can 
be induced to express TF by inflammatory mediators via a mechanism that commonly 
involves calcium and PKC (Camerer et al., 1996; Pettersen et ai., 1992; Ternisien et at.. 
1993; Yang et al., 1994). Upregulation of TF expression in these cells is achieved by 
oxidised low density lipoprotein, thrombin, cytokines (IL-l, TNF-a) mitogens (FGF. 
PDGF, EGF, insulin, HGF, TGF-pl, VEGF), endotoxins, viral infections, IFN and 
occupancy of cell adhesion molecules (Camerer et al., 1996) as well as FXa (Leadley et 
ai., 2001). LPS induces TF expression in both monocytes and endothelial cells ria 
interactions with the LPS binding protein/CD 14 complex (Read et al.. 1993: 
Steinemann et al., 1994). TF expression and activity has also been demonstrated on 
primary NHBE cells in culture (Keller et al., 2001). 
The liver was once considered to be the sole source of FVII, whereby its production is 
regulated by the liver-enriched transcription factor hepatocyte nuclear factor-4 (HNF -4) 
as well as transcription factor SP-l (Greenberg et al., 1995). Since then, expression of 
FVII mRNA has been demonstrated in macrophages, smooth muscle cells, fibroblasts 
and keratinocytes (Wilcox et al., 2003). However, expression of FVII in epithelial cells 
remains to be investigated. 
The liver is the main source of FX and gene expression is regulated by the transcription 
factor HNF -4 (Hung et al., 1996; Hung et al., 2001). Low levels of FX are synthesised 
in extra-hepatic tissues including the lung (Hung et al., 1996). The FX mRNA found in 
the lung may be from a number of cell types including the bronchial epithelium as \\ell 
as alveolar macrophages, which are a source of the protein (Osterud et al., 1980). 
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Fibrinogen is mainly derived from the liver and during inflammation the systemic le\els 
of fibrinogen are enhanced by the actions of IL-6 and glucocorticoids (Herrick et (il.. 
1999). In addition to hepatic synthesis, transfection and expression of fibrinogen has 
been demonstrated in a COS cell line and yeast (Zhang et al., 1996). Moreoyer. the 
A549 cell line derived from the alveolar basal epithelial cells has been demonstrated to 
express fibrinogen mRNA following stimulation with IL-6 and dexamethasone 
(Haidaris, 1997). 
The major sites of production of FXIII subunit A (FXIIIA) are from cells originating 
from the bone marrow, including megakaryocytes, platelets, macrophages and 
monocytes, whereas the liver only plays a minor role in its synthesis (Adany et al.. 
2003; Muszbek et al., 1996). It has been demonstrated that cis-elements and trans-
acting factors are involved in the constitutive and cell-type specific expression of 
FXIIIA. These include hematopoietic- or myeloid-specific elements such as MZF -1, 
GAT A-I , and Ets-l as well as general elements such as NF-l and SP-l (Ichinose.2001; 
Kida et al., 1999). Expression of FXIIIA mRNA has been demonstrated in homogenates 
of lung tissue, but the specific cell type from which it originated was not detennined 
(Kaczmarek et al., 1995). The liver is the sole site for the synthesis of the FXIII subunit 
B (FXIIIB) which forms a heterotetrameric complex with FXIIIA in plasma (Muszbek 
et al., 1996). 
It is established that within the respiratory tract, P AR-l and PAR-2 are abundant in the 
bronchial epithelium (Knight et al., 2001) as well as airway smooth muscle (ASM) 
cells endothelial cells and vascular smooth muscle cells (Lan et al., 2002). Tissue-, 
resident macrophages have been demonstrated to express PAR-l and PAR-2 (Knight et 
al., 2001). PAR-l and PAR-2 expression is also attributed to migratory cells such as 
mast cells and polymorphonuclear cells (Lan et al., 2002). Studies of cultured primary 
NHBE cells and cell lines have confirmed that different cell types express different 
PAR profiles. This may reflect selective responses to a variety of proteases acting in the 
airways. Studies involving RT-PCR analysis have demonstrated the presence of both 
PAR-l and PAR-2 mRNA in A549 and BEAS-2B cell lines as well as NHBE cells 
(Asokananthan et al., 2002) and 16HBE 140- cells (Page et aI., 2003). MoreO\er, PAR 
" . . d' d th t PAR 1 and P AR-'" are expressed by the actIvatIOn expenments have III lcate a - - . 
16HBE 140' cell line under the conditions used in the current study (Chapter 5). 
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Regulation of PAR activity at the gene transcriptional level may be achie\'ed by a 
variety of inflammatory mediators, which may induce or suppress both receptor gene 
expression and the presentation of the receptor protein on the cell surface. Regulation 
can also occur at the level of functional activity as a result of PAR 
activation/inactivation by endogenous or exogenous proteases (Sokolova et al.. 2007). 
In vitro studies have demonstrated several potential modulators of PAR expression. In 
endothelial cells, PAR-I and PAR-2 gene expression was enhanced by macrophage 
migration inhibitory factor, a proinflammatory cytokine which participates in the 
inflammatory phase of the wound healing process (Shimizu et aI., 2004). The 
proinflammatory, asthma-associated cytokine IL-I P has been demonstrated to stimulate 
the expression of PAR-2 in human ASM cells (Freund-Michel et at.. 2006). In 
fibroblasts, PAR-2 expression may be stimulated by the pro fibrotic growth factors TGF-
PI and PDGF (Gruber et aI., 2004). More recently, the pro inflammatory mediators LPS 
and TNF-a were demonstrated to enhance PAR-2 expression in fibroblasts 
(Ramachandran et aI., 2007). In macrophages, the asthma-associated cytokine IL-4 was 
demonstrated to downregulate PAR-I, PAR-2 and PAR-3 both at the mRNA and 
protein level (Colognato et aI., 2003). Interestingly, it is reported that persistent PAR 
activation can also influence PAR expression. For example, continuous activation of 
PAR-I and P AR-2 by peptide agonists resulted in upregulation of these receptors in the 
A549 cell line (Sokolova et aI., 2007). 
The receptors for PGE2 have been classified into four subtypes: EP-l, EP-2, EP-3 and 
EP-4. The tissue distribution and intracellular signalling pathways used by the 
subclasses of EP receptors differ substantially (Narumiya et aI., 1999). These 
differences may explain the wide array of effects that are induced by PGE2. According 
to Savla et al., the regulation of wound repair by PGE2 was mediated via EP-l and FP-
4. However, the stimulatory effects of PGE2 were not reproduced in the current model. 
Studies using RT-PCR analysis have detected mRNA corresponding to all four 
receptors in the mouse lung (Kat suyama et aI., 1995; Ushikubi et al.. 1995). I;P receptor 
distribution among cells within the lung is not well established, however. it is reported 
that various airway cell types can express multiple EP receptor subtypes (Tilley ct al.. 
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2003). EP receptors are reported to be regulated by prol·nflamm t . I·. . a ory stlmu 1 In VitrO. 
Expression of EP receptors is regulated by several factors thro h t· .. ug ac IOn on cls-actmg 
regulatory elements of the respective receptor genes (Narumiya et al., 1999). However, 
at present there is limited information available regarding this regulation. Stimulation 
with serum and bacterial LPS has been demonstrated to upregulate EP receptor 
expression on fibroblast and macrophage cell lines respectively. However. in vivo 
regulation of EP receptor expression has not yet been demonstrated. 
6.2 Aims and objectives 
To determine the expression level of mRNA for TF, FVII, FXa, fibrinogen, FXIII, 
PAR-I, PAR-2 and EP-l, EP-2, EP-3 and EP-4 in 16HBE 140- cells at baseline and in 
response to wounding. 
6.3. Methods 
6.3.1. Total RNA isolation 
16HBE 140- cells were seeded at a density of 400,000 cells per well in 6-well plates and 
cultured for 48 hours in 2 ml per well of full MEM until fully confluent. At confluence, 
cells were quiesced for 16 hours in 1 ml per well of serum-free MEM-ITS. Prior to 
experiment, MEM-ITS was refreshed. Cells were maximally wounded, i.e. 4 horizontal 
scrapes and 4 vertical scrapes, as described in section 2.2.5 and subsequently incubated 
for 2, 4, 6, 8 and 10 hours at 37°C. One 6-well plate was used for each time point. 
Following incubation, the cell culture supernatants were removed and harvested and 
cells were washed with 500 ~l per well of IX PBS then trypsinised by incubating with 
250 ~l per well of IX trypsin-EDTA for 5 minutes at 3TC. Once the cells had lifted, 
250 ~l per well of FBS was added to neutralise trypsin activity. The cell suspension 
from each well of the 6-well plate was combined and removed into 15 ml centrifuge 
tubes and centrifuged for 7 minutes at 670 x g (ALCPKI20 Centrifuge, Winchester 
Virginia, USA) to create a cell pellet. To each tube, 600 ~l of pre-chilled denaturing 
solution (Promega) was added, after which the mixture was homogenised (ULTRA-
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TURRAX T25, Janke & Kunkel lKA Labortechnik, Germany) at 24,000 revolutions per 
minute for 1 minute at room temperature. To the homogenate was added 60 III of 2.0 M 
sodium acetate (pH 4.0) (Promega) and the contents of the tube were thoroughly mixed 
by inversion of the tube 5 times. To each tube, 600 III of phenol:chloroform:isoamyl 
alcohol (99:24: 1, pH 4.7) (Promega), drawn from the lower, organic phase of the 
mixture was added, and the tubes were mixed by inversion 5 times and vigorously 
shaken for 10 seconds. The tubes were then chilled on ice for 15 minutes. The contents 
of the tube were then transferred to clean, sterile 1.5 ml centrifuge tubes, and 
centrifuged at 10,000 x g for 20 minutes at 4°C. The top aqueous phase of the mixture 
containing RNA was carefully removed using a pipette without disturbing the protein 
interface and DNA lower phase. The RNA-containing upper phase was transferred to a 
sterile 1.5 ml centrifuge tube and mixed with an equal volume of isopropanol and 
incubated at -20°C for 30 minutes in order to precipitate the RNA. The RNA was 
pelleted by centrifugation at 10,000 x g for 20 minutes at 4°C, after which the 
supernatant was decanted and the pellet washed with 1 ml of ice-cold 75% (Iv) ethanol. 
The pellet was broken up using a 1 ml sterile, RNase-free pipette tip and the tubes were 
centrifuged at 10,000 x g for 20 minutes at 4°C. The pellets were then air-dried in an 
RNase-free environment for 15 minutes, dissolved in 30 III of nuclease-free water after 
which RNA concentration and purity were estimated by optical density (OD) 
determination. The RNA concentration in solution was determined at 260 nm and 280 
nm based on the formula that an absorbance of 1 in a 1 cm path quartz cuvette at 260 
nm is approximately equivalent to 40 !J.glml. The 260/280 ratio was usually > 1.6, 
indicating suitable purity of RNA. 
6.3.2. Determination of RNA concentration by spectrophotometry 
As described in section 6.3.1, the concentration of extracted RNA was determined by 
measurement of absorbance at 260 nm (A260) in a spectrophotometer (ANTIIOS 
spectrophotometer, Cambridge Instruments, UK). The ratio of the readings at 260 nm 
and 280 run (A2601 A280) provides an estimate of the purity of RNA with respect to 
contaminants that absorb UV radiation, such as any proteins present in the solution. To 
.. I ted when the ratio was equal to or ensure accuracy, valId readmgs were on y accep 
greater than 1.6. An absorbance of 1 unit at 260 nm corresponds to 40 Ilg of RNA per 
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ml. This relationship is valid only for measurements in deionised water. Therefore. all 
necessary dilutions of the RNA in solution were performed in sterile water. The rati o 
between the absorbance values at 260 and 280 nm gives an estimate of RNA purit . For 
measurement of RNA samples, an RNase-free quartz cuvette was used; this \i a 
accomplished by washing the cuvette with 0.1 M NaOH, 1 mM EDT A followed b) 
washing with RNase-free water. A blank calibration reading was achieved using the 
buffer in which the RNA is diluted. This provided the zero value for subsequent 
spectrophotometric analysis of RNA samples. 
Samples were then diluted accordingly in order to use 1 I-1g of total RNA for first strand 
synthesis. 
6.3.3. Determination of RNA quality 
In order to determine the quality of the isolated RNA, 2 1-11 of the extracted RNA 
solution was mixed with 3 1-11 of loading dye (10 mM Tris, 50 mM EDTA, 10% ( Iv) 
glycerol, 0.25% (W/y) bromophenol blue, 0.25% (W/y) xylene cyanol FF, 0.4% (W/v) 
orange G) and electrophoresed at 150 V for 18 minutes on a 1 % e ly) agarose (BDH) gel 
containing 0.0001 % e ly) ethidium bromide until the dye front had travelled 75% along 
the total gel length. 
5 6 7 
"'- 28S rRNA 
"'-1 8S rRNA 
Figure 6.1. Representative gel demonstrating the presence of 28S rRNA and 18 rR 
in samples following RNA isolation. d (') 4 
Lane contents as follows: (1) Baseline (unwounded cells) (2) 2 hours post-woun j 
hours post-wound (4) 6 hours post-wound (5) 8 hours p ost- WO Lllld (6) 10 hour po. {-
wound (7) 12 hours post-wound. 
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6.3.4. Primer design 
The cDNA sequence of the gene of interest was obtained using the Entrez Gene 
database available on the NCBI website 
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene). The NCBI Reference 
Sequences (RefSeq) was used to identify the RefSeq mRNA sequence of interest (both 
species- and enzyme-specific) with the corresponding accession number. The sequence 
link was then used to determine the actual sequence from the GenBank Nucleotide 
sequence database, which was subsequently pasted into the primer design program, 
'Primer3' (http://frodo.wi.mit.edu/cgi-binlprimer3/primer3_ www.cgi). Forward and 
reverse primers were duly designed against a region of the gene in question according to 
the rules of primer design as outlined below: 
Rules for primer design: 
1. Primer sequences should be 17-28 bases in length; 
2. Base composition should be 50-60% G and C ('GC rich'); 
3. Primers should end 3' in a G or a C, or CG I GC. (i.e. 3' clamp). This prevents 
'breathing' of the ends and increases the efficiency of priming; 
4. T m (melting temperature) between 50-80°C is the most preferable; 
5. Runs of 3 or more Cs or Gs at the 3' end of primers may promote mis-priming at G- or 
C-rich sequences (due to the stability of annealing) and should be avoided; 
6. 3' -ends of primers should not be complementary, otherwise primer dimers may be 
synthesised preferentially to any other product; 
7. Primer self-complementarity (ability to form secondary structures such as hairpins) 
should be avoided. 
A potential problem with RT-PCR is the contamination of RNA with genomic DNA. 
Choosing primers that span introns is necessary in order to differentiate whether a band 
is amplified from genomic DNA or cDNA. If the primers span one or more introns and 
the RNA is contaminated with DNA, the result will be two bands, one of which \\'ill be 
from cDNA and the other from DNA. In order to determine whether the amplification is 
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from the cDNA template or from genomic DNA, RT-PCR primers are usually design~d 
to span introns or to bridge an exon-exon junction. 
Gene Direction Sequence Product Tm 
size (base CC) 
- ~airs) 
18SRNA Forward catgcatgtctaagtacgcacggcc 200 66.3 
Reverse gggctgaccgggttggtttt 61.4 
p-actin Forward gcgggaaatcgtgcgtgacatt 232 57.0 
Reverse gatggagttgaaggtagtttcgtg 56.0 
TF Forward caacagacacagagtgtgacctcaccgacg 502 66.0 
Reverse tctctgaattcccctttctcctggccc 63.0 
Fvn Forward agctcatggtgctcaacgtg 404 53.5 
Reverse atatgggatttggtgccagg 53.6 
FGC Forward cttgaagcacagtgccagga 413 53.6 
Reverse cccaccttgaacatggcata 53.1 
FX Forward ttcgacctgcttgacttcaac 430 52.0 
Reverse tcttctgcgtcatcagcgtg 54.7 
FXrn Forward gaaacagacacgtacattct 445 48.0 
Reverse aaaatgtgttaaagacacca 44.0 
PAR-l Forward ggatatttgaccagctcctgg 400 54.0 
Reverse agatggccagacaagtgaagg 54.0 
PAR-2 Forward ctgcatctgtcctcactggaa 400 54.0 
Reverse attgccagggagatgccaatg 54.0 
EP-l Forward gcgctgcccatcttctccatga 448 59.0 
Reverse tgccccgggtactgcagctcata 59.0 
EP-2 Forward tctccttgttccacgtgctg 446 54.0 
Reverse gagcaccgagacaatgagaa 52.0 
EP-3 Forward atgaaggagacccggggctacgga 515 63.0 
Reverse cgcgtcttcatgtggctcgcatac 61.0 
EP-4 Forward gcgagtacagcaccttcatt 543 52.0 
Reverse agatgaccatctggatctcg 52.0 
Table 6.1. Forward and reverse primer sequences used for RT-PCR. 
6.3.5. Internal control 
6.3.5.1. 18S RNA and f3-actin 
18S RNA was chosen as a suitable internal control since it is well established to ha\~ a 
constant expression level that is independent of the treatment condition and shows less 
variance in expression across a variety of treatment conditions than p-actin and 
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GAPDH. However, because 18S rRNA is so abundant, it amplifies rapidly during RT-
PCR, quickly exhausting the reaction reagents. It can therefore be difficult or eVen 
impossible to detect product from rare messages while remaining in the exponential 
phase of amplification for 18S rRNA. For this reason, ~-actin was also used. ~-actin 
encodes a ubiquitous cytoskeleton protein and is expressed at moderately abundant 
levels in most cell types (Kinoshita T et aI, 1992). The level of expression has been 
shown to vary in some types; however, there is no evidence to suggest that expression 
levels vary in bronchial epithelial cell lines. 
Expression of mRNA was analysed and presented as the ratio of the expression of the 
factor of interest to that of the internal control 
6.3.6. First strand complementary DNA (cDNA) synthesis of TF 
A 20 mM stock solution of dNTP (deoxynucleotide triphosphate) was prepared by 
adding equal volumes of dATP, dCTP, dGTP and dTTP (100 mM; Invitrogen), with the 
addition of nuclease-free water, each at a dilution of 1 in 5. The dNTP mix provides the 
units for which DNA molecules are constructed, with individual components each 
carrying a single nitrogenous base (adenine, cytosine, guanine and thymine). A 25 JlI 
reaction mixture was prepared consisting of 15 JlI of RNA, 1 JlI of20 mM dNTP, 1 Jllof 
random hexamer (0.2 JlgIJlI; Invitrogen) and 8 JlI of nuclease-free water in a 1.5 ml 
sterile tube. The reaction mixture was incubated at 70°C for 10 minutes in order to 
linearise the RNA, then the mixture was immediately chilled on ice. 8 JlI of five times 
concentrated first strand buffer (Invitrogen), 4 JlI of 0.1 M DTT (dithiothreitol; 
Invitrogen) and 1 JlI of RNaseOUT inhibitor (40 U/JlI; Invitrogen) were added to the 
reaction mixture before incubation for 10 minutes at room temperature. At this point a 
10 JlI aliquot of reaction mixture was removed and allocated for use as the negative 
control, prior to the addition of 2 JlI of Superscript II Reverse Transcriptase (50 UIJll; 
Invitrogen), after which the reaction mixture followed by incubation at 4~oC for 1 hour. 
Enzymatic activity was then removed by incubation a 70°C for 15 minutes. at which 
point the mixture was stored at -20°C until required. 
226 
6.3.7. RT-PCR for TF and 18S RNA 
A single host mix of 50 /-ll was created, consisting of 25 /-ll of two times concentrated 
Mastermix (Qiagen), 1 /-ll of forward (0.1 /-lg/ml) and 1 /-ll of reverse (0.1 /-lg/ml) primers 
for either TF or 18S RNA (Sigma-Genosys Ltd), 1 /-ll of complementary DNA which 
acted as a template for RT-PCR and 22 /-ll of nuclease-free water. RT-PCR reactions 
were subjected to 10 minutes at 72°C to linearise the cDNA, then 30 cycles or 17 cycles 
of amplification for TF and 18S RNA respectively, consisting of denaturation at 94°C 
for 20 seconds, annealing at 57°C for 20 seconds and extension for 40 seconds at 72°C. 
This was followed by a final extension step of 2 minutes at 72°C. 
6.3.8. One-step RT-PCR 
The SuperScript™ One-Step RT-PCR system (Invitrogen) was subsequently adopted for 
its convenient, sensitive and reproducible detection of RNA. Both cDNA synthesis and 
PCR are performed in a single tube using gene-specific primers and specific target 
RNAs from total isolated RNA. The system consists of two major components: 
SuperScript™ II RT/platinum® Taq Hi Fi Mix (a blend of SuperScript™ II Reverse 
Transcriptase and Platinum Taq DNA Polymerase High Fidelity) and 2X reaction mix 
(a buffer containing 0.4 mM of each dNTP and 2.4 mM MgS04)' 
6.3.8.1. One-step RT -PCR for FVII, ~-actin, fibrinogen gamma chain (FGC), FX, 
FXIII, PAR-I, P AR-2, EP-l, EP-2, EP-3 and EP-4 
A single host mix of 50 /-ll was created, consisting of 25 /-ll of two times concentrated 
reaction mix (Invitrogen), 1 /-ll of forward (0.1 /-lg/ml) and 1 /-ll of reverse (0.1 /-lg/ml) 
primers for either FVII, ~-actin, FGC, FX, FXIII, PAR-I, PAR-2. EP-1, EP-2. EP-3 or 
EP-4 (Sigma-Genosys Ltd), 1 /-ll of SuperScript™ II RT/platinum® Taq Hi Fi Mix. 1 /-ll 
of template RNA and 21 /-ll of nuclease-free water. RT-PCR reactions were subjected to 
50°C for 30 minutes to synthesise the cDNA then pre-denaturation for :2 minutes at 
940C; followed by either 40 cycles of amplification (FVII, FGC. FX. FXIIL PAR-I. 
PAR-2, EP-L EP-2, EP-3 and EP-4) or 30 cycles of amplification (p-actin). consisting 
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of denaturation at 94°C for 15 seconds, annealing at either 55°C (FGC, FX and FXIII), 
56°C (EP-2), 57°C (EP-4), 60°C (FVII, p-actin, PAR-l and PAR-2), 64°C (EP-l) or 
66°C (EP-3) for 20 seconds and extension for 45 seconds at 68°C. This was followed by 
a final extension step of 10 minutes at 72°C. 
6.3.9. Analysis of RT -PCR products by agarose gel electrophoresis 
10 III of each RT-PCR product was mixed with 2 III of loading dye (10 mM Tris, 50 
mM EDTA, 10% ely) glycerol, 0.25% (W/y) bromophenolblue, 0.25% (w/y ) xylenecyanol 
FF, 0.4% (W/y) orangeG) and run at 150 V for 18 minutes on a 2% (w/y ) agarose (BDH) 
gel containing 0.0001 % (/y) ethidium bromide until the dye front had travelled 75% 
along the total gel length. A 100 bp DNA ladder (Invitrogen) was also loaded. Bands 
were visualized by ethidium bromide fluorescence under ultraviolet light. Densitometry 
was then carried out using SynGene software; to semi-quantify the relative abundance 
of mRNA bands encoding each gene sequence compared with the internal control I8S 
RNA or p-actin. 
6.4. Results 
6.4.1. TF 
6.4.1.1. Optimisation of conditions for RT -PCR amplification of TF 
In order to optimise R T -PCR conditions for TF, the effect of cell cycle number on the 
abundance of the TF amplicon was investigated. 
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1 2 3 456 
502 base pairs 
Figure 6.2. Representative gel demonstrating the effect of cell cycle number on mRNA 
expression ofTF in 16HBE 140- cells (23-30 cycles of amplification) . 
2% (w/v) agarose gel electrophoretic separation of TF amplicons generated by RT-PCR 
using cDNA synthesised from total RNA extracted from 16HBE 140- cells at baseline. 
Lane contents as follows: (1) 23 cycles (2) 24 cycles (3) 25 cycles (4) 26 cycles (5) 27 
cycles (6) 28 cycles (7) 29 cycles (8) 30 cycles (9) 100 base pair ladder. 
With reference to figure 6.2, it was evident that linearity for TF mRNA with cycle 
number was achieved up to 30 cycles of amplification. Higher cycle numbers lead to 
saturation of the TF amplicon, therefore, 30 cycles of amplification were chosen for the 
RT-PCR conditions. 
6.4.1.2. 18S RNA internal control 
In order to optimise RT-PCR conditions for the internal control 18SRNA, the effect of 
cell cycle number on the abundance of the 18 SRN A amplicon was investigated. 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
.-200 base pairs 
Figure 6.3. Representative gel demonstrating the effect of cell cyc~e nu~ber on mRNA 
expression of 18S RNA in 16HBE 140- cells (10-24 cycles of amphficatlOn). 
Lane contents as follows: (1) 100 base pair ladder (2) 10 cycles (3) 11 cycles (4) 12 
cycles (5) 13 cycles (6) 14 cycles (7) 15 cycles (8) 16 cycles (9) 17 cycles (10) 18 
cycles (11) 19 cycles (12) 20 cycles (13) 21 cycles (14) 22 cycles (15) 23 cycle (16) _4 
cycles (17) 100 base pair ladder. 
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Figure 6.4. Represe~tati."e gel demonstrating the effect of cell cycle number on 18S 
RNA mRNA expressIOn m 16HBE 140- cells (25-30 cycles of amplification). 
Lane contents as follows: (1) 25 cycles (2) 26 cycles (3) 27 cycles (4) 28 cycles (5) 29 
cycles (6) 30 cycles (7) 100 base pair ladder. 
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Figure 6.5. Determination of linearity for 18SRNA. 
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With regards to figures 6.3 and 6.5, it was decided that 17 cycles of amplification were 
to be used for future RT-PCR conditions as this was the point at which the abundance 
of the 18SRNA amplicon was comparable with that of TF, was within the linear range 
and had not yet become saturated. 
6.4.1.3. TF mRNA expression pre- and post- wounding 
The effect of wow1ding on mRNA expression of TF in 16HBE 140' cells wa anal)' ed 
over 12 hours. 
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Figure 6.6. R~presentati.ve gel demonstrating the effect of time post-woundin on 
mRNA expressIOn ofTF III 16HBE 140- cells. g 
Lane contents as follows: (1) Baseline (unwounded cells) (2) 2 hours post-wound (3) 4 
hours post-wound (4) 6 hours post-wound (S) 8 hours post-wound (6) 10 hours po t-
wound (7). 12 hours post-wo~n~ (8) Negative control amplification using eDNA 
template pnor to reverse transcnptIOn (9) 100 base pair ladder. 
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Figure 6.7. Effect of wounding on levels of mRN A for TF in 16HBE 140- cells. 
Data bars represent the ratio of TF to the internal control 18SRNA. Data represent mean 
± SEM (n=4). BL=baseline i.e. unwounded cells. * Indicates P<O.OS and * * indicates 
P<O.OOS compared to BL. 
Immunohistochemical staining for TF in 16HBE 140- cells demonstrated constitutive 
expression of this coagulation factor (section 3.4.1). RT -peR analysis revealed that 
there was an increase in mRNA levels of TF that was time-dependent post-wounding. 
There was a significant increase in mRNA levels of TF at 10 hours (2.34 ± 0.6 1) and 1_ 
hours (1.S4 ± 0.20) post-wounding compared to baseline (0.27 ± 0.14). 
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6.4.2. FVII 
6.4.2.1. f3-actin internal control 
The SuperScript™ One-Step RT-PCR system (Invitrogen) was subsequently adopted fo r 
its convenient, sensitive and reproducible detection of RNA and ~-actin was used as the 
internal control. 
The effect of wounding on mRNA expression of ~-actin in 16HBE 140- cells was 
analysed over 10 hours. 
1 2 3 4 5 6 7 8 
232 base pairs--. 
Figure 6.8. Representative gel demonstrating the effect of time post-wounding on 
mRNA expression of f3-actin in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (no RNA) (3) 
Baseline (unwounded cells) (4) 2 hours post-wound (5) 4 hours post-wound (6) 6 hours 
post-wound (7) 8 hours post-wound (8) 10 hours post-wound. 
Figure 6.8 indicates that ~-actin mRNA is detected in 16HBE 140- cells and that its 
expression does not change with time post-wounding, therefore ~-actin was considered 
a suitable internal control for RT-PCR. 
The effect of wounding on mRNA expressIOn of FVII III 16HBE 140- cell s wa 
analysed over 10 hours (figure 6.9). 
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6.4.2.2. FVII 
04 base pairs • 
Figure 6.9. R~presentativ~ gel demonstrating the effect of time post-wounding on 
mRNA expressIOn ofFVII III 16HBE 140· cells. . 
Lane ~ontents as follows: (1) 100 base pair ladder (2) Negative control (no RNA) (3) 
Negative control (no DNA polymerase enzyme) (4) Baseline (unwounded cells) (5) 2 
hours post-wound (6) 4 hours post-wound (7) 6 hours post-wound (8) 8 hours pas/-
wound (9) 10 hours post-wound (10) Liver RNA (positive control). 
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Figure 6.10. Effect of wounding on mRNA levels ofFVII in 16HBE 140· ce lls. 
Data bars indicate the ratio of FVII to ~-actin internal control. BL=baseline l. e. 
unwounded cells. Data represent mean ± SEM (n=3). * Indicates P<0.05 and 
** indicates P<0.0005 compared to B1. 
RT-PCR amplification demonstrated that FVII mRNA is detected in 16HBE 140' cell 
and that there was a time-dependent increase in the level of FYII mRNA expre ion 
post-wounding. At 4 hours, mRNA expression levels were significantl y higher (1.30 ± 
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0.03) compared to the unwounded cell cultures (0 76 ± 0 06) Till U . " s ellect was 
maintained up to 10 hours (6 hours = 2.33 ± 0.37; 8 hours = 2.47 ± 0.14 and 10 hours = 
2.84 ± 0.14). 
6.4.3. FGC and FXa 
The effect of wounding on mRNA expression ofFGC and FXa in 16HBE 140- cells was 
analysed over 10 hours. 
123456789 
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Figure 6.11. Representative gel demonstrating the effect of time post-wounding on 
mRNA expression ofFGC and FXa in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) negative control (no RNA) (3) 
FGC: Baseline (unwounded cells) (4) FGC: 2 hours post-wound (5) FGC: 10 hours 
post-wound (6) FGC: liver RNA (positive control) (7) FXa: Baseline (unwounded cells) 
(8) FXa: 2 hours post-wound (9) FXa: 10 hours post-wound. (10) FXa: liver RNA 
(positive control). 
Although fibrinogen protein expression in culture supernatants of 16HBE 140- cells was 
determined by immunoblot (section 3.4.2.1), fibrinogen mRNA was not detected by 
RT-PCR in the same cell type. The fibrinogen primer pair was deemed valid since it 
was able to generate an abundant amplicon of 413 base pairs by R T -PCR, using RNA 
isolated from mouse liver (figure 6.11). Furthermore, in the absence of RNA, no 
amplicon was generated by RT-PCR. 
Despite evidence that FXa is present in 16HBE 140- cells due to inhibition of wound 
repair by two separate selective FXa inhibitors (section -I. -I. 8. 2); FXa mRNA was not 
detected by RT-PCR in the same cell type. The FXa primer pair was deemed valid since 
it was able to generate an abundant amplicon of 430 base pairs by RT-PCR. u ing RN 
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isolated from mouse liver (figure 6.11). Furthermore, III the absence of RNA, no 
amp Ii con was generated by R T -PCR. 
In view of the evidence that both fibrinogen and FXa are present in 16HBE 140· cell 
cultures, the possibility of gene repression by histone deacetylation was examined and 
preliminary results for fibrinogen and FXa are presented in Chapter 7, sections 7. 2. 3. 2 
and 7. 2. 3. 3 respectively. 
6.4.4. FXIII 
The effect of wounding on mRNA expreSSIOn of FXIII III 16HBE 140· cells was 
analysed over 10 hours. 
1234567 
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Figure 6.12. Representative gel demonstrating the effect of time post-wounding on 
mRNA expression of FXIII in 16HBE 140· cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Baseline (unwounded cells) (3) 2 
hours post-wound (4) 4 hours post-wound (5) 6 hours post-wound (6) 8 hours post-
wound (7) 10 hours post-wound (8) liver RNA (positive control) (9) Negative control 
(no RNA). 
Although FXIII protein expression in 16HBE 140· cells was determined by immunoblot 
(section 3.4.2.2), FXIII mRNA was not detected by RT-PCR in the same cell type. The 
FXIII primer pair was deemed valid since it was able to generate an abundant amplicon 
of 445 base pairs by RT-PCR, using RNA isolated from mouse liver (figure 6.12). 
Furthermore, in the absence of RNA, no amplicon was generated by RT-PCR. 
In view of the evidence that FXIII is present in 16HBE 140· cell cultures, the poss ibility 
of gene repression by histone deacetylation was examined and preliminary result for 
FXIII are presented in section 7.2.3.4. 
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6.4.5. P AR-l 
PARs 1-4 have previously been detected in NHBE cells and A549, BEAS-2B and 
16HBE 140- cell lines (Asokananthan et aI., 2002; Page et aI. , 2003). Since 16HBE 140-
cells responded to PAR-1 and PAR-2 peptide agonists (Chapter 5), it was of interest to 
confirm the expression of PAR-1 and PAR-2 in 16HBE 140- cells in the current study. 
Figure 6.13 represents the effect 
16HBE 140- cells over 10 hours. 
1 
400 base pairs -+ 
of wounding on mRNA expression of PAR-1 In 
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Figure 6.13. Representative gel demonstrating the effect of time post-wounding on 
mRNA expression of PAR-1 in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Baseline (unwounded cells) (3) 2 
hours post-wound (4) 4 hours post-wound (5) 6 hours post-wound (6) 8 hours post-
wound (7) 10 hours post-wound. 
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Figure 6.14. Effect of wounding on mRNA levels of PAR-l in 16HBE 140- cells. Data 
bars indicate the ratio of PAR-l to ~-actin internal control. BL=baseline i. e. unwounded 
cells. Data represent mean ± SEM (n =3). 
RT-PCR amplification demonstrated that the PAR-l receptor mRNA is detected in 
16HBE 140- cells; however, there was no change in PAR-l mRNA expression with 
time post-wounding with regards to any of the time-points investigated or compared to 
baseline. 
6.4.6. P AR-2 
Figure 6.15 represents the effect of wounding on mRNA expreSSIOn of PAR-2 111 
16HBE 140- cells over 10 hours. 
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Figure 6.15. Representative gel illustrating the effect of time post-woundino on mRNA 
expression ofPAR-2 in 16HBE 140- cells. b 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (no RNA) (3) 
Baseline (unwounded cells) (4) 2 hours post-wound (5) 4 hours post-wound (6) 6 hours 
post-wound (7) 8 hours post-wound (8) 10 hours post-wound (9) Platelet RNA (positive 
control). 
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Figure 6.16. Effect of wounding on mRNA levels ofPAR-2 in 16HBE 140' cells . 
Data bars indicate the ratio of PAR-2 to ~-actin internal control. BL=baseline I. e. 
unwounded cells. Data represent mean ± SEM (n =3). 
RT-PCR amplification demonstrated that PAR-2 is detected in 16HBE 140- cell. 
however there was no change in PAR-2 mRNA expression with time post-wound in g 
with regards to any of the time-points investigated or compared to baseline. 
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6.4.7. EP receptors 
PGE2 was previously reported to enhance bronchial epithelial repair in 16HBE 140-
cells (Savla et aI., 2001). However, this effect was not reproduced in this study (section 
4.4.10.2). However, when endogenous FXa was inhibited, there was evidence that 
prostanoids playa role in wound repair (section 4.4.10.1). Savla et al. reported that 
PGE2 mediated wound repair via EP-l and EP-4; therefore, it was of interest to 
investigate the presence of these receptors in the current model. For completeness, the 
presence ofEP-2 and EP-3 were also investigated. 
RT-PCR amplification demonstrated that mRNA for neither EP-l nor EP-4 was 
detected in 16HBE 140- cells at baseline or in response to wounding. However, mRNA 
expression for both EP-2 and EP-3 was detected at baseline, thus, the effect of 
wounding on mRNA expression for these receptors was investigated. 
Figure 6.17 represents the effect of wounding on mRNA expression of EP-2, the PGE2 
receptor in 16HBE 140- cells over 10 hours. 
446 base pairs ~ 
Figure 6.17. Representative gel demonstrating the effect of time post-wounding on 
mRNA expression ofEP-2 in 16HBE 140- cells. . 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (no RNA) (3) 
Baseline (unwounded cells) (4) 2 hours post-wound (5) 4 hours post-wound (6) 6 hours 
post-wound (7) 8 hours post-wound (8) 10 hours post-wound. 
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Figure 6.18. Effect of wounding on mRNA levels ofEP-2 in 16HBE 140- cells. 
Data bars indicate the ratio of EP-2 to ~-actin internal control. BL=baseline i.e. 
unwounded cells. Data represent mean ± SEM (n =3). 
RT-PCR amplification demonstrated that EP-2 mRNA is detected in 16HBE 140- cells, 
however there was no change in EP-2 mRNA expression with time p ost-wounding with 
regards to any of the time-points investigated or compared to baseline. 
Figure 6.19 represents the effect of wounding on mRNA expression of EP-3 , the PGE2 
receptor in 16HBE 140- cells over 10 hours. 
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Figure 6.19. ~epresentative gel demonstrating the effect of time post-wounding on 
mRNA expreSSIOn ofEP-3 receptor in I6HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Baseline (unwounded cells) (3) 2 
hours post-wound (4) 4 hours post-wound (5) 6 hours post-wound (6) 8 hours post-
wound (7) 10 hours post-wound. 
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Figure 6.20. Effect of wounding on mRNA levels ofEP-3 in 16HBE 140- cells. 
Data bars indicate the ratio of EP-3 to ~-actin internal control. BL=baseline i.e. 
unwounded cells. Data represent mean ± SEM (n =4). * Indicates P<0.05 compared to 
BL. 
RT-PCR amplification demonstrated that EP-3 mRNA is detected in 16HBE 140- cells 
and that there was an increase in mRNA expression ofEP-3 with time p ost-wounding (2 
hours = 1.02 ± 0.30; 4 hours = 1.28 ± 0.30; 6 hours = 1.38 ± 0.32 and 8 hours = 1.93 ± 
0.54) compared to baseline (0.84 ± 0.21) and at 10 hours (2 .62 ± 0.46). the increase in 
expression was significant compared to baseline. 
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6.5. Summary of results 
Both TF and FVII mRNA transcripts were detected at baseline in 16HBE 140- cells and 
an increase in mRNA expression for each factor was demonstrated in a time-dependent 
manner post-wounding. Levels of significance of TF and FVII mRNA expression were 
achieved at 10 hours and 4 hours post-wound respectively, compared to baseline. 
Transcripts for FXa, fibrinogen and FXIII were not detected at baseline or in response 
to wounding of 16HBE 140- cells. Both PAR-l and PAR-2 mRNA was detected at 
baseline in 16HBE 140- cells; however, there was no time-dependent change in mRNA 
expression post-wounding. Neither EP-l nor EP-4 mRNA was detected at baseline in 
16HBE 140- cells or in response to wounding. EP-2 mRNA was detected at baseline in 
16HBE 140- cells and in response to wounding; however, there was no time-dependent 
change in mRNA expression post-wounding. Finally, EP-3 mRNA was detected at 
baseline in 16HBE 140- cells and an increase in mRNA expression was demonstrated in 
a time-dependent manner post-wounding. A significant increase in EP-3 mRNA 
expression was achieved at 10 hours post-wound compared to baseline. 
6.6. Discussion 
The coagulation cascade depends on the formation of an initiation complex between TF 
and FVII. Thus, the expression of these coagulation factors at the mRNA level was 
investigated over the time-course of wound repair. R T -peR amplification demonstrated 
the novel observation that 16HBE 140- cells express TF mRNA. In accordance with 
immunohistochemical staining for TF, mRNA expression was detected in unwounded, 
confluent cell monolayers. Expression of TF mRNA increased in a time-dependent 
manner and levels of significance were achieved at 10 hours post-wounding. 
Similarly, human platelets have recently been shown to synthesise their own TF for 
thrombin generation (Panes et al., 2007). It was demonstrated that platelets contain TF 
mRNA, which is translated into de novo synthesised protein following acti\'ation. 
Expression of TF mRNA was observed following activation of platelets with a PAR-l 
peptide agonist. Circulating platelets are reported to contain sufficient TF to account for 
the initiation of their clotting function and it has been suggested that TF is pre-formed 
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and rapidly exposed in the active fonn (Camera et al., 2003; Muller et aI., 2003) or is 
more slowly decrypted (Bach, 2006) upon stimulation. In a separate study, platelet-
monocyte complexes demonstrated mRNA expression of TF within 15 mins of PAR-l 
activation and 2 hours post-stimulation with LPS (Lindmark et aI., 2000). Platelets are 
thus described as 'TF-bearing cells' as they enable the localisation ofTF when required 
and are therefore self-sufficient in the initiation of fibrin fonnation. 
Transcripts for FVII mRNA were also detected in unperturbed confluent 16HBE 140' 
cells. Expression of FVII mRNA increased in a time-dependent manner and a 
significant increase was demonstrated 4 hours post-wounding. Expression of FVII 
mRNA by 16HBE 140' cells is a novel observation. Since a significant increase in the 
release of FVII occurred rapidly, within 20 minutes post-wounding and FVII mRNA 
was not significantly increased until 4 hours post-wounding, it is evident that gene 
transcription is not responsible for FVII release in response to wounding. Instead, it is 
likely that FVII is prefonned and stored within epithelial cells in order to be rapidly 
released following cell injury. 
In hindsight, the design of the cell experiments to generate RNA for RT-PCR analysis 
was flawed as they displayed a lack of time-matched controls. If these experiments were 
to be repeated, they would include both unwounded and wounded cell cultures for each 
time-point investigated. 
Expression of PAR-l and PAR-2 mRNA in 16HBE 140' cells was unaffected by 
wounding. However, an increase in the release of a PAR-activating protease such as 
HAT (PAR-2) or thrombin (PAR-I) could lead to upregulation ofTF and possibly FVII 
expression. Thus, it would be interesting to investigate the expression of coagulation 
factors in response to PAR activation by incubating 16HBE 140' cells with PAR 
agonists prior to RNA extraction. 
Despite demonstration of FXa inhibition by two selective FXa inhibitors, determination 
of fibrinogen and FXIIIA protein in cell culture supernatants: inhibition of wound repair 
by anti-fibrinogen and anti-FXIIIA and immunostaining for FXIIIA, mRNA for FXa. 
fibrinogen and FXIIIA was not detected in 16HBE 140' cells. The primer sets \\-ere 
deemed valid since each of them were able to generate an abundant amplicon of the 
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appropriate base pairs using RNA isolated from mouse liver. The absence of mRNA for 
these coagulation factors was illogical therefore the possl·bl·ll·ty of g . , ene repreSSIOn was 
explored (see Chapter 7). 
Expression of P AR-l and P AR-2 was confirmed at the level of transcription in 16HBE 
140- cells in the current model. Expression of PAR-l and PAR-2 mRNA by wounded 
monolayers did not change with time post-wounding compared to unwounded cells. 
Thus mechanical wounding had no influence on PAR expression. 
Both exogenous and endogenous PGE2 were previously reported to enhance wound 
repair of 16HBE 140- cells (Savla et aI., 2001). However, these observations were not 
confirmed in the current model since both exogenously added PGE2 and the COX 
inhibitor indomethacin had no effect on wound repair. The levels of PGE2 in cell culture 
supernatants at baseline and in response to wounding were lower than the concentration 
ofPGE2 required to significantly enhance 16HBE 140- wound repair in Savla's model. 
Moreover, the addition of PGE2 had no effect on the release of fibrinogen or FXIIIA at 
baseline or from wounded 16HBE 140- cell mono layers. The differences in responses 
may be due to cell culture conditions. PGE2 is a lipid-derived autacoid, therefore the 
lack of serum in the current model reduced the availability of phospholipid for 
phospholipase A2 activity, arachidonic acid production and subsequent PGE2 synthesis. 
Savla et al. reported that the EP-l and EP-4 receptor subtypes were involved in the 
transduction of the stimulus from PGE2 in 16HBE 140- cells to promote wound repair. 
Interestingly, in the current study, mRNA expression of these receptors was not 
demonstrated in the same cell type. It is possible that the current culture conditions may 
have down-regulated expression of these receptors. COX-l and COX-2 are similarly 
down-regulated in serum-free conditions. Conversely, 16HBE 140- cells demonstrated 
mRNA expression of EP-2 and EP-3 receptors. There was no influence of time post-
wounding on EP-2 mRNA expression in this cell type, whereas EP-3 was constitutively 
expressed and expression was increased in a time-dependent manner post-wounding. 
with levels of significance achieved at 10 hours. However, Savla et al. demonstrated 
that treatment of 16HBE 140- cells with the EP-3 agonist enprostil resulted in neither 
stimulation nor inhibition of wound repair under the conditions used. Moreover. the 
same authors were unable to determine the importance of the EP-2 receptor subtype. 
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Thus, in order to determine whether EP-2 and EP-3 playa role in wound repair. the 
effects of the EP-2/EP-3 agonist misoprostol, or other available selective agonists could 
be investigated. 
The tissue distribution and intracellular signalling pathways used by the subclasses of 
EP receptors are reported to differ substantially (Narumiya et al.. 1999). These 
differences may explain the wide array of effects that are induced by PGE2 in vivo. For 
example, in cat trachea, PGE2 acts as a dilator, but is a constrictor in guinea pig ileum 
(Gardiner, 1986). Similarly, PGE2 may have dilator or constrictor effects on vascular 
smooth muscle (Walch et a!., 2001). The EP-2 receptor has been demonstrated to 
mediate the bronchodilatory effect ofPGE2 in mice (Fortner et aI., 2001; Hartney et aI., 
2006; Sheller et a!., 2000). However, activation of EP-3 by PGE2 was demonstrated to 
promote acute inflammation in a murine model (Goulet et aI., 2004). In terms of wound 
repair, there is no evidence to suggest that receptor subtypes EP-2 and EP-3 are 
involved. However, Savla et al. demonstrated that EP-4 mediated the effects of PGE2 
and stimulated wound repair following an increase in cAMP and EP-2 activation by 
PGE2 is also associated with an increase in cAMP. Thus, there is a possibility that EP-2 
may be involved in bronchial epithelial repair. The importance of EP-2 and EP-3 
expression by the bronchial epithelium is yet to be established. 
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7. Preliminary results indicating direction for future work 
7.1. Isolation ofTF complex 
7.1.1. Introduction 
Initiation of the coagulation cascade requires the formation of a complex of TF with 
FVIL TF is the cellular receptor for zymogen FVIl, facilitating its activation. FVII has 
minimal enzymatic activity in the unbound form and retains a zymogen-like 
conformation (Petrovan et al., 2001; Zur et al., 1982). Full catalytic activity of FVII is 
only acquired when present as part of a TF -FVII complex. Thus, the protease function 
ofFVIl in vivo is reported to be TF-dependent (Camerer et al., 1996). 
A second important feature of the initiation of coagulation is the interaction of the TF-
FVIl complex with FX. The Gla domain of FX provides critical phospholipid 
membrane binding and also interacts with an extended binding site in the C-terminal of 
TF and with the Gla domain of FVIla (Ruf et al., 1998). Together, the interaction of FX 
with TF -VIla accounts for the binding energy that is required for the formation of the 
initial ternary TF-FVIla-FXa complex (Shobe et al., 1999). In this complex, the scissile 
bond of FX is presented to the active site of FVIIa and cleaved, generating product FXa. 
Thus, a ternary TF-FVIla-FXa complex exists prior to the dissociation of product Xa 
(Kirchhofer et al., 2001). 
The formation of the TF-FVIla-FXa in bronchial epithelial cells has not yet been 
investigated. In the current study, abundant expression of TF and FVII was 
demonstrated in 16HBE 140- cells (Chapter 6) and FXa expression was demonstrated 
by use of FXa inhibitors (Chapter 4) and in preliminary experiments investigating gene 
repression (Chapter 7). Thus, it was of interest to investigate the formation of the 
ternary complex in response to mechanical wounding of bronchial epithelial cell 
monolayers. 
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7.1.2. Methods 
7.1.2.1. Immunoprecipitation of TF complex 
16HBE 140- cells were cultured for 48 hours on 6-well cell culture plates until fully 
confluent and quiesced for 16 hours in 1 ml per well of serum-free MEM-ITS. Prior to 
experiment, MEM-ITS was refreshed and cell mono layers were maximally wounded, 
i.e. 4 horizontal scrapes and 4 vertical scrapes, as described in section 2.2.5 and 
incubated at 37°C for 2, 5, 15, 30 and 60 minutes. Following incubation, supernatants 
were harvested and retained and cells were washed with IX PBSc (PBS supplemented 
with 1 mM CaCh and 0.5 mM MgCh). Cells were incubated on ice for 30 minutes with 
PBSc containing 0.5 mM DTSSP (3,3' -Dithiobis[ sulfosuccinimidylpropionate D, a 
water-soluble, thiol cleavable, homobifunctional and amine-reactive cross-linking agent. 
Cells were washed with 1 ml per well of TBS (50 mM NaCI, 50 mM Tris-HCI, pH 7.8) 
and 500 III of lysis buffer (IX PBSc containing 1 % Triton-x, 0.25% sodium 
deoxycholate, 0.5% SDS, IX protease cocktail inhibitor (Calbiochem)) was added to 
each well. Once the cells had lifted, the cell lysates were extracted from the plate into 
1.5 ml centrifuge tubes and centrifuged at 900 x g for 10 minutes at 4°C (ALC PM140R 
Centrifuge, Winchester Virginia, USA) to remove cell debris. 
The Seize® X Protein A Immunoprecipitation kit (Pierce) was used to 
immunoprecipitate the TF. 
7.1.2.2. Binding of antibody to immobilised protein A 
To spin cup columns, 400 III of the gel containing immobilised protein A was added and 
spin cup columns were placed inside 1.5 ml microcentrifuge tubes and centrifuged for 
one minute at 5000 x g (ALC PM140R Centrifuge, Winchester Virginia, USA). The 
flow-through was discarded and the spin cup columns returned to microcentrifuge 
tubes. The protein A gel was washed by adding 400 III of binding/wash buffer (1 X PBS 
containing: 0.14 M NaCI, 0.008 M sodium phosphate, 0.002 M potassium phosphate 
and 0.01 M KCI, pH 7.4). The gel was resuspended by inversion and gentle shaking and 
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tubes were centrifuged for one minute at 5000 x g at room temperature and the flow-
through was discarded. The wash step was repeated and spin cup columns were 
transferred into new micro centrifuge tubes. 40 JlI of mouse anti-human TF. (l mglml; 
American Diagnostica, Dundee, UK) was added to 400 JlI binding/wash buffer in each 
spin cup column and tubes were incubated for 2 hours at room temperature with 
rotation. Tubes were centrifuged for one minute at 5000 x g at room temperature, spin 
cup columns were transferred into new micro centrifuge tubes and 500 JlI binding/wash 
buffer was added to each tube. Tubes were inverted 10 times and centrifuged for one 
minute at 5000 x g at room temperature. The flow-through was discarded and the wash 
step was repeated twice more. Spin cup columns were transferred into new 
microcentrifuge tubes and 400 JlI binding/wash buffer was added. 
7.1.2.3. Cross-linking the bound antibody 
To spm cup columns containing the bound antibody support, 25 JlI of DSS 
(disuccinimidyl suberate; 25 mg/ml) was added and the tubes were mixed on a rotator 
for 60 minutes at room temperature. Following incubation, tubes were then centrifuged 
for one minute at 5000 x g and the flow-through was discarded. To spin cup columns, 
500 JlI of the ImmunoPure® IgG elution buffer pH 2.8 was added to remove IgG that 
was not covalently bound to protein A. The tubes were centrifuged for one minute at 
5000 x g and the flow-through was discarded each time. This was repeated four 
additional times to quench the reaction and to remove excess DSS and uncoupled 
antibody. Spin cup columns were transferred into new microcentrifuge tubes and 
washed twice with binding/wash buffer, centrifuging for one minute at 5000 x g and 
discarding the flow through each time. 
7.1.2.4. Antigen immunoprecipitation 
To 400 JlI of cell lysates (B/L, 2, 5, 15, 30 and 60 minutes post-wound) in 1.5 rul 
microcentrifuge tubes, 400 JlI of binding/wash buffer and 125 JlI of the cross-linked 
anti-TF protein beads was added and samples were rotated overnight at 4°C. 400 , ..d 
from each tube was transferred into new spin cup columns and centrifuged for one 
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minute at 5000 x g. The flow-through was discarded and 400 j.ll of anti-TF protein 
beads/lysate mixture was added to spin cup columns. Columns were centrifuged for one 
minute at 5000 x g, discarding the flow-through each time until all of the sample had 
been loaded into the spin cup columns. 500 j.ll of binding/wash buffer was added to the 
beads and the tubes were inverted 10 times then centrifuged for one minute at 5000 x g 
and the flow-through discarded. The wash step was repeated an additional two times 
and after the final wash, spin cup columns were placed into new microcentrifuge tubes 
and the wash step was repeated one additional time. 
7.1.2.5. Elution of the immunoprecipitated antigen 
The ImmunoPure® IgG elution buffer was neutralised by adding 10 j.ll of 1 M Tris pH 
9.5 per 200 /-11 of elution buffer. To spin cup columns, 50 /-11 of the neutralised 
ImmunoPure® IgG elution buffer was added and mixed by inversion, then centrifuged 
for one minute at 5000 x g. This was repeated three additional times and all four 
fractions were retained for separate analysis. 
7.1.2.6. SDS-PAGE 
The resultant fractions from immunoprecipitation for TF were sUbjected to SDS-P AGE 
(sodium dodecyl sulphate polyacrylamide gel electrophoresis) in order to separate the 
proteins according to their size. For this purpose, a 10% resolving gel was used. 
Samples were run slowly through the stacking gel at 60 V, and then the voltage was 
increased to 90 V until the samples had reached the bottom of the gel. The separated 
proteins from the gel were transferred to 0.45 /-1m nitrocellulose membrane by semi-dry 
electrophoretic transfer (BioRad) at 250 rnA for 60 minutes at room temperature. The 
nitrocellulose membranes were then blocked overnight in IX PBS-2% (Iv) Tween-20 at 
4°C to block non-specific binding sites. 
250 
7.1.2.7. Western blotting for TF 
Membrane blots were washed three times for 10 minutes each in PBS-0.05% (Iv) 
Tween-20, at room temperature, with shaking. For the detection of TF, the primary 
antibody (mouse monoclonal anti-human TF, 1 mg/ml stock: American Diagnostica. 
supplied by Axis-Shield, Dundee, UK) was diluted 1 in 200 in IX PBS-2% (Iv) Tween-
20, 1% (W/v) BSA. To each membrane blot, 5 ml of the antibody solution was applied. 
Membrane blots were placed on parafilm in plastic trays and incubated with antibody 
for 1 hour at room temperature. Blots were washed three times for 10 minutes each in 
PBS-0.05% (Iv) Tween-20, at room temperature, with shaking. Secondary antibody 
(biotinylated rabbit anti-mouse F(ab'h fragment, Dako) was diluted 1 in 300 in IX 
PBS-2% (Iv) Tween-20 1% (W/v) BSA and 5 ml of the antibody solution was applied to 
each membrane blot and incubated for 2 hours at room temperature. Blots were washed 
three times for 10 minutes each in PBS-0.05% (Iv) Tween-20 at room temperature, with 
shaking. Membranes were incubated in 40 ml SAB complex (StreptABComplex) for 45 
minutes at room temperature. The SAB complex was prepared 90 minutes prior to use 
by adding 2 /-ll A (streptavidin) and 2 /-ll B (biotin-HRP) to 496 /-ll PBS and made up to 
40 ml with PBS-2% (Iv) Tween-20 immediately before use. The blots were washed five 
times for 10 minutes each with PBS-0.05% (Iv) Tween-20. For chemiluminescent 
detection, Pierce West Pico SuperSignal substrate (Perbio, Northumberland, UK) was 
used. Activator and peroxidase solutions were added together in a 1: 1 ratio and 5 ml 
was added to the membrane blot for 5 minutes at room temperature. Blots were 
transferred into plastic, zip-lock bags and excess substrate removed by blotting. Blots 
were placed in a cassette and exposed to X-ray films overnight and films were 
developed using the Kodak X-ray developer. 
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7.1.3. Preliminary results 
7.1.3.1. Isolation of TF complex 
KDa 
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Figure 7.1. A representative image of the isolation of a TF complex. 
Lane contents as follows: (1) Biotinylated Molecular Weight Marker (2) Unwounded 
cells (3) 2 minutes post-wound (4) 5 minutes post-wound (5) 15 minutes p ost-wound 
(6) 30 minutes post-wound (7) 60 minutes post-wound. 
Preliminary data has demonstrated the presence of a TF complex that appears to 
increase with time following wounding. In the unwounded cells in lane 2, it is likely 
that the band at approximately 40 KDa is free TF (MW=47 KDa) and following 
wounding, this appears to form a high molecular weight complex around 97 KDa, 
whereby, its abundance is time-dependent following wounding and max imum 
abundance is achieved at 30 minutes post-wounding (lane 6) . 
7.1.4. Discussion 
Preliminary data represents the novel observation of the formation of a TF complex in 
16HBE 140- cells in response to mechanical wounding. With respect to the molecu lar 
weight of the coagulation factors , it is likely that the bands at 97 KDa relate to the initi al 
complex of TF-FVIIa (i .e. TF: 47 KDa and FVII : 50 KDa). It is poss ible that the hi gh 
molecular weight band present in lane 6 and 7 between 11 6-1 80 KDa may correlate to 
the ternary complex ofTF-FVII-FXa (146 KDa), however, detection i n gli gible. 
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The presence of a band at approximately 40 KDa (lane 2), indicative of unbound TF 
may relate to full length TF protein that consists of a 219-amino acid extracellular 
region, a 23-residue transmembrane domain and a 21-residue intracellular region. 
Alternatively, it may represent alternatively spliced TF (asTF), a naturally occurring 
soluble TF isoform which was identified in HL-60 cells and is composed of 206 amino 
acids, containing most of the extracellular domain of full TF but lacking its membrane 
anchorage (Szotowski et aI., 2006). The fact that TF was demonstrated in unwounded 
cell mono layers supports the immunohistochemical (section 3. 4.1. 1) and R T -peR 
(section 6. 4.1. 3) analysis that TF is constitutively expressed. It is evident that following 
mechanical wounding, there is rapid formation of a TF complex, which is required for 
initiation of coagulation. Conversely, TF mRNA is significantly increased over longer 
time frames of 10 hours, supporting the concept that following mechanical wounding. 
the initiation of coagulation is dependent on the release of preformed proteins as 
opposed to protein synthesis. 
The increased formation of D-dimers in response to wounding (section 3 . .f. 2. 3) at 2 
hours supports the notion that there is rapid formation of a TF complex prior to 
initiation of coagulation and that fibrin is rapidly generated and degraded post-
wounding. 
The initial aims of future work would be to improve the sensitivity of the method by 
optimising conditions such as to increase the loading volume and to use a lower 
percentage resolving gel (7.50/0) to improve the resolution of high molecular weight 
proteins. With more time, it would have been useful to probe for FVII and FXa as well 
as TF. In order to confirm the presence of these coagulation factors in complex with TF. 
the same TF immunoprecipitates could be used, with subsequent immunostaining for 
both FVII and FXa. In addition to wounding, the effect of other relevant factors kno\\n 
to induce TF expression could be investigated at baseline and in wounded cell cultures. 
One such possibility could be endotoxin as this relates to excessive fibrin formation in 
acute lung injury (Schultz et aI., 2003) and ARDS (Idell, 2002). It would also be of 
interest to investigate whether or not endotoxin also enhances epithelial repair. 
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7.2. Histone deacetylation 
7.2.1. Introduction 
Regulation of gene expression is largely influenced by the architecture of D A (de 
Ruijter et a!. , 2003). In resting cells, DNA is tightly compacted to prevent accessibility 
of transcription factors and DNA forms a highly dynamic and organised complex with 
chromatin. Chromatin contains a nucleosome that is composed of ~n octamer of fom 
core histones, i.e. an H3/H4 tetramer and two H2A1H2B dimers surrounded by 146 base 
pairs of DNA (Ito et a!., 2000; Strahl et a!. , 2000). During activation of gene 
transcription, the compacted DNA is made available to DNA binding proteins via 
modification of the nucleosome (Ito et a!. , 2000). The structure of chromatin is strongl y 
influenced by post-translational modifications of the core histones. One such 
modification is histone acetylation. 
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Figure 7.2. (A) Schematic representation of a nucleosome cOnSlS~1l1? of an ~3/H4 
tetramer and two H2A/H2B dimers. (B) Regulation of transcnptlOn by .h.1 tone 
modification. The upper panel indicating histone acetylation depi~ts the addition of 
acetyl groups to core histones by HAT to activate gene transcriptIOn and the 10 \ er 
panel indicating hi stone deacetylation represents the rem.ov.al of acetyl gro up fro m core 
histone by HDAC resulting in repression of gene transcnptlOn. 
h f-.:' t e tran cription and i Histone acetylation is a major modification t at alec s gen 
(HAT ) E h . hi tone ha a lon o terminal. controlled by hi stone acetyltransferases s. ac COl e 0 
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which is abundant in lysine residues that may be acetylated res It' . I . , 
u mg III a teratlOns ot 
electrical charge of the core histones, leading to transformation of the chromatin 
structure from the 'resting' conformation that is closed to an activated open form (Roth 
et al., 2001). This allows binding ofTATA box-binding protein (TBP), IBP-associated 
factors and RNA polymerase II, which initiates gene transcription. In contrast histone 
deacetylases (HDACs) remove the acetyl groups from hyperacetylated histones to 
counteract the effects of HATs and return histone to its basal state whereby gene 
expression is suppressed (Barnes et al., 2005). Thus, acetylation of histones by HA Is is 
associated with increased gene transcription, whereas hypoacetylation induced by 
HDACs termed 'histone deacetylation' is associated with suppression of gene 
expreSSIOn. 
HDACs play a major role in maintaining the balance between the acetylated and 
deacetylated states of chromatin. In humans, there are 18 potential deacetylase 
enzymes, HDAC1 to HDACll and silent information regulator (Sir)-like deacetylases. 
or sirtuins Sirl to Sir7, which are responsible for the removal of acetyl groups and 
maintenance of the equilibrium of lysine acetylation in histones (Glozak et aI., 2005). 
HDACs are divided into two major classes: class I HDACs (HDACs 1, 2, 3, and 8) 
which are closely related to the yeast (Saccharomyces cerevisiae) transcriptional 
regulator protein RPD3 and localized to the nucleus; and class II HDACs (HDACs 4, 5, 
6, 7, 9, and 10) which are homologous to the yeast HAD-l protein and are found in both 
the nucleus and cytoplasm (Barnes et al., 2005). The sirtuins represent class III HDACs 
(Grozinger et al., 2002). The sirtuin deacetylases contain a conserved 275 amino acid 
domain which is unrelated to the other classes of HDACs and the sirtuin deacetylases , 
function via a different mechanism that involves NAD as a substrate. Despite these 
structural and mechanistic differences, both the sirtuin deacetylases and HDACs are 
demonstrated to repress gene transcription at specific promoters or chromosomal 
domains by localised histone deacetylation (Grozinger et al., 2002). HDACl1 is the 
sole member of class IV HDACs. It shares sequence similarity with the catal)1ic core 
regions of both class I and II enzymes but does not have strong enough identity to be 
placed in either class (Gao et al., 2002). 
Inflammatory lung diseases such as asthma are typically associated with increased 
expression of multiple inflammatory genes that are regulated by prointlammatory 
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transcription factors such as nuclear factor (NF)-KB and activator protein (AP)-1 
(Barnes et aI., 1998). These inflammatory genes code for expression of cytokines. 
chemokines, enzymes that synthesise inflammatory mediators, mediator receptors and 
adhesion molecules (Barnes et aI., 2005). Many of these inflammatory genes are not 
expressed in normal cells under resting conditions, thus the increased expression of 
these proteins arises from enhanced gene transcription (Barnes et al.. 1998). Histone 
acetylation is an active process whereby minor changes in acetylases or deacetylases 
can markedly influence the overall HAT activity that is associated with inflammatory 
genes. Thus, hyperacetylation and increased gene expression may be a consequence of 
increased HAT activation or a reduction in HDAC activity or expression. Modifications 
in histone acetylation are targeted to regions of DNA associated with specific activator 
sites within the promoters of induced inflammatory genes (Urnov et aI., 2001). A study 
using bronchial biopsies from asthma patients has previously demonstrated a significant 
increase in HAT and a small reduction in HDAC activity compared with normal 
airways, thus favouring increased inflammatory gene expression (Ito et aI., 2002). A 
similar observation was demonstrated in alveolar macrophages obtained by BAL from 
asthmatic patients (Cosio et aI., 2004). 
Corticosteroids are largely used in asthma therapy (Barnes, 1998) and are reported to 
suppress inflammation by switching off inflammatory genes (Barnes et aI., 2003). 
Alternatively, corticosteroids may suppress inflammation by increasing the synthesis of 
anti-inflammatory proteins such as annexin-1, secretory leukocyte peptidase inhibitor 
(SLPI), IL-IO, IKB-a (inhibitor of NF-KB) and glucocorticoid-induced leucine zipper 
protein (inhibitor of both NF -KB and AP-l) (Ito et aI., 2000). Despite the fact that 
corticosteroids are highly effective in the control of asthma, the concern is that a 
proportion of patients are resistant to this therapy (Adcock et aI., 2003). Moreover, 
patients with chronic obstructive pulmonary disease (COPD) are largely unresponsive 
to corticosteroids (Barnes, 2000). 
As well as histones, other transcription factors such as NF-KB are targets for acetylation 
and deacetylation, which thereby modulate their transcriptional activity (Barnes L'l at.. 
2005). It was previously demonstrated in a study using the bronchial ah'eolar :\5'+9 cell 
line that activation ofNF-KB induced by exposing the cell to inflammatory signals such 
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as IL-lP, TNF-a or endotoxin lead to acetylation of lysine residues on histone H4 
which correlated to increased expression of the inflammatory mediator GM-CSF (Ito ef 
aI., 2000). NF-KB is a major regulator of inflammatory genes, including cytokines, 
chemokines, inflammatory enzymes and adhesion molecules (Barnes ef al.. 1997), and 
is therefore considered as a target for novel anti-inflammatory therapies (Karin ef at.. 
2004). A recent study demonstrated the effect of NF -KB inhibitors in the A549 cell line 
and in primary NHBE cells (Newton et aI., 2007). Stimulation of cells with IL-~ 1 and 
TNF-a induced NF-KB-dependent gene transcription, which was repressed by selecti\t~ 
NF-KB inhibitors (IKK inhibitors). Inhibition of NF-KB-dependent gene transcription 
correlated with loss of expression of intercellular adhesion molecule (ICAM)-l, IL-6, 
IL-8, GM-CSF, regulated upon activation normal T cell expressed and secreted 
(RANTES), growth-related oncogene-a and MCP-l. In contrast, the corticosteroid 
dexamethasone was without effect on NF-KB-dependent gene transcription. Since IKK 
inhibitors had a powerful anti-inflammatory effect on the bronchial epithelium, it was 
reported that these inhibitors might be beneficial in situations of resistance to traditional 
corticosteroid therapy. 
Inhibitors of HDAC activity (HDACls) increase histone acetylation and thereby 
increase gene expression by preventing deacetylation (Moreira ef aI., 2003). 
Trichostatin A (TSA) is a non-selective HDAC inhibitor which is known to alter gene 
expression by interfering with the removal of acetyl groups from histones and thereby 
altering the ability of DNA transcription factors to access the DNA molecules inside 
chromatin (Yoshida et aI., 2003). TSA has been demonstrated to overcome gene 
repression induced by HDACs by stimulating increased expression of inflammatory 
genes such as GM-CSF and IL-8 following exposure to inflammatory stimuli (Cosio ef 
al., 2004; Ito et aI., 2000; Tomita et al., 2003). Moreover, the HDACls TSA and sodium 
butyrate have both been demonstrated to stimulate the expression of t-PA in human 
umbilical vein endothelial cells (HUVECs) in a process that involved histone H4 
acetylation (Arts et aI., 1995). The relevance of increased t-PA expression is that this 
mediator plays a key role in fibrinolysis by converting the zymogen plasminogen into 
the active enzyme plasmin, which mediates the breakdown of fibrin. The acti\'ity of t-
PA is inhibited by PAl-I. The vascular endothelium plays an important role in 
.. b th ·sI·ng both t-PA and PAI-l (Kooistra cf at.. regulating plasma t-PA actIVIty y syn eSI 
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1994). Mice that are deficient in t-PA have been demonstrated to have a reduced 
fibrinolytic capacity and thereby display extensive fibrin deposition (Carmeliet et al., 
1994). In this situation, HDACIs may be beneficial in restoring the balance between 
fibrinogenesis and fibrinolysis. 
Gene repreSSIOn may also occur via the less well documented process of DNA 
methylation. DNA methylation involves the addition of a methyl group to a section of 
DNA, which can lead to repression of gene transcription. It has recently been uncovered 
that there is tight epigenetic regulation involved in the expression of ADAM33 and 
expression of this gene has recently been demonstrated in the H292 bronchial epithelial 
cell line following demethylation of DNA at the ADAM33 promoter region known as 
the 'CpG island' (Holgate et al., 2006). In bronchial epithelial cells, the CpG island of 
ADAM33 is hypermethylated, thus demethylation of DNA restores ADAM33 gene 
expression. ADAM33 has been identified as a susceptibility gene through genetic 
linkage analysis and association studies of families with asthma (Van Eerdewegh et al.. 
2002) and until recently, expression of this gene was reported to be localised to smooth 
muscle, fibroblasts and myofibroblasts but not inflammatory cells, immune cells or the 
bronchial epithelium (Howard et al., 2003; Van Eerdewegh et al., 2002). 
Since mRNA for fibrinogen and coagulation factors Xa and XIII was not detected in 
16HBE 140- cells (Chapter 6), it was of interest to investigate the possibility of gene 
repression using the HDACIs, TSA and sodium butyrate. 
7.2.2. Methods 
7.2.2.1. HDAC inhibition 
16HBE 140- cells were cultured for 48 hours on 6-well plates until fully confluent and 
quiesced for 16 hours in 1 ml per well of serum-free MEM-ITS. Prior to experiment 
MEM-ITS was refreshed, 1 ml per well. One 6-well plate of cells was used for each 
condition. Final concentrations of 1 mM and 300 nM of the non-specific HDACIs 
sodium butyrate and TSA respectively, were added to wells and cells were incubated in 
h b d f HDACIs for 48 and 72 hours With the exception of the tea sence an presence 0 . 
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unwounded cell controls, cells were wounded with maximum scrape damage (W8 = 4 
horizontal wounds and 4 vertical wounds) and incubated for 12 hours at 37°C. 
7.2.2.2. RNA Isolation 
Following wounding and subsequent incubation for 12 hours at 37°C, the cell culture 
supernatants were removed and harvested and cells were washed with 500 III per well of 
IX PBS then trypsinised by incubating with 250 III per well of IX trypsin-EDTA for 5 
minutes at 3TC. Once the cells had lifted, 250 III per well of FBS was added to 
neutralise trypsin activity. The cell suspension from each well of the 6-well plate was 
combined and removed into 15 ml centrifuge tubes and centrifuged for 7 minutes at 670 
x g (ALCPKI20 Centrifuge, Winchester Virginia, USA) to create a cell pellet. RNA 
was then isolated from the cell pellets: See section 6.3.1 for method. 
7.2.2.3. One-Step RT -PCR for fl-actin, FGC, FXa, and FXIII 
See section 6.3.9.1 for methods. 
7.2.3. Preliminary results 
7.2.3.1. mRNA expression of fl-actin in the absence and presence of HDAC 
inhibitors 
Expression of fl-actin mRNA in the absence and presence of HDACIs in unwounded 
and wounded cell cultures by RT-PCR analysis was investigated. 
259 
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Figure 7.3. Representative gel demonstrating the effect of sodium butyrate and TSA on 
mRNA expression of~-actin in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (No RNA) (3) 
No drug; Baseline (unwounded celis): RNA extracted after 72 hours (4) No drug; 
Baseline (unwounded cells): RNA extracted after 48 hours (5) 1 mM sodium butyrate ; 
Baseline (unwounded cells): RNA extracted after 72 hours (6) 300 nM TSA; Base line 
(unwounded cells): RNA extracted after 72 hours (7) No drug; 12 hours post-wound: 
RNA extracted after 72 hours (8) No drug; 12 hours post-wound: RNA extracted after 
48 hours (9) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 72 
hours (10) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 48 hours 
(11) 300 nM TSA; 12 hours post-wound: RNA extracted after 72 hours (12) 300 nM 
TSA; 12 hours post-wound: RNA extracted after 48 hours. 
RT-PCR amplification demonstrated that ~-actin mRNA was expressed in 16HBE 140-
cells and was used as a suitable internal control for RT-PCR. 
7.2.3.2. mRNA expression of FGC in the absence and presence of HDACIs 
RT-PCR amplification in section 6.4.3 indicated that fibrinogen mRNA was not 
detected in 16HBE 140- cells. The fibrinogen primer pair was deemed valid since it was 
able to generate an abundant amplicon of 413 base pairs by RT-PCR, using RNA 
isolated from mouse liver. FUlihermore, in the absence of RNA, no amp licon was 
generated by RT-PCR. However, evidence of fibrinogen protein expression in 16H BE 
140- cells was determined by immunoblot (section 3.4.2. 1), therefore, gene repre ion 
was investigated by RT-PCR analysis of fibrinogen mRNA expression in the ab ence 
and presence of HDACIs. 
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Figure 7.4. Representative gel demonstrating the effect of sodium butyrate and TSA on 
mRNA expression ofFOC in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (No RNA) (3) 
No drug; Baseline (unwounded cells): RNA extracted after 72 hours (4) No drug; 
Baseline (unwounded cells): RNA extracted after 48 hours (5) 1 mM sodium butyrate; 
Baseline (unwounded cells): RNA extracted after 72 hours (6) 300 nM TSA; Baseline 
(unwounded cells): RNA extracted after 72 hours (7) No drug; 12 hours post-wound: 
RNA extracted after 72 hours (8) No drug; 12 hours post-wound: RNA extracted after 
48 hours (9) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 72 
hours (10) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 48 hours 
(11) 300 nM TSA; 12 hours post-wound: RNA extracted after 72 hours (12) 300 nM 
TSA; 12 hours post-wound: RNA extracted after 48 hours. 
With reference to the unwounded cells injigure 7.4, RT-PCR analysis indicated that in 
the absence of HDACI, mRNA expression levels of FOC were low, resulting in 
extremely low abundance of FOC amplicons, regardless of time prior to RNA 
extraction. The addition of the HDACI, sodium butyrate had a positive effect on mRNA 
expression; this is evident in lane 5, whereby the abundance of the Foe amplicon is 
increased. The same pattern was apparent in the wounded cell monolayers; in the 
absence of drug, the low abundance of FOe amplicons depicted by lanes 7 & 8 suggest 
that mRNA expression levels of FOe are very low, but the addition of sodium butyrate 
(lanes 9 & 10) appeared to enhance expression. This was particularly evident in cell s 
that were incubated with sodium butyrate for 72 hours prior to extraction (lane 9). TSA 
however, had no effect on mRNA expression of FOe in the wounded or the unwounded 
cell monolayers. 
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7.2.3.3. mRNA expression of FXa in the absence and presence of HDACIs 
RT-PCR amplification in section 643 indicated that FXa mRNA d d . . . was not eteete In 
16HBE 140- cells. The FXa primer pair was deemed valid since it was able to generate 
an abundant amplicon of 430 base pairs by RT-PCR, using RNA isolated from mouse 
liver. Furthermore, in the absence of RNA, no amplicon was generated by RT-PCR. 
However, evidence that FXa is present in 16HBE 140- cells was determined by 
inhibition of wound repair by two separate selective FXa inhibitors (section -I. -1.8. 2), 
therefore, gene repression was investigated by RT-PCR analysis of FXa mRNA 
expression in the absence and presence ofHDACIs. 
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Figure 7.5. Representative gel demonstrating the effect of sodium butyrate and TSA on 
mRNA expression ofFXa in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (No RNA) (3) 
No drug; Baseline (unwounded cells): RNA extracted after 72 hours (4) No drug; 
Baseline (unwounded cells): RNA extracted after 48 hours (5) 1 mM sodium butyrate; 
Baseline (unwounded cells) : RNA extracted after 72 hours (6) 300 nM TSA; Baseline 
(unwounded cells): RNA extracted after 72 hours (7) No drug; 12 hours post-wound: 
RNA extracted after 72 hours (8) No drug; 12 hours p ost-wound: RNA extracted after 
48 hours (9) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 72 
hours (10) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 48 hours 
(11) 300 nM TSA; 12 hours post-wound: RNA extracted after 72 hours (12) 300 nM 
TSA; 12 hours post-wound: RNA extracted after 48 hours. 
In the absence of HDACI, mRNA expression levels of FXa (demonstrated b figure 
7. 5: lanes 3 & 4) in the unwounded cells were almost undetectable. The addition of 
sodium butyrate enhanced expression. This was evident from the FXa ampli con pre nt 
in lane 5, whereby the cell s were incubated with the HDACI for 72 hours prior to RN 
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extraction. However, this effect was not seen in the wounded cells and TSA had no 
effect on mRNA expression in the wounded or unwounded cell monolayers. 
7.2.3.4. mRNA expression of FXIII in the absence and presence of HDACI 
R T -peR amplification in section 6.4.4 indicated that FXIIIA mRN A was not detected 
in 16HBE 140- cells. The FXIII primer pair was deemed valid since it was able to 
generate an abundant amplicon of 445 base pairs by RT-PCR, using RNA isolated from 
mouse liver (figure 6.12). Furthermore, in the absence of RNA, no amplicon was 
generated by RT-PCR. However, evidence of FXIIIA protein expression in 16HBE 140-
cells was determined by immunoblot (section 3.4.2. 2) therefore, gene repression was 
investigated by RT-PCR analysis of FXIIIA mRNA expression in the absence and 
presence of HDACIs. 
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Figure 7.6. Representative gel demonstrating the effect of sodium butyrate and TSA on 
mRNA expression of FXIIIA in 16HBE 140- cells. 
Lane contents as follows: (1) 100 base pair ladder (2) Negative control (No RNA) (3) 
No drug; Baseline (unwounded cells): RNA extracted after 48 hours (4) No drug; 
Baseline (unwounded cells): RNA extracted after 72 hours (5) 1 mM sodium butyrate; 
Baseline (unwounded cells): RNA extracted after 72 hours (6) 300 nM TSA; Baseli ne 
(unwounded cells): RNA extracted after 72 hours (7) No drug; 12 hours post-wound: 
RNA extracted after 72 hours (8) No drug; 12 hours post-wound: RNA extracted after 
48 hours (9) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 72 
hours (10) 1 mM sodium butyrate; 12 hours post-wound: RNA extracted after 48 hours 
(11) 300 nM TSA; 12 hours post-wound: RNA extracted after 72 hours ( 12) 300 nM 
TSA; 12 hours p ost-wound: RNA extracted after 48 hours. 
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RT -PCR amplification demonstrated that in the absence of HDACI, the level of mRNA 
expression of FXIIIA is low (as depicted by the FXIIIA amplicon of low abundance in 
lane 4), whereby RNA was extracted after 72 hours incubation. 
With reference to the unwounded cells depicted by lanes 3-6; in the absence of HDACI 
at 48 and 72 hours (lanes 3 and 4), bands were present, but not in the position of 445 
base pairs for full length FXIIIA. The presence of the HDAC inhibitor sodium butyrate 
resulted in 3 amplicons of different size, one of which was of the correct size of 445 
base pairs and two others, which were around 400 and 500 base pairs. TSA did not 
appear to have any effect on the mRNA expression of FXIIIA compared to the no 
HDAC controls. 
In the wounded cell cultures (lanes 7-12), it appeared that wounding decreased the level 
of FXIII mRNA expression (lane 7) compared to the unwounded cell cultures (lane .J) 
at 72 hours. In the absence of HDACIs, abundance of FXIII amplicons was low (lanes 7 
and 8) but was slightly increased in the presence of the HDAC inhibitor sodium 
butyrate (lane 9). TSA did not appear to have any effect on the mRNA expression of 
FXIII compared to the no HDAC controls. 
7.2.4. Summary of results 
The HDACI sodium butyrate increased the mRNA expression of FGC in both the 
unwounded and wounded 16HBE 140- cell monolayers. FXa mRNA expression was 
increased in the unwounded cells only in the presence of sodium butyrate. TSA had no 
effect on mRNA expression of neither FGC nor FXa mRNA in either the unwounded or 
wounded cell cultures under the conditions investigated. Finally, sodium butyrate 
generated multiple amplicons of FXIII of varying size in the unwounded 16HBE 140-
cells and TSA had no effect on mRNA expression of FXIII in either the unwounded or 
wounded cell cultures under the conditions investigated. 
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7.2.5. Discussion 
Preliminary experiments investigating the effect of histone deacetylase inhibitors on 
fibrinogen, FXa and FXIII expression suggest that these genes are repressed in 16HBE 
140- cells, as mRNA expression was increased in the presence of the HDACI sodium 
butyrate. In all cases, amplicons were most abundant when RNA was extracted 72 hours 
after incubation with sodium butyrate suggesting that HDAC inhibition was time-
dependent. 
In the absence of sodium butyrate, unwounded 16HBE 140 - cell layers were 
demonstrated to express FXIII mRNA after 72 hours of culture, however its abundance 
was low. Previous experiments demonstrated that FXIIr mRNA transcripts were not 
detected in 16HBE 140- cells (section 6.4.4). However, for the purpose of that 
experiment, the RNA was extracted immediately, with no prior incubation period. This 
suggests that the levels of mRNA expression of FXIIr may be dependent upon duration 
of culture, prior to RNA extraction. 
Following incubation of confluent monolayers of 16HBE 140- cells with sodium 
butyrate, three FXIII amplicons of approximately 500 base pairs, 445 base pairs (correct 
size) and 400 base pairs were obtained (figure 7. 6). Since these amplicons were 
generated using a single primer pair, it is possible that three alternatively spliced 
variants of FXIII mRNA are encoded by a single gene. Another possibility is that 
genomic DNA is susceptible to environmental changes, giving rise to large missense 
mutations. In a previous study, molecular analysis of the FXIIIA gene in two unrelated 
FXIII-deficient individuals revealed three splice site mutations; a g-->a at the exon 6 
acceptor splice site, a g-->a at the exon 7 donor splice site and a coding sequence T -->G 
at the exon 8 donor splice site (Anwar et at., 1998). FXIIIA mRNA expression in these 
patients was also investigated and it was demonstrated that each mutation gave rise to 
multiple transcripts which varied in their relative abundance (Anwar et at., 1998). It is 
possible that alternatively spliced variants of FXIIr may relate to its various functional 
roles, including fibrin cross-linkage, wound repair and cross-linkage to fibronectin to 
anchor the fibrin clot to the site of injury. Another role performed by FXIII is to preyent 
spontaneous fibrinolysis by incorporation of a1-anti-plasmin into the fibrin clot. In 
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order to definitively identify the sequence of the three amplicons produced by RT-PCR 
as seen in lane 5 of the gel shown in figure 7. 6, it would be necessary to perform R T-
PCR reactions containing (1) forward primer only (2) reverse primer only and (3) both 
primers, in order to ascertain that the three amplicons present are not a false positive 
result, and are the result of amplification of three unique mRNAs transcribed from one 
section of genomic DNA. mRNA purification and subsequent sequence analysis would 
elicit the identity of the three aforementioned amplicons. 
The HDACI sodium butyrate exerts a very broad range of effects on many biological 
pathways via its inhibitory action on HDACs. Sodium butyrate has anti-inflammatory 
properties and is known to exert immune suppression in part by suppressing NF -KB 
activity (Joseph et al., 2004; Segain et al., 2000). Several investigators of histone 
acetylation recognised that to increase histone acetylation, either the activity of HAT 
must be increased, or conversely, the activity of HDAC be inhibited. The latter was 
found to be the mode of action of sodium butyrate (Boffa et al., 1978; Candido et aI., 
1978; Sealy et al., 1978; Vidali et al., 1978). Sodium butyrate inhibits most HDACs 
with the exception of class III HDACs representing the sirtuin (Sir) family, which 
includes yeast (Sir2) and class II HDAC6 and -10, however, the binding site by which 
sodium butyrate inhibits HDAC activity has not yet been established (Davie, 2003; Li et 
al., 2006). During inhibition of HDAC activity, HAT activity continues, which results 
in histone hyperacetylation. Histones, however, are not the only substrates of these 
enzymes. High mobility group (HMG) chromosomal proteins are acetylated. HMG 
proteins are common to all eukaryotes and bind DNA in a non-sequence-specific 
manner to promote chromatin function and gene regulation. They interact directly with 
nucleosomes and are reported to be modulators of chromatin structure. HMG-1 (Y) has a 
role in the transcription of many genes involved at different steps in the metastatic 
cascade and has been linked with cancer in human and animal models (Evans et al., 
2004). However, HMGs are also important in activating a number of regulators of gene 
expression, including p53, a transcription factor that regulates cell cycle and hence 
functions as a tumour suppressor (Sterner et al., 1979). Studies reveal that among the 
fatty acid HDACIs, sodium butyrate is the most effective in inhibiting HDAC activity 
and repressing the expression of specific genes (Davie, 2003). 
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Under the conditions investigated, TSA had no effect on the expression of fibrinogen. 
FXa or FXIII. TSA is structurally unrelated to sodium butyrate, however it has 
previously been shown to be a potent and specific inhibitor of histone deacetylase at 
lower concentrations than sodium butyrate (Arts et aI., 1995; Yoshida et aI., 1990). In a 
study involving stimulation of t-P A gene expression by TSA in HUVECS, 1 ~M TSA 
was determined to be the optimal concentration required for maximal induction of t-PA 
expression. These preliminary experiments only included one concentration of 300 nm 
TSA, therefore it would be necessary to investigate a concentration range of TSA in 
order to optimise conditions. However, following a previous study using a human 
lymphoid cell line, it was reported that only 2% of genes were regulated by TSA. 
Similarly, a study involving the effect of TSA in gastric cancer cells demonstrated that 
of the 2400 genes, only 5% were regulated (Glaser et al., 2003). Moreover, TSA as well 
as other HDACIs are reported to have the potential to both up-regulate and down-
regulate gene expression (Glaser et aI., 2003; Wang et aI., 2007). 
Both sodium butyrate and TSA are described as non-selective inhibitors of HDACs 
(Barnes et aI., 2005; Davie, 2003; Yoshida et aI., 2003). Moreover, there is evidence 
that different HDACs target different patterns of acetylation and regulate different genes 
(Peterson, 2002). Thus, for future experiments, it would be of interest to investigate 
exactly which HDACs are involved in repression of coagulation factor expression. This 
would be achieved by RT-PCR analysis of coagulation factor mRNA expression in the 
absence and presence of highly specific HDACIs. 
Although sodium butyrate enhanced the level of mRNA expression of fibrinogen, FXa 
and FXIII, the abundance of amplicons was low. Previous studies have indicated that 
the expression ofHDACs 1-3 is affected by cell density (Dangond et aI., 2001; Gray et 
aI., 1998). It was demonstrated in the hepatocellular carcinoma (Hep 3B) and human 
prostate adeno-carcinoma (PC3) cell lines that the level of mRNA expression was 
decreased at high cell densities and in the case of HDAC3, mRNA expression levels 
were almost undetectable. It was observed that as cells were actively growing, treatment 
with sodium butyrate upregulated expression of HDACs 1-3. However, the response to 
the HDACI was reduced at higher cell densities particularly in the case of HDAC2 
(Dangond et aI., 1998; Dangond et al., 2001). In the current study. HDACIs were added 
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to confluent cell cultures prior to incubation, therefore it is possible that the response 
was reduced due to high cell density. For future experiments it would be of interest to 
add the HDACIs in a time-course during cell growth. Equally, it would be interesting to 
investigate the mRNA expression of HDACs at different cell densities of 16HBE 140-
cells. 
Experiments involving neutralising antibodies have demonstrated that fibrinogen and 
FXrrI are essential to wound repair. Since these genes are repressed it would be 
beneficial to target the specific HDACs in order to activate gene transcription and 
increase their expression. First it would be necessary to identify which HDACs are 
involved. This could be achieved by HDAC-specific chromatin immunoprecipitation 
(ChIP) analysis ofHDACs bound to the promoter region of the coagulation factors, then 
to develop specific HDACIs to target them. ChIP analysis has recently been used to 
demonstrate the down-regulation of TF expression by HDAC3 (Wang et a!., 2007). 
Local production of coagulation factors to support bronchial epithelial repair may be 
important in asthma when there is reduced or no plasma exudation (refer to Chapter 8 
for more detail). However, it is becoming increasingly evident that the inflammation in 
asthma is largely driven by the increased expression of multiple inflammatory genes via 
activation of pro inflammatory transcription factors, such as NF-KB and 
AP-1, resulting in acetylation of core histones and thus increased expression of 
inflammatory mediators. Thus, the challenge would be to target HDACs that would 
increase expression of coagulation factors without switching on expression of 
inflammatory mediators. 
HDACs and HATs are known to bind to repressor and activator proteins, which are 
implicated in tumorigenesis and are therefore considered to playa central role in a wide 
variety of human cancers (Dangond et a!., 2001). Recent studies have revealed that 
HDACs are structurally and functionally diverse, therefore, it is recognised that 
inhibitors that are specific to individual enzymes must be developed as more promising 
agents for cancer therapy. Novel TSAlTPX hybrids have been synthesised, which will 
serve as a basis for developing enzyme-specific HDAC inhibitors (Yoshida ef at., 
2003). Thus, the goal of developing specific HDAC inhibitors for coagulation factors is 
not unobtainable. 
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8. General discussion 
Animal models have previously indicated that normal bronchial epithelial repair is rapid 
and supported by the formation of a provisional fibrin matrix that is exclusively plasma-
derived. However, this study has demonstrated for the first time that bronchial epithelial 
cells in culture are a source of coagulation factors and are able to initiate coagulation in 
the absence of plasma. Two lines of evidence point to the capacity of these cells to 
generate a cross-linked fibrin matrix in the absence of plasma. Namely, the detection of 
fibrinogen and FXIIIA in cell culture supernatants post-wounding and the formation of 
D-dimer fragments indicative of sequential fibrinogenesis and fibrinolysis. Furthermore, 
blocking antibody experiments indicate that locally produced coagulation cascade 
proteins are essential for normal epithelial repair and the formation of insoluble cross-
linked fibrin matrices is independent of plasma proteins providing evidence that repair 
of the wounded bronchial epithelium is autonomous. 
It is evident that initiation of coagulation is rapid in the current model since a significant 
release of D-dimers was evident at 20 minutes. However, RT-PCR analysis in Chapter 
6 demonstrated a time-dependent increase in TF mRNA that was only significant at 10 
hours post-wounding. Thus, with respect to the time frame of mRNA expression of TF, 
it would appear that gene transcription is not responsible for the rapid induction of TF-
initiated coagulation in response to wounding. The likely concept is that TF is 
upregulated by a process of de-encryption. TF encryption describes the suppression of 
TF procoagulant activity on the cell surface. TF may become decrypted in response to 
stimuli such as freezing and thawing of cells and in the presence of proteases (Bach et 
al., 1990; Le et af., 1992), which may explain why TF is constitutively active in the 
current model. However, the upregulation of TF at the wound edge is likely to be the 
cause of further decryption of TF in response to cell damage. In the plasma membrane 
of quiescent cells, phosphatidylserine, a major phospholipid, is localised on the inner 
leaflet of the bilayer (Zwaal et af., 1997); and an increase in cytosolic calcium of the 
same magnitude that decrypts TF procoagulant activity also disrupts phosphatidylserine 
asymmetry. The relevance of phosphatidylserine availability is that this phospholipid 
accelerates coagulation reactions on membrane surfaces (Hathcock et at., 2005: 
Kunzelmann-Marche et af., 2000). Interestingly, immunohistochemical staining in 
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Chapter 3 demonstrated the expression of TF localised in vesicles within cells at the 
wound edge. Thus, in response to wounding, it is likely that these vesicles are 
translocated to the plasma membrane to increase the phospholipid availability for TF 
pro coagulant activity and to initiate coagulation. This evidence supports the concept 
that TF in part is pre-formed and stored in vesicles and may therefore be readily 
available to support repair when cells are injured. 
Initiation of coagulation and PAR activation are believed to be inseparably linked 
(Chambers et al., 2002). The coagulation factor proteases FVIIa, FXa and thrombin are 
the most thoroughly established activators of PARs. Coagulation factors most 
efficiently activate PARs when they are localised at the cell surface. For example, FVII 
and FXa effectively activate PARs when they are bound to the transmembrane TF 
receptor to form the transient ternary TF:FVIIa:FXa complex (Bunnett, 2006). In 
response to extravascular injury, active TF may initiate the coagulation cascade or 
alternatively trigger cell signalling via PAR activation. It is now considered that 
TF:FVII-mediated coagulation and cell signalling involve distinct cellular pools of TF 
and that signalling TF refers to the encrypted form and de-encryption of TF is necessary 
to promote coagulation (Ahamed et aI., 2006). 
Data generated from immunoblots in Chapter 5 demonstrated that activation of PAR-1 
and PAR-2 by synthetic peptide agonists lead to an increase in the release of fibrinogen 
and FXIIIA from 16HBE 140- cells. In response to wounding alone, the release of 
fibrinogen and FXIIIA was also demonstrated. Thus, in the absence of exogenous PAR 
agonists, it is possible that following wounding of 16HBE 140- cells, the release of 
fibrinogen and FXIIIA may have been a result of coagulation, or alternatively due to 
activation of both PAR-1 and PAR-2 by proteases of the coagulation cascade. However, 
when anti-TF was employed to block initiation of the coagulation cascade and wound 
repair (Chapter 4), there was an accumulation of fibrinogen in cell culture supernatants 
which signified that fibrinogen was released from 16HBE 140- cells and NHBE cells but 
not consumed in the wound repair process. In this case, activation of PARs by 
coagulation cascade proteases was ruled out, implying that other endogenous proteases 
were responsible for the observed responses. It was suggested that MMP-1 and human 
airway trypsin (HAT) released from wounded epithelial cells may ha\'e been likely 
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candidates for the activation of PAR-l d P an AR-2 respectively, as proposed in the 
scheme represented in figure 8.1 . 
Mechanical wounding -----..... ----
~ 
TF 
FVlla 
FXa 
--4---'" 
~Fibrinogen ~~~---~~~----~---~ 
~ 
E::: 
~ +-FXIII~~~----~ ...... -~----1 
S 
\.,:, 
d 
\.) 
Fibrin 1 ~t D-dimers ~ 
REPAIR 
Figure 8.1. A schematic representation of the proposed mechanism of fibrinogen 
accumulation following blockade of the coagulation cascade. Mechanical wounding of 
16HBE 140- cells leads to the release of coagulation factors as a result of either 
initiation of coagulation or PAR activation. Supernatants demonstrated an accumulation 
of fibrinogen despite blockade of the coagulation cascade using a neutralising TF 
antibody. This may due to the release of MMP-l and HAT (human airway trypsin) from 
wounded 16HBE 140- cells and activation of PAR-l and PAR-2 respectively. 
Due to the highly simplified nature of the current model, the associated limitations are 
recognised. The epithelial cell monolayer displayed by the 16HBE 140' ce ll line 
remains undifferentiated, unlike the bronchial epithelium in vivo. With more time. it 
would have been beneficial to develop a model of NHBE cells cultured on tran we ll at 
the air liquid interface in order to achieve a fully differentiated epithelium. Once 
established, the same experiments, including immunoblot analysis of coagulat ion 
factors released into supen1atants and wound repair assays could ha\'e be n empl yed. 
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However, both the serum-free nature of the current culture conditions and the lack of 
other contributory influences such as the underlying mesenchyme, growth factors and 
sensory neuropeptides have uncovered a previously unrecognised role bronchial 
epithelial cells in the local production of coagulation factors that have the capacity to 
generate a provisional fibrin matrix to support epithelial cell migration and are 
functionally important in normal wound repair. 
Microvascular hyperpermeability and oedema formation are common features of 
inflammation. In patients with allergic asthma, inhalation of allergen produces both 
immediate and late-phase inflammatory responses, including the increased expression of 
various pro-inflammatory chemokines, cytokines, growth factors, lipid mediators, 
adhesion molecules and receptors for the same inflammatory mediators, during which 
plasma is exuded from the airway microcirculation (Greiff et aI., 2003; Liu et aI., 1991; 
Svensson et aI., 1995). Until this study, it had been assumed that coagulation factors 
were solely derived from plasma exudation in the inflamed airways, however, the local 
release of coagulation factors from bronchial epithelial cells in the absence of plasma, as 
demonstrated in the current study, may be important in the repair of the nonnal healthy 
bronchial epithelium as well as in asthmatic patients undergoing treatment, when 
plasma exudation may not follow epithelial injury. 
Treatment of asthma is divided into two categories, one for attenuating the chronic 
inflammation using corticosteroids and the other for the relief of symptoms of airflow 
obstruction usmg bronchodilators such as p-adrenoceptors, theophylline, 
antileukotrienes and anticholinergic agents (Bardin et aI., 1992). In patients with 
asthma inhaled corticosteroids have been shown to suppress the increased , 
microvascular permeability and plasma exudation into the airway lumen as detennined 
by measurements of concentrations of high molecular weight proteins such as U2-
macroglobulin in sputum and BAL fluid (Kanazawa et al., 2002; Schoonbrood et aI., 
1995). In addition, Schoonbrood et ai. demonstrated that inhaled corticosteroid therapy 
inhibited plasma exudation without affecting local protein synthesis. Moreover, a study 
of the effect of prednisone in patients with severe persistent asthma indicated inhibition 
of plasma exudation with no significant change in levels of fibrinogen in the airways, 
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suggesting the likelihood of a local cellular source of fibrinogen (Pizzichini et al.. 
1999). 
Although, anti-asthma therapies are effective in suppressing inflammation and reducing 
oedema formation by inhibiting plasma exudation, they do not prevent the occurrence of 
epithelial injury. However, the effect of corticosteroids on bronchial epithelial repair is 
controversial since there is a report that demonstrates that these agents enhanced the 
integrity of the bronchial epithelium in an in vitro study using bronchial biopsy 
specimens (Vignola et aI., 2001) and a conflicting report which demonstrates that 
corticosteroids decreased the rate of cell migration following mechanical injury in a 
bronchial epithelial cell line (Dorscheid et aI., 2006). The bronchial epithelium is in 
contact with, and continually damaged by infectious agents that are frequently inhaled 
from the environment. Thus, in the absence of plasma, the local release of coagulation 
factors to promote bronchial epithelial repair may be functionally important. 
In animal airways, steroid treatment is reported to induce indirect anti-vascular 
permeability effects via inhibition of inflammation (Persson et aI., 1998). The same 
research group demonstrated that other anti-asthma drugs including ~-agonists, 
chromones and theophyllines reduce plasma exudation in inflammatory challenge-
induced guinea pigs (Erjefalt et aI., 1991; Erjefalt et al., 1991; Persson et aI., 1986). In 
support of this, a study demonstrated that the selective ~2-adrenergic receptor agonist 
formoterol, which is known to have an anti-oedema effect, reduced plasma exudation by 
inhibiting endothelial gap formation in a rat model (Baluk et aI., 1994). Similarly, 
treatment of rats with dexamethasone significantly reduced ovalbumin-induced plasma 
exudation (Damazo et aI., 2001). 
TF-bearing cells are believed to be involved in the initiation of fibrin clot formation, 
while the expansion of the fibrin clot is dependent on the propagation of coagulation to 
bulk plasma (Ovanesov et aI., 2005). Thus, the release of coagulation factors from 
bronchial epithelial cells and subsequent formation of fibrin to support local bronchial 
epithelial repair is beneficial, provided that the fibrin clot is degraded after repair is 
complete. Efficient fibrin turnover is evident in the current study by the presence of D-
dimers post-wounding. However, under pathological conditions, the high level of TF 
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expression by activated bronchial epithelial cells may be detrimental and propagation of 
coagulation into exudated plasma could ultimately lead to excessive fibrin deposition 
and thrombus generation, as demonstrated in conditions such as ALI (Idell, 2003). 
ARDS, a form of ALI (ldell, 2002), and status asthmaticus (Wagers et aI., 2004). 
Therefore, these conditions represent a target for anticoagulant therapy. 
Anticoagulant therapy has already proven to be successful in the treatment of patients 
with sepsis and there is growing literature that suggests the possibility for use of 
selective anticoagulants for lung protection in conditions such as ALI. ALI arises from 
an imbalance in the lung characterised by enhanced coagulation and reduced 
fibrinolysis. However, it is recognised that the use of anticoagulant therapy to restore 
the abnormalities in coagulation and fibrinolysis may have a detrimental effect on 
pulmonary host defence since activation of coagulation not only leads to fibrin 
formation but is also associated with the modulation of inflammatory activation to 
produce protective anti-inflammatory cytokines (Schultz et aI., 2003). Thus, the benefit 
of anticoagulant therapy for ALI remains to be established. 
Anticoagulant therapy with pentasaccharides, low molecular weight heparins 
(LMWHs), and unfractionated heparin (UFH) has been used for more than six decades. 
These compounds are indirect inhibitors of FXa, requiring the presence of antithrombin 
for an antithrombin effect. For many years, several direct FXa inhibitors have been in 
preclinical development but have not yet reached the stage of advanced clinical trials 
(Schulman, 2003). The two selective FXa inhibitors that were employed in the current 
study may be of potential use as an anticoagulant therapy in status asthmaticus for 
example, as they would overcome the problem of excessive fibrin formation in addition 
to enhancing bronchial epithelial repair. 
In support of the concept that coagulation and PAR activation are inseparably linked 
(Chambers et aI., 2002), activation of PAR-I and PAR-2 by synthetic peptide agonists 
was demonstrated to enhance fibrin formation and bronchial epithelial repair in the 
current study. There is accumulating evidence to suggest that proteases and their 
receptors playa fundamental role in inflammation. During inflammation and injury. 
there is upregulation and generation of many proteases that can activate PARs and the 
receptors themselves are often over-expressed in inflamed tissues. Administration of 
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selective PAR agonists and proteases can induce signs of inflammation as demonstrated 
by models of PAR-deficient mice, which have implicated PARs in the deyelopment of 
asthma. 
In VIew of the emergmg role of proteases and PARs in inflammation, there is 
considerable interest in the use of antagonists and agonists of these receptors for the 
treatment of a variety of diseases, including asthma, however, the lack of antagonists 
has impeded investigations of the role of PARs in experimental models of human 
disease. Tissue fibrosis is predominantly mediated via P AR-1 (Chambers et al., 2002; 
Sokolova et al., 2007). Since P AR-2 is the only subtype that is reported to be 
cytoprotective in the airway and, in this study was shown to enhance bronchial 
epithelial repair, it may beneficial in the future to develop an aerosolised specific PAR-2 
agonist to promote repair of the damaged epithelium in asthmatics. 
Although P AR-2 receptors have been implicated in inflammatory responses in animal 
models in vivo (Sokolova et al., 2007), P AR-2 agonists .did not induce an overt 
inflammatory response in mice (Henry, 2006). The response to inhaled P AR-2 agonists 
will depend on the level of expression of PAR-2 receptors in the disease setting and 
subsequent activation of cell signalling pathways leading to the generation of PGE2, 
which is responsible for many of the beneficial effects of PAR-2 activation. The 
prostanoid receptors EP-1 and EP-4 are associated with bronchial epithelial repair 
(Savla et al., 2001), while the EP-2 and EP-3 receptors may be effective in producing 
bronchodilation and opposing allergen-driven inflammation. Thus, the increase in 
EP-3 receptor expression observed post-wounding in 16HBE 140- cell layers supports 
the notion that PAR-2 agonists may promote anti-inflammatory effects as well as 
bronchial epithelial repair. 
Activation of the PAR-2-PGE2-EP receptor axis in animal models of airway disease and 
in isolated human cells and tissues is demonstrated to produce a series of 
bronchoprotective effects including bronchorelaxation and anti-inflammatory effects 
(Henry, 2006). However, it is presently unclear whether these beneficial effects \vill be 
translated through to the treatment of human lung diseases. Moreover, it is unclear as to 
which component(s) of the PAR-2-PGE2-EP receptor axis should be the 
pharmacological target. Given that the majority of the bronchoprotective effects are 
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mediated via PGE2, it has been suggested that a better pharmacological approach may 
be to administer inhaled PGE2 rather than a PAR-2 peptide agonist. However. the 
disadvantage of this approach is that activation of irritant receptors within the upper 
airways and the induction of reflex bronchoconstriction and cough may occur as a 
consequence (Tilley et al., 2003). The current concern with the PAR-2 peptide agonists 
used in the majority of studies is that they have relatively low potency (micromolar 
range) and they are susceptible to degradation by aminopeptidases, which limits their 
usefulness in whole animal studies. However, a study has demonstrated that substitution 
of the N-terminal serine with a furoyl group in PAR-2 peptide agonists dramatically 
enhanced the agonistic activity and decreased degradation by aminopeptidase leading to 
the development of a more potent PAR-2 peptide (Kawabata et aI., 2004). 
Effective treatments for asthma are available, however, morbidity and mortality rates 
are not improving. Many attempts have been made to improve existing therapies rather 
than to develop new ones. For example, long acting inhaled Pragonists were developed 
after oral P2-agonists and were considered to be more effective and inhaled 
glucocorticoids were developed as they have fewer side effects than the oral 
formulation. Current asthma therapy is delivered predominantly by inhalation. 
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Decade Drugs currently available Drugs in Therapeutics that 
I;-------__ ~~~~~--------~de~v~e~lo~p~m~e~n~t--~h~a~ve~fu~il~e~d~to~d~at~e __ 
1930s Theophylline Neuropeptide 
1950s 
1960s 
1970s 
1980s 
1990s 
2000s 
Anti -cholinergics 
Short-acting B2 agonists 
Inhaled and oral corticosteroids 
Cytotoxics and 
immunosuppressants * 
Long-acting B2 agonists 
Leukotriene receptor antagonists 
Anti-human IgE mAb 
Anti-TNF 
Type IV PDE 
inhibitors t 
antagonists 
P AF antagonists 
Thromboxane 
inhibitors 
Bradykinin 
antagonists 
Anti-IL-5 mAb 
hr IL-12 
hr IFN-y 
hr IL-I0 
Soluble IL-4 receptor 
IL-4 double mutein 
Allergen-specific IL 
VLA-4 antagonists 
P-selectin mAb 
Antihistamines 
Mast cell stabilisers 
Table 8.1. A summary of the drugs that are currently available for asthma, therapies 
that have failed and drugs that are currently in development. *Rarely used and efficacy 
uncertain; tmostly targeted for COPD; PDE: phosphodiesterase; hr: human 
recombinant; mAb: monoclonal antibody; VLA: very late antigen. 
Adapted from the review by Holgate et al. (2007). 
For patients with mild-moderate asthma, regular inhalation of a low dose of inhaled 
corticosteroid is recommended; and for those with severe asthma that is not controlled 
on a low dose of inhaled corticosteroid alone, regular treatment with a long acting 
inhaled fh-agonist or leukotriene receptor antagonist is prescribed in addition (Holgate 
et al., 2003). Cortisone was first demonstrated to cause dramatic improvements in 
patients with rheumatoid arthritis in 1949; and since then, corticosteroids became 
established as the most potent anti-inflammatory agents in the pharmacotherapy of 
chronic inflammatory diseases such as asthma (Horvath et al., 2006). Glucocorticoids 
are reported to be highly effective in controlling asthma and the first line therapy for 
chronic asthma (Barnes, 1995). However, there are concerns about the local and 
systemic side effects of inhaled glucocorticoids (Barnes et al., 1993). The most common 
local side effect is dysphonia, which has previously been demonstrated to occur in 50% 
of patients that were receiving high dose therapy (Willey et al., 1982). Long term 
systemic side effects of inhaled glucocorticoids include growth stunting in children and 
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the development of osteoporosis in adults (Barnes, 1995). Another major concern 
includes the increasing problem of glucocorticoid resistance (Barnes et ai., 1995). 
Many of the existing therapies are targeted towards the inflammatory process that is 
associated with asthma rather than the inherently fragile bronchial epithelium. FXIII 
deficiencies have been described in chronic venous leg ulcer disease (Gemmati et ai., 
2004) and inflammatory conditions of the gut, including ulcerative colitis (Pihusch et 
ai., 2002; Seitz et ai., 1994). Moreover, a study has demonstrated that cutaneous wound 
healing is impared in FXIII-deficient mice and that this may be overcome by treatment 
with FXIII (Inbal et ai., 2005). Topical application of FXIII, namely Fibrogammin® 
represents a relatively new concept in the treatment of FXIII-deficient diseases such 
ulcerative leg disease and has been successfully used to enhance wound healing of leg 
ulcers in patients with this disease (Herouy et al., 2000; Wozniak et ai., 1999). 
Given that the release of local coagulation factors have proven to be essential to nonnal 
bronchial epithelial repair, it would be interesting to compare the expression of 
coagulation factors between primary HBE cells of normal and asthmatic individuals. It 
is possible that FXIII may be deficient in asthma. The deficiency may not necessarily be 
inherited, but acquired. Firstly, FXIII is inactivated by nitric oxide, which is upregulated 
in severe asthma (Catani et ai., 1998). Moreover, neutrophil elastase is abundant in 
severe asthma and this enzyme has been reported to cleave FXIII. In the event that 
FXIII was demonstrated to be deficient in asthmatic subjects, it is conceivable that 
FXIII could be used in an inhalable form to overcome the deficiency and to promote 
epithelial repair. One concern associated with FXIII treatment is the possibility of 
absorption into the blood circulation leading to risks of thrombus generation. This may 
be overcome by combined therapy with heparin, the anti-thrombotic. The additional 
benefit of heparin is that it has anti-inflammatory properties and there is clinical 
evidence that heparin treatment provides benefit in asthma (Tyrrell et ai.. 1999). 
Elucidation of the mechanisms involved in normal bronchial epithelial repair may lead 
to a better understanding of the defective repair that is seen in the asthmatic airway'. 
This could potentially lead to novel therapeutic strategies for the treatment of asthma. 
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